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Abstract 
Treat-all involves regular HIV testing and prompt initiation of ART for all those 
diagnosed HIV-positive, regardless of immunological status, aiming to improve health 
outcomes and reduce HIV incidence. It is a biomedical and social approach to HIV 
treatment and prevention, requiring active engagement of individuals. Questions remain 
as to how Treat-all will be experienced, interpreted and understood by people living with 
HIV, how ART initiation will be decided upon in the absence of clinical symptoms of 
disease, and how ongoing engagement with care will be navigated over time.  
This thesis aims to investigate how clinically asymptomatic people living with HIV 
experience engagement with HIV treatment and care under Treat-all, situated within a 
Médecins Sans Frontières/Eswatini Ministry of Health Treat-all pilot in Shiselweni, 
southern Eswatini. Research comprised 145 interviews, conducted February 2015 – 
September 2017, including repeated interviews with 30 people living with HIV, one-time 
interviews with 28 people living with HIV, and one-time interviews with 31 health care 
workers. Additionally, observations and focus group discussions were conducted. Data 
were analysed thematically, drawing upon principles of grounded theory to generate 
findings inductively from participant accounts. Nvivo 11 aided analysis.  
This research highlights the individually varied, potentially complex processes of coming 
to terms with an HIV diagnosis and deciding when to initiate ART, and the dissonance 
between biomedical interpretations of treatment necessity and individuals’ decision-
making processes and treatment readiness. It appears important for individuals to 
perceive need for treatment, have choice regarding when to initiate ART, to feel 
ownership over the management of their health and treatment-taking, and to have 
evidence of the treatment’s effectiveness to motivate treatment-taking and engagement 
with care. Doubts about diagnosis accuracy, treatment need and effect could undermine 
engagement and cause intermittent treatment-taking. Stigma persists in the context of 
Treat-all, driving engagement with treatment to avoid symptom development and status 
exposure, and also undermining engagement and causing treatment-taking fragility.   
As settings implement Treat-all, it is imperative to understand, reflect upon and address 
the views and experiences of people living with HIV, and to ensure programmes meet 
individuals’ needs. This thesis aims to contribute towards this understanding.   
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Chapter 1: Introduction 
Advances in antiretroviral therapy (ART) have transformed the HIV pandemic (De 
Cock and El-Sadr, 2013), and substantially reduced HIV-related mortality (Reniers et 
al., 2014). ART offers the potential to improve the health of individual people living 
with HIV and to prevent HIV transmission, thus having dual individual and public 
health benefits (Cohen et al., 2011a; INSIGHT START Study Group, 2015; The 
TEMPRANO ANRS 12136 Study Group, 2015). Since 2015, the World Health 
Organisation (WHO) treatment guidelines recommend ART for all people living with 
HIV, at any CD4 count, in recognition of the prevention and health benefits of ART 
(World Health Organisation, 2015). This “Treat-all” policy for HIV treatment and 
prevention, also referred to as “Universal Test and Treat” or “Test and Start”, 
recommends regular, annual HIV testing and immediate offer of ART for all 
individuals diagnosed HIV positive, irrespective of immunological status or stage of 
disease. It is hoped that universal HIV testing combined with immediate ART could 
reduce HIV incidence so substantially as to eliminate HIV as a public health threat 
(Hayes et al., 2014; World Health Organisation, 2016).  
Treat-all, together with new biomedical technologies, including treatment to prevent 
HIV acquisition, and medical circumcision, has bought the real possibility of ending 
the epidemic into view (Reynolds et al., 2016; The Lancet HIV, 2015). To facilitate this 
being realised, UNAIDS set the “90-90-90” targets, which propose that 90% of people 
living with HIV know their status, 90% of those diagnosed are on ART, and 90% of 
those on ART are virally suppressed by 2020, to achieve HIV elimination by 2030 
(UNAIDS, 2014).  
According to UNAIDS, 36.9 million people were living with HIV globally in 2017, of 
whom 21.7 million were accessing ART, and 70% of people living with HIV reside in 
Africa (2018). Access to ART has increased exponentially, from 8 million people on 
treatment in 2010. HIV incidence peaked in 1996, with 47% fewer new HIV infections 
and 1.8 million people becoming newly infected in 2017 (UNAIDS, 2018). Eastern and 
Southern Africa represents the world’s most affected region. By 2017, 76% of people 
living with HIV knew their HIV status, 60% of people living with HIV were on ART, 
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and 50% were virally suppressed, with almost 50% less mortality than 6 years 
previously (UNAIDS, 2017).  
The cascade of care is used as a standard way of describing and analysing patient 
behaviour between diagnosis and retention (Fox and Rosen, 2017), viewing patient 
care as a stepwise progression through a set of stages, where each prior level of 
engagement supports future engagement in health care services (Wademan and 
Reynolds, 2016). 90-90-90 targets are based upon key stages of the cascade, HIV 
diagnosis, treatment initiation and viral suppression, and may be used to evaluate 
the performance and success of HIV programmes (Levi et al., 2016), distinguishing 
success and failure in stark biomedical terms (Paparini and Rhodes, 2016). Whereas 
in reality, engagement with care is rarely experienced as a linear process, and people 
may engage, disengage and re-engage from HIV services at various times (Skovdal 
et al., 2017; Wademan and Reynolds, 2016).  
Narrowly focusing on the stages of the cascade and on viral suppression as a “goal” 
that needs to be achieved can detract attention from the broader aspects of HIV as a 
health and social condition, and from viral suppression as a state that must be 
maintained over time, thereby requiring continuous patient re-engagement (Paparini 
and Rhodes, 2016). Throughout this thesis, I use the term engagement to reflect the 
fluidity of people’s experiences with HIV, and with accessing treatment and care 
services, aiming to understand this process from the perspective of the individuals 
who are affected, and considering the broader complexity of individual and social 
practices that may influence engagement.  
This thesis is a study of the lived experiences of people living with HIV, examining 
how individuals navigate engagement with HIV treatment and care in the context of 
Treat-all in Eswatini, with fieldwork conducted between February 2015 and 
November 2017. This research is situated within a Médecins Sans Frontières (MSF) 
and Ministry of Health (MoH) of Eswatini Treat-all pilot, which was implemented 
from October 2014, with Treat-all being adopted to national treatment guidelines in 
October 2016.  
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Within this research, I focus on the experiences of people living with HIV who are 
considered clinically asymptomatic, and who would have otherwise been ineligible 
for treatment at the time, with CD4 counts greater than 500 and WHO disease stage 
1 (clinical markers used to distinguish stage of HIV). I consider how disease 
diagnosis, self-identity, treatment decision-making, and the treatment-taking 
experience may change in the context of Treat-all, when individuals are increasingly 
encouraged to initiate ART at asymptomatic stage of disease. Additionally, I explore 
the perspectives of health care workers involved in the provision of HIV treatment 
and care services, and the implementation of Treat-all, as well as situating the 
research within the broader health system context. Throughout this thesis, I refer to 
people living with HIV as individuals, unless it appears necessary to clarify for the 
reader, in which case I use the distinction “people living with HIV”. This is in respect 
of the importance of language in communicating meaning, in an effort to avoid the 
risk of defining people through an illness label, appreciating that there are other 
aspects to self and personhood. I have chosen not to abbreviate this term in the body 
of the thesis, to recognise that using abbreviations to define people can be reductive, 
dehumanising, and that language also has the potential to contribute towards 
stigmatisation (Dilmitis et al., 2012; Lytvyn et al., 2017). In some of the published 
papers comprising the results section, abbreviations have been used in line with 
journal expectations.  
Within this chapter, I describe the background to Treat-all, including the evidence 
upon which the approach is based and how Treat-all came to be introduced, in 
particular in terms of the use of treatment for prevention of HIV transmission. I 
consider the current findings relating to Treat-all implementation, such as the 
randomised controlled trials in six African countries aiming to measure the effect of 
increased and earlier ART on HIV incidence, in situating this PhD research. Then, I 
consider the assumptions underpinning Treat-all, pertinent areas to consider, 
examine and address within Treat-all implementation, and formulate the rationale to 
conducting this PhD research. Finally, I briefly outline the study context, describe the 
research aims and objectives, the role of the candidate and provide an overview of 
this thesis.  
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The advent of Treat-all and HIV treatment as prevention 
During the first 15 years of the HIV pandemic, there was no available treatment able 
to sustainably control viral replication, and CD4 count and clinical stage were used 
to estimate the degree of immunosuppression and risk of death, upon which clinical 
decisions were based, for example regarding the management of opportunistic 
infections (Eholié et al., 2016). The development of combined ART in 1996 
transformed HIV prognosis (Gulick et al., 1997; Hammer et al., 1997), seen as 
“miraculous” and creating hope for the survival of people living with HIV, for the 
first time in a decade of treatment trials (Kobayashi, 1997). HIV thus went from being 
a fatal, incurable disease to a chronic condition requiring lifelong treatment (Siegel 
and Lekas, 2002). However, ART carried toxicity risks, challenges with adherence to 
lifelong daily medication, and the potential for emergence of drug resistance, 
particularly with suboptimal adherence. Thus, decisions about when to initiate ART 
were framed by an avoidance of initiating ART earlier than necessary to spare 
patients the risks of resistance and toxicity, and ART initiation thresholds fluctuated 
over the period 1996 to 2014 (Eholié et al., 2016).   
In 2009, Granich and colleagues’ mathematical modelling study suggested HIV 
prevalence could be reduced to just 1% within 50 years through Treat-all (Granich et 
al., 2009). While mathematical models may offer encouraging findings, empirical data 
demonstrate their application to a “real-world” context (Hayes et al., 2014). 
Therefore, when results from the HIV Prevention Trials Network (HPTN) 052 Trial 
later evidenced a 96% reduction in transmission among serodiscordant couples with 
ART initiation (Cohen et al., 2011a), this provided exciting evidence in support of the 
potential for ART to prevent HIV transmission. Until then, trials seen as the “gold 
standard” for evidencing intervention effect had shown behaviour change 
interventions did not protect against HIV infection, nor even seem to change 
behaviour (Corbett et al., 2007; Gregson et al., 2007; Padian et al., 2010). Although the 
appropriateness of randomised-controlled study design for such socially complex 
interventions is questionable, the perceived failures of “behavioural prevention” 
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spurred enthusiasm for biomedical approaches to prevention (Kippax and 
Stephenson, 2012).  
Since the HPTN 052 trial, observational studies have also suggested that ART can 
reduce HIV incidence (Donnell et al., 2010; Tanser et al., 2013). However, the potential 
population level impact of Treat-all remains unknown, particularly prior to Treat-all 
implementation within health systems and the results of trials to prove a causal link 
between expanded ART access and HIV incidence (Hayes et al., 2014).  
The use of treatment for the prevention of HIV transmission has been referred to as 
the “treatment as prevention” paradigm, grounded on the proposition that bringing 
treatment to the maximum possible number of people living with HIV will enable 
enhanced survival for those accessing treatment, and will reduce the chance of HIV 
being transmitted (Adam, 2011). This has resulted in what Nguyen terms the 
“remedicalising” of HIV (Nguyen et al., 2011), ideologically driving HIV policy in 
terms of funding and focus (Bond et al., 2016; Kalichman, 2013). Many believe the 
potential for treatment to prevent HIV transmission will provide the sought-after 
solution, “bringing the era of HIV to a close” (Braunstein et al., 2011). The potential 
for ART to reduce HIV transmission was first applied to the context of preventing 
vertical transmission of HIV, referred to as Prevention of Mother to Child (PMTCT) 
Option B+, and throughout this thesis referred to as Option B+. Malawi pioneered the 
implementation of Option B+ in 2011 (Schouten et al., 2011), and the offer of lifelong 
ART to all pregnant women was included into WHO treatment guidelines in 2013 
(World Health Organisation, 2013). Evidence from Option B+ suggests that retention 
in care among women initiating ART under B+ is lower than among women starting 
ART for their own health (Clouse et al., 2014; Knettel et al., 2018; Tenthani et al., 2014), 
potential circumstances and reasons for which are explored further in Chapter 2.  
As mentioned above, increasingly biomedical technologies are being used to prevent 
HIV transmission or acquisition physically, chemically or immunologically 
(Vermund, 2014). While the focus of this thesis is Treat-all, and other approaches go 
beyond the scope of this research, I acknowledge that a combination approach to HIV 
prevention is recommended in updated 2016 WHO guidelines. Therefore, here I 
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briefly introduce these approaches. The offer of pre-exposure prophylaxis (PrEP) is 
recommended to all those diagnosed HIV-negative in populations with an incidence 
of above 3 per 100 person years, considered substantial risk for acquiring HIV (World 
Health Organisation, 2016). This follows evidence from 14 randomised controlled 
trials, with a meta-analysis of ten trials finding a 51% reduction in risk of HIV 
infection with PrEP compared to placebo (Fonner et al., 2016). However, adherence 
to PrEP can be challenging and can undermine the potential for the approach (Amico 
et al., 2013). Additionally, WHO suggests the offer of male circumcision to prevent 
heterosexually acquired HIV in men (World Health Organisation, 2016), following 
three randomised trials demonstrating approximately 60% reduction in female-to-
male transmission (Auvert et al., 2005; Bailey et al., 2007; Gray et al., 2007). These 
approaches are being implemented in a range of settings alongside Treat-all. 
The long-standing debate regarding when to initiate ART was accentuated by 
recognition of the preventative benefit ART provides, with calls for the need for 
definitive data on which to base treatment guidelines (De Cock and El-Sadr, 2013). In 
2015, the START and TEMPRANO Trial findings provided “compelling evidence that 
the benefits of early initiation outweigh any reasons for delay” (Nsanzimana et al., 
2015). Both demonstrated a significant reduction in risk of negative health outcomes 
with early (CD4 count above 500), rather than delayed ART initiation (CD4 count 
below 350), with 44% and 57% lower risk of severe morbidity respectively (The 
TEMPRANO ANRS 12136 Study Group, 2015; INSIGHT START Study Group, 2015). 
Thus these findings, together with evidence of the preventative benefits of ART, 
spurred the WHO treatment guidelines recommending Treat-all in 2015 (World 
Health Organisation, 2015).  
Treat-all implementation findings 
As of mid-2018, 74% of all low and middle income countries were implementing 
Treat-all, and WHO anticipates that by the end of 2020, 92% of these countries will 
have adopted the policy (World Health Organisation, 2018). There are national 
differences in how Treat-all is implemented, for example in how rapidly ART 
initiation is recommended following diagnosis, and the sense of urgency with which 
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the policy is interpreted (Ford et al., 2018a). It remains to be seen how approaches to 
implementation may translate to how Treat-all is experienced by people living with 
HIV.  
In 2016 the Undetectable=Untransmissible (U=U) slogan was launched by the 
Prevention Access Campaign, recognising that people with HIV who have a stably 
suppressed viral load cannot transmit the virus (Leahy, 2018; The Lancet HIV, 2017). 
Evidence supporting U=U is extensive (for example, Attia et al., 2009; Bavinton et al., 
2018; Rodger et al., 2016), and it has been argued that health care providers should 
routinely communicate this message to all of their patients living with HIV 
(Calabrese and Mayer, 2019). Nevertheless, there appears to be a moral dimension to 
treatment as prevention, with people living with HIV holding both the blame for 
potentially spreading the virus, and the emphasis of responsibility for containing it 
(Bond et al., 2016). Delaying ART initiation or sub-optimal adherence may also 
become morally framed in this context (Keogh and Dodds, 2015). Formative research 
prior to Treat-all implementation in Eswatini described local resistance to the 
treatment as prevention terminology, due to locally ascribed meanings of treatment 
concerned with taking responsibility for one’s own health rather than relying upon 
or promoting ART for preventing HIV transmission, instead being framed as Early 
Access to ART for All (Vernooij et al., 2016). 
Although mathematical modelling, the HTPN 052 trial among serodiscordant 
couples, and observational studies suggest ART reduces HIV transmission, the 
impact of Treat-all implementation on population-level HIV transmission has not yet 
been demonstrated. Five randomised trials underway in Southern and Eastern Africa 
from 2013 to 2020 aim to investigate whether Treat-all reduces HIV incidence. These 
trials include PopART (HTPN 071) in South Africa and Zambia, Sustainable East 
Africa Research in Community Health (SEARCH) in Uganda and Kenya, TasP 
(ANRS 12249) in South Africa, MaxART in Eswatini, and The Ya Tsie Botswana 
Prevention Programme, the findings from which are summarised in Appendix 1. The 
preliminary results from these trials are positive, with good uptake of HIV testing, 
ART initiation and viral suppression. For example, within the SEARCH trial, 
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retention in care at one year was around 95% (Brown et al., 2017, 2016). However, the 
link between Treat-all implementation and HIV incidence reduction appears to be 
more complex. Results from the largest trial, PopART, presented at the Conference 
on Retroviruses and Opportunistic Infections (CROI) in March 2019, showed that 
HIV incidence reduced by 30% in Arm B compared to Arm C (standard of care), 
though Arm B included a PopART intervention according to national treatment 
guidelines, which adopted Treat-all in 2016. Arm A, which implemented Treat-all 
from the outset, had a non-statistically significant reduction in HIV incidence of 7% 
(Hayes et al., 2019). After two years of intervention, the SEARCH trial observational 
analysis of interim data reported 96% of HIV-positive individuals within the trial 
communities were diagnosed, 93% of previously diagnosed residents had initiated 
ART, and 90% of residents with prior ART initiation had achieved viral suppression 
(Petersen et al., 2017). However, recent incidence results presented at the AIDS 
conference in 2018 showed that while there had been a reduction in HIV incidence 
and mortality during the trial period, there was no difference in three-year 
cumulative incidence between the intervention and the control arms of the trial 
(Havlir et al., 2018). Findings from the TasP trial presumed the found absence in 
difference in HIV incidence between the intervention and the control arms to be a 
result of low rates of linkage to HIV care following diagnosis, with only around 30% 
of individuals registered at a trial clinic within 6 months of diagnosis (Iwuji et al., 
2018).  
Botswana appears to be on track for achieving the 90-90-90 targets, with national 
estimates that in 2015 83% of people living with HIV knew their status, 87% of whom 
were receiving ART, and 96.5% of whom were virally suppressed, leading to a 
population viral suppression of 70% for all people living with HIV (Gaolathe et al., 
2016). It is hoped that such high levels of viral suppression will translate to a 
reduction in HIV incidence over time, and ultimately to control of the HIV epidemic 
(Marukutira et al., 2018). Eswatini has also had promising results, with a recent 
national survey finding HIV incidence was 44% lower in 2016 than in 2011, presented 
as the “first direct measure of the national impact of expanded HIV prevention and 
treatment programmes” at the IAS conference in 2017 (Nkambule et al., 2017). 
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Thus far, evidence proving an attributable effect of ART on population viral 
suppression (Larmarange et al., 2018), or a significant difference in HIV incidence 
between trial intervention and control arms is still awaited (Havlir et al., 2018; Hayes 
et al., 2019). This could be due to a number of factors, and potential reasons cited 
within the trial data interpretation include the change in treatment guidelines to 
national adoption of Treat-all potentially dampening intervention effect (Hayes et al., 
2019). Other cited reasons include that men and young people have consistently 
lower rates of engagement and viral suppression, which could contribute to HIV 
incidence (Brown et al., 2019, 2017; Gaolathe et al., 2016; Iwuji et al., 2018). Population 
mobility and sexual networks are purported to influence potential challenges with 
realising HIV incidence reductions (Gaolathe et al., 2016; Iwuji et al., 2018; Lundgren 
and Phillips, 2018). Suboptimal linkage to HIV care may undermine the population-
level coverage of ART (C. Iwuji et al., 2016; Iwuji et al., 2018; Plazy et al., 2016), with 
linkage to and retention in care being undermined by poverty (Ayieko et al., 2018). 
Additionally, current testing approaches largely miss those within the acute stage of 
HIV infection, with research suggesting that risk of transmission is much higher for 
those with acute, early infection than for those with established infection (Cohen et 
al., 2011b). 
Importantly, 90-90-90 targets are based on models, underpinned by a range of 
assumptions, and which do not capture the complexity of factors that contribute to 
HIV transmission (Gaolathe et al., 2016). These unilinear metrics do not reflect and 
account for individuals’ variation in response to the Treat-all policy and time for 
treatment readiness, and this divergence should be examined (Kawuma et al., 2018). 
Successful implementation of Treat-all relies upon the engagement of individual 
people living with HIV with HIV testing, access to HIV care, treatment initiation, 
maintained adherence and long-term sustained engagement with care (Ford et al., 
2018b; Hayes et al., 2015). However, shortfalls exist at each of these stages, with the 
potential to undermine the success of Treat-all efforts to reduce HIV incidence 
(Ayieko et al., 2018; Gardner et al., 2011; Kilmarx and Mutasa-Apollo, 2013; Nachega 
et al., 2014).   
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Treat-all is both a biomedical and a social intervention, requiring modifications to 
behaviour and practice and the active engagement of people and communities, 
situated within social, cultural and political dimensions (Adam, 2011; Kippax and 
Stephenson, 2012). Increasingly people initiate ART at earlier, asymptomatic stage of 
disease, and the time between diagnosis and ART initiation is expedited. The 
biomedical logic framing Treat-all presumes individuals will adjust their actions once 
they are educated, when individuals’ treatment decisions are situated beyond the 
biomedical realm (Beckmann, 2013).  
Study rationale 
A growing body of evidence has documented that expanding access to HIV testing 
and treatment within Treat-all has important health benefits for individual people 
living with HIV, and for the prevention of HIV transmission. However, many aspects 
relating to how Treat-all implementation will be experienced by people living with 
HIV, and the social circumstances which surround it, remain unknown. The question 
is not whether the biomedical technologies are efficacious, but rather how to 
implement them and how to effectively support individuals to engage with and 
benefit from them (Reynolds et al., 2016).  
Rather than adopting a public health approach that is underpinned by neoliberal 
notions of individual responsibility, we must recognise the collective nature of 
epidemics (Henderson et al., 2009), and engage with the lived world of those affected 
by HIV (Kippax and Stephenson, 2012). The biomedical paradigm risks reducing 
disease to an abstract physical matter within the realm of clinics, with rigid 
distinctions between individuals’ physicality and the broader social world, 
abstracting people from their social contexts and the other aspects to self and 
personhood, which extend beyond the biomedical sphere (Beckmann, 2013; Hickel, 
2012).  
There may be anticipated and unanticipated factors within individuals’ life contexts 
which could undermine Treat-all interventions from having the desired beneficial 
effects (Camlin et al., 2016a). Understanding and accounting for such complex 
dynamics and the contextual, social circumstances which surround HIV and 
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engagement with care is essential to the success of Treat-all (Reynolds et al., 2016), as 
is consideration of the behavioural aspects of HIV treatment and transmission 
(Kalichman, 2013). It is therefore vital that socio-behavioural contexts and 
dimensions are examined, understood and addressed as integral to Treat-all 
approaches (Adam, 2011; Keogh and Dodds, 2015; Kippax and Stephenson, 2012; 
Young et al., 2016). 
Individuals who are increasingly being encouraged to initiate ART when clinically 
asymptomatic may have differing support needs, such as for those who do not feel 
unwell, who may have fears regarding ART side effects and the potential impact of 
taking ART on their lives (Camlin et al., 2016a). It is important to consider how 
interventions such as Treat-all interact with everyday exigencies, including the 
competing demands of treatment with work, home, family, relationships and other 
social and lived realities (Adam, 2011). For example, social science research from the 
context of Treat-all has found that some individuals are not able to engage with 
treatment and care, despite being aware of the benefits early treatment can bring. This 
is due to a range of competing priorities and responsibilities which can place pressing 
demands on life, such as the need to work and earn a living (Bond et al., 2018).  
There may be dissonance between clinical guidelines and individuals’ interpretation 
of what constitutes treatment necessity (Kawuma et al., 2018), and behaviours judged 
as “irrational” such as interrupting treatment or changing doses, instead represent 
“ways in which people enact agency in the context of their day-to-day needs” 
(Paparini and Rhodes, 2016, p.506). Under Treat-all, motivations for ongoing 
engagement with treatment and care may change, as the circumstances surrounding 
treatment initiation differ from those in the past, when individuals would largely 
initiate treatment when experiencing symptoms and feeling unwell. Existing 
evidence suggests that motivation for adherence may be stronger among those who 
initiate treatment when sick, as illness histories are drawn upon to motivate 
continued treatment-taking, and improved health and strength create a sense of need 
for treatment and belief in its efficacy (Bernays et al., 2015; Nam et al., 2008). Initiating 
ART when in good health may have implications for sustained treatment-taking, as 
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people living with HIV may not see the benefits of sustained ART adherence if they 
have not experienced any deleterious HIV-related health effects (Pell et al., 2019), and 
thereby initiating ART without HIV-related symptoms may undermine treatment-
taking (Boyer et al., 2016). However, a study from Treat-all in Eswatini found 
acceptance of HIV diagnosis to be more important than disease stage on initiation, 
for sustaining treatment-taking and engagement with care (Pell et al., 2019).  
As settings move forward with Treat-all implementation, it is an imperative to 
understand individuals’ views, experiences and broader life context to ensure that 
support is tailored to meet individuals’ needs, so that the benefits of Treat-all can be 
realised, and engagement sustained over the longer term. This is vital for enabling 
individuals to experience improved health outcomes. Additionally, it is important 
from a public health perspective, due to the potential risk of drug resistance 
developing with inconsistent treatment-taking, which has been highlighted as a 
critical threat to eliminating AIDS by 2030 (Jena, 2013; Wagner and Blower, 2012; 
World Health Organisation, 2017a, 2017b). The findings of this thesis aim to 
contribute towards this understanding. 
Study setting 
This PhD research is embedded within an MSF/MoH project in the Shiselweni region 
of southern Eswatini. The Kingdom of Eswatini, formerly named Swaziland, is a 
small landlocked country in southern Africa, which borders South Africa to the north, 
west and south, and Mozambique to the east (Figure 1.1). Throughout this thesis, the 
country is referred to as Eswatini, and the people of Eswatini as Swati(s). However, 
as the country’s name changed during the research, some results, such as those 
presented in Chapter 4, and quotes from participants refer to Swaziland and Swazi 
(for the people of Swaziland). 
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Figure 1.1: Map of Eswatini showing the location of the MSF/MoH project. Source: Ministry 
of Education and Training, 2018. 
Within the Shiselweni project where this research is based, MSF and the MoH have 
been collaboratively providing decentralised HIV and tuberculosis care since 2007, 
predominantly at the primary health care and community level. In 2013, the project 
began a pilot of combination biomedical approaches to HIV prevention, aiming to 
contribute towards reduced HIV incidence. These approaches included the 
implementation of Option B+ in 2013, and of Treat-all in October 2014. This pilot 
aimed to assess the acceptability and feasibility of Treat-all under routine 
programmatic conditions. At the time the Treat-all pilot began, national treatment 
guidelines recommended ART for those with a CD4 count greater than or equal to 
350, which then changed to 500 during the pilot. Treat-all was adopted to national 
guidelines in October 2016. More recently (2017) the project also began piloting oral 
HIV self-testing and PrEP for young women and men who have sex with men.  
Eswatini has the highest reported HIV prevalence worldwide, estimated as 27% of 
adults aged 15 to 49 years, and much higher among women (35%) than men (19%) of 
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the same age (UNAIDS, 2016). The prevalence peaks at 54% among women aged 35 
to 39 years, and at 49% among men aged 45 to 49 years (Swaziland Ministry of Health, 
2017). Further information on the study context is presented in the methods chapter 
(study context section).  
Research aim and objectives 
This study aims to examine the lived experiences of people living with HIV, and how 
engagement with HIV treatment and care is navigated in the context of Treat-all in 
Eswatini 
Objectives: 
1. To understand how an HIV diagnosis is interpreted and understood in the 
context of Treat-all, and how this may influence engagement with care 
2. To examine how treatment is perceived and experienced by those who are 
asymptomatic  
3. To explore treatment initiation decision-making 
4. To examine how ongoing engagement in HIV care and treatment-taking is 
navigated over time 
5. To generate policy and practice recommendations for consideration of MSF 
and the Eswatini MoH, including for the national adoption of Treat-all  
 
The research objectives align with different phases of the research, and with results 
that are presented through papers in Chapters 4-7 (Table 1.1). 
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Table 1.1: Research objectives aligned with research phase and results focus 
Research 
objective 
Research 
phase 
Results 
chapter 
Topic focus 
Objective 1 
and 5 
Preliminary 
phase 
Chapter 4 Processing an HIV diagnosis, 
engagement with HIV care 
Objective 3, 4 
and 5 
Main phase Chapter 5 ART initiation decision-making 
processes, sense of choice and 
ownership influencing 
engagement  
Objective 2, 4 
and 5 
Main phase Chapter 6 Perceived need for treatment and 
evidence of treatment 
effectiveness influencing 
treatment-taking 
Objective 3, 4 
and 5 
Main phase Chapter 7 Stigma framing engagement with 
treatment and care under Treat-
all 
 
Role of the candidate 
I worked with MSF within the MSF/MoH project in Eswatini as a Qualitative 
Researcher, based primarily in Eswatini, from early 2015 to end 2017. Within my role, 
I managed several research projects, and responded to operational needs for research 
support, as well as conducting qualitative research studies. I was the Principal 
Investigator for the research presented in this thesis. I contributed to the study 
conception, designed the study, including developing the study protocol and the 
tools for data generation (Appendix 2). I managed a research team including two 
research assistants, who I trained and led in qualitative research methods, and who 
supported implementation of the research throughout the fieldwork. A research 
assistant acted as an interpreter within field visits and observations that I conducted, 
for example of community and clinic activities. Research assistants contacted 
potential people living with HIV participants to arrange meetings to invite study 
participation and to engage with the informed consent process, under my 
supervision. I conducted interviews with health care workers, and the research 
assistants conducted interviews with people living with HIV. Focus group 
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discussions were conducted by myself and a research assistant. Research assistants 
also helped with translation and data transcription.  
The individuals that participated in this research had received MSF/MoH health care 
services, either through HIV testing, or through having been registered at one of the 
clinics in the region. Additionally, health care workers were either employed by MSF 
or the MoH. As the research was embedded within this MSF/MoH project, MSF 
primarily have ownership of the data, the research topic aligned with the project 
priorities (as Treat-all was being implemented, hence the desire for social science 
research on the topic), and MSF approval was required for the study protocol. 
However, I was autonomous in my approach to the study design and the methods 
that I adopted. I also had absolute autonomy in my analysis and interpretation of the 
results, and my choice for paper topics, or for topics of abstracts to submit to 
conferences. I reflect further on my positionality and my influence on the process of 
data generation and analysis in the Methodology chapter (in particular see 
Reflexivity section). The conferences that abstracts were submitted to depended on 
MSF support in terms of potential funding of conference attendance.  
For each paper included in this thesis, I contributed to data generation, and I led on 
data analysis, with input to interpretation and analytical thinking from the research 
assistants. I conducted full data analysis, and then wrote the first full draft of each 
paper. I collated co-author feedback and made edits to the paper, and submitted each 
paper as the corresponding author. I liaised with journal editors, responded to 
reviewer comments, and made any necessary edits to papers before resubmitting for 
publication.  
The work I present within this thesis sits within the discipline of public health, as it 
concerns the science and art of preventing disease, prolonging life and promoting 
health through the organised efforts of society (Acheson, 1988). The Treat-all 
approach for HIV aligns with the public health goals of promoting the biological, 
physical and mental well-being of all members of society (Detels, 2009), and this 
research aims to investigate how people experience their health in relation to HIV 
and Treat-all biologically, socially and psychologically. I therefore also draw upon 
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the disciplines of Medical Sociology, Anthropology and Psychology, as these 
disciplines provide important insights towards understanding people’s lived 
experiences with a health condition such as HIV, and experiences engaging with 
treatment and care services. These disciplines informed the study design, choice of 
methods, and the theories that I apply in situating and interpreting the research 
findings, detailed in Chapter 2 and 3. 
Funding 
MSF sponsored this PhD research, including providing a scholarship towards tuition 
fees. As the research was conducted within the MSF project, research costs were 
covered by the field project including for all logistics relating to interviews and focus 
group discussions, field worker salaries and required flights, for example to the UK. 
Conference costs and open access publication charges were also provided by MSF.  
Structure of the thesis 
In Chapter 2, I engage with the literature from the fields of health, anthropology, 
sociology, psychology and HIV. I draw upon empirical findings, theory and concepts 
to situate Treat-all within existing knowledge and to consider how such knowledge 
may support the understanding of individuals’ experiences with Treat-all, as well as 
potential evidence gaps. The topics I explore include the HIV normalisation discourse 
and HIV stigma. I reflect upon theoretical contributions to stigma in defining my own 
position and interpretation of the stigma process, and I draw upon existing evidence 
relating to how stigma manifests in the context of HIV and affects individuals’ lives 
and engagement with treatment and care in multiple ways. I consider how stigma 
may be changing in the context of Treat-all. Then I explore chronic disease diagnosis, 
how individuals may respond to and process an HIV diagnosis, how this may be 
experienced in the context of Treat-all and potential implications for engagement 
with care. I consider treatment decision-making processes and again reflect upon the 
Treat-all context. Finally, I explore how ongoing engagement with treatment and care 
may be navigated over time, and what may be unique about this experience for those 
who are asymptomatic.  
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Chapter 3 describes the study methodology. Here I outline the epistemological 
approach underpinning the research, which draws upon interpretive, 
phenomenological and feminist theories in aiming to understand the world from the 
point of view of its participants, recognising that there is no single interpretive truth 
and paying attention to the ways in which the researcher and the researched shape 
and contribute to study findings. I describe the approaches to participant 
recruitment, data generation, interpretation of accounts generated through 
interviews and focus group discussions, and to data analysis. I position the research 
in the setting of Shiselweni, Eswatini, describing the study context and socio-political 
information of potential relevance to the research. I describe the methods that I 
adopted, and finally, I reflect upon the ethical dimensions of the research, including 
steps to uphold ethical principles and to protect participants from potential harm.  
The findings of this thesis are presented through four papers, three of which have 
been published in peer-reviewed journals and one which has been accepted for 
publication. The first, published in Social Science and Medicine, examines how 
individuals process an HIV positive result, and what influences their engagement 
with HIV care following diagnosis, presented in Chapter 4. This paper highlights the 
individually varied, potentially complex process of coming to terms with, and 
accepting an HIV diagnosis, which is important for care seeking. The second paper, 
submitted to Medical Anthropology and presented in Chapter 5, uses narrative 
methods to examine decision-making processes regarding ART initiation and 
ongoing engagement with care, finding it important for individuals to have sense of 
choice and ownership over the management of their health and treatment-taking, for 
supporting their engagement with care. The third paper in Chapter 6, published in 
the Journal of the International AIDS Society, examines how engagement in care is 
navigated over the longer term, drawing upon a sub-sample of individuals who have 
been on ART for at least 12 months. Perceiving need for treatment and having 
evidence of its effectiveness motivated treatment-taking. Those who did not feel 
unwell at treatment initiation, and who expressed doubts about treatment need and 
effect described treatment fatigue and experimenting with treatment-taking. The 
final paper in Chapter 7, published in the African Journal of AIDS Research, examines 
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the influence of stigma on individuals’ engagement with Treat-all HIV care. Stigma 
was pervasive within participants’ narratives, and appeared to cause treatment-
taking fragility and potentially undermine engagement with care.   
Finally, Chapter 8 is the discussion chapter. Here I summarise the overall findings, 
situated within existing literature and highlighting the novel contribution of this 
research to knowledge. I reflect upon the approaches taken within the research, and 
the potential influence of this in shaping the data, including reflexivity to the role of 
the researcher, the strengths and limitations of the research, steps taken to 
disseminate the research findings, and recommendations for policy and practice.  
The appendices include a table summarising the main Treat-all trial findings, 
example topic guides for each of the phases of data generation, certificates of ethical 
approval, and informed consent forms that were used with participants. 
Presentations (oral and poster) of the study findings that I prepared and delivered at 
conferences, detailed recommendations for policy and practice from the extensive 
programmatic feedback report that I wrote for MSF and the MoH, and key findings 
summary documents are included.   
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Chapter 2: Literature Review 
I begin this chapter by considering the positioning of HIV as a “normalised”, 
manageable chronic condition through increased access to ART. I then examine HIV 
stigma, in terms of the theoretical construction of stigma, its drivers, causes and 
potential impacts, how stigma manifests in the context of HIV, and how increasing 
access to ART, while changing forms of stigma, does not appear to be “normalising” 
HIV or addressing the fundamental causes of stigma. In the following section, I 
examine how individuals may process and respond to an HIV diagnosis, drawing 
upon literature and theory from chronic conditions, and from the sociology of health 
and illness, to explore how illness can cause changes to identity which people living 
with HIV navigate and may reconcile. I then examine treatment initiation decision-
making processes, considering choice, autonomy, and the importance and influences 
of perceived treatment necessity for motivating individuals’ engagement with care. I 
reflect on evidence from the Treat-all context to position this within the experiences 
of those who are asymptomatic. Additionally, I consider the multitude of rationalities 
which can influence individuals’ engagement with care, reflecting on patients as 
socially situated, and with aspects of self and personhood which extend beyond the 
biomedical realm, and which affect treatment-taking. Finally, I consider extant 
knowledge that may be applied to the Treat-all context in understanding how 
ongoing engagement in treatment and care may be navigated over time. This includes 
how treatment-taking might be motivated in the absence of experiential, embodied 
evidence of treatment effect through physical improvements, and how ownership 
and self-management may support determination for continuing with treatment over 
the longer term.  
HIV normalisation: the biomedicalised framing of HIV 
The medicalised normalisation discourse of HIV-as-ART (Bernays et al., 2017) frames 
HIV as a manageable chronic condition, likened to other health conditions such as 
diabetes or asthma (McGrath et al., 2014; Moyer and Hardon, 2014). This discourse 
first emerged as early as 1989, when experts at the fifth annual AIDS conference in 
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Montreal, Canada described AIDS as a chronic condition (Altman, 1989), as opposed 
to an acute or fatal one, with the possibility of managing HIV and being able to live 
with it for a prolonged time period (Bernell and Howard, 2016). The possible 
management of HIV was presented as akin to cancer or other chronic conditions, 
through a cocktail of new and existing drugs at the time (Altman, 1989). In 1991, HIV 
as a chronic condition then appeared in the nursing and medical sociology literature 
(Nokes, 1991; Siegel and Krauss, 1991). Following the introduction of effective 
antiretroviral-based therapies in 1996, the view of HIV as a chronic illness became 
more widely accepted (Siegel and Lekas, 2002).  
As chronic illnesses are typically incurable, the goals of medical care are to slow 
disease progression and manage symptoms (Siegel and Lekas, 2002). The chronic 
disease paradigm emphasises biomedical disease management, self-care, social 
normalisation and uncertainty (McGrath et al., 2014). The self-care that is required for 
successful disease management is considerable, for example requiring individuals to 
take medications, monitor symptoms and side effects, and eat healthily (McGrath et 
al., 2014; Siegel and Lekas, 2002). Additionally, chronic diseases can spur identity 
changes as an individual attempts to integrate the illness into their life (Bury, 1982; 
Polak, 2017). The identity work and processing that can occur following diagnosis 
with a chronic disease such as HIV are further explored in the following sections, as 
are some of the processes involved with self-management. Chronic illnesses 
necessitate some degree of dependency, for example on medical care or treatment to 
prevent disease progression, as well as uncertainty about the potential for changes to 
health status, mortality, or treatment availability in the future (Moyer and Hardon, 
2014; Siegel and Lekas, 2002). Adjustment to a new life on ART can therefore pose 
significant medical, economic and social challenges, particularly in a setting of 
poverty and treatment insecurity (Rhodes et al., 2009; Russell and Seeley, 2010). In 
fact, Colvin argues that transforming HIV infection to a chronic condition may 
actually worsen “the economic vulnerabilisation of people”, due to adherence 
difficulties, episodic illness, transaction and opportunity costs related to lifelong 
treatment and the need for sustained investment of public resources to fund 
treatment programmes (2011, p.2).  
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The scale-up of ART represents an example of what Biehl termed the 
“pharmaceuticalization of public health” (2007), which alongside a biomedicalised 
approach (Clarke and Shim, 2011), highlight an increasing tendency towards relying 
on biomedical “magic bullets” to treat and prevent diseases (Persson, 2015; Williams 
et al., 2011). However, the journey towards universal ART access in Africa has by no 
means been plain sailing. Peter Mugyenyi was one of the leaders in advocating for 
universal access to ART in Africa, and he and colleagues provided ART through a 
research centre in Kampala, Uganda from 1991. During the 1990s, the high cost of 
drugs prevented ART from being accessible to more than a privileged few 
individuals, and there was the sense that providing ART in Africa would not be 
viable due to pharmaceutical companies’ control over drug pricing, and therefore 
availability (Mugyenyi, 2008). As reflected in Janet Seeley’s book on HIV in East 
Africa (2014), by 2011, the cost of treatments had reduced due to competition from 
generic producers and lobbying of activists, and treatment availability has since 
continued to improve. However, associated treatment costs persist for people living 
with HIV, such as transport and time off from work required for clinic visits, and 
poverty undermines individuals’ access to treatment and care (Seeley, 2014).  
Within the process of medicalisation, a range of problems, including those previously 
considered non-medical, or not solely medical, become defined, viewed and treated 
as purely medical; requiring technical, biomedical solutions and management by 
biomedical professionals and scientists (Bell and Figert, 2015). The pharmaceutical 
industry increases in importance and power within medicalisation (Williams et al., 
2011), and many countries are reliant upon international donors to fund ART 
programmes (Whyte et al., 2013). Mattes describes HIV “normalisation” and the 
medicalised framing of HIV as a “cultural form of social control, in that it creates new 
expectations for bodies, behaviour and health” (2014, p275). This echoes the work of 
Irving Zola on how medicine can serve as an institution of social control (1972).  
An approach that is solely medicalised risks marginalising the non-medical aspects 
of living with HIV (Squire, 2010). It does not call for the structural drivers of HIV to 
be addressed, nor consider the social context that shapes the lived experiences of 
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people living with HIV (Hickel, 2012; Nguyen et al., 2011). For example, medical 
anthropologist Paul Farmer describes the “structural violence” driving HIV (Farmer, 
2004), whereby existing inequalities and vulnerabilities become embodied through 
HIV (Hunter, 2010), which biomedicine alone cannot speak to. Didier Fassin shares 
two narratives connecting the HIV epidemic in South Africa to structural violence, 
one of President Mbeki linking the spread of HIV to apartheid, and another of a 
woman living with HIV, who presents and understands her infection as resulting 
from the structural violence of the township within which she lives (Fassin, 2007). 
Additionally, a study examining experiences of HIV-related stigma in Eswatini 
conceptualised women’s rejection from their familial or marital homestead due to 
their HIV status as a form of structural violence, in light of women’s sexual and 
socioeconomic vulnerabilities in this context (Root, 2010). Existing evidence from 
medical anthropological studies demonstrates that there is no simple causal link 
between biomedicalising HIV and normalising the social and economic realities of 
the disease (Moyer and Hardon, 2014), and for people living with HIV, medication is 
not always the easy solution (Zhou, 2016). 
The scale-up of ART has been accompanied by a narrative of hope and restitution for 
the HIV pandemic (Rhodes et al., 2009), and one of the cited benefits of increased 
access to treatment is that this will further normalise HIV and decrease stigma (Castro 
and Farmer, 2005). It has been argued that there is the potential for ART to 
reconceptualise HIV, as a controllable condition rather than a death sentence (Russell 
et al., 2016a), as a disease “like many other diseases”, and one of many potential 
causes of death, which counselling messages may facilitate (Russell et al., 2015). 
However, evidence suggests that ART can serve as an unwelcome reminder of HIV, 
and a loss of independence and freedom (Persson et al., 2016), and it remains to be 
seen how this may be experienced by people living with HIV in the context of Treat-
all.  
HIV differs from other chronic conditions due to its infectiousness (McGrath et al., 
2014). In particular, the predominantly sexual nature of HIV transmission raises 
connotations surrounding morality, and results in the persistence of blaming 
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attitudes towards people living with HIV (Roura et al., 2009a, 2009b). Therefore, 
Squire poignantly states that the association of HIV with “transgressive sexuality, 
particularly for women, will always render it socially pathological” (2010, p409). 
Existing evidence suggests that HIV continues to be seen as exceptional, in particular 
in terms of the experiences of those living with HIV, and those providing care and 
support to individuals living with HIV (Colvin, 2011; Mattes, 2014; Moyer and 
Hardon, 2014). I will now further explore what contributes to HIV being considered 
exceptional, the stigma surrounding HIV, how this influences engagement with care, 
and how forms of stigma may change as access to ART increases in the context of 
Treat-all.  
HIV-related stigma 
Stigma theory and definition 
Historically, stigma theorists have predominantly focused on individual-level 
stigma, aiming to understand the psychology of the stigmatised person, and the 
process through which stigma is internalised and shapes behaviour (Kleinman and 
Hall-Clifford, 2009). Although Erving Goffman’s seminal work on stigma dates from 
1963, his framework for understanding and examining stigma is still heavily drawn 
upon today, and he remains the predominant stigma theorist. For over a decade pre-
Goffman, the work on stigma was primarily situated in the fields of psychology and 
sociology, examining the individual who is disqualified from full social acceptance 
(for example see Lemert, 1951; and Wright, 1960). Goffman (1963) acknowledged the 
dearth of work exploring the structural preconditions of stigma, or clearly defining 
the concept, which he aimed to examine from a sociological, and particularly a 
symbolic interactionist perspective. Symbolic interactionism considers the 
construction of meanings through social interaction (Goffman, 1963), where the self 
is developed and maintained through social relations (Charmaz, 1983).  
Goffman considers the psychological and social elements of stigma, viewing it as a 
process through which identity is socially constructed. He considers the ways in 
which society categorises people through evidence of their possessing an attribute 
signifying difference or ‘othering’, or an undesirable difference, with such an 
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attribute being a stigma symbol. Based upon this, individuals are judged in terms of 
their relative social value, thus being reduced from “a whole and usual person to a 
tainted, discounted one” (p12).  
Other sociological theorists have also examined stigma from a symbolic interactionist 
perspective. For example Scheff (1966) proposed a “labelling theory” for mental 
illness, based on the application of deviant labels leading to changes in individuals’ 
self-perception and social opportunities. Additionally, Jones and colleagues describe 
a deviant condition identified by society using the term “mark”, which might define 
the individual as spoiled or flawed (Jones et al., 1984). These views echo the work of 
Goffman in considering stigma symbols (e.g. p114) and attributes (1963) in 
influencing how difference comes to be identified.   
Goffman (1963) outlined the distinction between “discredited” and “discreditable” 
identities. He examines the “social information” that is conveyed by particular stigma 
symbols, and how an individual may conceal and manage such information in 
navigating social reality and protecting a social identity which is not perceived as 
“spoiled” or discounted. Those who are discredited possess an evident or visible 
attribute, requiring them to devise coping mechanisms to manage the resulting 
prejudice and discrimination, which can also be referred to as “enacted stigma”. 
Conversely, conditions which can be hidden from the public eye create discreditable 
identities, where the main focus is managing and concealing information to “pass” 
as “normal”, to avoid becoming discredited and experiencing the expected resultant 
stigma, which can also be referred to as “anticipated stigma” (Goffman, 1963; 
Scambler, 2009; Steward et al., 2008).  
In order for someone to be stigmatised and to possess a discrediting attribute, this 
requires the existence of a social context which defines the attribute as devaluing 
(Crocker et al., 1998). It is important to consider the structural conditions that produce 
exclusion from social life, and that cause someone to be stereotyped and devalued 
(Parker & Aggleton 2003). Stigma is relational, in that the discrediting attribute is 
something others affix to the person, rather than it being inherently present (Link and 
Phelan, 2001). Thereby a rationale is constructed for devaluing, rejecting and 
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excluding the stigmatised individual (Link and Phelan, 2006). This “language of 
relationships” (Goffman, 1963) speaks of and to extant social inequality (Alonzo and 
Reynolds, 1995; Parker and Aggleton, 2003). Additionally, stigma is entirely 
dependent upon social, economic and political power, required for a stigma 
component to have weight and influence, and imbuing discriminatory consequences 
for the stigmatised (Link and Phelan, 2001; Yang et al., 2007). Parker and Aggleton 
(2003) highlight the importance of considering how people come to be socially 
excluded, and the forces that create and reinforce such exclusion. They draw upon 
the work of Foucault and Goffman, in positioning the function of stigma at the “point 
of intersection between culture, power and difference”, with “culturally constituted 
stigmatisation (i.e. the production of negatively valued difference)… central to the 
establishment and maintenance of social order” (Parker and Aggleton, 2003, p.17). 
Stigma processes can have a multitude of impacts on the outcomes of those affected, 
including a dramatic effect on life chances, for example through undermining 
employment opportunities, housing and access to medical care (Link and Phelan, 
2006). An individual with an assigned inferior social status has less power than the 
non-stigmatised and therefore less access to resources valued by society (Steward et 
al., 2008), which can affect a range of life domains including social relationships, 
health and psychological wellbeing (Link and Phelan, 2006). Stigma is said to “reduce 
the humanising benefits of free and unfettered social intercourse” (Alonzo and 
Reynolds, 1995, p.304), and can cause chronic stress which has negative consequences 
for mental and physical health (Link and Phelan, 2006; Yang et al., 2007).  
Critiques of Goffman have argued that while it is important to understand the 
psychology of the stigmatised and the processes through which stigma comes to be 
internalised and to shape behaviour, this must not be to the exclusion of considering 
how social life and relationships are changed by stigma (Kleinman and Hall-Clifford, 
2009). Some anthropological contributions to stigma theory view stigma as 
embedded in the moral experience, with moral standing being determined by an 
individual’s local social world, i.e. the domain within which daily life occurs, and 
upon meeting social obligations and norms (Yang et al., 2007; Yang and Kleinman, 
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2008). These approaches aim to focus on the lived, social experience in examining 
how “stigma decays what matters most to ordinary people in a local world… wealth, 
relationships, life chances…” (Kleinman and Hall-Clifford, 2009, p418).   
Within this thesis, I use the term stigma to refer to a social process occurring in the 
context of power, where an individual’s difference, condition or attribute is 
considered unfavourable and linked to negative stereotypes. This definition of stigma 
is based on the work of Goffman, Link and Phelan, and Parker and Aggleton in 
particular. I acknowledge that the manifestations of stigma are socially constructed 
and context specific, and that being judged as possessing a stigma symbol generally 
results in loss of status, devaluation, and leads to unequal outcomes for the 
stigmatised individual (Gilbert and Walker, 2010; Goffman, 1963; Link and Phelan, 
2001; Parker and Aggleton, 2003; Steward et al., 2008). It is important to examine the 
ways in which stigma may be experienced and made manifest, as in order for stigma 
to be addressed, it must first be understood, ideally by examining the perspective of 
those affected.  
HIV stigma and judgements of immorality 
HIV-related stigma is widespread, and has been described as debilitating and 
intrusive (Gilbert and Walker, 2010). Simbayi and colleagues (2007) suggest that HIV 
could be the most stigmatised medical condition in the world, with negative views 
towards people living with HIV being common. HIV infection is associated with 
immorality, with judgements of responsibility for HIV infection, which is assumed to 
result from “promiscuous” behaviour and immoral conduct, thereby instilling a 
culture of blame and discrediting of the identities of those living with HIV (Mattes, 
2014; Mbonye et al., 2013; Moyer and Hardon, 2014; Simbayi et al., 2007). Fear-driven 
attributions include those of contagion and death, due to the transmissibility of HIV, 
and its incurability (Mbonu et al., 2009), which exacerbate stigmatising processes of 
othering and separation.  
When HIV was first identified in the 1980s, one of the dominant narratives 
surrounding the epidemic was that of vilification and blame for HIV transmission, 
particularly apparent in the media and public response to then-named “Patient Zero” 
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in the USA, including that he intentionally transmitted HIV through “promiscuous” 
sexual behaviour (McKay, 2014). In studying the epidemic in Africa, where 
transmission was largely heterosexual, one response was to invoke culture to explain 
transmission (Sovran, 2013), with descriptions of “promiscuity” and “sexual 
deviance” (Packard and Epstein, 1991), which Sovran argues may have been at the 
expense of considering the powerful effects of structural factors such as poverty in 
shaping the epidemic (2013). Such narratives can influence the response to an 
epidemic, and may have contributed towards how HIV infection came to be 
interpreted and perceived, including the shame, blame and moral judgements which 
can surround living with HIV (Caldwell et al., 1992). 
Religion may serve to reinforce stigma, rather than promoting tolerance (Kayal, 
1992). Stigma can be related to moral and religious beliefs, in which a person is 
considered sinful or evil (Duffy, 2005), and HIV is often seen as punishment for the 
sinful behaviour of the affected individual (Alonzo and Reynolds, 1995; Mbonu et al., 
2009). As HIV may be socially judged as a punishment for those who have challenged 
sexual and gendered social norms (Campbell et al., 2011), HIV stigma can thus be 
seen as central to the establishment and maintenance of social order (Foucault, 1978, 
1977; Parker and Aggleton, 2003), and the control of sexual behaviour (Mbonu et al., 
2009). In Campbell and colleagues’ (2005) study of stigma and HIV management in 
South Africa, the link between stigmatisation, the policing of sexuality, and social 
inequalities are described. The authors suggest that the combination of church 
teachings with the construction of “traditional culture” serve to “place limits on the 
sexuality of African women, preserving the patriarchal social relations that continue 
to dominate in South Africa, despite challenges and resistance” (Campbell et al., 2005, 
p.809). Manifestations of stigma are exacerbated by fear, ignorance, lack of 
knowledge, shame, moral judgements and concepts of punishment (Gilbert and 
Walker, 2010). Thus, such moral and religious beliefs of sin and punishment may 
serve to further exacerbate the culture of blame and judgement, and feed stigmatising 
processes which surround HIV.  
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As HIV-related stigma operates within existing inequalities, gender dynamics can 
create unique vulnerabilities for women regarding judgements surrounding HIV 
infection, and in terms of the consequences of stigma, which may be particularly 
acute in patriarchal settings (Katz et al., 2013; Mbonu et al., 2009). Some women face 
severe consequences of HIV status disclosure, including abandonment, relationship 
dissolution and denying access to care, which can be particularly acute where women 
are financially dependent on their partners, and women may fear violence on their 
partners discovering their status (Maeri et al., 2016). Additionally, the deleterious 
judgement of “promiscuity” attributed to HIV infection may be particularly 
damaging for women (Duffy, 2005), although also described as being of concern for 
men (Maeri et al., 2016).  
In Eswatini, a vast majority of the population identify as Christian (Central 
Intelligence Agency, 2018). The construction of social value and personhood is closely 
linked to social respectability, based on a conservative sexual morality (Kuper, 1986), 
similar to that described in Zimbabwe (Campbell et al., 2011). This influences the type 
of sexual practices considered acceptable, and frames social stature as dependent 
upon notions of being a moral, upstanding citizen, threatened by judgements relating 
to HIV and immorality. There may be dissonance between cultural scripts relating to 
an “ideal culture”, i.e. the norms that are publicly affirmed, and “real” or lived 
culture, i.e. the norms that are actually followed by individuals (Chambliss and 
Eglitis, 2013). In a study examining relationships and HIV risk in Eswatini, 
participants described an ideal of marriage and monogamy which were equated with 
social respectability, although many described low rates of marriage in their 
communities, and having multiple concurrent sexual partners (Ruark et al., 2016). In 
addition to the health impacts which are described further below, HIV-related stigma 
influences individuals’ lived experiences in terms of marriage prospects, sexual 
relationships, having children, all of which can be important aspects of identity and 
particularly in societies (such as in Eswatini) within which having children is of 
importance for societal value (Mattes 2014). It will therefore be important to consider 
how stigma may be experienced by people living with HIV and made manifest in this 
context. 
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The impact of stigma on engagement with HIV care 
Stigma complicates the prevention, management and treatment of HIV worldwide 
(Mbonye et al., 2013; Steward et al., 2008), compromising the wellbeing of individuals 
living with HIV (Gilbert and Walker, 2010), and influencing a myriad of factors. 
Experiencing HIV stigma can undermine individuals’ care seeking, uptake of testing, 
response to an HIV diagnosis, identity, engagement with care, treatment initiation, 
adherence and access to support, which have been evidenced extensively in the 
southern and eastern African context (Ayieko et al., 2018; Katz et al., 2013; Maeri et 
al., 2016), and which are hereby explored further.  
Avoiding a disease label may mean individuals avoid care seeking altogether (Link 
and Phelan, 2006; Maeri et al., 2016), with clear resultant negative health impacts in 
terms of morbidity and mortality from delayed access to HIV treatment and care 
(INSIGHT START Study Group, 2015; Lahuerta et al., 2013; Reniers et al., 2014; The 
TEMPRANO ANRS 12136 Study Group, 2015). Fear of stigma and inadvertent 
disclosure on engaging with care, for example through people living with HIV being 
seen by others at the clinic, can undermine access to HIV services (Gilbert and Walker, 
2010; Nakigozi et al., 2013). Additionally, people living with HIV may have feelings 
of despair, fear of dying, and the anticipation of potential stigma and rejection may 
lead to non-acceptance of HIV status and avoidance of care seeking (Raveis et al., 
1998). The perceived need to conceal may be a strategy that is of particular 
importance in the asymptomatic phase of infection (Mbonye et al., 2013), when HIV-
related symptoms are not visible and therefore enacted stigma can be avoided.  
Fear of the potential consequences of a positive HIV test result, including stigma and 
discrimination, can deter individuals from getting tested (Gilbert and Walker, 2010; 
Niehaus, 2014). For example in the context of Treat-all in South Africa, study 
participants described a reluctance to seek clinic-based testing due to confidentiality 
concerns and fear of status exposure (Orne-Gliemann et al., 2016). Likewise, 
treatment initiation can also be delayed due to concerns about the difficulty of 
maintaining a confidential status while on lifelong treatment, also found in the 
context of Treat-all in Uganda (Mbonye et al., 2016). In South Africa, Moshabela and 
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colleagues describe people feeling it is “better to die with dignity, than live with 
shame” of others knowing of your HIV status (Moshabela et al., 2016, p.7).  
Stigma can undermine adherence both directly and indirectly. Attempts to hide 
treatment from others have been described as contributing to treatment interruptions 
in several studies included in a systematic review (Katz et al., 2013). Additionally, 
studies from several African settings have described how some individuals may opt 
to use a clinic far from their home community in order to avoid being seen by people 
they know while accessing treatment and care, thereby avoiding inadvertent 
disclosure (Bond, 2010; Gilbert and Walker, 2010; Maeri et al., 2016). This can create 
challenges for adherence by adding to the burden of treatment and undermining the 
sustainability of treatment-taking over the longer term, with potential for extensive 
investment of time and effort to maintain the appearance of health and thereby avoid 
anticipated stigma (McGrath et al., 2014). Stigma also indirectly affects adherence 
through reducing access to social support due to non-disclosure. Existing evidence 
points to the importance of such support for ART adherence, in terms of emotional, 
financial support, and treatment reminders, particularly from a partner/spouse or 
family members (Katz et al., 2013).  
ART access and changing forms of stigma  
ART enables the management of HIV-related symptoms and therefore the potential 
for HIV status concealment (Abadía-Barrero and Castro, 2006; Roura et al., 2009a, 
2009b). Castro and Farmer suggested that increased availability of ART would result 
in a decline in AIDS-related stigma, based on their experience in Haiti, where they 
said treatment “decreased stigma dramatically” (2005, p57). However, experiences of 
living with HIV, and with ART are not uniform (Seeley, 2014). Castro and Farmer’s 
(2005) findings reflected a context where the majority of individuals engaging with 
treatment and care were at advanced stages of disease, with symptoms which caused 
their HIV status to be visible, thereby creating discredited social identities. For those 
who initiate ART when symptomatic, ART can facilitate a “return to normality” 
(Beckmann, 2013). Ecks describes how biomedicine can “de-marginalise the suffering 
individual”, rendering them acceptable to society (2005, p.242). However, Persson 
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highlights that this is dependent upon patients’ compliance with biomedical 
solutions and fulfilment of their obligations as citizens (2015). Talcott Parsons 
presents the doctor as the guardian of established order, and as “the embodiment of 
the “sacred” order of normality” (Parsons, 1951; Turner, 1999, p.174), on whom 
patients depend for this “normality” to be achieved and sustained.  
The ability of ART to resurrect bodies (Colvin, 2011), and to bring people back from 
the edge of death, has been described as the “Lazarus effect” (Seeley and Russell, 
2010; Siegel and Lekas, 2002). These restorative benefits of ART and the concealment 
of symptoms or stigma symbols could thereby enable the lived experience of stigma 
to become more manageable, as acts of overt discrimination or enacted stigma are 
reduced (Beckmann and Bujra, 2010), and as individuals can conceal information 
regarding their status and have discreditable, rather than discredited identities 
(Goffman, 1963). 
Additionally, the ability of ART to alleviate physical symptoms enables social and 
economic participation, through which individuals can reconstruct their sense of 
social value, again countering processes of stigma (Bernays et al., 2010; Campbell et 
al., 2011; Mattes, 2014). ART has been described as a “technology of invisibilisation” 
(Mattes, 2014), as it enables the avoidance of visible symptoms and therefore supports 
status secrecy and the avoidance of stigma (Beckmann, 2013; McGrath et al., 2014; 
Moyer, 2012). However, although ART may facilitate status concealment, stigma 
continues to persist (Niehaus, 2014; Russell et al., 2016b), and increased ART access 
may generate new forms of stigma, linked to social judgements of morality and 
concerns about treatment hiding individuals’ HIV positivity (Roura et al., 2009b, 
2009a). Individuals taking ART may “remain mired in conflictual symbolic 
relationships between the HIV/AIDS people and the untested” (Campbell et al., 2011, 
p. 1004).  
While ART may enable status concealment through preventing the development of 
HIV-related symptoms, this does not address the fundamental causes or the 
structural drivers of stigma. For example, ART does not challenge the views which 
lead to the labelling of difference, stereotyping, separating and devaluing of 
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individuals with HIV, by individuals or groups with the economic, social and 
political power to be able to influence such processes (Link and Phelan, 2001). 
Likewise, ART does not counter the underlying social inequalities which can create 
vulnerability for stigma and exclusion, such as racism, gender inequality, poverty 
and class (Link and Phelan, 2001; Parker and Aggleton, 2003; Russell et al., 2016b). 
Additionally, such concealment requires individuals living with HIV to sustain 
engagement with HIV treatment and care services and treatment-taking. This carries 
risks for status exposure, as well as creating dependence on ART programmes, and 
uncertainty relating to potential changes in health status or treatment availability in 
the future (Moyer and Hardon, 2014; Siegel and Lekas, 2002).  
In the context of Treat-all, increasingly individuals are initiating ART when clinically 
asymptomatic, with therefore no visible signs and symptoms of HIV, and with 
discreditable rather than discredited social identities (Goffman, 1963). The MaxART 
Treat-all study in Eswatini found health care workers appropriated HIV-related 
stigma to encourage patients to initiate ART under Treat-all, in describing the benefits 
of avoiding HIV status disclosure to the wider community, and in the ability of ART 
to hide visible signs of illness, an approach which may in fact exacerbate HIV-related 
stigma (Pell et al., 2019). This evidence highlights the perspectives of health care 
workers relating to how stigma may be experienced in the context of Treat-all, and it 
remains to be examined how this may be experienced by people living with HIV. 
Evidence from Treat-all in Mozambique suggests that severely ill people living with 
HIV are less likely to fear unwanted disclosure and resultant stigma on engaging with 
HIV care, due to the priority of regaining health. However, for those who feel healthy, 
the potential for unwilling disclosure is exacerbated by engaging with HIV services, 
which can dissuade individuals from treatment initiation and can undermine longer 
term adherence (Magaço et al., 2019). This therefore warrants further investigation, 
in examining how stigma may influence individuals’ engagement with HIV 
treatment and care under Treat-all.  
46 
 
Adjusting to illness: HIV, identity and conceptions of health and ill health 
Coming to terms with an HIV diagnosis can be complex and individually varied. 
Adjusting to “illness” and to changes in identity that such a diagnosis infers may be 
particularly challenging in the absence of any symptoms or signs of ill health, 
requiring prevailing conceptions of health and ill health to be reframed. In the 
following section, I explore extant evidence on the processing of disease diagnosis. I 
draw upon psychological and sociological theory, particularly relating to the 
sociology of health and illness and to chronic conditions, to further understand how 
such a diagnosis may be experienced by asymptomatic people living with HIV in the 
context of Treat-all, and to consider the potential impact of such processes on 
individuals’ outcomes and engagement with care.  
As described further above (section on the impact of stigma on engagement with 
care), the fear of potentially being diagnosed HIV positive, and the anticipated stigma 
for example in terms of social isolation and exclusion that may result, can dissuade 
test-seeking and access to HIV care (Lindkvist et al., 2015). This is important to 
address, as HIV testing is the “crucial entry point to effective HIV prevention” 
(Alsallaq et al., 2013), and timely linkage to medical care can improve individuals’ 
health outcomes as well as contributing to HIV transmission reduction (Jenness et al., 
2012). 
Processing an HIV diagnosis 
Reactions to health and illness are shifting and contextual (Harris, 2009). However, 
receiving an HIV diagnosis is frequently accompanied by shock, doubt and disbelief, 
and an inability to accept the HIV positive test result (Beer et al., 2009a; Nakigozi et 
al., 2013; Raveis et al., 1998), or to acknowledge and embody the realities of living 
with HIV (Moitra et al., 2011). A lack of HIV-related symptoms can make it 
particularly challenging to accept an HIV positive result, as individuals who perceive 
themselves as healthy may deny the significance of infection (Raveis et al., 1998), and 
not having symptoms may reinforce disbelief and doubts about being HIV-infected 
(Beer et al., 2009a; Wringe et al., 2009). This has been found in the Treat-all context in 
Mozambique, where feeling healthy discouraged treatment initiation among some 
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individuals who struggled to accept their HIV positive status, associating HIV with 
sickness (Magaço et al., 2019). 
Stigma can exacerbate this process of status non-acceptance, as denial is a defensive 
response which partly results from avoidance of anticipated HIV stigma (Lyimo et 
al., 2014), making it difficult to reconcile with (Denis, 2014). Avoidance of anticipated 
stigma results in the suppression of any thoughts related to living with HIV (Moitra 
et al., 2011), and can dominate all aspects of behaviour relating to HIV (Lindkvist et 
al., 2015). Fear of experiencing stigma can result in self-rejection, denial and as a result 
self-medication and care secrecy (Ajala, 2012). Commonly held views around HIV 
infection and morality, or “careless” sexual behaviour can mean that individuals who 
do not identify with this image of who gets HIV therefore do not perceive themselves 
as being at risk, thereby undermining HIV status acceptance (Skovdal et al., 2011). 
Views about HIV risk and susceptibility, which are important for status acceptance, 
can also be influenced by concepts of HIV aetiology. For example extant views that 
HIV is caused by witchcraft and may be cured by traditional medicine or spirituality 
can undermine engagement with biomedical care, and may in turn be driven by the 
stigmatisation of HIV as a sexually transmitted infection, offering a more socially 
palatable (and therefore less stigmatising) cause of infection (Beer et al., 2009a; 
Wringe et al., 2009). There can be duality between traditional medicine and clinical 
biomedicine, and individuals may alternate or combine different approaches. The 
alluring promise of cure offered by alternative systems and the deterring HIV stigma 
of being known to take ART can render traditional medicine and spiritual healing 
particularly appealing (O’Brien and Broom, 2014). 
Denial is arguably the most common psychological barrier to initiating medical 
treatment, as seeking care serves as a reminder of an HIV status that an individual 
may be attempting to avoid thinking about (Raveis et al., 1998). Denial has been 
associated with poorer physical and mental health (Kamen et al., 2012), with delayed 
testing, access to care and initiation of treatment (Ayieko et al., 2018; Lindkvist et al., 
2015), and may exacerbate symptoms and cause poor adherence to ART (Moitra et 
al., 2011).  
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The concept of denial was first explored psychologically by Sigmund Freud (1856-
1939) within the language of defence mechanisms, which were identified as processes 
the ego applies to avoid the anxiety of a threatening situation (Freud, 1961). Freud 
presented denial as functional in the short-term, as it allows a patient to avoid an 
unbearable situation and the feelings which accompany it, however, in the longer 
term it can lead to pathology including personality disorders. Elisabeth Kübler-Ross 
(1969) describes the stages of grief that patients go through following a terminal 
diagnosis, presented as five stages between awareness of serious illness and death. 
These include denial, which may be accompanied by a sense of “no, not me”, and can 
last seconds or months; then anger, “why me?”, and bargaining “yes me, but…”, for 
example where a patient asks for more time. This is followed by depression, which 
can be reactive and despondent, where the patient mourns the loss that they will 
inevitably experience with their diagnosis. Finally comes the stage of acceptance, “the 
miracle is that I am ready to go now, and it is no longer frightening”. Kübler-Ross’s 
later work (1987) applied this grief model to AIDS, presenting acceptance as an 
adaptive state, whereby individuals reach a state of peace and resignation to the 
inevitable. While this applied to the pre-ART era, an HIV diagnosis will likely be 
experienced quite differently now, but an understanding of these psychological 
processes may still be of use, and relevant during the roll-out of Treat-all in many 
African countries. Kübler-Ross highlights the importance of health care workers’ 
listening to patients, understanding their individual experiences and supporting 
them on the journey of processing a diagnosis, for example through helping them to 
express their anger, rather than discounting it or encouraging them to suppress it 
(Kübler-Ross, 1969).  
The stages of grief model has been critiqued for being reductive and presenting 
emotional adjustment in terms of linear stages that all individuals go through, and 
based on the assumption that a person is only able to more forward when they have 
come to terms with the reality of a changed life (Kralik, 2002). It is important to have 
an understanding of the illness response that prioritises individuals’ experiences, 
including the complexity and uniqueness of how each person may adjust to living 
with an illness such as HIV (Telford et al., 2006).  
49 
 
Acceptance of HIV status has been described as willingness to acknowledge infection 
and its implications for future life, as well as openness to altering behaviours in order 
to maintain healthy living (Moitra et al., 2011). Accepting a positive HIV test result 
can take time, and may involve re-testing for HIV to confirm the accuracy of the test 
result, which McLean and colleagues describe as potentially occurring over months 
or even years (2017). Where the process of acceptance is accompanied by hope for the 
future, this may improve individuals’ wellbeing, with hope being linked to both self-
reported health and directly measured immunological status (Scioli et al., 2012). 
Acceptance and overcoming stigma are interlinked, with acceptance supporting 
status disclosure, which in turn can facilitate engagement with treatment and care, 
and support adherence (Nam et al., 2008). Coming to terms with such a diagnosis, 
adjusting to illness and the required identity work are explored further in the sections 
below. 
Adjusting to chronic illness 
Illness refers to the human experience of disease, which is “an explicitly social 
phenomenon with both an objective and a subjective reality” (Idler, 1979, p.723). 
Adjusting to, and learning to live with chronic illness can be a complex process, which 
involves fluctuation and movement back and forth (Kralik, 2002). There are several 
theoretical contributions towards understanding a patient’s response to chronic 
illness, which can be considered in the context of HIV within Treat-all. Overall, 
theoretical work has shifted from “the doctor’s legitimation of illness, using the 
disease model, towards an understanding of the meanings which patients place upon 
their situation” (Radley, 1989, p.230). Here disease refers to an “abstract, biological-
medical conception of pathological abnormalities in people’s bodies” (Idler, 1979, 
p.723). There may be divergence between scientific interpretation of disease, and a 
person’s experiential account of illness, and it is important to look beyond the 
biomedical perspective to understand how chronic illness is experienced (Telford et 
al., 2006).   
Michael Bury’s  (1982) work on chronic illness as a biographical disruption is often 
cited, and has also since been critiqued and adapted (e.g. Williams, 2000). 
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Biographical disruption relates to the experience of chronic illness disrupting the 
structures of everyday life and the forms of knowledge underpinning them. The 
worlds of pain and suffering, which are normally seen as distant possibilities or the 
struggle of others, must be recognised. Additionally, rules of reciprocity and mutual 
support are disrupted as an individual becomes increasingly dependent. To make 
sense of the illness, an individual draws knowledge and meaning from their own 
biography, and in searching for the cause of the illness one likewise finds its meaning 
(Bury, 1982). Stages involved in the process include bringing to attention bodily states 
which are not normally conscious, making decisions relating to help seeking, 
fundamentally re-thinking biography and self-concept as extant explanatory systems 
are disrupted, and mobilising resources in facing an altered situation. Several of the 
aspects of this theoretical construction of chronic illness imply an illness where 
someone is symptomatic and debilitated as a result, creating increasing dependency 
on social networks and families, which are not as relevant in the context of HIV Treat-
all, as increasingly individuals living with HIV are diagnosed when asymptomatic 
(Bury, 1982).  
The critique of Bury’s theorisation of chronic illness includes the view that 
biographical disruption does not account for the possibilities in which illness may 
already be a central part of one’s biography, for example from birth, early childhood, 
or later life, including so-called “normal crises” (Williams, 2000). Gareth Williams 
explores the meaning and experience of chronic illness through narrative 
reconstruction, including how an individual may reify illness and symbolically 
attempt to “reconstitute and repair ruptures between body, self and world by linking-
up and interpreting different aspects of biography in order to realign present and 
past, and self with society” (Williams, 1984, p.197). Illness may bring about 
biographical continuity or reinforcement, rather than disruption, particularly in 
circumstances of hardship and adversity (Williams, 2000), where illness may 
reinforce components of identity and lifetime illness experiences or struggles. 
Chronic illness diagnosis has also been conceptualised in terms of transition, in 
reflecting the move towards incorporating illness into life, which can be facilitated by 
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reflective processes and taking action (Kralik, 2002). Transition to living with HIV as 
a chronic condition may involve quests to regain control, create order and to feel 
‘normal’ again (Russell and Seeley, 2010). The conceptualisation of transition 
supports reflection on the dynamic aspects of living with chronic illness, a process 
which is nonlinear, potentially cyclical, convoluted and may occur over a long period 
of time (Kralik, 2002; Meleis et al., 2000). 
In a high HIV prevalence context, such as in southern Africa and Eswatini, risk of 
exposure to HIV is widespread, and an HIV diagnosis could thereby serve as a 
biographical reinforcement. However, HIV-related stigma creates a unique context, 
where it could be more likely that due to the association of HIV with “immoral” and 
“sexually deviant” practices, the majority of individuals would not associate with the 
socially normative image of the type of person who gets HIV. Therefore in the context 
of stigma, even if the HIV prevalence is high, it may still be more appropriate to 
consider an HIV diagnosis in terms of a potential biographic disruption, as it disrupts 
the “socially set standards and cultural prescriptions of ‘normality’” (Bury, 1982; 
Williams, 2000, p.50), likely requiring particular work in terms of adjustment and 
identity. 
Illness and identity 
Being diagnosed with a chronic illness is said to fundamentally necessitate identity 
work (Siegel and Lekas, 2002; Telford et al., 2006). Such identity work requires that a 
person diagnosed with HIV takes on the identity of a chronically sick person, and 
recognises the long-term nature of the condition, committing to its ongoing lifelong 
management within the realm of everyday life (McGrath et al., 2014). The former self-
image may crumble away as the experiences and meanings upon which previous self-
images were built persist to be available, and control over life and the future 
diminishes, resulting in a diminished self-concept, with loss of self-esteem and self-
identity (Charmaz 1983).  
Social identity theory suggests that identity rests on the process of social comparison, 
whereby individuals compare themselves with similar others during social 
encounters (Exley and Letherby, 2001). In Mead’s (1934) analysis of the self, the “I” 
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and the “me” are differentiated, with the “I” representing the principle of action and 
impulse and the “me” representing the socialised aspect of personhood. Thereby the 
self is considered a social being, and it is through social process that a biological being 
gets a mind, self and rationality (Mead, 1934). Adams describes the “I” and the “me” 
as “personal identity” and “social identity” respectively (1997). Living with a chronic 
illness becomes a part of personal identity and social and personal frameworks, with 
resultant impact on conceptions of self, time, and relationships with others (Roth and 
Nelson, 1997). Within HIV, both aspects of personal and social identity work may be 
required, as identities and responses to the epidemic are forged by individuals, which 
can both reinforce or undermine overarching social and cultural norms (Keogh and 
Dodds, 2015).  An HIV diagnosis necessitates reconstruction of the self, and of the 
new identity through illness (Fassin, 2007), an ongoing process which may be 
undertaken within a macro-social context by the individual, family members and 
health care providers (Roth and Nelson, 1997). 
Although less common in the Treat-all era, treatment can still be interpreted as 
symbolising illness and death. For example, a study examining attitudes towards 
early ART in Kenya found initiating ART was perceived as signifying the final stage 
of HIV illness, when one was “nearing the grave” (Curran et al., 2014). Treatment 
may reinforce an illness label which individuals do not identify with, whereby 
medicines are seen as an unwelcome reminder of illness (Pound et al., 2005), and 
patient identity (Siegel and Lekas, 2002). Polak describes the devalued identity of 
being a pill-taker in the context of statins, with resisting medication being framed as 
resisting an illness label, and treatment-taking posing a direct threat to a presentable 
identity (2017).  
In the context of HIV, ART may be associated with stigmatising judgements of HIV 
including immorality, sin and sexual deviance. This could exacerbate the 
undesirability of associating with such an identity, which on the one hand involves 
identifying with an illness for which individuals in the Treat-all context may have no 
symptoms, and which also is aligned with a stigmatised and devalued social identity. 
Adams and colleagues describe the avoidance of membership of a stigmatised group 
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in the context of asthma, whereby asthma was reconstructed to enable denial of the 
label or social identity of “asthmatic”. Asthmatics were viewed as “weak” and 
“decrepit”, holding problematic repercussions for individuals’ self-concepts in 
reconciling self-identity with living with asthma (1997). Within HIV, this has been 
described in terms of concepts of masculinity, with the identity of being “a real man” 
attributed to physical strength, resilience to illness, responsibility and success in 
sustaining a family, which an identity of living with HIV may threaten and contradict 
(Chikovore et al., 2016; Siu et al., 2013; Skovdal et al., 2011). This may change in the 
context of Treat-all, as the promise of ART prolonging good health may appeal to 
such concepts of masculinity and strength, potentially motivating test-seeking 
(Camlin et al., 2016b).  
Within this section, I have reflected that adopting the identity of a chronically ill 
person who must continually navigate and engage in health services may be 
particularly challenging for those without symptoms of ill health, for whom 
treatment can reinforce an identity with which they do not identify, and which is 
stigmatised and socially devalued. As adjustment to illness and identity work may 
be necessary precursors for committing to ongoing management of health and 
treatment-taking, it will be important to consider how this may influence the 
experiences of people living with HIV engaging with treatment and care in the 
context of Treat-all in Eswatini. For example, in examining whether and how self-
identity influences how an HIV diagnosis is processed and decisions to engage with 
treatment and care in this context.  
I will now go on to explore the existing literature on the processes that people living 
with HIV may go through when deciding upon ART initiation. I will consider how 
individuals’ identity and conceptions around health and ill health may influence their 
decisions about treatment necessity, with particular reflection on how this may be 
experienced by asymptomatic people living with HIV within Treat-all.  
Choice and decision-making regarding ART initiation within treat-all  
There may be dissonance between the biomedically framed rationale of Treat-all, 
which posits that HIV is an imperceptible illness which is made visible only through 
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a positive test result indicating that an individual is sick, and the rationale framing 
individuals’ conceptions of illness and treatment necessity (Zhou, 2016). It has long 
been recognised that individuals’ perceptions of their own health, illness and 
symptoms, and decisions regarding their help-seeking are not necessarily congruent 
with the views held by medical professionals (Bury, 1982). Despite biomedical 
evidence showing that ART should be initiated immediately following diagnosis in 
order to achieve its beneficial effects (INSIGHT START Study Group, 2015; The 
TEMPRANO ANRS 12136 Study Group, 2015), how individuals living with HIV view 
and experience their decision regarding when to initiate ART may not align with this 
biomedical rationale (Mbonye et al., 2016). In this section, I will outline and define 
treatment decision-making, consider concepts of autonomy and choice relevant to 
Treat-all, how patients may determine treatment necessity and decide when to 
initiate ART in the absence of HIV-related symptoms, which may be relevant to the 
research context.  
ART initiation decision-making processes 
Before considering decision-making processes, and how decisions to initiate ART 
may be experienced within Treat-all, it is important to first reflect on the concept of 
choice within health care, and whether and why such choice matters.  
Autonomy is one of the principles of health care ethics, along with beneficence, non-
maleficence and justice. Beneficence refers to the obligation to provide benefits that 
outweigh risks, non-maleficence the obligation to avoid causing harm, justice the 
obligation of fairness in the distribution of benefits and risks, and autonomy refers to 
the obligation to respect the decision-making capacities of autonomous people 
(Warnock, 1994). Respect for autonomy is a moral obligation, requiring that 
individuals are consulted, informed, heard and their agreement obtained prior to 
medical intervention, i.e. informed consent (Gillon, 1994). Autonomy can be seen as 
the obverse of dependency (Polak, 2017). Within autonomy, individuals are 
considered self-determining agents whose decisions and actions are their own, and 
liberty, power and privacy may be necessary for individuals to develop their own 
aims and interests (Dworkin, 1988). Thus, a “capacitous individual is entitled to 
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decide whether or not to accept medical treatment”, even if this decision is considered 
to be unwise or medically not in their best interests (Cave, 2017, p.529). This may be 
additionally complicated in a public health context, as there can be dissonance 
between the public health agenda and an individual patient’s choice. For example, 
health care workers can experience perceived moral responsibility in the 
implementation of Treat-all, to reduce the risk of HIV transmission in the community, 
or to protect an unborn child from HIV acquisition (Vernooij and Hardon, 2013). It 
will be important to consider how this potential dissonance is experienced, and how 
it might be reconciled in the Eswatini context. 
Within the rationale of autonomy, choice is assumed to be good because it offers 
individuals autonomy, claiming that by making choices we become in control of our 
own lives (Mol, 2008). However, Polak argues that “this binary framing fails to 
represent the complex calibration process people may undertake in resolving the 
tension between stubborn rejection or passive acceptance of health care worker 
advice” (Polak, 2017, p. 611). Within the logic of choice, Mol (2008) describes how 
patients are considered “consumers” and health products “goods”. However, there 
is a negative starting point with disease, as individuals would prefer not to have it, 
so it is therefore not a “good” around which they are actively choosing to “consume”. 
Additionally, actually making decisions about our own care can be difficult, as fear 
and emotion can cloud judgement, and making rational, objective choices is near 
impossible when many risks (and in the context of Treat-all, potentially benefits) are 
unknown and the future is uncertain (Mol, 2008). Mol argues that choice can actually 
erode good care, and proposes an alternative approach, the logic of care (2008). Here, 
rather than seeking equality between patients and healthy people, the aim is to 
establish living with a disease (not ‘normality’) as the standard. The active patient is 
resilient and flexible, and through caring strives to achieve as much health as the 
disease allows (Mol, 2008). However, Mol’s perspective on patient choice as eroding 
good care has been critiqued, and in Uganda and Kenya, Hardon and colleagues 
found that choice can actually complement good care rather than eroding it (Hardon 
et al., 2011).  
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The updated (2016) WHO treatment guidelines state that the decision to accept or 
decline ART within Treat-all lies with the individual patient, who can also choose to 
defer, and that health care workers should discuss patients’ willingness and readiness 
to initiate ART with them. I will consider evidence regarding how this decision may 
be experienced in practice, and what might influence a person’s willingness and 
readiness to initiate ART. 
Historically, a paternalistic model of patient care was common. Within this approach, 
physicians would make decisions in the best interest of the patient, with minimal 
patient involvement, and the focus being solely the patient’s biomedical problems 
(Byrne and Long, 1976). In this context, patients represent “docile bodies”, who 
submit to medical authority (Foucault, 1977). Within such hierarchical medical 
systems, it is argued that medical professionals can act to carefully guard their 
“expert knowledge”, holding the power and control, for example over the drug 
administration on which patients rely (Beckmann, 2013; Russell et al., 2015). Talcott 
Parsons described a patient’s “sick role” as an assigned social position (Parsons, 
1951a, 1951b), requiring patients to enter into a relationship of dependency, 
compliance and cooperation, looking to medical authority with admiration and 
deference (Crossley, 1998). Parsons argued that asymmetry of knowledge and power 
in favour of doctors was necessary for an effective practitioner-patient relationship 
(Parsons, 1975). However, the paternalistic medical model has since been extensively 
criticised, including for requiring patients’ submission to expert medical opinion and 
blind obedience to doctors’ orders (Bader et al., 2006; Childress, 1982). Additionally, 
the narrow focus on biosociality does not account for the range of social relations that 
characterise and shape people’s daily lives (Whyte, 2009). The term biosociality was 
introduced by Paul Rabinow (1996), reflecting the construction of sociality based on 
biological nature, as portrayed and controlled by and through science.  
The theory of patient-centred medicine was first introduced by Balint (1964), with a 
view to consider and understand illness from the patient’s perspective, rather than 
assuming medical practitioners know best. Negotiated care can create a power 
balance in the practitioner-patient relationship (Goodyear-Smith and Buetow, 2001), 
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and can improve patient outcomes (Nafradi et al., 2017). This approach has been 
developed further with the theorisation of person-centred care, which holistically 
situates patients in their social and biologic entirety, drawing medical attention to 
patients’ personal identities, their subjectivity, environment and social situation, 
avoiding the reduction of people to disease alone (Ekman et al., 2011; Olsson et al., 
2013). Rather than passively receiving health care, the patient is considered an active 
participant in their care (Leplege et al., 2007).  
The model of shared decision-making posits that both health care workers and 
patients have a legitimate investment in the treatment decision within a collaborative 
relationship. Here, rights and responsibilities are distributed between both the health 
care worker and the patient, with “active” forms of patient-hood being recognised, 
and treatment decisions which explicitly refer to evidence being valued (Charles et 
al., 1999, 1997). Individuals’ decisions are shaped over time by knowledge and 
encounters beyond the initial medical consultation (Rapley, 2008). People can consult 
a variety of sources of information, and do not rely solely on medical advice 
regarding taking medicines. (Pound et al., 2005). Decisions individuals take are 
rational within the context of their beliefs, responsibilities and preferences, for 
example, weighing up the costs and benefits of medicine offered in accordance with 
desired outcomes, which may differ for the patient and the health care worker 
(Adams et al., 1997; Conrad, 1985).  
Decision-making is deeply embedded in, shapes and is shaped by interactions with 
others. Autonomy can thus be considered as relational (Keller, 1997), with a patient’s 
agency potentially “emerging in and through a web of intersubjectivity and 
relationality” (Rapley, 2008, p.436). For example, a study examining views towards 
provider-initiated HIV testing in Kenya and Uganda found it rarely the case that an 
individual made a choice to accept HIV testing in isolation of other influences. 
Decisions were socially embedded, and included consideration of the views of family 
members, partners, religious leaders, friends and others (Hardon et al., 2011). In 
Eswatini, meanings of treatment offering the potential to prevent HIV transmission, 
and conceptions of initiating ART early, before one becomes visibly ill, are 
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“incorporated into existing socialities such as kinship relations, and should be seen 
in relation to specific local moral worlds” (Vernooij et al., 2016, p.11).  
Within this thesis, I take a person-centred perspective, focusing on understanding the 
illness experience and thought processes informing treatment decisions (Conrad, 
1985; Pierret, 2003; Zhou, 2016), aiming to understand this from the perspective of the 
individual experiencing the illness, whilst considering the broader social, cultural 
and health system context. I define decision-making as a process involving multiple 
encounters and interactions with multiple people, and relying on multiple sources of 
information and knowledge, occurring over a period of time (Rapley, 2008). Patients 
consider medical advice, and also weigh the possible benefits of treatment against 
anticipated costs such as of side effects, drug dependence, stigma and clinic 
attendance (Conrad, 1985; Wringe et al., 2009; Zhou, 2016). Decisions may involve an 
interpretation of past events, imagining of future trajectories, and judgements in 
response to changing situations (Zhou, 2016). Additionally, decisions are influenced 
by structural factors such as education, class, gender and race (Cockerham, 2005). 
Thus decision-making should be considered based on rationality that is situated 
(Beckmann, 2013), with the prioritisation of ART and physical health above other 
areas of life, such as generating an income, securing food, providing for family, or 
maintaining social position, not always being realistic, achievable or possible. “Many 
individuals may simply choose not to forefront HIV as the central or defining issue 
in their lives” (Kielmann and Cataldo, 2010, p.25), and people can have logical 
reasons for not taking ART (Pound et al., 2005). Thus seemingly “irrational” 
behaviours such as not taking treatment as prescribed, may be “ways in which people 
enact agency in the context of their day-to-day needs” (Paparini and Rhodes, 2016, 
p.506). 
Treatment readiness 
As outlined above, it can take time to process an HIV positive result, to come to terms 
with and adjust to illness and the identity work this requires, and to undertake 
decision-making processes regarding whether and when to initiate ART. In a Treat-
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all study in Eswatini, some individuals were described as delaying ART initiation in 
order to have time to come to terms with their diagnosis (Pell et al., 2019).  
When individuals initiate ART before they are ready, this can undermine their 
subsequent engagement in care (Katirayi et al., 2016), including in terms of adherence 
(Pell et al., 2019) and retention in care (Cataldo et al., 2017). This is particularly 
evident in the context of Option B+. For example in Malawi, Tanzania and Uganda, 
Mclean and colleagues (2017) found that the way in which ART initiation was offered 
and encouraged during pregnancy could cause some women to “accept” ART before 
feeling ready, as many women believed HIV testing and ART initiation were 
obligatory parts of antenatal care. Pregnant women who did not feel ready for 
treatment described various avoidance tactics, including accepting and then 
discarding treatment, or stopping treatment once the perceived primary motivation 
for ART, protecting their unborn child, was fulfilled (McLean et al., 2017). Health care 
workers can feel a moral responsibility to protect babies from the risk of HIV 
acquisition, and a professional need to promote and adhere to the public health goals 
of preventing further HIV infections, which may translate to pressure felt by women 
who access services during pregnancy to initiate ART quickly (Vernooij and Hardon, 
2013). If treatment initiation occurs before individuals are psychologically ready, 
their capacity to prepare for ART and to sustain engagement with treatment and care 
may be reduced (Bulsara et al., 2018). 
Health care workers can experience pressure to encourage patients to “comply” with 
treatment policy and programmes, employing various strategies to “convince” 
patients (McLean et al., 2017). For example, counsellors may attempt to engage clients 
by “making appeals” or by “prescribing rules for living” (Cawley et al., 2016). Such 
“rules for living” can include abstinence, condom use, reduction in sexual frequency 
and number of sexual partners, which may be appropriated by counsellors to 
encourage individuals’ adoption of healthy lifestyle behaviours, with potential 
disadvantages and sanctions presented as penalties for breaking such rules (Allen et 
al., 2011). There may be asymmetries of power between practitioners and patients, 
which establish order and direct codes of conduct, whereby submissive people living 
60 
 
with HIV who subscribe to rules of engagement are seen as cooperative and 
rewarded with labels of “good patients”, as opposed to those of “bad patients” 
(Ondenge et al., 2017). Health care workers may also adopt more extreme measures, 
potentially using their position of authority to attempt to control patients, for 
example, with threats of withdrawing treatment and care, including for pregnancy 
or other health conditions, “if patients are not obedient, passive, and compliant, 
fashioning a form of subordinated therapeutic citizenship” (Russell et al., 2015, p.2). 
Health care workers who are trained to convince women to test for HIV during 
pregnancy can be judged as having failed at their jobs if the woman refuses (Vernooij 
and Hardon, 2013). Women receiving provider initiated testing during pregnancy in 
Malawi described not perceiving HIV testing as a choice, but rather as compulsory in 
order to receive antenatal care (Angotti et al., 2011), and in Uganda HIV testing within 
antenatal care was described as an “offer they can’t refuse” (Vernooij and Hardon, 
2013, p.S563). 
A systematic review of Option B+ studies found that newly diagnosed HIV-positive 
women could feel alienated by perceived pressure from providers to initiate ART 
immediately following their diagnosis, with some not feeling ready to make a lifelong 
commitment to ART, and needing time to consider their options (Knettel et al., 2018). 
While patients may subscribe to medical hierarchy and follow health practitioner 
advice, individuals are also self-determining agents who challenge and resist the 
structures of power and domination in modern society, with the potential to resist or 
rebel from following medical advice as prescribed (Foucault, 1963). Where 
individuals feel pressured to initiate ART before they are ready, their agency may be 
enacted through their choices once they leave the bounded domain of the health 
services. People may assert their agency by refusing to take medication, or by giving 
health care workers as little information as possible (Telford et al., 2006). For example 
in Eswatini, women who engage with HIV services during pregnancy can appear to 
engage with care and initiate ART, then throwing away the medication on leaving 
the clinic, or delaying their actual initiation until they feel ready (Katirayi et al., 2016). 
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In the context of Treat-all, the time between diagnosis and treatment initiation is 
expedited for many people living with HIV. This may cause barriers to treatment 
initiation to be compounded, particularly for those who do not feel unwell and 
therefore do not experience the same motivation for treatment as those who initiate 
when symptomatic, or under previous treatment guidelines (Magaço et al., 2019; 
Nhassengo et al., 2018). It is important to ensure that programmes still allow for and 
support individual variation in response to an HIV diagnosis, and time to treatment 
readiness. Some individuals may benefit from being given more time to accept an 
HIV positive status, and to receive counselling tailored to their specific needs until 
they feel ready to initiate ART (McLean et al., 2017).  
Conceptions of treatment necessity 
Existing evidence from southern Africa describes predominant conceptions of illness 
as being experiential and embodied. For example, within research on Option B+ in 
Malawi, health and illness are described by women as experiences they can see and 
feel, with sickness equated with feeling pain, weakness, weight loss and observable 
changes in appearance, whereas health is understood in terms of being pain-free, 
being fat and beautiful, strong, energetic and capable of work (Zhou, 2016).  
In the pre-Treat-all era, several studies highlighted the influence of not feeling unwell 
on undermining engagement with HIV care and treatment initiation (Gold and 
Ridge, 2001; Govindasamy et al., 2012; Newman et al., 2015). The perceived severity 
of an HIV infection and its potential consequences may be interpreted based on the 
presence of physical symptoms, with accordant influence on accessing care (Beer et 
al., 2009a; Nakigozi et al., 2013; Wringe et al., 2009). Not having symptoms, or feeling 
able to manage symptoms, have led to treatment being described as “not yet 
necessary” by people living with HIV in Uganda and Zimbabwe (Kawuma et al., 
2018).  
Those who feel “normal” and healthy may want to protect that state of being, and 
treatment-taking can be associated with illness rather than health, with loss of control 
and autonomy rather than empowerment, and with shame and difference, not 
normalisation (Pound et al., 2005). This is reiterated by Persson and colleagues (2016), 
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whose research examining decisions not to take ART in context of Treat-all found that 
treatment was seen to signify a “loss of control” over one’s condition and life, and an 
unending reliance on the medical establishment from thereon. Few participants felt 
the need to initiate ART, due to feeling healthy (Persson et al., 2016). Further, in the 
context of Option B+ in Eswatini and Malawi, many women have been found to have 
difficulty accepting treatment when feeling healthy (Katirayi et al., 2016; Kim et al., 
2016; Zhou, 2016).  
Within the context of Treat-all in Eswatini, many people living with HIV perceive 
ART as being for the treatment of symptomatic illnesses, which may undermine the 
perceived need for treatment for those who are asymptomatic, and influence ART 
initiation decisions (Pell et al., 2018). Additionally, a study examining men’s views 
about Treat-all in Eswatini found men had concerns about taking treatment while 
feeling healthy, with one man stating: “I will take ARVs once my body deteriorates, 
so that I can regain my strength” (Adams and Zamberia, 2017, p.300). This may 
change as Treat-all becomes more commonplace (Pell et al., 2018). In addition to good 
health potentially undermining a desire to initiate ART, ART may offer perceived 
benefits of preserving good health and productivity which can motivate some to want 
to start even in the absence of symptoms or signs or ill health (Magaço et al., 2019; 
Pell et al., 2018; Vernooij et al., 2016). The desire to protect good health has been 
described as a mechanism through which to achieve future roles and responsibilities, 
and seen as essential for maintaining normalcy and concealment of HIV status, 
thereby avoiding inadvertent disclosure (through the development of visible HIV-
related symptoms), and resultant anticipated stigma (Magaço et al., 2019).  
Navigating ongoing treatment-taking and engagement with care 
As explored in the section above on decision-making for treatment initiation, patients 
may weigh perceived benefits of taking treatment against the costs (Conrad, 1985; 
Pound et al., 2005), which is also relevant to how treatment-taking is sustained. 
Additionally, in the section above on conceptions of treatment necessity, I highlight 
that patients may seek evidence from their embodied experience to determine 
whether a drug is worthwhile to take (Zhou, 2016). While there is extant literature 
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from the Treat-all context examining ART initiation, as of yet, there is a dearth of 
knowledge from Treat-all programmes examining how individuals navigate longer 
term engagement in treatment and care following initiation of ART when 
asymptomatic. In this section, I will consider how this might translate to the context 
where patients are increasingly initiating ART when asymptomatic, to reflect on how 
treatment-taking may be motivated and navigated over the longer term.  
Evidencing treatment effect 
Initiating ART when in good health can have implications for treatment-taking, as 
people living with HIV may not see the benefits of sustained treatment-taking if they 
have not experienced any deleterious HIV-related health effects prior to starting it 
(Pell et al., 2019). Therefore, initiating ART without HIV-related symptoms may 
reduce motivation for treatment-taking (Boyer et al., 2016; Nhassengo et al., 2018). In 
the past, under previous treatment guidelines, individuals would draw upon illness 
histories to motivate continued treatment-taking, and improved health and strength 
with ART created a sense of need for treatment and belief in its efficacy (Bernays et 
al., 2015; Nam et al., 2008). 
Within Treat-all, the costs of taking treatment such as side effects or risks of 
inadvertent disclosure and resultant stigma may have a greater influence when not 
balanced against experiential benefits of improved physical health. For example, 
evidence from Option B+ highlights how side effects may influence women’s 
engagement with care differently within Treat-all than in the past. Women in Malawi 
who stopped taking treatment said they did so as they felt less healthy after taking 
ART than they did prior to starting it (Kim et al., 2016). This is reiterated by Renju 
and colleagues (2017), who found side effects were better tolerated by individuals 
who had experienced past illness, suggesting that those who initiate treatment 
earlier, prior to sickness, may not have sufficient motivation to overcome them (Renju 
et al., 2017).  
Where evidence of the treatment’s effect is not clearly apparent, patients may alter 
the course of their treatment in order to evaluate its efficacy, for example through 
altering the dose or stopping medication to observe the resulting effects (Pound et al., 
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2005). Modification of the treatment regimen is particularly common when side 
effects are troublesome or when patients perceive the medication to be ineffective 
(Adams et al., 1997). Such experimentation has been seen within Option B+ in 
Malawi, where having few symptoms and no obvious benefits of treatment led some 
women to alter their regimens, comparing their health before and after interrupting 
treatment or adjusting their dose to test the treatment’s efficacy. Where there was no 
experienced physical difference between taking the treatment and not taking it, this 
could undermine motivation for engagement with treatment (Zhou, 2016). Conrad 
describes “non-compliance” as a form of “self-regulation”, whereby patients take 
control of their disease management (Conrad, 1985). Rather than there being two 
types of patient, adherent and non-adherent, or compliant and non-compliant, 
individuals’ perception of treatment can change over time, and many weave in and 
out of treatment (Zhou, 2016). 
Viral load tests may offer evidence of the effectiveness of ART, which could be 
particularly important within the context of Treat-all, where viral load monitoring 
results have been found to offer a means through which patients can monitor the 
progress of their condition (Pell et al., 2019). In fact, some argue that the need for 
accessible and affordable routine viral load monitoring is crucial for Treat-all 
implementation, in order to enable individuals to measure their health improvements 
(Renju et al., 2017).  
Until now, viral load monitoring has mainly been used as a tool through which to 
monitor adherence, rather than as a useful tool for patients’ self-management. Blood 
counts may be used as clinical evidence towards determining whether patients are 
maintaining their part of a therapeutic deal, at the expense of considering the 
everyday demands that can affect treatment-taking, when in fact viral suppression is 
a state that must be maintained, not a goal that needs to be reached (Paparini and 
Rhodes, 2016). Thereby viral load monitoring may be used as a form of surveillance 
and control, which Vale describes as being the ultimate “Panopticon”, prompting 
patients to take their treatment as prescribed or to risk discovery and reprehension 
(Vale et al., 2017).  
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Foucault highlights the ways in which care can provide an opportunity for control, 
as the receipt of care may involve submission (Foucault, 1979), illustrating an 
“inherent dialectic between care and coercion within systems of discipline”, and how 
those involved in “webs of discipline are also involved in appropriating, re-inventing 
and resisting techniques of power” (Vale et al., 2017, p.1288). If health care workers 
use their authority to control patients, they may thereby contribute to fashioning a 
form of subordinated therapeutic citizenship (Russell et al., 2015).  
The medicalised framing of Treat-all can produce pharmaceutical (Ecks, 2005; 
Persson, 2015) or therapeutic citizens (Cataldo, 2008; Nguyen et al., 2007), as people 
living with HIV appropriate ART as a set of rights and responsibilities (Nguyen, 
2005). Patients are co-opted into rigid conditions that determine treatment access and 
align their behaviour with what is deemed “appropriate” and “healthy” (Mattes, 
2011; Vale et al., 2017). Additionally, power is displaced from the nation-state, which 
becomes increasingly reliant on donor-funded programmes for sustaining ART 
provision (Whyte et al., 2013). As therapeutic citizens, people living with HIV become 
citizens of funded programmes over and above being citizens of their state (Colvin et 
al., 2010). Through ART provision, people living with HIV may gain increasing 
awareness of their own rights, which they can seek to extend to other areas of services 
beyond those relating to HIV (Biehl, 2007; Cataldo, 2008). 
Neoliberal biomedical approaches consider patients as physical, biological 
individuals whose health is their primary priority over which they have self-efficacy 
and volitional control, when in fact people are socially situated, with other aspects of 
their personhood (Whyte et al., 2013). Considering patients as “entrepreneurial, free 
and autonomous individuals capable of caring for themselves” (Beckmann, 2013) 
may be inappropriate in socially collectivist societies, where functioning social 
relationships are important for survival (Beckmann, 2013), and where the self is 
commonly conceptualised as an element of larger social units (Kielmann and Cataldo, 
2010). Neoliberal biomedical models view patients as consumers of a product, 
namely health care (Colvin et al., 2010; Whyte et al., 2013). Their relationships with 
health services are framed by contractual obligations and expectations which must 
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be upheld and fulfilled, also referred to as patient responsibilisation (Beckmann, 2013; 
Whyte et al., 2013).  
This approach does not consider people living with HIV as socially embedded, 
situated within a wider context and with other aspects to their personhood beyond 
the biomedical realm, and it does not acknowledge the demand and restrictiveness 
of treatment-taking routines. Treatment may become “the central organising 
principle” for people living with HIV (Stone et al., 1998, p.589), so overwhelming that 
individuals “no longer feel in control of their lives” (Pound et al., 2005, p.138). HIV 
care incurs a range of direct and indirect costs, including relating to the cost of 
maintaining health, accessing healthy food, and the time required to seek and access 
care (McGrath et al., 2014). People may have to balance the preservation of a 
“biomedical” self against a side effect free self that is able to work (Paparini and 
Rhodes, 2016). Treatment fatigue can also undermining treatment-taking, with 
participants in Uganda describing over time “becoming tired of ART” and taking 
“drug holidays” (Bukenya et al., 2019, p.4). Within Treat-all, increasingly individuals 
will be required to continue with treatment for longer periods of time, with 
potentially less embodied, experiential evidence of treatment effect. Therefore the 
burden of treatment and potential for treatment-taking fatigue may increase (Ayieko 
et al., 2018).   
Ownership and self-management 
Disease self-management refers to the “ability of the individual, in conjunction with 
family, community, and healthcare professionals, to manage symptoms, treatments, 
lifestyle changes and psychosocial, cultural and spiritual consequences of health 
conditions” (Richard and Shea, 2011, p.261). It involves a range of processes deriving 
from an individual’s work to sustain wellbeing, to incorporate illness and treatment 
into life and to maintain a positive worldview in the face of a health challenge (Russell 
et al., 2016a). Corbin & Strauss (1988) were the first to identify processes of self-
management within chronic illness, including tasks of medical management, 
behavioural management and emotional management. Within this thesis, I define 
self-management broadly based on three areas identified by Schulman-Green and 
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colleagues (2012): focusing on illness needs, activating resources and living with a 
chronic illness. I have explored adjusting to living with a chronic illness, and the 
identity work this may involve in the section above. What is of particular relevance 
here is the process individuals undertake to learn about their illness, to take 
ownership of their health needs, and to perform health promotion activities.  
Taking ownership of health needs involves tasks and skills relating to learning about 
and managing body responses (whether responses to treatment, other triggers, or 
general health changes in response to the condition), completing health tasks such as 
keeping appointments, and becoming an expert (Schulman-Green et al., 2012). 
Acquiring knowledge about HIV and ART can reduce uncertainty, offer hope, and 
provide individuals with inner strength to carry on, with the possibility of regaining 
control over health and life feeling attainable (Russell et al., 2016a). Self-management 
is a complex, dynamic and interactive process (Russell et al., 2016a). In order to 
integrate illness into daily life, individuals must modify their lifestyle, and may seek 
normality through balancing the pursuit of meaningful activities with the 
appropriate level of attention to their illness needs, with the process thus involving 
complex interaction between illness and life context (Schulman-Green et al., 2012).  
Prior to Treat-all, ART could enable a dramatic recovery of health, which could 
“transform subjectivities and create more empowered HIV patients able to self-
manage their condition in a disciplined way” (Russell et al., 2015, p.3; Russell and 
Seeley, 2010). This will differ in the Treat-all context, where the work required for 
disease management, which can be ongoing, difficult, expensive and demanding 
(McGrath et al., 2014), may require new motivations for self-management that are 
based on health preservation rather than recovery.  
Taking ownership of health needs includes developing confidence and self-efficacy 
for the condition and its treatment (Schulman-Green et al., 2012), which may be an 
important source of determination for motivating ongoing treatment-taking and 
engagement with treatment and care. As we have seen from the context of Option B+, 
where the decision to initiate ART is not intrinsically based, and where individuals 
may feel coerced to test and take treatment, this can influence their disengagement 
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from care (An et al., 2015; Wringe et al., 2017). These are important considerations for 
Treat-all, where maximising individuals’ capacity for self-management, ownership 
of health needs and ability to sustain longer-term treatment-taking and engagement 
with care may require that people living with HIV have sense of choice and readiness 
for treatment.  
In conclusion, this chapter has outlined the myriad of factors which could influence 
individuals’ engagement with HIV treatment and care in the context of Treat-all, 
considering existing theoretical, conceptual and empirical evidence relating to 
chronic diseases, HIV and asymptomatic treatment-taking. This chapter aimed to 
define concepts which are further explored and drawn upon in the latter chapters of 
this thesis, and to critically engage with the knowledge base from which I will 
examine individuals’ lived experiences with Treat-all in Eswatini. In summary, I have 
outlined the basis of HIV “normalisation” discourse in framing the Treat-all rationale 
and rhetoric, and considered how and why HIV may continue to be considered 
“exceptional” despite increased and earlier ART access. I define the theoretical basis 
to stigma’s conceptualisation, considering the ways in which HIV is particularly 
stigmatised and moralised. It remains to be seen how this may translate to the lived 
experiences of people living with HIV in the context of Treat-all in Eswatini, and how 
stigma may influence engagement with HIV treatment and care here, which I aim to 
explore in this thesis. 
I have considered the ways in which an individual may psychologically process and 
respond to an HIV diagnosis, and what this may mean in terms of their lived social 
context. There may be identity work required for an individual to adjust to the “new 
normal” of living with HIV, potentially necessary prior to engagement with care and 
influencing how an HIV diagnosis is processed. In the context of Treat-all, it remains 
unknown how individuals who do not feel unwell may reconcile with an identity 
which is stigmatised and socially devalued, with which they may not see themselves 
aligning, and how this may influence experiences of engagement with care. The 
literature suggests that the process of HIV status acceptance can support overcoming 
stigma and may be important for individuals’ engagement with treatment and care, 
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which can be undermined by the absence of symptoms, and which can require time, 
warranting exploration in the Treat-all context where the time between diagnosis and 
treatment initiation is expedited. Treatment decision-making processes can involve 
multiple encounters with multiple people and sources of knowledge, and it may be 
important for individuals to have experiential, embodied experiences indicating 
treatment necessity. This thereby indicates potential dissonance between the 
biomedical logic framing Treat-all, which assumes that individuals will adjust their 
actions once they are educated, and individuals’ conceptions of health and treatment 
need, which should be investigated.  
There are various perspectives regarding whether and why patient autonomy and 
choice may be important for engagement with HIV care, and on the potential 
influence of mechanisms of patient control and coercion, which I have reflected upon. 
There is the potential for conflict between the public health agenda and the individual 
right to choice within Treat-all approaches, which I will attempt to further consider 
within this thesis, including in terms of how differing priorities (for example of health 
services and individuals) may be reconciled. Finally, I have considered existing 
knowledge relating to how ongoing engagement in treatment and care may be 
navigated over time. For example, there is evidence suggesting the importance of 
patients’ having evidence of treatment effectiveness for motivating their treatment-
taking, and under previous treatment guidelines individuals could draw upon their 
illness histories prior to initiating ART to motivate continued treatment-taking. There 
may be need for adjustments to health management and motivation for ongoing 
treatment-taking in the Treat-all context.  
Next, I outline my study methodology, including the epistemological approach, and 
the methods that I adopted during this PhD research.  
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Chapter 3: Methodology 
Overview 
In this chapter, I outline my research approach in terms of the epistemological and 
theoretical influences which underpin it. I explain the approach taken for participant 
recruitment; for data generation through in-depth interviews, focus group 
discussions and observations; the approach to interpreting participant accounts; and 
data analysis. I describe the study setting of Eswatini, reflecting on information 
relating to the socio-political context in framing the research. I then describe how I 
applied the theoretical and epistemological approaches of this research through the 
methods that I adopted in the preliminary and main phases. Finally, I discuss the 
ethical considerations relating to various aspects of the research. The aim is to present 
the theoretical lens through which participants’ views and experiences relating to 
living with HIV and engaging with treatment and care in the context of Treat-all were 
explored and interpreted. This research primarily draws upon interview data from 
interviews with people living with HIV, including longitudinal, repeated interviews, 
and interviews with health care workers. The epistemological approach presented in 
the following section underpins the approach to data generation and analysis which 
follow.  
Epistemological approach 
It is important to identify and outline the epistemological approach that underpins 
research as this refers to what is taken to constitute knowledge and its justification 
(Carter and Little, 2007), and therefore influences the chosen methodological 
approach and how knowledge is constructed and interpreted. Epistemology can be 
defined as “a philosophical inquiry into the nature of knowledge”, including how 
beliefs are justified and what a claim to truth can be taken to mean (Alcoff, 1998). The 
positivist approach posits that “truth” can be objectively measured through value-
free research which treats social facts as existing independently of researcher and 
participant activities (Silverman, 2013). Positivist, experimental sciences are said to 
be “seen as the crowning achievements of Western civilisation, and in their practices, 
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it is assumed that “truth” can transcend opinion and personal bias” (Carey, 1988; 
Denzin and Lincoln, 2013, p4), presuming there is a stable, unchanging reality which 
can be studied with empirical methods of objective science (Huber, 1995). 
Non-positive traditions, on the other hand, view this as a narrow, reductive lens 
which does not consider the complexity of social reality, and the ways in which 
interpretations of experience can change and be re-evaluated in different 
circumstances or with different people (Schwandt, 2000). Qualitative research 
involves interpretive practices which aim to make the world visible through 
representation and description, and by exploring lived experience. Within 
interpretive epistemologies, the knower and known interact and shape each other, 
and there is no single interpretive truth (Denzin and Lincoln, 2013). Rather, the focus 
is on understanding the world from the point of view of its participants (Green and 
Thorogood, 2009). For example, how individuals diagnosed with HIV interpret and 
understand this diagnosis, and the meaning of treatment for those who do not have 
symptoms of HIV infection.  
This research aligns with the interpretive tradition, and draws upon 
phenomenological and feminist epistemologies. Phenomenology refers to the study 
of meaning of experience of a phenomenon for individuals (McCaslin and Scott, 
2003), aiming to examine the lived experience of a person or people in relation to a 
concept or phenomenon of interest, and how people make sense of this experience 
(Smith, 2004). This research is phenomenological in that the aim is to investigate the 
lived experiences of people living with HIV, and how Treat-all is interpreted, 
understood and experienced from the perspective of those affected by HIV and 
involved with Treat-all. Therefore, people living with HIV who engage with 
treatment and care services under Treat-all are the main focus of inquiry.  
Phenomenology stems from the work of Edmund Husserl (1970) and Maurice 
Merleau-Ponty (1962), with Husserl positing that human consciousness is the means 
through which to understand social reality. Alfred Shultz (1967) contributed to 
developing phenomenology, with his interest in exploring how people process 
experience in everyday life (the “lifeworld”), valuing the sympathetic understanding 
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of conscious experiences (Schutz, 1967). Phenomenology has also been linked to 
symbolic interactionism, which addresses how meanings are constructed by 
individuals during interactions with others, through social processes (Carter and 
Fuller, 2016; Denzin, 1987; Smith and Osborn, 2008). 
Phenomenology aims to understand and describe individuals’ experiences of their 
everyday world as they see it (Liamputtong, 2013), and to remain as faithful as 
possible to the phenomenon and the context in which it appears in the world (Giorgi 
and Giorgi, 2008). Phenomenology is intellectually connected to hermeneutics and 
theories of interpretation, combining an empathetic hermeneutics (trying to 
understand what it is like to be living with HIV and offered lifelong treatment from 
the point of view of participants) with a questioning one (critically examining 
participant accounts and asking questions relating to the nature of the account and 
the dynamics that produced it) (Smith and Osborn, 2008). The key focus is how 
individuals lived through and interpreted situations (Giorgi and Giorgi, 2008). In 
accordance with an interpretive phenomenological approach, I did not start this 
research with a predetermined hypothesis, rather I aimed to examine the experiences 
of people living with HIV with Treat-all broadly, taking an inductive approach to the 
generation of insights and findings. I then explored emergent findings in the context 
of existing knowledge and theories, which I explored, tested and investigated further 
as data generation progressed. I thereby adopted an iterative approach to generation 
and analysis, which aimed to remain as close to, and as reflective of, participants’ 
voices and perspectives as possible.  
Within this research I also draw upon feminist theories regarding knowledge 
production, valuing researcher reflexivity and considering the power relations that 
are implicated in various methodological approaches (Oakley, 1998). The impact of 
the social status and gender of the researcher, the “knower”, upon the production of 
knowledge are acknowledged and considered, including the intrinsic connections 
between values, politics and knowledge, and the unequal power relations implicated 
in theories of knowledge (see section of this chapter on power in the construction of 
knowledge) (Alcoff and Potter, 1993). I align with the feminist perspective that 
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research should be used in support of advocating for change in practice and policy 
(Campbell and Wasco, 2000; Deutsch, 2004; Harding, 1987; Oakley, 1998), aiming to 
generate findings which can inform improvements to service delivery to better align 
with individuals’ needs, and which can inform policy and practice relating to HIV 
treatment and care more broadly.  
Approach to participant recruitment 
I adopted a purposive sampling strategy, to include those most able to provide 
insight to the phenomenon being investigated (Marshall 1996).  This sampling 
approach aims to select information-rich cases for study in depth, to elucidate issues 
of central importance to the purpose of the inquiry (Patton, 2002). Therefore, people 
living with HIV in the context of Treat-all in Eswatini are the primary participant 
group, as these individuals can provide insight into their experiences being 
diagnosed with HIV and offered ART under Treat-all. Additionally, health care 
workers involved in Treat-all implementation and the delivery of HIV treatment and 
care within Treat-all can provide insight into the health provider perspectives on this 
topic, and health care workers can also draw upon experiences with a wider group 
of patients.  
The study population was stratified to examine particular sub-groups of theoretical 
importance (Guest et al., 2013), including age and gender. Additionally, sample 
selection aimed to enable exploration of a diversity of opinions (Guest et al., 2013), by 
including those with a range of different testing, access to care or treatment-taking 
experiences (for example those recorded as engaged with care, lost from treatment, 
or as diagnosed HIV positive but not accessing care). Sampling decisions fluctuated 
between the aims of covering as wide a field as possible with a range of different 
perspectives investigated, and of conducting analyses which are deep and rich (Flick, 
2014). 
Additionally, I adopted theoretical approaches to sampling, whereby the number of 
participants was decided based upon evidence of data saturation. This was 
determined based on the iterative process of data generation and analysis (see also 
section on data analysis), when adding further participants does not result in new 
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categories, themes or explanations relating to the topic of investigation (Glaser and 
Strauss, 1967; Marshall, 1996).  
Approach to data generation 
Various methods of data generation were adopted in this research, including in-
depth interviews, focus group discussions and observations. Using a variety of 
methods enables integration of participants’ accounts of phenomena, generated via 
co-produced interactions during in-depth interviews and focus group discussions, 
with the interactions, environment, meanings and context of the health services that 
are observed. The approaches that I adopted for each of these methods of data 
generation are outlined as follows.  
In-depth interviews 
I considered interviews as actively constructed narratives which reflect a particular 
time and space (Silverman, 2013). The interview itself represents a social encounter, 
which reflects the “local interactional contingencies in which the speakers draw from, 
and co-construct, broader social norms” (Rapley, 2001, p.303). As interviews are 
interactional events, the narrative and meaning is constructed jointly between the 
interviewer and interviewee (Gubrium and Holstein, 1997; Riessman, 2008; Seale, 
1999). With this in mind, and due to the language, racial and background differences 
between myself and participants, I decided it more appropriate for interviews with 
people living with HIV to be conducted by same-gendered siSwati speaking Swatis. 
Both were aged 30-40 years, educated (one having completed high school and one in 
the process of completing a university degree), and from the capital city, rather than 
being from the Shiselweni region where the research was conducted. This may have 
led to them being perceived by participants as having higher socioeconomic status. 
Reflections on this decision are elaborated in the Discussion Chapter (section: 
Interview dynamics and data co-production). One trained female researcher 
conducted interviews with women, and one trained male researcher conducted 
interviews with men. The decision to have same-gendered interviewers was linked 
to the patriarchal context in Eswatini, and the sensitive nature of topics being 
discussed, which included relationships, sexuality, sexual practices, and health. I 
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conducted interviews with health care workers, largely in English, or in siSwati with 
the assistance of an interpreter where participants felt more comfortable.  
As I was not present for interviews with people living with HIV, this created a certain 
level of distance from the process of co-construction, from the participants’ lived 
context and from the data. I therefore took steps to try to remain close to the data, 
including meeting several of the participants at the study finish to thank them for 
their time and to discuss the study findings. Living in the study context, and visiting 
communities within which people lived enabled me to have some familiarity with 
and understanding of the broader social context. I held debriefing discussions with 
the interviewer after each interview, with detailed field notes subsequently written 
up. These discussions included reflecting on the environment within which the 
interview was conducted, and as this was usually participants’ homes, a reflection on 
their home environment and their social circumstances. We reflected on the 
participant’s broader situation including their living environment, potential 
employment, and relationships. Additionally, we considered the interview 
dynamics, the methods that were adopted and how the participant might have 
perceived the interview and the interviewer.  
The in-depth nature of the interviews encouraged open discussions, and while being 
broadly based on topic guides (see Appendix 2), were flexible to participants’ 
language, narrative and allowed the order of topics discussed to develop naturally 
rather than following a prescriptive, structured order and flow. The interviewer was 
also familiar enough with the topic guide to be able to ask questions and probe 
conversationally (Oakley, 1998), which aimed to promote a more natural, informal 
atmosphere and to ease participants’ comfort. The style of interviewing that was 
adopted aimed to encourage participants to elaborate and provide detailed narratives 
of their experiences, or “thick descriptions” (Rapley, 2001), including the use of non-
verbal and verbal probing. This approach aimed to generate deep insights into 
participants’ understanding and interpretation of their social world (Arskey and 
Knight, 1999; Gubrium and Holstein, 1997; Roulston, 2010; Silverman, 2001). Oakley 
highlights the importance of a relationship of mutual trust and reciprocity between 
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the interviewer and interviewee (1981), which we aimed to achieve through rapport 
building before the interviews, and also through the longitudinal nature of repeated 
interviews.  
As data generation progressed, topic guides were adapted to further test emerging 
themes, in line with the iterative nature of data generation and analysis that was 
adopted (see section on data analysis), and likewise topic guides for the second and 
subsequent interviews with individuals were devised following analysis of the 
previous interview with each participant.  
Longitudinal, repeat interviews were chosen to assist with the development of trust 
and rapport between the interviewer and interviewee, aiming to enable access to the 
multiple layers of participants’ narratives, beyond that which is deemed to be socially 
desirable (and often closely linked to health messaging that is disseminated). 
Repeating interviews over time also aimed to gain insight into how individuals’ 
accounts of their experience with Treat-all may change over time. 
Focus group discussions 
Focus group discussions can facilitate an understanding of group norms, providing 
access to a wider variety of communications than one-to-one interviews (Kitzinger, 
1994) and a range of perspectives (Arskey and Knight, 1999), as well as providing 
access to the interaction between participants (Brocki and Wearden, 2006). Therefore, 
I decided to include certain focus group discussions within this research, to gain 
insight into socially normative accounts regarding HIV testing and access to HIV care 
in the context of Treat-all in Eswatini.  
While some sensitive issues may be more readily discussed in group settings, such as 
dissatisfaction with health service provision (Green and Thorogood, 2009), generally 
the group environment can inhibit certain people from talking about certain things, 
particularly for those who may feel hierarchically lower in status, and if a perspective 
or topic deviates from the group standards (Kitzinger, 1994). With this in mind, and 
also as confidentiality cannot be guaranteed within a group setting (the researcher 
cannot control whether other members of the group maintain confidentiality 
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regarding topics of discussion), I decided not to encourage personal disclosures, for 
example regarding HIV status, but rather to focus on general perspectives regarding 
HIV among community members in Shiselweni.  
Observations  
In this research, I draw upon ethnographic principles, recognising that it is important 
to understand, examine and consider the social contexts within which findings from 
interviews and other data sources are produced and used (Atkinson et al., 2001), and 
for researchers to actively witness the phenomena that is being studied in action 
(Adler and Adler, 1994).  
Qualitative observation is fundamentally naturalistic in essence, and draws the 
observer into the phenomenological complexity of the world, where connections and 
correlations can be witnessed as and how they unfold (Adler and Adler, 1994). It has 
been argued that all social research is a form of participant observation, as we cannot 
study the world without being a part of it (Hammersley and Atkinson, 1983). 
Participant observation reflects the inevitability of the researcher’s participation 
influencing what is observed (Flick, 2014). While steps may be taken to mitigate this 
influence, and to try to observe events in as “natural” a context as possible, it is still 
important to reflect upon this process within the research. Such observation aims 
towards an empathetic immersion in daily life and the meaning systems of those 
studied, which involves gaining access to and immersing oneself in the social world 
being investigated (Emerson et al., 2001).  
The observations offer a view to how Treat-all implementation may be experienced 
in practice, and to enable insight into the interactions between health practitioners 
and patients, the information shared, approach taken, and the communication style. 
This contextualises data generated in interviews and focus group discussions, and 
aids understanding of the health system and practitioner-patient relationships, 
including how these might influence patients’ experiences with Treat-all, as well as 
their accounts during interviews. 
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Data capture 
Interviews and focus group discussions were audio recorded following participants’ 
informed consent, which all participants agreed to. Detailed field notes were 
produced for each interview, capturing information on the interview arrangement 
and setting, reflecting on the specific time and space within which the interview data 
were generated, and reflecting on the interview dynamics and methods (including 
power dynamics and whether certain questions may have been misunderstood). 
Field notes additionally included a summary of the participant’s account, a reflection 
on emerging themes and areas to follow up on in future interviews, therefore 
supporting the analytic process beginning from the point of data generation.  
Following each interview and focus group discussion, audio recordings were 
transcribed verbatim, or transcribed and translated where conducted in siSwati, by 
the same researcher who conducted the interview. For translation, direct translation 
was used as much as possible, and equivalent translation where not possible to 
directly translate, which was indicated in the text. This approach aimed to maintain 
the meaning and integrity of participant’s accounts as much as possible. For data 
quality purposes transcriptions were then checked against the audio recording by a 
research assistant, and amended where discrepancies between the audio and 
transcript were identified.  
Approach to data analysis 
Data generation and analysis followed an iterative process, allowing for emergent 
concepts, and any potential discrepancies from majority themes, to be further 
explored (Corbin and Strauss, 2008). Topic guides for later interviews were adapted 
according to preliminary data analysis, supporting further exploration of emergent 
themes.  
Approach to interpreting accounts 
The positivist sciences view interview accounts and their interpretation as invalid 
and unreliable due to their subjective nature (Golsworthy and Coyle, 2001), and 
criticisms of qualitative research include that it is “soft” science, or unscientific, being 
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only exploratory and subjective (Denzin and Lincoln, 2013). However, the 
interpretivist tradition values interview data because it is subjective, and provides 
insight into how an individual evaluates, makes sense of, and accounts for their 
reality (Atkinson and Silverman, 1997). 
In this research, I consider interview data as a window through which to explore the 
ways in which participants try to make sense of their world, whereby the researcher 
is trying to make sense of the participants trying to make sense of their world (Smith 
and Osborn, 2008). Interview data are considered co-constructed, generating situated 
accounts that reflect a ‘locally produced subject’ (the participant) in relation to the 
interviewer, and reflecting the particular time and space within which the interview 
occurs (Roulston, 2010). I also pay attention to the researcher role, issues relating to 
the “outsider” or “insider” status of the researcher and how this might influence the 
type of account that is generated (Best, 2003; see sections in this chapter: Reflexivity; 
and Power in the construction of knowledge).  
Within this research I consider interview accounts as offering a view on how 
participants interpret and talk about their life worlds, rather than seeing them as 
offering a direct view to their experiences. Mazanderani and Paparini describe 
research interviews as “talking technology”, and as performative, rather than 
representative of people’s experiences of living with HIV (2015). In this thesis, 
interview accounts are taken to reflect how participants interpret and ascribe 
meaning relating to living with HIV and engaging with treatment and care when 
clinically asymptomatic, rather than as evidencing what participants actually do. 
Therefore changes in participants’ accounts, which may arise during longitudinal, 
repeat interviews, are not interpreted as a threat to data accuracy or validity, but 
rather offer insight to how perceptions and opinions can change over time, and 
according to circumstance (Walford, 2007). Changes in account offer an opportunity 
to gain insights into participants’ processing of an event or their circumstances, and 
to reflect on the interview-interviewee dynamic, as participants continually come to 
re-evaluate and re-position themselves within the interview setting.  
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Data analysis 
I adopt a primarily inductive approach to data analysis, with findings emerging from 
the data and aiming to remain grounded in participant accounts, rather than having 
pre-determined hypotheses to then test. Within this research, this followed a cyclical 
approach of examining emerging themes, re-visiting literature, and then re-visiting 
the data. The approach to data analysis was primarily thematic, using coding to 
identify emergent patterns, categories and concepts from participant accounts, and 
drawing upon principles of grounded theory (Bradley et al., 2007; Glaser, 1999; Glaser 
and Strauss, 1967), elaborated below. 
Initially I read and re-read interview transcripts, and applied open, descriptive 
coding, with the use of in vivo codes which mirrored the words of participants (e.g. 
“dirty blood”) where possible. This formed the initial approach to analysis in order 
to try to remain close to the data and to stay true to participants’ accounts, 
interpretation and description of events (i.e. avoiding my influencing data 
interpretation with my own pre-conceived ideas about the research or pre-existing 
knowledge from the literature). This approach aimed to ensure interpretations were 
grounded in participants’ accounts (Brocki and Wearden, 2006), and to distinguish 
between the participant’s original account and the analyst’s interpretation (Smith and 
Osborn, 2008).  
Following initial open, descriptive coding, I re-read and analysed transcripts, moving 
between concrete data and abstract concepts and between inductive and deductive 
reasoning (Merriam, 2009). On the basis of preliminary analysis of transcripts, I 
developed a coding framework, which I then developed and refined as analysis 
progressed. Initially, a subset of transcripts were analysed by myself and the two 
research assistants, and discussions were held to explore the differing interpretations 
and emergent codes from each analysis, which also contributed to the developing 
coding framework as I progressed with full data analysis. 
In drawing upon principles of grounded theory, I aimed to build theories inductively 
through data analysis by creating theoretical categories directly grounded in data 
(Charmaz, 2008), raising findings to an interpretive, conceptual level (Bradley et al., 
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2007; Glaser, 1999). However, I do not claim to have adopted a grounded theory 
approach in its entirety, as I recognise that it is not possible to fully “bracket off” pre-
existing knowledge and theoretical influence, which will influence my interpretation 
of data, and which helped to guide and situate analytic interpretations. For example, 
during the research process, findings relating to HIV status secrecy emerged. Many 
people living with HIV emphasised the importance of others’ not knowing their 
status, and the described impact this could have on their treatment-taking and 
engagement with care. Status secrecy was then explored further in subsequent 
interviews to try to understand why this appeared so important to individuals, and 
the implications they anticipated from having their status known, as well as to better 
understand how this affected their lives and influenced their engagement with HIV 
treatment and care services. During data analysis, extant theories relating to 
processes of stigma were drawn upon, as these enriched the interpretations and 
understanding of the findings, and further supported the development of theory 
grounded in participant accounts. 
The principles of grounded theory that I applied include constant comparison within 
and between cases, ascertaining patterns within the data leading to concepts about it, 
built into broader theoretical propositions, which can then be evaluated and tested 
with other comparison groups (Glaser and Strauss, 1967). Additionally, I paid 
attention to discrepancies from majority themes and exceptions within the dataset, 
recognising the unique opportunity these can provide for additional insight and 
understanding to the topic being investigated, as well as the importance of this for 
validity (Green and Thorogood, 2009).  
Analysis involved connecting emergent findings from different data sources, and 
exploring how these may confer or differ, particularly with how health care worker 
accounts compare to those of people living with HIV. This provides a fuller picture 
of the Treat-all experience, as these differing perspectives all have an influence on 
how services may be implemented, perceived and experienced. Potential 
contradictions were examined to consider meaning, and to reflect upon the different 
dimensions of narrated experience that these data sources and methods can capture. 
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Data generated through interviews and focus group discussions were integrated with 
the interactions, environment and health services that were observed, with 
observational evidence enabling participants’ accounts to be situated in the lived 
context. Using various methods of data generation was flexible and iterative, aiming 
to enable an in-depth, nuanced view to the topic being explored. 
Data analysis was manual, with use of Nvivo 11 as an analytic aid, which helped to 
organise the large volumes of data. Analytic memos were used to aid the 
development of analytic thought and to track its progress. 
In addition to the thematic analysis that I conducted, I also analysed interview 
transcripts using narrative methods, which aimed to reflect on the extended accounts 
of participants (rather than their fragmented thematic categories) (Riessman, 2008). 
This approach focused on participants’ stories and how these were told (Green and 
Thorogood, 2009), providing a richer, more detailed perspective of how participants 
narrated their experiences being diagnosed with HIV and offered treatment within 
Treat-all (Flyvbjerg, 2013).  
Reflexivity 
Sensitivity and paying attention to the ways in which the researcher(s) and the 
research process shape the data are a crucial part of qualitative research, and are 
inherent within the co-produced nature of data generation (Mays and Pope, 2000). 
The nature of research is recognised as co-constituted, jointly produced by 
participants, researcher(s) and their relationship, and reflexivity to this aims to 
examine how knowledge is actively constructed (Finlay, 2002). This can be done 
through bringing the researcher’s roles and actions into view, and taking into account 
the researcher’s construction of emergent concepts (Charmaz, 2013). Reflexivity in 
the form of “confessional accounts” have been common within anthropology and 
social science (Seale, 1999). However, this approach to reflexivity has been critiqued 
for being self-indulgent on the part of the researcher, and for displacing the focus of 
attention from the researched to the researcher (Finlay, 2002). Additionally, focusing 
on reporting researcher characteristics such as age, gender and ethnicity may appear 
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arbitrary, not necessarily adding meaning to analytic interpretations of benefiting the 
reader’s interpretation of such analysis (Brocki and Wearden, 2006).   
Some argue that a more useful approach may be to consider how a personal aspect, 
belief or worldview can influence data generation, analysis and contribute to broader 
research focus and findings (DeVault, 1997). In phenomenology, this can start with 
trying to make known and explicit pre-existing beliefs and conceptions, for example 
about the topic of investigation, so they can be “bracketed out” in order that the 
researcher is fully able to enter the participant’s view and understand their lived 
experience (Husserl, 1970). While it is unlikely that full “bracketing out” can be 
achieved, within this research I aimed to make visible the researchers’ influence on 
the data as much as possible. Beginning at the point of study conception and design, 
I reflected upon the questions asked and the approach to data generation and 
analysis, taking steps to actively remain as close as possible to participants’ accounts 
and to access alternative layers of participants’ narratives beyond those deemed to be 
socially acceptable. For example, through using repeat interviews over time and 
trying to have interviews in participants’ lived context where possible, and through 
the inductive approach taken to data analysis. At the start of the research (for both 
the preliminary phase and main, longitudinal phase), I facilitated a team session to 
discuss our views about the topic, including possible areas or findings we anticipated 
could emerge. For Treat-all, this included engaging with questions such as would we 
as individuals want to take lifelong treatment if we were diagnosed with HIV and 
did not have symptoms, why/why not? What concerns did we have about Treat-all, 
what benefits did we think it may bring? Also, what do we think about the concept 
of treatment as prevention? Making these views explicit enabled us to acknowledge, 
and then park them, trying not to let them influence our interactions with participants 
and the questions we might ask, but also then being able to explore their presence 
and influence where it did emerge through data analysis.  
Reflexivity was also taken in reflections following each interview, with the use of field 
notes and debriefing discussions, which included actively exploring and reflecting 
on interview dynamics and personal feelings about the interview process and the 
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topics which emerged. Consideration of what is being said, by who and in what 
context or circumstance included these reflections after each interview and also 
during data analysis, to explore the way participants referred to the researcher and 
the type of talk being generated.  
Through my experience with previous research in this setting, the potentially 
contradictory positions as qualitative researchers who are there to confidentially, 
non-judgementally and empathetically try to understand people’s stories and 
experiences, whilst at the same time being part of an operational research team 
attached to the health programme could pose challenges. For example, in the past I 
had noticed an association of the interviewer with the health services, as participants 
referred to the interviewer as “nurse”, and as some narratives appeared to closely 
reflect the health messages that were disseminated. It could therefore be challenging 
to access thoughts, views or accounts of experience beyond the surface level. I 
therefore implemented steps to try to minimise the association with the health system 
in this research, for example in the way the research was introduced, and our position 
as working alongside the health services but also independent from them, using 
language such as “we”/”they” when referring to the health services and reiterating 
confidentiality. The longitudinal approach with repeat interviews also seemed to 
help in building a relationship with participants and gaining trust and rapport. 
However, the researcher will likely have been perceived in a certain way, which 
could influence the data and the account generated.  
As I was working as a researcher within the MSF project in Eswatini during the 
period of this research, my positionality as a member of the project team may have 
influenced the research process. I regularly reported and shared research findings 
with the project and other stakeholders, and also aimed to confidentially and 
impartially interview health care workers and understand their experiences, which 
may have been perceived as contradictory. Initially certain health care workers 
appeared to perceive my role as evaluating their performance, for example during an 
observation of counselling sessions a counsellor said that I was there to see if they 
shout at patients. Building rapport, explaining the purpose of the research, interviews 
85 
 
and observations, and emphasising the measures adopted to protect confidentiality 
(including anonymity and use of pseudonyms) did appear to reassure health care 
workers. Interview discussions were open, lengthy and in-depth, with health care 
workers openly sharing challenges they face in their work. However, my 
positionality is likely to have influenced the nature of discussions and may have 
dissuaded certain health care workers from sharing critical views or accounts that 
could be perceived as less socially desirable.  
The decision for interviews with people living with HIV to be conducted by same-
gendered siSwati speaking Swatis, may enable access to an “insider” perspective, and 
particularly where participants were of a similar age and socio-economic (including 
educational) background, this sense of shared understanding could lead to in-depth, 
open, rich descriptive narrative. For example, in Best’s (2003) work in an interracial 
context (where the interviewer is a white woman and the interviewees are black 
women), she examines the interactional nature of the interview in which race 
meanings are constructed. Here language indicated presumed difference and an 
“outsider” status of the researcher, which also allowed exploration of what taken-for-
granted statements or concepts may mean for the interview participants (Best, 2003). 
Power in the construction of knowledge 
In line with feminist approaches to research, in this research I aim to minimise and 
mitigate unequal power relations between the interviewer and interviewee as much 
as possible (Alcoff and Potter, 1993; Harding, 1987). However, I also recognise that it 
is not always possible to mitigate power dynamics (Oakley, 1981; Roulston, 2010). It 
is therefore important to attempt to bring these to consciousness and to actively 
engage with the ways in which power may influence the co-created data. As taking 
responsibility for the reproduction of power may be more possible than equalising 
power, for feminist researchers this involves considering ways to reciprocate the time 
given by participants (Skeggs, 2001). This is linked to the decision in this research to 
reimburse participants with a small financial contribution towards their time, and 
with refreshments provided at each interview and focus group discussion.  
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The epistemological recognition that all knowledge is situated, partial, contingent 
and interpretative underpins this research, and the researcher and participants form 
a collaborative, reciprocal quest for understanding (Skeggs, 2001). However, I also 
acknowledge that while steps towards collaboration and consideration of power are 
adopted, the research project is ultimately that of the researcher, and offers my 
interpretation and voice in addition to trying to reflect the voice of participants 
(Skeggs, 2001). In the Discussion Chapter (section: Reflection on the approaches taken 
within the research) I further reflect on how power dynamics may have influenced 
the data and findings that emerged from this research. 
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Study context 
The Kingdom of Eswatini is the last remaining absolute monarchy in Africa, with 
King Mswati III in power since 1986 (Figure 3.1). Eswatini has a dual monarchy, and 
the king (referred to as Ngwenyama meaning lion), represents the father of the nation, 
ruling alongside the queen mother (Ndlovukazi meaning lady elephant), who 
represents the mother of the nation, with an undefined delicate balance of power 
between the two (Matsebula, 1976). While all powers centre on the dual monarchy, 
the use of such powers are restrained by their relationship, by officials whose 
positions depend upon maintaining the monarchy rather than supporting a 
particular king, by the local government system and councils of state (Kuper, 1986). 
The king is responsible for the distribution of land, and he and the queen mother 
share powers of rainmaking that are necessary for ensuring the fertility of the land 
(Booth, 1983). A king’s successor is not known during the king’s lifetime, but is 
chosen based on the Royal Family Council meeting after the death of a king, by 
deciding upon who among the queens will be the queen mother, with her son then 
assuming the heirship (Matsebula, 1976).   
 
 
 
 
 
Figure 3.1: Photos depicting King Mswati III (left) and the annual Umhlanga ceremony (right) 
Britain formally controlled the administration of Eswatini from 1903 until 
independence in 1968, governing the country through the Transvaal in neighbouring 
South Africa. However, the order-in-council did not define or declare the official 
status of Eswatini in relation to Britain, so some argue that Eswatini was not legally 
a “protectorate”, “colony” or “possession” of Britain during this period (Matsebula, 
1976). Eswatini was not conquered by force, and the political system was allowed to 
 
Photo credit: Claire Elise Burdet  Photo author’s own 
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continue under the British administration (Kuper, 1986), with the arrangements 
including an expressed respect for Swati law and custom (Matsebula, 1976). 
However, there was a longstanding dispute regarding land concessions which 
predated this period. These concessions, pushed by the British and the Boers, have 
been described as “economic weapons representing a type of warfare beyond the 
traditional system…. [that included] laws of land ownership that clashed with rights 
of customary usage… the commerce and banking of an expanding capitalist 
economy” (Kuper, 1986, p.13). 
King Mbandzeni (reign 1875-1889) asserted that he had not sold the land within such 
concessions, but had simply leased it. However, what has been termed fraudulent 
activity relating to concession claims led for a push towards two-thirds to one-third 
land division, whereby Swatis would only have one-third (Matsebula, 1976). There 
were political killings among the aristocracy regarding the concessions controversy, 
and by 1893, sales in the UK from companies based on acquired concessions 
capitalised at £2 million (Booth, 1983). Many native Swati lived on European-owned 
land and had to perform arduous unpaid services to landowners in order to be able 
to stay there (Marwick, 1940), thus highlighting the historical race and power 
dynamics that were present. In 1946, although European people comprised just 1.66% 
of the population, they owned around half the land, with all major advances in 
mining, agriculture, industry and commerce being concentrated in these areas, and 
schools were racially segregated until 1961 (Kuper, 1986).  
Eswatini is a small, mountainous country with a population of 1.2 million people. 
Although classified as a lower middle income country, 60% of the population lives in 
poverty, of which 38% are in extreme poverty, and income inequality is high (The 
World Bank, 2018). Historically, the traditional way of life is rural and revolves 
around subsistence farming, with crops including maize, millet, sugar cane and 
pumpkins, normally grown in the gardens of familial homesteads (example 
homestead see Figure 3.2). Food supplies tend to vary seasonally, and many live at a 
precarious subsistence level (Kuper, 1986). Cattle are the most important livestock, 
and cattle are attributed to wealth and power (Marwick, 1940). The majority of Swatis 
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live on Swazi National Land, which is the property of the nation, held by the king in 
trust and distributed to citizens through chiefs (Matsebula, 1976). Rights to land are 
secured by allegiance and usage, rather than through purchase or rental, and 
therefore, wealth generated through such land is communal, and the system 
strengthens citizens’ ties to the monarchy (as well as strengthening its power). 
Historically, citizens who were deemed to have too many wives or cattle (measures 
of wealth) were judged as “evil doers” with potential for suspicion of witchcraft and 
the death penalty. Land rights and fear of witchcraft can prevent economic enterprise 
and restrain the ambition and ability of citizens (Kuper, 1986; Marwick, 1940). 
 
Figure 3.2: Photo depicting an example Swati homestead 
The influx of Europeans and the introduction of money into a primarily subsistence 
economy created the necessity for other sources of income and opportunities, which 
challenged the traditional way of life in Eswatini (Marwick, 1940). Advancement was 
seen as unanimous with education, and increasingly educated individuals sought 
jobs in urban areas (Booth, 1983). In 2018, the main land use in Eswatini was still 
pastoral, as well as timber forest (Central Intelligence Agency, 2018). Limited 
economic opportunity and high unemployment have resulted in widespread 
dependence on labour migration, with the majority of migrant labourers travelling to 
neighbouring South Africa for work, including in the mining industry, with such 
labour migration attributed as increasing HIV transmission risks between partners 
(Corno and de Walque, 2012; Hickel, 2012). 
Photo author’s own 
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Traditionalist and conservative values are emphasised in Swati society, with these 
ideals being consciously promoted as the “guiding ideology of the nation” (Booth, 
1983, p.34). Respect and politeness are considered important, generosity can be seen 
as the hallmark of achievement and the primary virtue of buntfu (humanity) (Kuper, 
1986, p.30), and Swatis are a peaceful people. The Swatis were one of the few 
powerful Bantu tribes whose relations with Europeans did not lead them into war, 
which is seen to partly stem from a powerful tradition against fighting the settling 
white people, as led by Sobhuza I, and subsequently reinforced by his successor 
Mswati II. It is said that as the Europeans were never fought, the Swati were never 
conquered by them (Matsebula, 1976). As society becomes increasingly 
industrialised, urbanised and with increasing education, many of the traditional 
social values are being questioned and at times challenged (Booth, 1983).  
The importance of social collectivism in Swati society is reflected in the southern 
African concept Ubuntu, which is a philosophy of humanity revolving around lived 
community and respectful, caring relations with other living beings and the 
environment (Seehawer, 2018). It is based upon primary values of intense 
humanness, caring, sharing, respect and compassion (Tarkang et al., 2018), and 
structures individual consciousness in communitarian terms, serving as an 
indigenous knowledge system and a collective identity (Root et al., 2017), where the 
group is prioritised over the individual (Fassin, 2007).  
Christianity was introduced to Eswatini in the nineteenth century, with the first 
chapel and missionary being built in Shiselweni in 1845, where missionaries began to 
convert Swatis to Christianity, alongside providing broader education (Matsebula, 
1976). Christianity is now embedded in society, blending with traditional religion in 
multiple ways (Golomski, 2014). In 1921, 4% of the Swazi population was listed as 
Christian (Booth, 1983), which subsequently increased dramatically, and in 2018, 90% 
of people in Eswatini were said to identify as Christian (Central Intelligence Agency 
2018). Traditional religion in Eswatini is spiritual, and recognises a higher power as 
well as the influence and power of ancestors (Kuper, 1986; Matsebula, 1976). Now 
many Swatis belong to African Independent Churches, some of which follow Zionist 
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denominations, emphasising divine healing and prophecy, and which may combine 
Christian dogma and liturgy with traditional spirituality and custom (Booth, 1983; 
Kuper, 1986). To explore matters relating to the spiritual world, and in situations 
requiring deep, esoteric knowledge, 
tinyanga (traditional medicine 
practitioners, see Figure 3.3) and/or 
tangoma (diviners) may be consulted by 
individuals (Kuper, 1986), and sickness 
may be regarded as resulting from 
spiritual causes rather than natural or 
physiological (Marwick, 1940).  
Figure 3.3: Photo depicting example tinyanga materials 
Swati society is patriarchal and patrilineal, with the patriarchal headman being in 
control of the homestead, his prestige being enhanced by the size of his family, and 
with men holding the superior, stronger position socially, politically and legally 
(Kuper, 1986; Marwick, 1940). Predominant socially constructed gender values 
celebrate concepts of masculinity connected to physical strength, power and sexual 
potency, which may be demonstrated through men having multiple sexual partners, 
and relationships within which condom use can be seen to reduce this potency or 
strength, as well as reducing pleasure (Ruark et al., 2016). A very high proportion of 
Swazi girls experience violence and abuse, with 33% having experienced sexual 
violence, 25% physical violence, and 30% emotional abuse by the time that they are 
just 18 years of age (UNICEF, 2007). Violence against women causes additional 
vulnerability for HIV, and women who experience violence are one and a half times 
more likely to become infected with HIV than those who do not (UNAIDS, 2018). 
Uptake of male circumcision amongst Swati men is low, with 26.7% of males aged 15 
years and older having undergone medical circumcision (Swaziland Ministry of 
Health, 2017). Low uptake has been attributed to the perceived threat circumcision 
poses to masculinities and sexual pleasure (Adams and Moyer, 2015). 
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This study is based in the predominantly rural southern region of Shiselweni. Here, 
subsistence farming is widely practiced, and the region has been particularly affected 
by drought in recent years, which has caused food insecurity (Root et al., 2017). 
Health care is primarily delivered through decentralised services, with two 
secondary health facilities (in Nhlangano and Hlatikhulu), and several primary 
health clinics (Figure 3.4). This PhD research is primarily based in Nhlangano health 
zone, which has eight primary health care clinics offering integrated HIV services, 
and one secondary facility, which offers HIV care within a specific HIV-related care 
department, as well as being included within antenatal care.   
 
Figure 3.4: Photo depicting example health facility in Shiselweni 
 
  
Photo credit: Claire Elise Burdet 
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Methods 
Study design 
A longitudinal, prospective qualitative study design was adopted in order to examine 
the lived experiences of people living with HIV, and their engagement with HIV 
treatment and care services in the context of an MSF/MoH Treat-all pilot in the 
Shiselweni region of southern Eswatini.  
This research comprised of an initial phase of data generation and analysis, which 
focused on examining individuals’ experiences with HIV testing, diagnosis and 
linkage to HIV care, hereby referred to as Phase 1. Data for phase 1 were generated 
in February to May 2015, through one-time in-depth interviews with people living 
with HIV and health care workers, and focus group discussions with community 
members. Preliminary analysis was conducted during data generation, with more 
extensive analysis being performed from September 2015, and subsequent write-up 
and manuscript submission in March 2016. The methods adopted for phase 1 are 
presented in the following section (Phase 1: Linkage to HIV care), and the results from 
phase 1 are presented in Chapter 4.  
The main phase of the research began in August 2015, with participant recruitment 
and data generation through repeat interviews with people living with HIV from 
August 2016 to September 2017, one-time in-depth interviews with health care 
workers in March to April 2017, and formal observations of community and clinic 
activities in August to September 2015, and in March 2016. The results from the main, 
longitudinal phase of the research are presented in Chapter 5, 6 and 7. I was primarily 
based in the study setting of rural Eswatini from February to May 2015, and from 
August 2015 to November 2017, which also provided greater contextual familiarity 
and understanding. Table 3.1 shows a detailed timeline of research activities.  
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Table 3.1: Time line of research activities (data generation and analysis) 
 
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Jan Feb Mar Apr
Field visit, observations
Data generation:
 - One-time interviews with PLHIV
 - One-time interviews with HCW
 - FGDs with community members
 - Repeat interviews with PLHIV
Preliminary data analysis
Feedback/dissemination findings
Extensive data analysis
Write up 
Chapter 4 paper submission
Chapter 5 paper submission
Chapter 6 paper submission
Chapter 7 paper submission
2015
Activity
20172016
Int. 3Int. 2Int. 1
2018 2019
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Phase 1: Linkage to HIV care 
Phase 1 of the research focused on examining the experiences of individuals who 
were diagnosed with HIV through the MSF/MoH provided community-based HIV 
testing services in Shiselweni, Eswatini, in particular exploring factors influencing 
their linkage to HIV care. Data were generated through interviews with people living 
with HIV and health care workers, and focus group discussions with community 
members. Linkage to care was defined as attendance at a specified referral facility 
and registration in the pre-ART or ART register within six months of the HIV test 
date. This phase of the study relates to the first research objective. The following 
sections outline the participant sampling and recruitment strategy that were adopted, 
and the methods of data generation and analysis used for this phase of the research.  
Phase 1 sampling and recruitment strategy 
Community members who were diagnosed HIV positive between June and 
November 2014 were identified for recruitment to the study, having been tested 
through the community-based HIV testing services provided by MSF with the MoH. 
The community testing register was used to sample participants, which records 
details of all individuals who are tested for HIV, including their contact and testing 
information. The initial sample was stratified to include those linked to care (using 
the recorded pre-ART or ART enrolment date) or not (no pre-ART registration 
recorded within 6 months of diagnosis). Individuals were then purposively selected 
to include an equal gender balance and range of ages, and a mix of rural and urban 
dwellings. Identified participants were contacted by telephone by a member of the 
research team with information about the study, requesting their participation in an 
interview at a time, date and location convenient to them.  
Health care workers were identified to include those employed in a range of positions 
involved in delivering HIV testing services, and HIV treatment and care services, and 
who could therefore provide insight to their experience offering HIV testing and 
supporting individuals’ diagnosed HIV positive to process their diagnosis and link 
to HIV care. This included members of the MSF community-based HIV testing team, 
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clinic-based HIV testing staff, nurses, and then-named “expert clients” (now referred 
to as adherence counsellors; HIV positive lay counsellors involved in post-test 
counselling, pre-ART sessions and assessing patients’ readiness for ART). All health 
care workers who were invited to participate in an interview agreed to do so, leading 
to a sample of 11.  
Community members of unknown HIV status were identified through community-
based adherence counsellors, so their views on HIV testing and access to treatment 
and care for HIV positive individuals could be explored and understood. Six to eight 
members were recruited for each focus group discussion, of the same gender and 
aiming to recruit those of a similar age, with three focus group discussions were held 
in total. Table 3.2 shows participant information.  
Table 3.2: Preliminary phase participant information 
Participant information Number of participants 
All people living with HIV 28 
Recorded linked to care 14 
Recorded not linked to care 14 
Total women 
- 16 to 24 years 
- 25 to 34 years 
- 35 to 44 years 
- 45 to 69 years 
14 
3 
4 
4 
3 
Total men 
- 16 to 24 years 
- 25 to 34 years 
- 35 to 44 years 
- 45 to 69 years 
14 
2 
4 
3 
5 
All health care workers 11 
HIV testing counsellor – clinic based 3 
HIV testing counsellor – community based 6 
Nurse 1 
Adherence counsellor 1 
All community members 19  
Group discussion 1 – women (aged 17-39 years) 6 
Group discussion 2 – men (aged 16-30 years) 6 
Group discussion 3 – women (aged 19-24 years) 7 
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Phase 1 methods of data generation and analysis 
Interviews were undertaken with the aim of exploring the ways in which experiences 
with HIV testing, and receiving an HIV diagnosis may be processed, interpreted and 
understood, and the factors which may influence linkage to HIV care in the context 
of Treat-all. Interviews with health care workers aimed to explore perspectives on 
HIV testing, diagnosis and linkage to care. Focus group discussions with community 
members explored attitudes, views and beliefs surrounding HIV testing and access 
to HIV treatment and care in this context 
Interviews with people living with HIV were held at the individual’s home, a private 
room within the health clinic or a private room within the project office. These were 
conducted in siSwati by same-gendered Swati researchers, bar one interview with a 
man which was conducted by a woman. There were some challenges with interview 
technique and several of the interviews were shorter and less open or in-depth than 
hoped. This was particularly apparent in interviews with men recorded as not linked 
to care, which averaged 30 minutes, compared to nearly 60 minutes for women. For 
those recorded linked to care the interview length was more similar, with mean 45 
minutes for men and women. On reflection and analysis of data, it was felt that this 
was likely linked to an issue with interview technique rather than reflective of “not 
linked” men’s accounts more broadly, and additionally an interview conducted with 
a “not linked” man by a woman was 75 minutes long. However, it would be difficult 
to definitively draw conclusions about this, as it could have been influenced by a 
myriad of factors. The author provided ongoing training and support for 
interviewing techniques, and regular team meetings were held to discuss and reflect 
on interviews and potential opportunities for probing and encouraging further 
discussion and open narratives. The use of open probes was encouraged, including 
non-verbal such as nodding, use of silence to encourage elaboration, and “mmhmm”, 
as well as questions such as “how did that make you feel?”, “what thoughts went 
through your mind at that time?”, “could you tell me more about that?”. 
Health care worker interviews were conducted by the author, with the majority being 
held in English (n=9), or in a combination of English and siSwati with the assistance 
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of an interpreter (n=2) when preferred by the participant. These interviews were held 
in the clinics where each health care worker was based, during working hours, and 
averaged 50 minutes.  
Focus group discussions were co-facilitated by a Swati research assistant and myself, 
with the assistance of an interpreter. These discussions (n=3) averaged one hour and 
40 minutes, and were based on topic guides with an ice breaker activity at the start 
(see appendices for example topic guide).  
Data were analysed thematically, drawing upon principles of grounded theory (as 
outlined in section titled: Approach to data analysis above), and using Nvivo 10 as 
an analytic aid.  
Main phase: Longitudinal study 
The main, longitudinal phase of research investigating people living with HIV’s 
experiences engaging with HIV treatment and care in the context of Treat-all in 
Eswatini began in August 2015.  
The approach to participant recruitment and the data generation tools were initially 
piloted with four women. This enabled adaptation of participant recruitment, study 
introduction and the life history interview tool (see sections on participant 
recruitment and data generation below). Following this pilot, repeat interviews with 
people living with HIV were conducted from August 2016 to September 2017 (all but 
one conducted by June 2017; see Table 3.3). I conducted health care worker interviews 
in February to March 2017, and observations of clinic and community activities in 
August-September 2015 and March 2016. 106 interviews were conducted in total, and 
13 days of formal observations.  
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Table 3.3: Interview outline for people living with HIV participants 
Interview Date range No. of 
participants 
No. of 
meetings 
1 – Life history, family and 
relationships, hopes and 
aspirations, key life events 
22/08/16 – 31/10/16 30* 33 
2 – HIV testing, diagnosis, 
treatment offer and treatment 
initiation decision-making 
17/11/16 – 07/02/17 29 31 
3 – Living with HIV, ongoing 
treatment-taking and 
engagement with HIV services 
25/03/17 – 08/09/17 26 27 
*Certain interviews were conducted over more than one meeting, for example due to length 
of discussion and available time. 1 participant was lost to follow up after the first interview, 
attempts were made to contact her but she was not available to arrange another meeting. 3 
participants completed 2 interviews and 1 completed 4 interviews.  
Sampling strategy  
The sampling frame used for participant identification and recruitment was the 
project patient database for the Treat-all pilot. This was reviewed in April 2016, and 
an initial sample was prepared that included individuals enrolled into HIV care 
under Treat-all between the start of the pilot (October 2014) and the end of the pilot 
(31 March 2016), for potential recruitment to the longitudinal qualitative study. On 
reviewing the patient database, I selected potential participants to include only those 
recorded as newly diagnosed with HIV at enrolment to care under Treat-all (within 
6 months of enrolment, the majority of whom were diagnosed within 1 month of 
enrolment). I also selected participants who were registered as having WHO disease 
stage 1 and a CD4 count ≥500 at time of enrolment to HIV care, and who therefore 
would be considered clinically asymptomatic and otherwise ineligible for treatment 
according to national treatment guidelines in place at the time.   
After selecting potential participants on the basis of these criteria, the sample was 
then stratified for gender and age, to include men and women, young adults (aged 
16 to 25 years) and adults (aged 26 to 49 years). Sample selection also aimed to enable 
exploration of a range of treatment-taking experiences, and therefore those recorded 
as initiating ART the same day as diagnosis, those recorded lost from treatment (LFT), 
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those enrolled to care at the beginning of the pilot (October to December 2014) and 
those enrolled more recently (January to December 2015 and January to March 2016) 
were purposively selected. LFT was defined as those whose last visit date was 4 
months ago or more from time of study recruitment (those considered LFT had last 
clinic visit date before 30th November 2015). 4 months was chosen as many patients 
stable on ART have 3 monthly refill appointments. 
Sample selection reflected the fact that more women than men were enrolled in the 
Treat-all pilot, there were also very few potential young men due to the epidemiology 
of HIV in Eswatini (i.e. there are more young women newly infected with HIV than 
men), and men often access care later in this context. It was therefore expected that 
the sample would have less men than women, and the goal was a gender balance that 
reflected the epidemiology of HIV in Eswatini, rather than an equal one. I also 
decided to not stratify the sample to young men if there were less than five young 
men available to recruit from, in order to protect individuals’ confidentiality, and as 
it would be difficult to draw analytic conclusions from a small participant sub-group.  
Health care worker participants were identified and recruited to include those from 
all of the nine clinics involved in the Treat-all pilot (Nhlangano health zone), both 
MoH and MSF staff, and a range of different treatment and care-related positions 
(such as adherence counsellor, nurse, nurse supervisor and doctor).  
Participant recruitment 
Once potential participants were identified for recruitment to the study, names and 
phone numbers for these individuals were obtained by looking up individual patient 
files at their respective clinic using their unique identifiers (ART number, as the Treat-
all patient database only included confidential patient information including ART 
number and date of birth but not full name or contact information). All people living 
with HIV enrolled to the Treat-all pilot had consented to being contacted for 
invitation to participate in a qualitative interview at the time of their consenting to 
Treat-all pilot participation. However, as this was up to two years ago for some 
individuals, many did not remember having consented, which we initially 
discovered during the pilot phase of participant recruitment.  
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During the pilot phase, an approach to recruitment was tested whereby adherence 
counsellors at each clinic were approached to act as the gatekeeper, contacting the 
identified individuals themselves in the first instance to briefly introduce the study 
and ask for the individual’s permission for someone from the research office to 
contact them to discuss further. Following the pilot, I decided not to continue with 
this approach. It proved difficult to implement in practice, was time consuming, and 
it may have also influenced the quality of interview interactions and the data 
generated, as participants appeared to associate us with the health programme due 
to the initial introduction coming from a member of staff at the clinic. Practical 
difficulties that we faced adopting this approach included issues such as adherence 
counsellors not being provided with airtime to call clients unless for “defaulter” (LFT) 
tracing, in which case they had to log all such calls, and there were therefore questions 
around affordability of their calling patients on our behalf. Logistically we were not 
able to provide additional airtime to all of the adherence counsellors who would be 
involved in contacting potential participants from each clinic. Additionally, the 
process of preparing a shortlist of potential participants to contact, giving this to the 
adherence counsellor from the relevant clinic, subsequently following up and 
reminding the adherence counsellor and seeking feedback from the calls, and having 
to prepare an additional list of participants if the initial calls were unsuccessful 
(including if the number was incorrect or unavailable, or if the patient did not 
answer) added several additional steps to the process of recruitment than if we were 
to contact patients ourselves directly, and was fairly time consuming. Adherence 
counsellors had made suggestions that we instead contact some of the “good” 
patients that they had more regular contact with and felt it would be easier to engage, 
which we were concerned may influence the study, particularly as we wanted to 
purposively try to include those “harder to reach” and LFT. As this approach to 
recruitment did not seem to improve the quality of interviewer-interviewee rapport, 
of the data generated, or add ethical value to the recruitment process, we therefore 
decided not to continue with this approach to recruitment following the pilot.  
Therefore, we subsequently decided to adapt the approach to contact potential 
participants directly, with research assistants’ briefly outlining the research and 
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seeking consent to meet in person to discuss further, or to proceed with an interview 
if they were comfortable doing so.  
Contact history 
The strategy employed for contacting individuals was to call the number listed from 
their patient file first, and if unsuccessful, to then contact the listed treatment 
supporter. When contacting the treatment supporter care was taken to avoid 
potential deductive disclosure, as although this person had been selected and 
provided to the clinic by the individual, we did not want to make assumptions 
regarding what individuals had chosen to disclose, and it was important to avoid risk 
of potential harm. If these were both unsuccessful, in certain instances we then 
contacted the clinic adherence counsellor to ask if they had any other means of 
contacting these individuals, such as an updated phone number.  
Fifty four percent of individuals who were contacted to invite participation were 
unidentifiable due to their listed number being unavailable or incorrect. 64% of those 
contacted agreed and participated, 18% silently refused (agreeing to meet and not 
attending the arranged appointment, further reflected on in the Discussion Chapter, 
section: Ethical dilemmas ), 10% were out of the study region, 4% were unwell and 
unable to meet, and 4% did not have time due to work commitments (Table 3.4).  
Table 3.4: People living with HIV participant contact history 
Participant contact history information Number of individuals (%) 
All women attempted to reach 78 
Contactable 31 (40%) 
Uncontactable 47 (60%) 
Agreed and participated 20 (26%) 
Silent refusal 4 (5%) 
Out of study area/region (e.g. South Africa) 5 (6%) 
Unwell and unable to meet/talk 2 (3%) 
All men attempted to reach 31 
Contactable 19 (61%) 
Uncontactable  12 (39%) 
Agreed and participated 12 (39%) 
Silent refusal 5 (16%) 
Refusal due to work commitments – no time 2 (6%) 
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For recruitment of health care worker participants, the MSF head of clinical activities 
was first point of contact, as it was important to respect organisational hierarchy of 
communication and to fit in with established procedures within the project. He 
would therefore make initial contact with each of the clinics and would introduce me 
to staff there, for me to then arrange a convenient time to come back to conduct 
interviews with various individuals. Interview appointments were then arranged in 
consideration of what was convenient for each health care worker, as well as project 
logistics such as car movement schedules for visiting each clinic (some clinics were 
up to 2 hours’ drive away from the project office).  
All health care workers who were approached and invited for interview agreed to 
take part. Arranging interviews at one privately funded clinic proved more 
challenging than the other clinics, with one health care worker discussion being 
informal (rather than a recorded interview), one interview quite brief as this 
individual had limited time available, and one longer (with an MSF employed 
member of staff there).  
Study participant information 
The final sample included 30 people living with HIV, 29 of whom were interviewed 
two to four times, and 20 health care workers, who were interviewed once (Table 3.5).  
As described in the earlier section on the approach to participant recruitment, the 
number of participants was decided based upon evidence of data saturation, with an 
iterative process of data generation and analysis. I interpreted data saturation as 
being evidenced when adding further participants did not appear to generate new 
findings relating to the topic of inquiry. For people living with HIV, this was 
determined based on analysis and reflections on findings emerging from the first 
interview with participants. I also considered the risk of attrition between first and 
repeated interviews, with a sample of 30 individuals aiming to allow for the potential 
for some participants to be lost between interview phases.   
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Table 3.5:  Main research phase participant information 
Participant information* Number of participants 
 
All people living with HIV  30 
Treatment-taking category: 
On ART 18 
Lost From Treatment  12 
Enrolment period: 
Early (Oct 2014 – Mar 2015) 13 
Mid (Apr 2015 – Sep 2015) 12 
Late (Oct 2015 - Mar 2016) 5 
Gender and age: 
Women 
• Young women (17-25 years; 
average 21) 
• Adults (26 to 46 years; average 
33) 
18 
9 
9 
Men 
• Young men (16 to 25 years) 
• Adults (26 to 49 years; average 
37) 
12 
0 (none eligible in patient cohort**) 
12 
All health care workers 20 
Position: 
Nurse supervisor 5 
Nurse 8 
Adherence counsellor 5 
Doctor 1 
Employer: 
MoH 12 
MSF 8 
*Participant information relates to that recorded on the project patient database at time of 
recruitment; or for health care workers the positions they identified with during interviews. 
** No young men were eligible due to the epidemiology of HIV in Eswatini meaning less 
young men are infected, and additionally men can access care later. 
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Methods of data generation 
In-depth interviews 
The first interview with people living with HIV focused on the participant’s life 
history, establishing rapport, exploring their family background, education, 
relationships, interests, and key life events. The second interview focused on general 
health management and experiences accessing health services. Following 
participants’ disclosure of their HIV status, their story regarding past HIV testing 
experiences; how receiving an HIV diagnosis was understood, interpreted and felt 
(psychosocially and physically); their experience being offered early ART; their 
decision-making regarding the initiation of ART; and their experience with HIV-
related health services was then explored. Subsequent interviews sought to 
understand how participants’ on-going treatment-taking and engagement with HIV 
services is navigated over time, identifying and exploring changes in the lived 
experience of HIV and being on treatment (particularly where ART was initiated 
when ‘asymptomatic’), as well as re-visiting topics explored in previous interviews. 
Topic guides for subsequent interviews were developed based on analysis of the 
previous interview for each individual participant, which enabled further 
exploration of certain areas which had been discussed, greater depth of insight, as 
well as providing a view as to changes in participants’ accounts regarding their 
experiences. For example topic guides see appendix 2. Interviews with health care 
workers explored views and experiences relating to implementing Treat-all and 
providing treatment and care to asymptomatic patients.  
Interview arrangement and setting 
When requesting to meet with participants, we tried to arrange meetings at 
participants’ homesteads as much as possible, as long as individuals were 
comfortable with this (Table 3.6). This approach aimed to create a relaxed, informal 
environment for interview discussions, and to gain insight to the context within 
which people lived. As Riessman says, “working ethnographically with participants 
in their setting over time offers the best conditions for story telling” (2008). Where 
participants did not feel comfortable having interviews held at their homestead, for 
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example due to lack of privacy or fear of inadvertent disclosure, we avoided the use 
of clinics as much as possible, to mitigate association with the health programme and 
to ease participants’ comfort, particularly regarding discussions relating to their care 
and relationship with health care workers. One man was interviewed at the clinic 
because this was most convenient for him, he was studying in Mbabane and would 
come to Nhlangano to get his treatment refills, so we coordinated our meetings with 
him around his visits to the clinic and met him there while he was waiting. As this 
suggestion was led by him and he was comfortable having the discussions in this 
environment, it did not seem to negatively impact on the nature of what was 
discussed. However, it would be difficult to know this definitively.  
Table 3.6: People living with HIV participant interview location 
Interview location Number of interviews 
Homestead 48 
Private office room (project office or 
fixed HIV testing site) 
15 
Car 9 
Outside (e.g. under a tree) 6 
Private room at clinic 7 
Total 86 
Health care worker interviews were all held at the clinic where they worked, during 
working hours.  
For each interview with people living with HIV, individual participants were 
reimbursed 60 emalangeni (around £3.20) as a contribution towards their time, which 
was framed as a transport reimbursement (but provided for all participants including 
for interviews conducted within participants’ homes). It was decided to provide this 
amount to all participants based on consultation with the local research team, as this 
amount had also been provided in previous research in the setting, and with the same 
amount provided to all to ensure fairness. Providing this amount to participants was 
in appreciation of participants’ time, and the income generation they may have lost 
as a result of their time participating in the interview. Additionally, 30 emalangeni 
was spent on refreshments including a savoury sandwich or stew/meal with meat, a 
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drink and fruit, provided at each interview. See also section of this chapter: Ethics in 
research; Avoiding risk of harm to participants.  
As interviews with health care workers were held at the clinics where they worked, 
within working hours, such reimbursements or refreshments were not provided for 
these interviews.  
Observations 
I conducted observations of community and clinic-based activities relating to Treat-
all implementation, which aimed to provide further understanding and insight into 
the context of HIV treatment and care service delivery, as well as to the socio-cultural 
context within which participants were situated. These observations included health 
talks in various clinics (delivered at the secondary health facility and primary health 
clinics within Nhlangano) and communities; HIV testing sessions; pre-ART 
counselling sessions, clinical consultations where ART is offered in the context of 
Treat-all, routine ART counselling and enhanced adherence counselling sessions (for 
those with unsuppressed viral load results). I also observed differentiated models of 
treatment and care, including community ART groups, treatment clubs and 
treatment outreach.  
I conducted observations with a research assistant who interpreted the observed 
discussions from siSwati to English. The potential influence of language on the 
quality of observational evidence are reflected in the Discussion chapter: strengths 
and limitations.  
Additionally, I conducted informal discussions with traditional healers including 
four tinyanga (traditional healer) and one umthandazi (faith healer) in September 
2015 and June 2016, with the assistance of an interpreter. These were held because 
medical pluralism is common in Eswatini, and there are traditional conceptions of 
health and illness which can both contradict, as well as working alongside, 
biomedical models. Therefore, I felt it important to better understand the extant 
alternative health systems, as this was relevant to the accounts of several participants.  
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I recorded field notes for each session that was observed, including reflections on the 
setting, what was said, body language and potential interpretations.  
Methods of data analysis 
For each participant included in the longitudinal research, I analysed transcripts for 
each of their interviews separately and in succession, comparing emergent themes 
within an individual interview for each case, and across their different, repeated 
interviews to explore how these might change over time, and then comparing across 
the sample of different people living with HIV.  
For the narrative analysis component, narratives that I examined included the 
decision-making processes regarding ART initiation, and navigation of ongoing 
engagement with treatment and care. Within this approach, I also aimed to maximise 
the use of longitudinal data, by focusing on the narrative of an individual in each 
interview, and looking at how this might have changed across the repeat interviews. 
An example of the coding framework that I developed during data analysis is 
included in Appendix 4.  
Ethics in research 
Ethical issues in research are inextricably linked to views about the ontological and 
epistemological foundations which underpin it (Murphy and Dingwall, 2001). Within 
this research, I take steps to adopt both consequentialist and deontological 
approaches to ethics, considering the potential outcomes of research in terms of the 
harm or benefit that could result from participation, and how to mitigate risk of harm; 
as well as considering the rights of participants, including to respect, privacy and 
autonomy (Murphy and Dingwall, 2001). In the proceeding section I outline the steps 
which I undertook to uphold these ethical principles within this research. However, 
these were not exhaustive, and many ethical reflections and decisions continued 
throughout the research process, rather than occurring prior to or at the start of 
participant recruitment and data generation. I further reflect upon the ethical 
dilemmas raised in this research in the Discussion Chapter (section: Reflection on the 
approaches taken within the research; Ethical dilemmas).  
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Ethical approval 
Prior to study commencement I prepared a study protocol for the preliminary and 
main phase of research, including informed consent forms for the various participant 
groups (see Appendix 3), and addressing potential risk of harm and benefit to study 
participants and communities, which I then submitted to the relevant ethics review 
boards for review. 
For the preliminary phase of research, ethical approval was granted by the Eswatini 
(then named Swaziland) Scientific and Ethics Committee and MSF Ethics Review 
Board. 
For the main phase of research, ethical approval was granted by the Eswatini 
Scientific and Ethics Committee, the London School of Hygiene and Tropical 
Medicine Ethics Review Board, and MSF Ethics Review Board.   
Informed consent 
Informed consent refers to the principle that individuals should not be coerced, 
persuaded, or induced to participate in research against their will, rather 
participation should be based on voluntarism, and on a full understanding of the 
implications of participation (Green and Thorogood, 2009). Consent is a process, 
which should be assessed on an ongoing basis, with sensitivity to any changes in 
participant decision-making capacity (Hewitt, 2007). In post-colonial settings signing 
a consent form may carry different meanings to the protective intent embedded in 
western discourse, potentially functioning to establish control and ownership over 
the information gathered, and to release research institutions from liability 
(Riessman, 2005), which it is important to consider.  
An information sheet was given to all participants, available in siSwati and English, 
which was also discussed verbally at the first meeting with participants, with the 
opportunity for questions and further discussion, and offering participants the option 
of having some time to consider and to reconvene for the interview at a later date. 
Study information presented the purpose of the study, who was conducting it, why 
individuals were being requested to participate, and included contact details of the 
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Eswatini Scientific and Ethics Committee, and the qualitative research office phone 
number, should participants require further information about the study. 
Information included the steps taken to try to ensure confidentiality would be 
protected, also explaining that confidentiality could not be fully guaranteed. 
Participants were informed that they could withdraw their participation or end an 
interview at any point, and could chose to not answer certain questions or share 
information if they wished. Informed consent included provisions requesting consent 
for oral recording of interviews, explaining that these recordings were for the 
purpose of wanting to capture everything that was said in the interview, and that 
these would be securely stored (password protected), and not heard by anyone 
beyond the research team. For repeat interviews, the consent process was revisited 
verbally at each interview, reminding participants of the provisions for 
confidentiality and their rights to withdraw participation.  
For focus group discussion participation, an information sheet was given to all 
participants prior to the discussion, which was discussed verbally. Participants were 
informed that while being requested to respect each other’s confidentiality and not 
further discuss things that were shared in the group, that this could not be guaranteed 
by the researchers. Again, steps taken to remove individually-identifying 
information from study reports and documents were outlined. Verbal consent was 
requested from all individuals prior to discussion commencement.  
It has been posited that signed consent forms may actually jeopardise the 
confidentiality of participants by making them identifiable (Murphy and Dingwall, 
2001), so it is important to consider how informed consent forms will be stored 
securely and to also discuss with participants where they will keep their information 
sheet and how they will respond if someone finds it. Within this research, all signed 
consent forms were stored securely in a locked cabinet in the qualitative research 
office, which was also locked whenever empty.  
Using consent forms which must be signed by participants may not be appropriate 
for all participant observation research (Punch, 1994). Before observations started, 
myself and a research assistant were verbally introduced, the research and the 
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purpose of observations were outlined, and verbal consent was sought from 
individuals for each observation. If an individual wanted me to leave the observed 
session at any point, they were encouraged to indicate this, and I would leave without 
asking any questions (and without any negative implications for them for example in 
terms of their care). This was emphasised for all counselling and HIV testing sessions. 
Where not possible to seek each individuals’ verbal consent (for example for large 
group sessions, such as health talks in the community or clinics), the health care 
worker leading the session would introduce me, explain why I was there and ask 
generally if people were OK with this.  
Although individuals in the study sample had given consent to be contacted for 
interview at enrolment to the Treat-all pilot, many said they could not remember 
having consented to this when they were contacted requesting participation in the 
qualitative research. In consultation with colleagues, I therefore decided to change 
the approach and introduce the study as focusing on health, so participants could 
decide if, when and how they disclosed their HIV status to us, rather than us pushing 
them to discuss something which may be painful and uncomfortable for them. I 
therefore anticipated that not all participants would disclose their HIV status and 
planned participant recruitment with this in mind. 
Interviews may be filled with conflicting expectations and assumptions, as 
participants are constructed as sources of social knowledge, and the interviewer may 
be interpreted as someone who can provide medical knowledge (Riessman, 2005). It 
was important to clarify our role and position throughout the research, to offer 
participants signposting or referrals to further information and support, and to 
provide information ourselves where appropriate. Additionally, the final interview 
included questions to explore participants’ expectations surrounding the research, 
how they had understood their invitation to participate, their motivations for 
agreeing to take part, and what they understood would happen with the information 
they had shared. Participants were asked to reflect on their experience participating 
in the research, including whether there were any good or bad experiences resulting 
from their participation. This allowed for more detailed reflection and exploration of 
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the consent process and participants’ experiences taking part in the research (see 
Discussion Chapter section: Reflections on the research approach).  
Avoiding risk of harm to participants 
The ethical principles of beneficence and non-maleficence include an obligation that 
research should result in benefits, and that such potential benefits should be balanced 
against risks (Beauchamp and Childress, 2001). Additionally, participating in 
research should cause participants no harm (Hewitt, 2007). Research should be worth 
doing, in the sense that the results are likely to lead to tangible benefit for patients 
(Richards and Schwartz, 2002).  
Protecting participants from harm includes taking steps to ensure that participant 
confidentiality is maintained within research, with confidentiality referring to all 
information that is hidden from anyone not in the primary research team. This 
includes through anonymity, so that an individual’s identity should not be traceable 
from the data presented about them (Saunders et al., 2014). However, it may be 
impossible to guarantee complete anonymity to participants in qualitative research, 
and it is possible that quotations and context could be sufficient information for 
participants to be identified by themselves or others (Hewitt, 2007).  
Within this research I wanted to protect participants’ confidentiality as much as 
possible, which is particularly important due to the sensitive nature of the topics 
discussed within interviews, and as HIV is a highly stigmatised condition in the study 
context. Steps taken to protect confidentiality included the use of pseudonyms and 
avoidance of any individual-identifying information within reports or publications. 
Additionally, data was stored securely using password protected files, only 
accessible by members of the qualitative research team. Privacy was also considered 
within interview settings, requesting somewhere quiet without others present who 
may overhear discussions, for example in a private room within a homestead. If there 
were disturbances, such as someone entering the interview space, then the discussion 
would be stopped and resumed once others left. This was also emphasised to 
participants during introduction meetings and discussions about interview location. 
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I took steps to avoid the risk of inadvertent disclosure of participants’ HIV status 
through their participation in the research. This included through paying attention to 
the association of MSF with HIV, to avoid exposure of participants or potential 
deductive disclosure within the community when visiting homesteads. The use of an 
MSF vehicle was discussed with participants when arranging visits, and for most 
visits, a plain sign saying “social research” was used to cover the MSF logo on the 
vehicle. Some participants requested that the car not be parked directly outside their 
homestead, in which case it would be parked somewhere nearby and the interviewer 
would walk to the interview location. Participants were asked how they would like 
to introduce the researcher to others that may be present, for example family 
members at the homestead.  
It is important to consider the potential risk of harm to participants from interview 
discussions themselves, and how to manage and prepare for emotional distress that 
may arise. The probing nature of interviews has the potential to lead to participants 
divulging more information than they had planned when consenting to participation 
(Hewitt, 2007). Attempts to mitigate such risk are reflected in the approach to in-
depth interviews adopted within this research (see section Methodology: Approach 
to data generation:  In-depth interviews), which were participant-led and empathetic.  
Some say that the process of sharing in interviews may be cathartic for certain 
individuals (Richards and Emslie, 2000), with findings that participants feel it is good 
to have someone to talk to (Finch, 1984). However, there is the potential that revealing 
emotionally sensitive and painful details can cause participants emotional distress 
(Stacey, 1988). Within this research, the nature of the topic being explored (in 
particular HIV and relationships) is sensitive and could be upsetting for participants. 
Attention was paid to how participants appeared to be feeling during discussions. 
Anyone who became distressed, who raised anything suggesting potential risk of 
harm, or who appeared in need of further support could be referred for additional 
psychosocial support and counselling. This would always be discussed with the 
participant first, and their consent for referral sought. Interview discussions were 
managed to not start or end with emotive topics, in preparing for interview endings 
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and avoiding the risk of leaving participants in any emotional distress. Listeners can 
also be deeply affected by the narratives they hear, with the potential to upset or even 
traumatise the investigator (Riessman, 2005), and within debriefing sessions 
following each interview, interviewers were supported with processing any 
uncomfortable emotions they themselves experienced as a result of the nature of the 
discussions.  
Although rapport is important for participant comfort and openness,  this 
relationship should not be exploitative (Goodwin et al., 2003). Additionally, there 
may be unintended consequences of growing emotional intimacy (Hewitt, 2007), and 
participants may experience loss when the study ends and the researcher withdraws 
(Murphy and Dingwall, 2001). With this in mind, participants were prepared for the 
study ending in advance of the last interview, and the interviewer checked in during 
the penultimate interview to ask participants how they felt about the research coming 
to an end and the next meeting being the final one.  
In considering the importance of reciprocity and respect, power dynamics and 
valuing participants’ time, I decided to offer participants a contribution in 
appreciation of the time they shared during interviews. Some argue that 
reimbursement is an ethical requirement (Draper et al., 2009), particularly among 
feminist researchers (Head, 2009). However, it is important to consider the 
appropriate amount of compensation, which can have differing meaning in different 
contexts, and if an incentive is too high there is the risk that those on low incomes 
may feel coerced to participate (Head, 2009). The decision to offer participants a small 
financial contribution, as well as refreshments, for each interview, was based on 
consultation with local researchers, knowledge of the study context, and what was 
feasible within the project resources.  
In this chapter, I have presented my epistemological approach, which underpins this 
thesis, influencing the choice of methods that I adopted, and the study findings that 
are presented in the following chapters. I have outlined my approach to participant 
recruitment, to data generation including in-depth interviews, focus group 
discussions and observations, and to data analysis and the interpretation of accounts. 
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I described the study context of Eswatini, reflecting on information relating to the 
socio-political context, which influence and shape this research and frame the 
findings. I describe the methods that I adopted within the preliminary and main 
phase of this research, and the steps I took to uphold ethical principles.   
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Overview 
Within Chapter 2, I engaged with existing literature and theory to consider how 
individuals may respond to and process an HIV diagnosis in the context of Treat-all, 
when increasingly individuals are offered treatment when asymptomatic, and how 
this may influence health seeking and engagement with care, which remains 
unknown. Existing evidence suggests that conceptions of health, ill health and 
treatment need likely differ and extend beyond the biomedical rationale framing 
Treat-all, and it is important to consider how this may influence individuals’ access 
to HIV treatment and care. Evidence has highlighted how crucial linkage to HIV care 
is for individuals to be able to benefit from early treatment within Treat-all, and sub-
optimal linkage may undermine Treat-all effectiveness in reducing HIV incidence.  
In this chapter, I examine individuals’ experiences with HIV diagnosis and linkage 
to HIV care in the context of Treat-all in Eswatini, to understand what influences 
individuals’ response to their diagnosis, and their access to HIV treatment and care. 
This paper reflects the preliminary phase of this PhD research, with data generated 
through one-time interviews with people living with HIV, one-time interviews with 
health care workers, and focus group discussions with community members, which 
were conducted in Shiselweni, Eswatini February to May 2015.  
The findings presented in this paper highlight the importance of the process of HIV 
status acceptance for supporting access to HIV treatment and care. Status acceptance 
can be particularly challenging for those who struggle to identify with an HIV 
diagnosis, for example through not having physical symptoms or signs of infection, 
and through conceptions of HIV risk and views about who gets HIV. Support for 
coming to terms with an HIV diagnosis should be available, adapted to meet 
individuals’ needs, and focusing on status acceptance.  
This paper aligns with research objective 1:   
1. To understand how an HIV diagnosis is interpreted and understood in the 
context of Treat-all, and how this may influence engagement with care 
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Abstract 
Background: Timely uptake of antiretroviral therapy, adherence and retention in care 
for people living with HIV (PLHIV) can improve health outcomes and reduce 
transmission. Médecins Sans Frontières and the Swaziland Ministry of Health 
provide community-based HIV testing services (HTS) in Shiselweni, Swaziland, with 
high HTS coverage but sub-optimal linkage to HIV care. This qualitative study 
examined factors influencing linkage to HIV care for PLHIV diagnosed by 
community-based HTS. 
Methods: Participants were sampled purposively, exploring linkage experiences 
among both genders and different age groups. Interviews were conducted with 28 
PLHIV (linked and not linked) and 11 health practitioners. Data were thematically 
analysed to identify emergent patterns and categories using NVivo 10. Principles of 
grounded theory were applied, including constant comparison of findings, raising 
codes to a conceptual level, and inductively generating theory from participant 
accounts. 
Results: The process of HIV status acceptance or denial influenced the accounts of 
patients’ health seeking and linkage to care. This process was non-linear and varied 
temporally, with some experiencing non-acceptance for an extended period of time. 
Non-acceptance was linked to perceptions of HIV risk, with those not identifying as 
at risk less likely to expect and therefore be prepared for a positive result. Status 
disclosure was seen to support linkage, reportedly occurring following the 
acceptance of HIV status. HIV status acceptance motivated health seeking and tended 
to be accompanied by a perceived need for, and positive value placed on, HIV health 
care. 
Conclusions: The manner in which PLHIV process a positive result can influence 
their engagement with HIV treatment and care. Thus, there is a need for individually 
tailored approaches to HTS, including the potential for counselling over multiple 
sessions if required, supporting status acceptance, and disclosure. This is particularly 
relevant considering 90-90-90 targets and the need to better support PLHIV to engage 
with HIV treatment and care following diagnosis.  
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Introduction 
Timely uptake of antiretroviral therapy (ART) has a considerable effect on individual 
HIV-related health outcomes and on reducing the likelihood of HIV transmission 
(Cohen et al., 2011a; Gardner et al., 2011; INSIGHT START Study Group, 2015; 
Jenness et al., 2012; The TEMPRANO ANRS 12136 Study Group, 2015). The UNAIDS 
90-90-90 targets propose that with 90% of people living with HIV (PLHIV) knowing 
their status, 90% ART initiation for those diagnosed and 90% viral suppression for 
those on ART, HIV could be eliminated by 2030 (UNAIDS, 2014). Several countries 
are now adopting ‘Test and Start’ approaches in light of recent WHO guidelines 
(World Health Organisation, 2015), whereby providers offer ART for all individuals 
diagnosed HIV positive, irrespective of CD4 count. High coverage and uptake of HIV 
testing, linkage to HIV care, treatment initiation, retention in care, and maintained 
adherence to ART are required for Test and Start to reduce HIV incidence 
successfully (Gardner et al., 2011; Gardner and Young, 2014; Hayes et al., 2015). 
However, shortfalls exist at each of these stages (Gardner et al., 2011; Kilmarx and 
Mutasa-Apollo, 2013; Nachega et al., 2014).  
Community-based HIV testing services (HTS) can achieve high uptake, particularly 
among first time testers, underrepresented groups such as men, and those in early 
stages of disease (Bassett et al., 2014; Mills and Ford, 2012; Negin et al., 2009; Parker 
et al., 2015; Tumwebaze et al., 2012; Tumwesigye et al., 2010; van Rooyen et al., 2013; 
Wachira et al., 2012). Yet, reported rates of linkage to HIV care following diagnosis 
can be low. Recent findings from the ANRS 12249 TasP trial in South Africa 
demonstrated just 36.9% linkage to care within three months, among those tested HIV 
positive by home-based HTS and not in HIV care at the time of referral (Plazy et al., 
2016), compared to linkage rates found in Kenya, which were 42% following home-
based HTS (Medley et al., 2013).  
Factors that can support or undermine linkage to HIV care have been documented, 
including access barriers such as transport costs and distance to health services (Mills 
and Ford, 2012), and the perception that medical care is not required in the absence 
of symptoms (Braunstein et al., 2011; Nachega et al., 2014; Rosen and Fox, 2011). The 
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reasons for patients' clinic non-attendance may be complex and unintentional, 
including competing time demands and anticipated harsh provider attitudes (Ware 
et al., 2013). Authors argue that how people process an HIV-positive result, their 
subsequent actions and their support needs remain insufficiently understood (Gerdts 
et al., 2014; Mills and Ford, 2012; Wachira et al., 2012). The need for more research on 
this topic is increasingly pertinent in light of the move towards Test and Start, with 
linkage to care presenting a critical gap that could undermine its effectiveness in 
reducing HIV incidence (C. Iwuji et al., 2016). Swaziland is one of the first countries 
in sub-Saharan Africa to pilot Test and Start amongst the general population, with a 
Médecins Sans Frontières (MSF) and Swaziland Ministry of Health (MoH) 
implementation study in Shiselweni since 2014 and plans for national adoption 
imminently.  
Swaziland has the highest reported HIV prevalence worldwide (31% of 18-49 year 
olds; Swaziland Ministry of Health, 2012). As part of an MSF/MoH decentralised HIV 
and tuberculosis care project in the Shiselweni region of southern Swaziland, 
community-based HTS is one of the services provided. These HTS approaches were 
recently evaluated and found to have achieved high levels of HIV testing (e.g., 86% 
uptake reported by a home-based HTS campaign) but with just 34% of those testing 
HIV positive then recorded as linked to pre-ART care at an HIV care facility within 
six months of the test date (Parker et al., 2015). Project data suggest that these rates of 
linkage to care have improved to around 50% since 2015, following the 
implementation of a range of linkage support strategies. These strategies include 
individual case management with intensive counsellor follow-up, point-of-care CD4 
count, and a buddying scheme, which connects newly diagnosed HIV-positive 
individuals with a Rural Health Motivator in their community. Yet, it is not exactly 
known why linkage to care rates improved (or which strategies had the greatest 
effect), and the factors supporting or hindering individuals' from linking to care 
following HIV diagnosis are not well understood. It was therefore pertinent to 
examine individuals' experiences with HIV testing and linkage to HIV care to inform 
potential adaptation of support strategies to meet identified needs satisfactorily.  
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Methods  
In early 2015, qualitative research was conducted in Swaziland to examine 
community member and health practitioner experiences with MSF/MoH-provided 
community-based HTS in the Shiselweni region, in particular exploring factors 
influencing linkage to care for those testing HIV positive. Data were collected 
through semi-structured interviews and focus group discussions.  
For the purposes of this study, linkage to care refers to attendance at a specified 
referral facility and registration in the pre-ART or ART register within six months of 
the HIV test date as this information is recorded and available through the project 
linkage to care database. The study area was Shiselweni, southern Swaziland, which 
includes three health zones: Nhlangano, Hlatikhulu and Matsanjeni.  
Full ethics approval was granted by the Swaziland Scientific and Ethics Committee 
and the MSF Ethics Review Board before study commencement.  
Sampling strategy and participant recruitment  
A stratified purposive sampling strategy was adopted to identify and recruit those 
able to provide insight into community-based HTS and linkage to HIV care  
(Marshall, 1996). The study sample included three participant groups (Table 4.1): 
Patients who tested HIV positive by community-based HTS interventions (group 1), 
including those who had linked to care (group 1a) and those who had not (group 1b); 
health practitioners with knowledge and experience of community-based testing 
and/or linkage to HIV care (group 2); and members of the communities where the 
HTS interventions were delivered (group 3, HIV status unknown).  
Group 1 participants were selected from a larger cohort of patients in the project's 
community-based testing and linkage database, including those who had tested HIV 
positive by community-based HTS between June and November 2014 and either 
linked to care (using the pre-ART or ART enrolment date) or not (no pre-ART or ART 
registration recorded) within six months, to explore their experiences with HIV 
diagnosis and subsequent health seeking. The research team selected patients to 
include a gender balance and a range of ages, those from each of the three health 
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zones, and a mix of urban and rural dwellings. A team member contacted identified 
participants with information about the study, requesting their participation. 
Interviews were arranged with those who agreed at a time, date and location of their 
choice, which was either in the patient's home, a private room within the health clinic, 
or a private room within the project office.  
Group 2 participants were recruited to include health practitioners from the 
community-based HTS team, clinic-based HTS staff, expert clients (HIV positive lay 
counsellors) and nurses responsible for pre-ART and ART enrolment to explore their 
views and experiences working with patients during HIV diagnosis and linkage to 
care. Recruitment of this participant group aimed to give insight into provider 
perspectives on their rapport with HIV patients and to understand how their views 
on the social and cultural factors influencing linkage to care may confer or differ from 
patient accounts.  
Finally, group 3 participants (community members from the community-based HTS 
sites) were recruited for focus group discussions to explore their views on HIV testing 
and access to HIV services, providing important contextual information through 
insight into shared perspectives and commonly held views.  
Community members were identified through community-based expert clients who 
recruited six to eight members of their com- munity with unknown HIV status and 
of the same gender and a similar age.  
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Table 4.1: Characteristics of study sample participants and methods adopted for each 
Participant group Participants Data collection method 
Group 1 Patients diagnosed HIV 
positive by community-based 
HTS 
Semi-structured interviews 
(n=28) 
Group 1a Who are registered 
linked to care 
n=14  
Group 1b Who are registered 
not linked to care 
n=14 
Group 2 Health practitioners (with 
knowledge/experience of 
HTS and linkage to care) 
Semi-structured interviews 
(n=11) 
 
Group 3 General community 
members (HIV status 
unknown) 
Focus group discussions 
(n=3, 6–7 participants per 
group, 19 participants total; 
2 with women aged 17–39 
years, 1 with men aged 16–
30 years) 
 
Data generation and analysis  
Data were generated through semi-structured interviews with patients and health 
practitioners and focus group discussions with community members in Shiselweni 
from March to May 2015. Interviews with female patients were conducted by a female 
research assistant (RA). All interviews with male patients were conducted by a male 
RA save one, which was conducted by the female RA, and all were in siSwati 
language. The principal investigator (PI; SH) conducted interviews with health 
practitioners, with most being in English and two a combination of English and 
siSwati, with the assistance of an interpreter. Interviews averaged 50 min. An RA 
facilitated focus group discussions in siSwati, with an interpreter and the PI co-
facilitating and taking notes, averaging one hour and 40 min. Interviews and focus 
group discussions were conducted according to topic guides following written 
informed consent. The consent process included an informed consent form 
(discussed verbally), with provisions for confidentiality, data storage and requesting 
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consent for audio recording. All interviews were transcribed verbatim or transcribed 
and translated equivalently to maintain meaning and integrity of data.  
Data generation and analysis followed an iterative process, with analysis beginning 
at the point of data generation and participants being recruited until evidence of data 
saturation, when adding further participants generated no new findings (Green and 
Thorogood, 2009; O’Reilly and Parker, 2013). Data were analysed thematically using 
coding to identify emergent patterns, categories, and concepts from participant 
accounts. Principles of grounded theory were drawn upon including constant 
comparison of codes within and between cases to raise codes to a conceptual level 
and generate theory inductively from participant accounts, and through actively 
seeking discrepancies from majority themes (Bradley et al., 2007; Glaser, 1999; Glaser 
and Strauss, 1967).  
To ensure analytic rigour, interview transcripts were initially analysed by three 
researchers independently to identify patterns and descriptive codes from participant 
narratives. These patterns were discussed, results were checked, and an initial coding 
framework was developed. Full analysis was conducted by the PI with NVivo 10 as 
an analytic aid, with the initial coding framework being adapted as analysis 
progressed. Attention was paid to the role of the researcher in shaping data analysis 
and interpretation, emergent themes were tested by examining exceptions and 
counter examples, and findings were triangulated by comparing participant groups. 
Finally, a fourth researcher (BS) reviewed the NVivo project data and coding to 
enhance validity and minimise researcher bias.  
Results  
Thirty-nine interviews were conducted, with 28 patients who tested HIV positive 
through community-based HTS initiatives and 11 health practitioners (online 
supplement Tables 2 and 3). Half of the patients were female, and ages ranged from 
16 to 69 years. Among the patients identified for recruitment from the project patient 
database, 52% were contactable, and for those who were non-contactable, there was 
no telephone number listed on their testing form, the number listed was incorrect, or 
they are now living outside the study area. For the patients who were contactable 
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(n=31), 100% agreed to be interviewed; of these, 90% completed the interview, 
obtaining a final sample of 28. Three focus group discussions were conducted with 
19 community members in total.  
Of the 28 patients who were interviewed, half of them were recorded as having linked 
to HIV care and half as not. It is noteworthy that during interview 8 of the 14 ‘not 
linked’ participants reported having actually linked to care, either to the clinic they 
were referred to or another clinic elsewhere.  
Data analysis led to the identification of several key themes as influencing 
individuals' linkage to HIV care: (1) processing an HIV-positive result and status 
acceptance and (2) value placed on health care and the perceived need for HIV care 
services. Figure 4.1 depicts these themes, as elaborated in this section.  
 
Figure 4.1: The process of HIV status acceptance or non-acceptance: influencing factors and 
consequences.  
Processing an HIV-Positive result: shock, doubt and disbelief  
Many participants reported experiencing shock after receiving an HIV-positive test 
result, feeling distressed, and questioning how they were infected and the source of 
HIV infection. Many struggled to accept the diagnosis, with several doubting or 
disbelieving the test result.  
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‘I was refusing to accept the result when they were telling me ... I'm still asking myself 
how I got infected.’ P06  
‘I really cried, I felt pain and was shocked that “oh my word”.’ P02  
‘When sisi [HTC] told me that I am positive, I just did not believe it. So I stayed for 
two years, and some people would come to do testing, and I would not test because I 
was like these people tell lies ... ’ P05  
Periods of non-acceptance that were described ranged from months to years and had 
marked consequences for many individuals' mental and physical health, seen as a 
significant barrier to accessing care.  
‘It is what can make someone ill, the fact that they do not accept.’ C06  
‘I came back and stayed here at home for almost a year, and I would go to Nhletjeni 
and get some pills [not ART], and then it later got worse and I lay down.’ C04  
Non-acceptance of HIV status was particularly evident among those who had not felt 
unwell or were not experiencing symptoms, which was reiterated by health 
practitioner participants. Participants reported confusion over receiving an HIV-
positive result and not identifying themselves as being HIV positive because of their 
expectation that HIV infection comes with common symptoms.  
‘If I had got it from him, there would be a difference by now. I would have gotten sick 
and bedridden, but I just think that I do not know.’ C01  
‘I stayed for the year telling myself that they are lying. It means that my mind was 
acting childish because I would tell myself, how come I am not sick and I do not have 
any pain.’ P05  
Many participants reported undergoing re-testing for HIV to confirm whether the 
result they had received was true. Re-testing and verifying the HIV-positive result 
appeared to be an important step in accessing HIV treatment and care and ‘taking the 
necessary steps’:  
‘I wanted to see if the test was for real. I wanted to see if what we did last time was 
realistic, and I found that it was realistic ... I found that I am really HIV positive, and 
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that is when I accepted that I am really HIV positive and when I started the ART.’ 
C08  
‘I was tested, and the result was the same as the one I got before ... and then I decided 
that I should then go to the clinic ... because I have heard two different people sharing 
that information with me...’ P11  
Still, this could potentially add to participants' confusion, as one participant 
described receiving discordant results on re-testing:  
‘I did not believe that they say now I am positive because you see I had tested just that 
week, and I tested again, I found it positive, and I tested again the last time and found 
it negative. It made me think, what is happening. That is what is making me question.’ 
C06  
Perceptions of HIV risk  
Non-acceptance of HIV status was exacerbated by not associating oneself with HIV 
through judgements about who gets HIV, which shaped a sense of personal risk of 
infection. The reflections individuals made about their perception of risk for HIV 
included the described introduction of HIV in Swaziland linked to ‘prostitution’; 
therefore, those who reported few sexual partners felt they were not at risk. 
Perception of HIV risk continues to have associations with the concepts of morality 
or social standards despite the generalised HIV prevalence.  
‘The way in which HIV was first introduced, that HIV is in those who go sleeping 
around, so for those who know that they take care of themselves, they are far away 
from thinking of being HIV positive.’ HP 02.  
‘I can say I never got to accept it. What came to me was that I questioned “me and 
HIV? But I am well behaved”.’ P05.  
Certain men presented as not identifying themselves with risk of HIV infection, as 
having multiple partners was seen as a positive and celebrated achievement for men, 
which they did not associate with the negative connotations of ‘promiscuity’. Many 
men described living a life of Christianity and not believing in sex before marriage, 
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which could be at odds with the reality of their sexual practices, thereby creating 
misalignment of their beliefs, religious practices, and HIV risk.  
‘I live a life of Christianity. I was very shocked to find that it is there ... when it comes 
to sex ... [pause] hmm let me say it is possible for me to have gotten it through that 
because it does not mean that I am this old and I have never, never had sex without a 
condom.’ C13, male  
Those who expected that a positive result could be possible and perceived themselves 
to be at risk of HIV could accept their status. This was particularly apparent in the 
accounts of some of the women who suspected HIV exposure through their partner's 
refusal of condom use or their partner's infidelity, which they felt put them at risk of 
HIV infection:  
‘I found my boyfriend's treatment, and he had not told me that he is HIV positive ... 
I went to get tested and found that I am HIV positive ... I was expecting it because my 
boyfriend is HIV positive.’ C08, female  
Readiness to test and acceptance  
Preparedness for the chance of receiving a positive result and pre-test information 
appeared to be vital for acceptance of one's HIV status. Participants described their 
feeling of being able to exert choice in testing as influencing their preparedness for 
dealing with the result and therefore their likelihood of accepting it. Testing 
incentives were said to undermine this process, and participants described instances 
where individuals' motivation to test was the incentive (e.g., a t-shirt), rather than to 
know their health status, which caused them to go into shock on receiving a positive 
result.  
‘Testing when you want to test and you wish to test, it is better in your spirit because 
you initiated it, so the results will also not be so hard to accept emotionally.’ C06  
‘At the tents sometimes, they give incentives. And because as Swazis, we are hungry, 
so if there is some incentive, I will now stay behind, but that is not good ... because 
they want to receive those things but will they accept after that? I do not know.’ FGD 
02-P3  
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HIV-related counselling and information were seen to be crucial in providing support 
and reassurance that there is life after HIV diagnosis. Some participants reported 
needing time to process and come to terms with their result.  
‘I ended up going for counselling and accepting it. What helped me the most and what 
I can advise that every person does is to go for counselling because counselling helps 
a lot; it soothes the soul and makes you able to accept the status you have.’ C08  
Individuals' acceptance of their HIV diagnosis and their sense of hope and belief for 
living with HIV was emphasised through social support and encouragement (which 
was achieved through disclosure). Participants had seen others with HIV surviving, 
realised that they were not alone or the minority affected by HIV, and had seen the 
transformative effects of ART, compared to the past when many had seen people 
around them dying due to HIV-related illnesses. These experiences enabled 
individuals to move from questioning where HIV could have come from to accepting 
and looking towards the future.  
‘I accepted my situation because I have seen others surviving with the virus.’ C03  
‘I was not scared because there are others I know that are living with HIV ... That is 
what made me not be nervous, as well as looking at other relatives who have passed 
on because of it and not being educated about it.’ C06  
HIV status disclosure and linkage to care  
Non-acceptance was described as a barrier to disclosure of HIV status as the disbelief, 
perceived stigma, and fear of negative judgement may force the HIV-infected 
individuals to hide their positive result. Disclosure was seen to help the process of 
acceptance and support engagement in care and receiving treatment. It enabled 
access to social support, reassurance, and encouragement, including for treatment 
initiation decisions, clinic visits, and treatment reminders.  
‘I was able to [disclose] after I had accepted ... I told them that I am now someone who 
is like this. If you see me taking pills, do remind me to take the pills when it is time.’ 
C08  
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‘I accepted and decided to let them know because I'm going to need their help and I 
want them to remind me when it's time to take the treatment and also when going to 
the facility.’ P01  
Disclosure could influence linkage to care, with some participants who had not 
accessed care stating that they were waiting to disclose before going to the health 
clinic. Participants described how those who feared inadvertent disclosure of their 
status would struggle to take their treatment consistently because they did not want 
to be seen taking their treatment. This concern was considered significant enough to 
deter people from even seeking treatment.  
‘I'm waiting to talk to her first before I can go to the clinic.’ C12  
‘Some people die because of not telling their relatives. You find that a male person has 
his friend but is unable to tell them that they are taking treatment, so he ends up 
hiding the treatment ... they stop taking them because they are scared to tell the lover 
... that is what kills them.’ P03  
Perceived need for and value placed on health services  
The perceived need for and belief in the benefits of health care were seen to influence 
whether individuals would link to care or not. This was particularly evident where 
individuals did not feel unwell, they had not experienced symptoms that they 
associated with HIV, and where they did not accept their HIV status. This belief 
therefore created the sense that seeking health care was not urgent, and other life 
needs, such as work, household activities, and responsibilities, have higher priority.  
‘I have not gone because I have not even had that cold. I am someone who is working, 
and I have not felt that I was sick and I cannot even work.’ C01  
‘Some would feel strong, see themselves very good, very healthy, so they wouldn't see 
the reason for coming to the clinic.’ HP 01  
For some, avoiding potential imminent health deterioration motivated them to access 
services even in the absence of symptoms because of the perceived benefits of 
accessing early care to avoid reaching a ‘bedridden state’.  
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‘Going there when you're bit healthy is better than going there when you're already 
lying down. This way you can live longer, as if you don't have this thing.’ C09  
‘We want life ... it is better to go to the clinic while you still can walk there unlike 
when you're already sick and bedridden. That is what motivated us.' P08  
Avoiding a ‘bedridden state’ was not only associated with health benefits including 
avoiding risk of death, but was also seen in terms of stigma reduction. Participants 
felt they would be able to maintain good physical health with early access to 
treatment, thereby preventing them from developing symptoms and being 
identifiable as HIV positive.  
‘I do not want to fall sick and get bedridden ... and be a written book for anyone to 
read.’ P07  
Though ART was described as enabling stigma reduction, some participants felt 
reluctant to visit health clinics for fear that doing so could reveal their HIV status. 
They feared confidentiality breaches by health practitioners or of being seen queuing 
for ART-related services, which could instil feelings of shame. These fears could be 
particularly influential for those who had not fully accepted their HIV status and who 
described them as deterring these individuals from accessing HIV care.  
‘The minute you sit on the bench, you are engulfed with embarrassment and you feel 
ashamed, but then you must accept yourself and not worry yourself about whether 
you see your neighbour or anybody. We are all there to get the treatment.’ P14  
Seemingly, socio-cultural norms and expectations relating to men could create 
difficulties for their accessing health services, which was mainly described by health 
practitioner participants who stated that males are less involved in all aspects of 
health services. Furthermore, men were perceived as not wanting to go to the clinic 
due to its association as being a woman's place, and the expectation that men should 
be strong and not seek health care.  
‘Going to the clinic is something I wouldn't have done except when I'm being driven 
there in a wheel barrow.’ P06 (male)  
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‘They are afraid to use hospitals ... Mainly Swazi men ... They don't believe that much 
in hospitals. They prefer to do some- thing else.’ HP 04  
Counsellor attitudes and the approach taken with linkage follow-up were important 
to patients. When patients felt as though the health practitioner valued their life and 
wanted them to seek care for their own well-being, it tapped into their sense of 
valuing and prioritising healthcare. On the contrary, more aggressive approaches 
when patients felt they were being followed up for the sole purpose of getting them 
to go to the clinic could undermine their motivation and could cause feelings of 
disappointment and distrust.  
‘She really followed up on me, and called me and called me to ask me and said she 
loved me very much. She stopped once I went there, and I usually say, aw I thought 
she loved me but she stopped calling me. She stopped once I went there.’ P05  
Discussion  
Our study findings suggest that HIV status acceptance is important for a person's 
engagement with HIV care and access to social support, quality counselling, 
knowledge, attitudes, and practices regarding health care. The process of status 
acceptance was influenced by an individual's awareness that there was a heightened 
probability they would receive an HIV-positive result. Although past studies 
describe linkage to care and HIV status denial, as far as we are aware, our study is 
the first to portray acceptance as a longitudinal process in which supporters can 
intervene to facilitate individuals' acceptance of an HIV-positive result.  
While the exact way in which someone processes an HIV- positive result is 
heterogeneous and individually defined, certain factors could influence the transition 
towards acceptance. These include the perception of risk for potential HIV infection, 
including judgements about HIV; an association of self with images of HIV positivity; 
and counsellor support offering reassurance, encouragement, and hope for life after 
diagnosis. Although Swaziland has the highest reported HIV prevalence rate in the 
world with a generalised epidemic, an association of HIV with ‘promiscuity’ and 
‘prostitution’ persists. Most participants did not identify themselves with these 
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behaviours and therefore did not perceive themselves to be at risk. This non-
association with HIV risk led many to experience shock and disbelief on being 
diagnosed HIV positive and made accepting the diagnosis particularly challenging.  
Other studies have found non-acceptance of HIV status, often termed as denial, to 
negatively affect individuals' access to HIV care, ART initiation and adherence (Beer 
et al., 2009b; Jenness et al., 2012; Lindkvist et al., 2015; Manirankunda et al., 2009; 
Nakigozi et al., 2013; Nam et al., 2008; Otieno et al., 2010; Stinson and Myer, 2012; 
Wringe et al., 2009). Reiterating our findings, doubt and disbelief on receiving a 
positive HIV result are associated with a lack of HIV-related symptoms (Beer et al., 
2009b; Nakigozi et al., 2013; Raveis et al., 1998; Wringe et al., 2009), and time can be 
required to process, come to terms with, and accept an HIV-positive result (Gilbert 
and Walker, 2010; Raveis et al., 1998). In our study, many reported re-testing for HIV 
to verify if their result was true, and HIV testing incentives were seen to undermine 
status acceptance. Denial of HIV status has been linked to poor mental and physical 
health (Kamen et al., 2012; Moitra et al., 2011). Still, our findings are unexpected, 
given that shock and disbelief can prevail and prevent PLHIV from accessing HIV 
care in a setting where HIV knowledge and familiarity is high and where HIV is 
perceived to be increasingly ‘normalised’ through increased access to ART, 
transforming it to a chronic manageable condition (Bernays et al., 2015; Russell and 
Seeley, 2010).  
How individuals respond to chronic diseases, including HIV, are varied and 
contextual (Bernays et al., 2015; Harris, 2009). Various theories can be applied in 
understanding individuals' reactions to health and illness, and an HIV diagnosis has 
been described as a transition (Russell and Seeley, 2010) and biographical 
reinforcement (Bernays et al., 2015; Carricaburu and Pierret, 1995; Williams, 2000) 
through reinforcing components of identity and lifetime illness experiences or 
struggles. Yet, because of commonly held views related to morality and behaviour, 
an HIV diagnosis in this context appeared to disrupt the ‘socially set standards and 
cultural prescriptions of normality’ (Bury, 1982), with a reaction of disbelief and 
anxiety thus being more common, in line with Bury’s (1982) theory of biographical 
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disruption. The reactions to an HIV- positive result described in our study echo some 
of the stages of grief that Kübler-Ross described by following a patient's diagnosis 
with a terminal illness, which include shock, denial, anger, bargaining, depression, 
and acceptance (Kübler-Ross, 1969). As individuals progressed towards acceptance, 
elements of transition appeared, with active adaptation to incorporate illness and its 
treatment to daily life, developing approaches for self-management of HIV and 
feeling ‘normal’ again (Kralik et al., 2004, 2003; Russell and Seeley, 2010; Telford et 
al., 2006). We found that acceptance, disclosure of HIV status, and linkage to HIV care 
appeared connected. Disclosure enabled support and reassurance, which aided 
accessing care and cultivated hope (Gilbert and Walker, 2010; Nakigozi et al., 2013; 
Nam et al., 2008).  
The perceived need for and value placed on health services increased individuals' 
motivation for seeking HIV care. This could be challenged in the absence of 
symptoms, where the need for health care was less evident, a factor that has been 
reported previously (Jenness et al., 2012; Nachega et al., 2014; Nakigozi et al., 2013; 
Rosen and Fox, 2011). However, some participants described learning about the 
benefits of early access to treatment and care through receiving HIV information 
linked to the Test and Start pilot and through seeing others with HIV experience 
health deterioration in the absence of treatment. The avoidance of a ‘bedridden state’, 
which could render an individual identifiable as HIV positive, had the potential to be 
a powerful motivator for accessing care. Yet, fear of health practitioner confidentiality 
breaches and experiencing stigma on being seen attending a health clinic for HIV-
related care were reported, as found by others (Beer et al., 2009b; Nakigozi et al., 2013; 
Raveis et al., 1998; Tumwebaze et al., 2012; Wringe et al., 2009). In our study, this was 
particularly prevalent among those who had not fully accepted their HIV status and 
appeared to be more vulnerable to self-stigma.  
Limitations  
During initial patient interviews, it was clear that the interviewer was being 
associated with the medical programme, which subsequently improved following 
adaptations to the study introduction, such as reiterating the non-association of the 
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researchers with medical teams. Interviews conducted with male patients recorded 
as not linked to care were shorter and less in-depth (including less participant open 
narrative) than those with females (average interview length: 30 min for males vs. 55 
min for females, with the exception of one 72-min interview conducted by a female 
RA). Interviewer technique is likely to have influenced the narratives of these 
participants, although this could also reflect characteristics of the participant group.  
Nearly half of the identified participants for study recruitment were non-contactable 
because of a missing or incorrect phone number captured during HTS. This reflects 
the operational challenges with linkage follow-up and may have affected the results, 
with these participants potentially having different experiences with testing and 
linkage to HIV care. In addition, two patients (one recorded as not linked and one 
linked) did not attend the agreed interview appointment, with unknown reasons for 
non- participation. However, it appears that the themes that emerged were robust 
and reiterated sufficiently to evidence data saturation. Furthermore, the general 
participation response rate was good. Although we had requested that focus group 
discussions be held with community members who were similar in age, two of the 
groups had a large age range. These differences may have influenced the group 
dynamics, as younger participants were quieter than older participants, which 
reflects the social interactions that can be found within wider Swazi society. The 
generalisability of the study's findings is limited to the concepts presented, which 
also may not apply in different contexts or settings.  
Conclusions  
This research shows that how individuals process an HIV- positive result can 
fundamentally affect their engagement with health services. Status acceptance 
enabled access to social support and increased a sense of need for and value placed 
on HIV services, thus influencing individuals' linkage to HIV care. Although situated 
within a generalised high-prevalence epidemic setting, many participants in our 
study did not perceive themselves to be at risk of HIV and struggled to accept a 
positive result. Being asymptomatic could pose particular challenges for accepting an 
HIV diagnosis and could create less sense of urgency regarding the need for health 
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services. Still, there were also perceived benefits from accessing treatment and care 
early.  
Our findings indicate the need to develop and test linkage support strategies that 
address individuals' needs and facilitate progression to HIV status acceptance. These 
could include sup- porting diagnosis preparedness (e.g., through pre-test 
information), exploring individuals' perceptions relating to HIV risk, and 
expectations for the chance of receiving an HIV-positive result. Counselling with 
clear goals is important within programmes to support status acceptance and 
disclosure. A flexible approach to patient follow-up should be considered, with 
varied intensity and types of support provided depending on the needs of each 
individual and with the opportunity for multiple sessions beyond the point of HIV 
testing if required. For example, certain individuals may require more time to process 
and come to terms with an HIV diagnosis before engaging in HIV care or initiating 
ART than others. HIV prevention programmes should consider our finding that HIV 
testing incentives undermined status acceptance as individuals may be less prepared 
for a potential positive result.  
These findings are particularly important in light of the move towards the adoption 
of Test and Start approaches in many settings, including in Swaziland. Engaging with 
how people respond to an HIV test result is critical to the success of these initiatives, 
given how crucial the processes of HIV diagnosis and follow-up are for patients' 
access to HIV care. Without addressing specific patient support needs and improving 
linkage to HIV care, these approaches risk being ineffective in reducing HIV 
incidence and improving the quality of care to PLHIV.  
Acknowledgements  
We thank all the patients and staff involved with the MSF/MoH project in Shiselweni 
who contributed to this study, with particular thanks to Dr. Bernhard Kerschberger, 
Dr. Inoussa Zabsonre and Thomas A. Obulutsa and to the heads of clinical activities 
and heads of community activities (MSF Swaziland). Thanks to Alison Wringe 
(LSHTM) for reviewing the drafts and providing technical input, and to Janet Seeley 
(LSHTM).   
139 
 
Appendix A Supplementary data  
Table 4.2: Patient participant information 
Interview 
Code 
Gender Age 
group 
(years) 
Health zone Linkage 
recorded in 
database 
Linkage reported in 
interview 
P01 Male 25-34 Nhlangano Linked Linked 
P02 Female 25-34 Hlatikhulu Linked Linked 
P03 Female 55-69 Matsanjeni Linked Linked 
P04 Male 16-24 Nhlangano Linked Linked 
P05 Female 35-44 Nhlangano Linked Linked  
P06 Male 45-54 Hlatikhulu Linked Linked 
P07 Female 35-44 Hlatikhulu Linked Linked 
P08 Male 35-44 Nhlangano Linked Linked 
P09 Female 35-44 Matsanjeni Linked Linked 
P10 Male 55-69 Matsanjeni Linked Linked 
P11 Male 55-69 Matsanjeni Linked Linked 
P12 Female 35-44  Matsanjeni Linked Linked 
P13 Male 55-69 Hlatikhulu Linked Linked 
P14 Female 16-24 Hlatikhulu Linked Linked 
C01 Female 55-69 Hlatikhulu Not linked Not linked 
C02 Female 55-69 Nhlangano Not linked Linked elsewhere 
(NATICC) 
C03 Male 35-44 Nhlangano Not linked Linked outside of 
region 
C04 Male 55-69 Hlatikhulu Not linked Linked to agreed clinic 
(on ART) 
C05 Female 25-34 Nhlangano Not linked Linked to agreed clinic 
(on ART) 
C06 Female 16-24 Hlatikhulu Not linked Not linked 
C07 Male 16-24 Matsanjeni Not linked Not linked 
C08 Female 16-24 Matsanjeni Not linked Linked outside of 
region 
C09 Male 35-44 Matsanjeni Not linked Linked to agreed clinic   
C10 Female 25-34 Nhlangano Not linked Linked as agreed and 
transferred out 
C11 Male 25-34 Matsanjeni Not linked Not linked 
C12 Male 25-34 Nhlangano Not linked Not linked 
C13 Male 25-34 Nhlangano Not linked Linked elsewhere 
(NATICC) 
C14 Female 25-34 Nhlangano Not linked Linked and on ART 
P=patient. C=”not linked” client. NATICC=Nhlangano AIDS Training Information 
and Counselling Centre 
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Table 4.3: Health practitioner participant information 
Participant code Position 
HP 01 HTC (clinic-based) 
HP 02 HTC (clinic-based 
HP 03 HTC (community-based) 
HP 04 HTC (community-based) 
HP 05 HTC (community-based) 
HP 06 HTC (community-based) 
HP 07 HTC (community-based) 
HP 08 HTC (community-based) 
HP 09 Nurse Supervisor (MoH) 
HP 10 Expert Client (clinic-based) 
HP 11  HTC (clinic-based) 
HP=health practitioner. HTC=HIV testing counsellor. 
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Overview 
In this chapter, I examine individuals’ decision-making processes regarding ART 
initiation in the context of Treat-all and how sense of treatment choice and ownership 
over the management of treatment and health influence ongoing treatment-taking 
and engagement with care. This chapter builds upon the literature that I engaged 
with in Chapter 2, as well as building on the findings presented in Chapter 4.  
In Chapter 2, I highlight the potential dissonance between the biomedical logic 
framing Treat-all, and the priorities of a public health agenda, with those of 
individuals living with HIV, who may have differing conceptions of their health and 
treatment needs. This chapter reflects on this potential dissonance, exploring how 
individuals experience the treatment offer in the context of Treat-all, and their 
decision-making processes regarding when to initiate ART. I draw upon theoretical 
contributions to decision-making presented in Chapter 2, and literature relating to 
adjusting to illness, identity work, and aspects of self-management, in particular 
considering how ownership of one’s health needs and treatment may support 
ongoing engagement with care. 
The findings in this chapter draw on data generated during the main research phase. 
I focus on the narratives of four individuals, each interviewed three times, to enable 
a deep, rich exploration of decision-making and engagement with care accounts. I 
reflect on data from interviews with health care workers and observations to consider 
how health care worker perspectives may converge and differ from those of 
individuals, and how potential dissonance between the health and individual 
perspectives and priorities may be reconciled.    
This paper aligns with research objectives 3 and 4: 
3. To explore treatment initiation decision-making 
4. To examine how ongoing engagement in HIV care and treatment-taking is 
navigated over time  
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Abstract 
Treat-all recommends prompt treatment initiation for those diagnosed HIV positive, 
requiring adaptations to individuals’ behaviour and practice. Situated within a 
longitudinal qualitative study in Eswatini, we examine the choice to initiate treatment 
when asymptomatic, dissonance between the biomedical logic surrounding Treat-all 
and individuals’ conceptions of treatment necessity, and how ongoing engagement 
with care may be navigated over time. We reflect on the perspectives of healthcare 
workers, responsible for implementing Treat-all and holding a duty of care for their 
patients, demonstrating considerable care and empathy in wanting to support people 
to achieve good health outcomes. We explore how the potentially differing needs and 
priorities of individuals and the public health agenda are navigated and reconciled. 
Rationalities regarding treatment-taking extend beyond the biomedical realm, 
requiring adjustments to sense of self and identity, and decision-making that is 
situated and socially embedded. Sense of choice and ownership for this process is 
important for individuals’ engagement with treatment and care.  
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Antiretroviral therapy (ART) offers individual and public health benefits, with dual 
roles for HIV treatment and transmission prevention (Cohen et al., 2011a; INSIGHT 
START Study Group, 2015; The TEMPRANO ANRS 12136 Study Group, 2015). 
Reflecting this duality, the Treat-all approach is now being implemented in many 
settings, aiming to improve health outcomes and reduce HIV incidence through the 
immediate offer of ART following HIV diagnosis (World Health Organisation, 2016).  
Treat-all is both a biomedical and a social intervention, requiring modifications to 
behaviour and practice and the active engagement of people and communities, 
situated within social, cultural and political dimensions (Adam, 2011; Kippax and 
Stephenson, 2012). The biomedical logic framing Treat-all assumes that individuals 
will adjust their behaviour once they are informed about their condition, accordingly 
engaging with care and with taking daily medication (Beckmann, 2013). This logic 
reflects the broader “biomedical paradigm”, which we define as the constellation of 
beliefs, values, techniques and skills shared by members of the health and 
pharmaceutical community, whereby health is defined in terms of the absence of 
disease, and experiences and perceived symptoms are reduced to the biological 
(Ashcroft and Katwyk, 2016).  
The biomedical paradigm can be seen as regarding a range of problems through a 
medical lens (the “biomedical gaze”; Foucault, 1963), requiring technical, biomedical 
solutions and management by biomedical professionals and scientists (Bell and 
Figert, 2015), with the pharmaceutical industry holding significant power and 
importance (Williams et al., 2011). The biomedical gaze stems from Foucault’s 
conceptualisation of the “medical gaze” separating a person’s identity from their 
body, thereby constructing patients as medical objects rather than people situated 
within a social context (Foucault, 1963). Such an approach may risk reducing disease 
to an abstract physical matter within the bounded realm of clinics, with rigid 
distinctions between individuals’ physicality and the broader social world, 
abstracting people from their social contexts and the other aspects to self and 
personhood, which extend beyond the biomedical sphere (Beckmann, 2013; Hickel, 
2012). 
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Yet, individuals’ decisions to engage with ART are situated beyond the biomedical 
realm (Beckmann, 2013). The prioritisation of ART and physical health above other 
areas of life, such as generating an income, securing food, providing for family, or 
maintaining social position, may not always be realistic, achievable or possible 
(Kielmann and Cataldo, 2010). For example, a study in South Africa and Zambia 
found some individuals delayed ART initiation following diagnosis due to 
contradictory priorities of needing to work taking precedence over clinic attendance 
(Seeley et al., 2018). Thus, seemingly “irrational” behaviours such as not taking 
treatment as prescribed, may be “ways in which people enact agency in the context 
of their day-to-day needs” (Paparini and Rhodes, 2016, p.506). Additionally, there can 
be dissonance between clinical guidelines and lay interpretations of what constitutes 
treatment necessity (Kawuma et al., 2018). It is thus an imperative that socio-
behavioural contexts and dimensions be considered, understood and integrated 
within Treat-all approaches (Kippax and Stephenson, 2012).  
WHO treatment guidelines, updated in 2016, state that healthcare workers should 
discuss patients’ willingness and readiness to initiate ART, with the choice to accept 
or decline ART lying with the individual patient, who can also choose to defer (World 
Health Organisation, 2016). Patient autonomy is one of the four principles of 
healthcare ethics (in addition to beneficence, non-maleficence and justice), i.e. 
individuals should give informed consent (Gillon, 1994) and have the right to choose 
whether or not to accept medical treatment, even if this decision is not deemed to be 
medically in their best interests (Cave, 2017). While presenting important principles, 
there are competing interests to be reconciled in the practice of bioethics, with claims 
to universality not necessarily mapping onto the details of everyday life that shape 
the ethical landscape (Kingori, 2013). The relationship between the action being 
undertaken (i.e. the “choice” to initiate ART) and the agent (the healthcare worker 
and the person with HIV) are pivotal in the production of ethical practice and 
perspectives (Ricoeur, 1992). Within Treat-all, the premise of choice for treatment is 
presented as singular and linear, whereas choice involves multiple pathways that an 
individual may take. It is therefore important to understand people’s lived 
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experiences, and how their priorities and concerns may extend beyond and 
potentially conflict with bioethical principles.  
Through the biomedical gaze, health professionals seek rational, objective, 
measurable indices of health, illness and treatment success, which within Treat-all 
are namely rates of HIV diagnosis, treatment initiation, and viral suppression. The 
UNAIDS “90-90-90” targets are the diagnosis of 90% of people living with HIV, 
ensuring 90% ART initiation for those diagnosed and 90% viral suppression for those 
on ART (UNAIDS, 2014). However, the unilinear metrics of 90-90-90 do not reflect 
and account for individual variation in response to the policy and time for treatment 
readiness, and this divergence must be examined (Kawuma et al., 2018). Healthcare 
workers may perceive moral responsibility, for example to reduce the risk of HIV 
transmission to others in the community, or to protect an unborn child from HIV 
acquisition (Vernooij and Hardon, 2013). However, what will happen when patients’ 
choices conflict with public health goals, and how will the tension between these 
potentially differing priorities be managed? 
In the context of Treat-all, it is important to consider how the individual right to 
choice is balanced against the public health good, and how the seemingly 
straightforward logic employed within healthcare ethics may translate to how Treat-
all is implemented and experienced in reality. We aim in this article to critically 
engage with these questions, through examining the lived experiences of individuals 
seeking to make choices about when to initiate ART, and the perspectives and 
experiences of healthcare workers who operate at the heart of this interface.  
Choice for treatment: extending beyond the biomedical gaze 
Decision-making is deeply embedded in, shapes and is shaped by interactions with 
others. Autonomy can thus be considered as relational (Keller, 1997), with a patient’s 
agency potentially “emerging in and through a web of intersubjectivity and 
relationality” (Rapley, 2008, p.436). For example, a study examining views towards 
provider-initiated HIV testing in Kenya and Uganda found it rarely the case that an 
individual made a choice to accept HIV testing in isolation of other influences. 
Decisions were socially embedded, and included consideration of the views of family 
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members, partners, religious leaders, friends and others (Hardon et al., 2011). In 
Eswatini (formerly Swaziland), meanings of treatment offering the potential to 
prevent HIV transmission, and conceptions of initiating ART early, before one 
becomes visibly ill, are “incorporated into existing socialities such as kinship 
relations, and should be seen in relation to specific local moral worlds” (Vernooij et 
al., 2016, p.11).  
Decision-making can be considered as an ongoing event occurring over multiple 
encounters, and distributed over interactions with a number of different people, 
forms of information and technologies (Rapley, 2008). Recognising the distributed 
nature of decision-making may facilitate moving from an overly prescriptive (and 
simplified) view to a more plausible set of ideas, which capture its complexity 
(Rapley, 2008), and reflect that decision-making processes are fluid and not 
necessarily linear. 
Following diagnosis with a chronic illness such as HIV, individuals may undertake 
what can be described as “identity work”, involving a process of coming to terms 
with their diagnosis and the changes this may instil to their sense of self and their 
health identity (Exley and Letherby, 2001; McGrath et al., 2014; Roth and Nelson, 
1997). Polak describes the identity work involved in individuals’ decisions to take 
statins, and how resisting medication can be portrayed as a way of resisting an illness 
label (Polak, 2017). Identity work is also a part of managing a perceived “spoiled 
identity” (Goffman, 1963), as individuals may take steps to conceal information 
which can be discrediting, with ART offering the potential to facilitate this through 
preventing the development of HIV-related symptoms which may render one’s 
status visible (Horter et al., 2019a). Nguyen proposed the concept of “therapeutic 
citizenship” (Nguyen, 2005), considering changes in identity that. Arise through 
interactions with biomedical authorities, and as people with HIV appropriate ART as 
a set of rights and responsibilities (Nguyen, 2005). However, ART can serve as a daily 
reminder of ill health, and those who feel healthy and “normal” may want to protect 
that state of being, thereby resisting from treatment-taking (Persson et al., 2016). 
“Many individuals may simply choose not to forefront HIV as the central or defining 
issue in their lives” (Kielmann and Cataldo, 2010, p.25), and people can have logical 
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reasons for not taking ART (Pound et al., 2005). Thus seemingly “irrational” 
behaviours such as not taking treatment as prescribed, may be “ways in which people 
enact agency in the context of their day-to-day needs” (Paparini and Rhodes, 2016, 
p.506). 
There can be several processes of self-management involved in living with a chronic 
illness, including adjusting to and accepting the “new normal”, making sense of 
illness, and adjusting expectations of life and self (Schulman-Green et al., 2012). 
Schulman-Green and colleagues present taking ownership of health needs as a key 
component of the self-management process, including learning about and managing 
body responses, and developing confidence and self-efficacy for managing the 
condition and its treatment (Schulman-Green et al., 2012).   
We build upon the work of Rapley and Schulman-Green to examine how patients in 
Eswatini decide to initiate ART under Treat-all when considered asymptomatic, and 
how this may influence their ongoing treatment-taking and engagement with care. 
We engage with the juxtaposition of the biomedical gaze, which focuses on Treat-all 
success based on unilinear metrics such as 90-90-90, compared to the lived reality of 
people’s experiences and choices for engaging with care. Individuals’ choices include 
more than one potential pathway, albeit taking one that does not involve immediate 
ART involves resistance to the biomedically prescribed “necessary” pathway. We 
also situate these findings within extant relevant literature and theory, to interpret 
and understand patient perspectives on this topic in the context of existing 
knowledge, and to compare healthcare workers’ perspectives with those of patients. 
Study methods 
This analysis draws on data from a longitudinal, qualitative study, conducted in the 
Kingdom of Eswatini from August 2015 to November 2017. The broader study 
included repeat interviews with individuals living with HIV enrolled in HIV 
treatment and care under Treat-all, one-off interviews with healthcare workers, and 
observations of clinic and community activities relating to Treat-all.  
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Eswatini is a small, landlocked country in southern Africa, bordering South Africa 
and Mozambique, with a population of 1.3 million (UNESCO, 2018). It is the last 
remaining absolute monarchy in Africa.  The country grapples with a high HIV 
prevalence, generalised epidemic. An estimated 27% of adults (aged 15-49 years) are 
HIV positive, and the majority of transmission is through heterosexual sex (UNAIDS, 
2016). The Shiselweni region is a largely rural area in southern Eswatini, where the 
[institution] and [institution] provide decentralised treatment and care for HIV and 
tuberculosis. In October 2014, a Treat-all implementation pilot began in Nhlangano 
health cluster of this region, aiming to contribute towards reduced HIV incidence and 
improved clinical outcomes for PLHIV. Treat-all was rolled out nationally in October 
2016. 
The broader qualitative study comprised of 106 interviews; including interviews with 
29 people living with HIV, who were interviewed between two and four times from 
August 2016 to September 2017; and 20 interviews with healthcare workers employed 
in a range of positions relating to the implementation of Treat-all, conducted in March 
2017. Thirteen days of formal observations were conducted of clinic and community-
based activities relating to Treat-all (including health talks, HIV testing and 
counselling, pre-ART counselling and adherence counselling for those with 
unsuppressed viral load results), in August to September 2015, and in March 2016. 
Broader ethnographic insights were generated through fieldwork conducted by the 
lead author in Eswatini during the period February 2015 to November 2017.  
Interviews with healthcare workers and observations were conducted by the lead 
author, and interviews with people living with HIV were conducted by same-gender 
siSwati speaking research assistants, supervised by the lead author.  
All people living with HIV included in the study were considered clinically 
asymptomatic and would have been otherwise ineligible for treatment at the time, 
had it not been for the Treat-all pilot (i.e. CD4 count ≥ 500 and WHO disease stage 1). 
They were all enrolled into HIV care under Treat-all, and were selected to include a 
gender distribution reflective of the proportion of women to men on treatment, range 
of ages and treatment-taking experiences (for example, those recorded lost from 
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treatment, and those on treatment for differing periods of time). Healthcare workers 
included those employed by [institution] and [institution], from each of the clinics 
involved in Treat-all implementation (eight primary healthcare and one secondary 
health facilities), with a range of positions (adherence counsellor, nurse/nurse 
supervisor, doctor).  
For the purposes of this analysis, four people living with HIV were selected to allow 
a deeper exploration of decision-making and self-management processes relating to 
individuals’ engagement with HIV treatment and care under Treat-all. Focusing on 
fewer individuals enables greater detail, richness, completeness, and variance, than 
other analytical approaches that draw upon interviews from a higher number of 
people (Flyvbjerg, 2013; Prior, 2016). Each of these individuals were interviewed 
three times over a period of 10 months. The first interview focused on exploring the 
individual’s life story, including their upbringing, key life events, relationships and 
hopes and aspirations, aiming to build an understanding of the participant’s social 
and lived context, and to develop rapport. Subsequent interviews explored 
experiences relating to health management, visiting the clinic, HIV testing and 
diagnosis, ART offer and initiation decision-making, and ongoing treatment-taking 
and engagement with care. Interviews were conducted in siSwati by same-gendered 
interviewers, mostly held at participants’ homes. Following each interview, field 
notes were written to capture information including the interview arrangement, 
setting, and interviewer-interviewee dynamics. These also included a reflection on 
methods, emerging themes and a summary of the individual’s account, thereby 
supporting the analytic process beginning from the point of data generation. 
Interviews were audio-recorded following written informed consent, and then 
translated and transcribed.  
These four individuals were chosen for presentation in this paper as their narratives 
highlight a range of experiences and exemplify the type of experiences reflected in 
the data more broadly. We also situate their narratives within the broader health 
system context by drawing upon healthcare worker interview and observational 
data, examining how various perspectives may confer and differ. Healthcare workers 
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play a pivotal role in implementing Treat-all, and their narratives can provide insight 
to the potential tensions and dissonance between public health and individuals’ 
goals. Interview data (transcripts and field notes) were analysed using narrative 
methods, exploring how language is used to communicate meaning, how individuals 
construct identities through story-telling, and how accounts can be used to recount, 
interpret and make sense of past experiences (Riessman, 2008). Additionally, how 
individuals’ accounts of their diagnosis, treatment offer, treatment decisions and 
treatment-taking might change over time were examined, through analysing 
decision-making narratives within each interview and longitudinally across repeat 
interviews for each person.  
The Eswatini Scientific and Ethics Committee, the [institution] and [institution] Ethics 
Review Boards granted ethical approval before study commencement. Pseudonyms 
are used to protect individuals’ confidentiality. 
Findings 
Zandile: adjusting to illness and ART decision-making 
Zandile is 26 years old and has two young children from two separate relationships. 
She had hoped both relationships would lead to marriage and had then discovered 
each partner to be having relationships with other women, who they then went on to 
marry. She is an educated, ambitious young woman who was training to be a teacher 
throughout our conversations with her, and hoped to be able to build a home and 
provide for her mother and her children. According to her clinical record, she was 
diagnosed with HIV in April 2015 and initiated ART the same day as her diagnosis.  
This diagnosis came as a shock to her. 
How difficult processing an HIV diagnosis can be is apparent in Zandile’s narrative. 
She described herself as being Christian, “well behaved” and never thinking she 
would have HIV. During the first interview in September 2016, she told us she felt 
she had ‘fallen from Christian values’ and appeared to carry a lot of self-blame and 
shame. She then appeared to come to terms with her diagnosis in the later interviews 
in January and May 2017. This reflects the challenging processing of emotions that 
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can occur following diagnosis with a chronic condition, described by Schulman-
Green and colleagues, including dealing with the shock of diagnosis, self-blame, guilt 
and grief, followed by making sense of illness and accepting the “new normal” (2012).  
When Zandile described her diagnosis in the first interview it was unprompted, as 
we had been talking to her about her life story. She said that she “messed up”, and 
she thinks she should have left her boyfriend before they slept together, but they slept 
together and she became pregnant. She first attended a clinic for her pregnancy, 
where she was tested for HIV and tested negative, and then she decided to change 
clinics as that particular clinic was expensive and she felt that it did not do thorough 
checks including for STIs, which she wanted. When she changed and went to the 
health centre her blood was tested, and in the second interview she told us that she 
was not informed of the results, but was just given a piece of paper, which she did 
not read. When she eventually saw another nurse and was told that she had been 
diagnosed with HIV she said: “I felt like the hair on my head is coming off… and as 
though I would get into a hole and the earth just curves in”. This visceral reaction 
shows this experience was a fracturing moment in which everything was going to 
change, a moment of biographical disruption (Bury, 1982; Charmaz, 1983). 
She was then advised to go for counselling in a different room. When she got to the 
counselling room, she said several people were there relaxing and drinking tea, as 
though they were not expecting her and did not know the situation she was in, which 
she found difficult. She said: 
I am just standing there, and they said I should ask and I didn’t know what 
to ask… I went back there, and the nurse gave me the pills… I was scared… 
and she said, “if you start them you start for the rest of your life”, and then I 
got so nervous… really, I felt like I was dying and being buried at that time. 
They gave me huge containers of pills… and I was carrying a mini bag, it’s 
too small to put everything inside, and people will be looking at me, you see 
that when you are taking treatment people are looking at you, really I was 
very low. 
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Zandile’s description of how she felt captures the gravity and shock that 
accompanied the news of her receiving a positive test result. In the context of Treat-
all it may be presumed that a positive HIV test result provides a final confirmation of 
an existing embodied sense of potential HIV positivity or risk. However, in the 
absence of symptoms  this can be challenging (Kawuma et al., 2018; Persson, 2013), 
as appeared to be the case for Zandile. HIV does not appear to be a normalised life 
event, nor does being on ART appear to be considered a normalised state, certainly 
not immediately, as is evident in Zandile’s account. This shows that while HIV testing 
and ART initiation may be becoming an increasingly routinised process within the 
healthcare system, at an individual level it can be cataclysmic. The recognition of such 
a reaction is subsumed within the momentum that is integral to Treat-all.   
In the first interview she told us of her hopes that if she tested again at a different 
clinic maybe they would find a different result, as the testing machines are not the 
same. She hoped if she spoke to a pastor who she had heard on the Voice of the 
Church had healed people who are positive, that they could heal her, “I am trying for 
this thing to move from my body, I do not want it”. She also asked us about how far 
the research was progressing with the possibility for curing HIV, and said she was 
too scared to ask about this at the facility. She told us that she took the treatment from 
the facility and hid it in a bush near her home for around 3 weeks, appearing to 
engage with care to healthcare workers at the clinic, but not swallowing the pills. 
Zandile’s narrative highlights how difficult processing an HIV diagnosis can be, and 
there may be identity work involved in coming to terms with and absorbing an 
identity related to a chronic disease. This identity work may involve adjusting to the 
shock of an HIV diagnosis and the threat of illness, as well as reconciling oneself to 
the options available for ensuring good health and keeping the illness at bay.  Taking 
prescribed treatment can be a concretisation and reinforcement of illness rather than 
health, with loss of control and autonomy rather than empowerment, and with shame 
and difference, not normalisation (Pound et al., 2005). This is alluded to in Zandile’s 
account, when in her third interview she reflected on her initial decision not to take 
treatment:  
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When you go to the hospital and they give you Panadol [pain killer], you do 
not have to take it again once the headache is gone… but these [ART] that you 
have to take for the rest of your life, pills every day… and they are this big… 
no, no, no, I felt like it meant I was really sick.  
By the third interview she talked about how she was adjusting to her “new” self and 
accepting the “new normal” (Schulman-Green et al., 2012), for example she said “I 
decided to make HIV my friend” and spoke of not letting it have too much influence 
over her sense of self and her life: 
I do not take note of it, I do not give myself time to think that I am positive. 
When I get angry I do not then have pity and think “oh because I am 
positive”… I just don’t think about it and dwell on it, it is just something I 
have put on its own shelf. 
This reveals the continuum of identity work that is required in initiating and 
committing to sustained treatment-taking. Zandile’s perception of treatment 
appeared to shift over time, from ART initially symbolising illness and therefore 
being potentially frightening, to later signifying a means to contain the illness and 
deflate the significance of HIV in her life and identity. Over time HIV may therefore 
come to be considered contained, rather than signified through ART (Pound et al., 
2005). This process of transformation took time and work, and will likely require 
ongoing work to maintain, rather than representing a fixed state.    
Decision-making can be considered as a process occurring over multiple encounters 
with healthcare workers, and with a range of other people and technologies, as 
outlined by Rapley (2008). When Zandile narrated her experience of being diagnosed 
with HIV and offered ART, her account highlighted multiple encounters with 
healthcare workers even within her first clinic visit. The information she received 
from providers at the clinic formed part of the knowledge that she was processing 
towards her decision to initiate ART. She described reflecting on what the healthcare 
worker had told her, that she would give birth to a positive child if she did not take 
treatment, which she did not want and which influenced her decision to eventually 
start treatment, although ‘it was not easy’. 
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Before starting treatment, Zandile underwent a process of thinking and seeking 
information through consulting people and technologies. First, she told us that she 
spoke to her boyfriend, who assumed that she had discovered her HIV positive status 
before she had told him of the outcome of the clinic visit herself, which led to her 
suspecting that he had already known his status and infected her with HIV. She said 
her boyfriend was not on treatment, and he advised her to re-test elsewhere as her 
test result may have been inaccurate or untrue. She said that what he told her made 
her think they were lying at the clinic, hoping he might be right, and that she might 
be negative, so she said she stayed without taking treatment and continued to think 
about it.  
She described seeking information on the internet, listening carefully to programmes 
about HIV on the radio and reading about relevant articles in the news. These sources 
of knowledge all seemed to reinforce the same perspective, that there is no cure for 
HIV and that treatment is the means through which to prolong health and life.  
She then contacted a pastor, seeking advice and hoping he would be able to heal her. 
When this pastor advised her to follow the advice at the clinic and take the treatment, 
that is when she said she decided to start the treatment. This highlights how the 
support of faith networks can provide a confirmatory catalyst for taking up 
treatment. However, there may be variation in effect of the influence of faith, which 
in other examples has been described as potentially contradicting engagement with 
biomedical services (Roura et al., 2010; Wringe et al., 2009). 
The words “my whole life” scared me, because I thought now I have to take 
pills for the rest of my life, when I do not like pills and they scared me too 
when I looked at them, ha they are so big! So I stayed for some days, or was 
it weeks… I had just put them there and did not take them. I would listen to 
“HIV kills”, and I did not have any peace. I called this pastor… because he 
did not know me… I told him that at the hospital they told me this… and the 
pastor said “do everything they say at the hospital, we will pray for you”. I 
said, “so should I take the treatment?”, and he said “take them”. And that is 
when I started taking the treatment, I started that way. 
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Zandile’s story emphasises  treatment decision-making processes as non-linear. If an 
individual feels forced or shamed into initiating ART, and if genuine patient 
engagement and consensus is not achieved, there may be greater risk of an individual 
reversing their decision to initiate treatment, or not digesting ART despite receiving 
a prescription. 
Sifiso: taking time to reconcile a sense of self with HIV 
The identity work involved in processing an HIV diagnosis and deciding whether or 
when to take ART can also be seen in the story of Sifiso. Sifiso is a 29-year-old man 
who was studying at tertiary level in Mbabane, the capital city, when we met with 
him. He was recorded by the HIV clinic as being newly diagnosed in February 2015, 
with a CD4 count of 812, and as initiating ART two months later. However, during 
interviews with us in September 2016, December 2016 and June 2017, he narrated his 
HIV diagnosis as having occurred several years earlier. He told us that he initially 
doubted whether he was really HIV positive and re-tested for HIV as though he was 
testing for the first time, wanting to confirm whether his HIV diagnosis was accurate 
or true. He described eventually starting to experience signs, which he later 
interpreted as indicative of HIV, including weight loss, lethargy (waking up tired), 
chest pains and coughing. He spoke of this triggering his decision to start treatment, 
as he did not want his health to deteriorate further. The importance of embodied, 
experiential evidence of treatment need for initiation decisions is reinforced by 
findings from other studies with people living with HIV (Kawuma et al., 2018; Zhou, 
2016).  
The resolution of identity that can be undertaken through engaging with treatment, 
and that can work to reconcile a spoiled identity is described by Camlin and 
colleagues in Kenya and Uganda (Camlin et al., 2017). Sifiso’s story extends the 
concept of therapeutic citizenship, showing how this may unravel and be threatened 
by refusing or delaying ART initiation. This illuminates contrary currents wherein 
Treat-all is based primarily on a notion of patient compliance rather than patient 
choice, and there is a thorniness with how healthcare ethics may translate in practice. 
In this context, taking an alternative route, such as wanting more time before 
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initiating ART, is characterised as resistance, and could potentially contribute to an 
additional spoiled identity (Goffman, 1963) through subverting the expected order.  
In the second interview, Sifiso said: “I was having doubts that, do I really have it? But 
then again, I looked at my system that some days I would wake up tired and yet I 
didn’t do anything, and then I felt it’s time to take the treatment”. In the third 
interview he went on to say: “When you’re still strong there’s nothing that 
encourages you to start the treatment… it’s just that you feel you’re still fit… I was 
still feeling fit and that I can still continue living… but as time goes on you realise 
that the immune system gets weak and so it needs something to boost it”.  
Sifiso’s account of his treatment-taking decisions highlights the importance of 
embodied, experiential evidence indicating the need and time for treatment. This 
echoes Conrad’s theorisation of embodied self-regulation, which emerged from his 
work with epilepsy patients whereby individuals would interpret their physical 
symptoms and alter the course of their treatment in order to test its efficacy, seeking 
evidence that the treatment was necessary and effective for motivating their 
engagement with it (Conrad, 1985). We also describe the importance of individuals 
having evidence of treatment need and effect for motivating treatment-taking in the 
broader study context (Horter et al., 2019b). This demonstrates that the act of 
interpretation based on physical symptoms requires the passing of time for evidence 
to become manifest and for responsive actions to be taken, which therefore cannot be 
instantaneous for those who are asymptomatic.  
Celiwe: the journey to treatment readiness beginning prior to the clinic 
encounter 
For others, the decision-making process and identity work may have begun before 
the initial ‘clinic encounter’ at the point of HIV diagnosis, when each individual 
diagnosed with HIV is then referred for ART. Celiwe is a 19-year-old woman who is 
married with 2 children. She completed primary school education and works at a 
textile factory. She was recorded as diagnosed in January 2015, and as initiating ART 
less than a week later. She described her health seeking as initially being prompted 
by embodied experiences that something was not right, as she had repeated stomach 
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ache, diarrhoea, felt weak and had lost weight. This health-seeking process was 
influenced by different people, in particular her mother who told her she should go 
to the hospital, and then by the healthcare worker who told her to get tested, and then 
diagnosed her with HIV.  
Although there may be a common epidemiological trend lending towards the 
anticipation of HIV acquisition, in the context of Treat-all in South Africa for example, 
acceptance of HIV-testing remains constrained by poor self-assessment of HIV risk 
(Orne-Gliemann et al., 2016). However, Celiwe describes reflecting back on her 
lifestyle in conceiving her own HIV risk, which supported her coming to terms with 
her diagnosis and engaging with treatment. Prior to the initial clinic encounter where 
she was diagnosed with HIV, she described her processing of past experiences, in 
light of her current physical symptoms, which led to her thinking she might be HIV 
positive and feeling prepared for the chance of a diagnosis and the potential need for 
treatment before she tested for HIV. In the second interview in November 2016 she 
said: 
When you are doing bad things, you don’t think of the risk, like when I was 
in [city] living that life I never thought of it. But when I was sick with stomach 
ache, it then came back to me that in [city] I was living that life and not even 
protecting myself, and that is when it dawned on me that it could happen that 
I too am like this. That is what made it easy for me to test and further accept 
the treatment.  
This decision was also influenced by other sources of knowledge, including observed 
experiences from her family life, as she had seen someone in her family who she knew 
had HIV living a “normal” life with treatment. She described the decision to initiate 
treatment as being her “choice”, saying that healthcare workers gave her the space to 
make her own decision and told her that it was up to her if she wants to start them or 
not, as her CD4 count is high whereas if it were lower she would be “forced to start 
them”. While she appeared to embrace treatment, she said she quickly accepted her 
diagnosis and felt ready for treatment; this engagement with treatment appeared to 
be more about resisting health deterioration and death than a positive “choice”: 
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I am scared that I will become too sick maybe… I think it is better than for me 
to end up dying and my children are left alone. So it is better for me to take 
them… I had heard that if you are positive and do not take the treatment you 
could die… I looked at having a child and if I do not start them and I fall sick 
and die, who will take care of my child  
Nobuhle: navigating and resisting engagement with treatment and care 
Evidence suggests that where the decision to initiate ART is not intrinsically based, 
and where individuals may feel coerced to test and take treatment, this can influence 
their disengagement from care, particularly found in the context of Option B+ for the 
prevention of vertical HIV transmission (An et al., 2015; Wringe et al., 2017). This is 
reflected in the story of Nobuhle, who was diagnosed with HIV during pregnancy. 
She described testing as “not up to you”, but as a necessity during pregnancy in order 
to access other pregnancy-related health services. She appeared not ready to test for 
HIV, and had not been able to adjust to her HIV diagnosis and undergo the identity 
work described by others. She did not believe her diagnosis, having a high CD4 count 
and no physical “signs of HIV”, and she felt she was too young to have HIV. In her 
second interview she described her experience being diagnosed with HIV and offered 
treatment:  
It is the name [HIV], because the CD4 is high and it is just the positive word 
that is pointing, there are no other signs… I will take them [ART] when I can 
see that it is now really there… They [HCW] did not ask me, they told me that 
I will start them [ART] because I am pregnant… They told me that when you 
are pregnant… whether you like it or not you take the treatment because they 
say when a baby is found to be positive, you will be arrested 
In her first and second interview she told us that she was not taking the treatment, 
and had stopped taking it after her pregnancy, “because I was doing it for the child, 
not that I was ready to start taking treatment until I die”. As well as not believing her 
HIV diagnosis and need for treatment in the absence of any signs of ill health, she 
also had concerns about taking treatment herself without having disclosed to her 
boyfriend, fearing the anticipated negative consequences of him potentially 
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discovering her status through her treatment-taking. However, by the third interview 
she said she had re-engaged with treatment, re-testing and starting afresh at a 
different clinic, as she feared the healthcare workers would assume she would stop 
again if she told them her treatment history and that she already knew her status. She 
said that she now felt ready for treatment, and did not want to become sick and 
bedridden, when she felt she may not be able to fully recover. She also described 
embodied changes including weight loss and feeling as though she was not 
recovering physically, as influencing her decision to re-engage with treatment: 
Instead of recovering, I kept on losing more weight. Only to find that even the 
CD4 count was less, from what it was, they had dropped drastically… I feel 
like I am ready now 
Dissonance between policy and patient priorities: healthcare worker 
perspectives 
We have seen the complex process that individuals can go through in coming to terms 
with an HIV diagnosis and deciding when to start ART. However, this is not 
necessarily reflected or accounted for through the biomedical gaze which measures 
success of Treat-all implementation based on unilinear metrics, whereby almost all 
of those diagnosed HIV positive should initiate treatment within a short timeframe.  
Healthcare workers’ accounts highlight the ways in which providers straddle, and 
try to reconcile, the differing demands and priorities of patients and public health 
policy. Healthcare workers unanimously describe a strong desire to support patients 
to achieve good health outcomes and a positive life with and beyond HIV, 
demonstrating empathy and flexibility in caring for patients. Their accounts are 
interwoven with descriptions of their perceived pressure and responsibility to meet 
targets and to ensure patient “compliance” in successfully implementing Treat-all. 
Health care workers also recognise that some patients cannot be “convinced”, and 
that they cannot force patients to engage, or to take treatment once they are home.  
The regional and national monitoring events at which each clinic’s achievements are 
displayed and judged were described, where questions are asked as to why staff have 
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not initiated all those who had been diagnosed HIV positive. Healthcare workers 
described feeling that they must demonstrate their competency in testing and 
initiating patients, and several appeared to blame themselves and their abilities if 
they were not able to “convince” patients to “comply”. This echoes Vernooij and 
colleagues’ finding that healthcare workers felt they would be judged as having failed 
if a woman refused an HIV test during antenatal care (Vernooij and Hardon, 2013). 
One clinic nurse told us: 
We know that counselling takes time and convincing someone takes a lot of 
effort. If only the program would allow and not judge us like we have failed. 
They just make sure that they are following us, just to see what are we doing 
about it. 
Healthcare worker accounts highlighted how this pressure could translate to the 
messaging they disseminated to patients and their approach in trying to achieve good 
results, which appeared to be particularly acute for pregnant women, as healthcare 
workers felt additionally responsible for the health of the child. A nurse at a different 
clinic explained: 
Maybe we are coercing them much... because they are already forced to come 
to the facility for antenatal care, so when they come for antenatal care, every 
time they come you have to force them, "you have to start the ART".  So they 
felt no, the best thing is to take the tablets and put them at home so that you 
will think I’m taking them while I’m not, because they felt they were forced.  
This highlights the complexity of healthcare ethics in reality, and how the 
individual’s right to choice is navigated and balanced with healthcare workers’ trying 
to encourage and ensure what is “best” for the greater good. The sense of greater 
good, and the perceived responsibility for upholding and protecting it, may have 
differing parameters and scales, with healthcare workers potentially feeling 
responsible for their patients, their community, or the broader community. The wider 
the scope, the more emphasis can be placed on treatment as prevention, whereas 
aligning the parameters with an individual patient can heighten the tension in 
encouraging someone to start treatment even when they are known to not be ready. 
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This suggests a moral dimension to treatment as prevention, whereby people living 
with HIV are considered at blame for potentially spreading the virus, and responsible 
for containing it (Bond et al., 2016), and where delayed ART initiation and sub-
optimal adherence may also become morally framed (Keogh and Dodds, 2015). 
While patients may subscribe to the hierarchy that exists within practitioner-patient 
relationships, and follow healthcare worker advice, individuals are also self-
determining agents who challenge and resist the structures of power and domination, 
with the potential to resist or rebel from following medical advice as prescribed 
(Foucault, 1963). Foucault highlights the ways in which care can provide an 
opportunity for control, as the receipt of care may involve submission (Foucault, 
1979), illustrating an “inherent dialectic between care and coercion within systems of 
discipline”, and how those involved in “webs of discipline are also involved in 
appropriating, re-inventing and resisting techniques of power” (Vale et al., 2017, 
p.1288). If healthcare workers use their authority to control patients, they may 
thereby contribute to fashioning a form of patient identity which reinforces this 
hierarchy (Russell et al., 2015). The clinic may offer a space within which healthcare 
workers can exert their authority and encourage patients to comply, but once patients 
leave the bounded realm of the clinic their sustained engagement relies on an 
individual’s agency and commitment to ART.  
Biomedical responsibility assumes that individuals will adjust their actions once they 
are educated, with their rationality being scientifically or biomedically based 
(Beckmann, 2013). Patients are co-opted into a set of rigid conditions that determine 
treatment access and align their behaviour with what is deemed ‘appropriate’ and 
‘healthy’ (Mattes, 2011), with their inclusion therefore resting on a performance of the 
deserving citizen-consumer (Vale et al., 2017). Healthcare worker accounts 
emphasised the importance of patient responsibility, in that patients’ must be 
responsible for their lives, for their health and treatment-taking. This was also 
reflected in the approach observed in counselling sessions. Blood tests to monitor 
patients’ treatment success appeared to also be appropriated as means of ensuring 
patient “compliance” with treatment-taking, representing a surveillance technology 
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and mechanism for control, encouraging patients’ self-regulation of their treatment-
taking to avoid detection (Foucault, 1979). We observed this within adherence 
counselling sessions, for example when one patient who was presumed to be non-
adherent was told that the tests they were going to run (viral load monitoring) would 
reveal the truth about their treatment-taking.  
Healthcare workers talked about how important it was to them to support patients 
towards achieving the best outcomes possible, and ultimately to live a long healthy 
life. Many spoke of the emotional toll from working with large numbers of patients, 
and the difficulties they faced with trying to encourage patients to successfully 
engage with treatment and care. Several highlighted the importance of patients 
feeling they had choice and ownership over their health and treatment-taking and 
asked for more support and understanding from programmes in their performing 
their work. As one nurse said: 
You cannot just give that patient treatment, they would not adhere, it’s not 
their treatment. They need to be on the team, and actually say yes. Because if 
you push the treatment on them, it becomes your treatment. So, it has to be 
theirs, they should own it… the whole programme, they should own it, so 
that they keep their appointments, they take their tablets even. 
Taking ownership of health needs: How sustained treatment-taking is 
navigated over time 
Taking ownership of health needs involves learning about one’s condition, managing 
and taking medicines, and becoming an expert  (Schulman-Green et al., 2012). 
Additionally, patients’ perceptions of their own capacity for disease management 
and their beliefs about how much control they have over their health outcomes 
influence treatment-taking (Nafradi et al., 2017). This highlights the importance of 
individuals being involved in their treatment and care, taking control, and being “on 
the team”.    
Zandile spoke of the treatment-taking routine she established, and adjusting her life, 
so she is now used to going to the clinic regularly. She appeared to feel a sense of 
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responsibility for her treatment-taking and for managing her health, drawing upon 
various approaches to continue to persevere and motivate herself to take it. She spoke 
with a sense of pride of how she would continue, and “stand up properly and take 
them”. Sifiso said he felt his life was dependent upon treatment-taking, and it was of 
utmost importance to “be faithful to them at all times”. He described ensuring he 
checked the time for taking his treatment, telling himself to take it and focusing on 
the dreams he wants to fulfil in the future that he feels treatment can help him 
achieve.  
According to Celiwe, this was not always easy. She spoke of “begging” herself to take 
treatment, using her faith to find strength to persevere and reminding herself of her 
reasons for taking it (including to avoid death), for example she told us “I just tell 
myself that by missing a dose I am killing myself”. She said she had many difficulties 
taking treatment while pregnant, with morning sickness and vomiting, leading to her 
stopping work so she could have more time to eat and then take the treatment, 
thereby prioritising treatment-taking over other areas of her life and highlighting the 
sacrifices being on treatment can require (Beckmann, 2013). She felt able to make this 
choice because she was supported by her husband and mother, whereas for others 
this may not be the case.  
These findings provide insights into the complex process that individuals can go 
through in coming to terms with an HIV diagnosis, feeling ready for, and deciding to 
initiate ART. This process is both temporally and individually varied, and an 
individual’s priorities may differ from the priorities of the public health and 
biomedical agenda framing Treat-all care. Healthcare workers describe the ways in 
which they are confronted with, and try to reconcile these two agendas, recognising 
the importance, and also the underlying challenges, of achieving targets for testing 
and initiations, and that some patients cannot be “convinced” to “comply”. Several 
individuals described the importance of having a sense of choice regarding their 
treatment initiation, which could potentially influence their ownership over the 
management of their condition, in turn potentially supporting their motivation for 
sustained treatment-taking.  
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Conclusion 
It is important to understand the complexity of the ART initiation decision-making 
process, which for some may involve multiple encounters, with multiple people and 
multiple sources of information. Additionally, the identity work and process of 
adapting to the “new normal” following an HIV diagnosis may take time, and can 
require embodied, experiential understandings of the need for treatment, additional 
to the sources of knowledge that may be experienced and received. Some individuals 
engage with HIV testing services having already begun or undergone these processes 
and feeling ready for the chance of an HIV diagnosis and lifelong treatment, whereas 
others need more time, and tailored information to support this journey. Once 
individuals feel they have come to terms with their diagnosis and have chosen to 
engage with treatment and care for themselves, the process of ownership of health 
needs can support and foster determination and self-responsibility to navigate and 
overcome challenges with treatment-taking, thereby supporting engagement with 
care over time.  
Healthcare workers’ perspectives and experiences should also be considered, in 
particular in terms of the pressure they may experience to achieve successful Treat-
all implementation and meet targets for patient “compliance”. Having more 
understanding of the challenges patients can face coming to terms with an HIV 
diagnosis, starting and continuing on ART, and the challenges healthcare workers 
can face in supporting patients on this journey, will hopefully enable an environment 
conducive towards supportive practitioner-patient relationships and service delivery 
which is tailored to individual patient needs, as opposed to one which is coercive. 
Allowing healthcare workers to engage with the logic of different individuals, which 
for some will involve giving an individual time to consider the benefits of treatment 
according to their own rationale, could be important for their sustained engagement. 
Our findings suggest that where patients feel coerced to undertake testing or 
treatment this may undermine their engagement with care, while conversely choice 
and ownership may support sustained engagement.  
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Overview 
The literature that I presented in Chapter 2, and the findings presented in Chapters 4 
and 5 suggest the importance of individuals having evidence of treatment need for 
motivating their engagement with treatment. Conceptions of health and treatment 
need that are experiential and embodied may be particularly important in framing 
individuals sense of treatment necessity, which can be challenging for those without 
signs or symptoms indicating ill health. Additionally, the literature I engage with in 
Chapter 2 suggests that such experiential conceptions may also relate to ongoing 
treatment-taking, with evidence of treatment effect potentially important for 
motivating continued engagement with it. In the past, illness histories could be 
drawn upon to motivate ongoing treatment-taking, highlighting the difference 
treatment made for individuals’ health. Under Treat-all, when individuals 
increasingly initiate treatment when asymptomatic, this difference may be less 
apparent, and it is important to consider how ongoing engagement will be motivated 
and navigated in this context.  
This paper explores how treatment need is understood in the context of Treat-all, and 
how ongoing engagement in care is navigated.  Findings draw upon a sub-sample 
from the main phase of research, of 17 people living with HIV who had been on ART 
for a mean of 20 months, and 20 health care workers. The findings presented in this 
chapter highlight the importance of individuals’ perceiving need for treatment and 
having evidence of the difference it is making to their health, for motivating sustained 
treatment-taking.  
This paper aligns with research objectives 2 and 4: 
2. To examine how treatment is perceived and experienced by those who are 
asymptomatic 
4 To examine how ongoing engagement in HIV care and treatment-taking is 
navigated over time 
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Abstract 
Introduction: Treat-all is being implemented in several African settings, in 
accordance with 2015 World Health Organisation guidelines. The factors known to 
undermine adherence to antiretroviral therapy (ART) may change in the context of 
Treat-all, where people living with HIV (PLHIV) increasingly initiate ART at earlier, 
asymptomatic stages of disease, soon after diagnosis. This paper aimed to examine 
asymptomatic PLHIV’s experiences engaging with early ART initiation under the 
Treat-all policy, including how they navigate treatment-taking over the longer term. 
Methods: A longitudinal qualitative study was conducted within a Médecins Sans 
Frontières/Ministry of Health Treat-all pilot in Shiselweni, southern Eswatini. The 
Treat-all pilot began in October 2014, adopted into national policy in October 2016. 
Participants were recruited purposively to include newly diagnosed, clinically 
asymptomatic PLHIV with a range of treatment-taking experiences, and health care 
workers with various roles. This analysis drew upon a sub-sample of 17 PLHIV who 
had been on ART for at least 12 months, with mean 20 months on ART at first 
interview, and who undertook three interviews each. Additionally, 20 HCWs were 
interviewed once. Interviews were conducted from August 2016 to September 2017. 
Data were analysed thematically using coding, drawing upon principles of grounded 
theory, and aided by Nvivo 11. 
Results: It was important for PLHIV to perceive the need for treatment, and to have 
evidence of its effectiveness to motivate their treatment-taking, thereby supporting 
engagement with care. For some, coming to terms with an HIV diagnosis or re-
interpreting past illnesses as signs of HIV could point to the need for ART to prevent 
health deterioration and prolong life. However, others doubted the accuracy of an 
HIV diagnosis and the need for treatment in the absence of symptoms or signs of ill 
health, with some experimenting with treatment-taking as a means of seeking 
evidence of their need for treatment and its effect. Viral load monitoring appeared 
important in offering a view of the effect of treatment on the level of the virus, thereby 
motivating continued treatment-taking.  
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Conclusions: These findings highlight the importance of PLHIV perceiving need for 
treatment and having evidence of the difference that ART is making to them for 
motivating treatment-taking. Patient support should be adapted to address these 
concerns, and viral load monitoring made routinely available within Treat-all care, 
with communication of suppressed results emphasised to patients.   
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Introduction 
Treat-all is being implemented in several African settings, accordant with 2015 World 
Health Organisation (WHO) guidelines recommending regular HIV testing and 
immediate offer of antiretroviral therapy (ART) for all those diagnosed HIV-positive, 
irrespective of immunological status (World Health Organisation, 2015). To 
contribute towards reduced HIV incidence and the hoped-for elimination of AIDS, 
Treat-all requires engagement of individual people living with HIV (PLHIV) with 
HIV testing, prompt initiation of ART and continued lifelong treatment (Baggaley et 
al., 2015; Gardner et al., 2011; Granich et al., 2013; Nachega et al., 2014). However, 
shortfalls exist across the treatment and care cascade (C. C. Iwuji et al., 2016; Iwuji et 
al., 2018; Plazy et al., 2016).  
There is extensive research examining adherence to ART in African settings under 
previous treatment guidelines, highlighting the individual, social and structural 
factors influencing engagement with treatment and care among PLHIV (Heestermans 
et al., 2016; Tucker et al., 2017; Vervoort et al., 2007). Motivation for adherence may 
be stronger when patients are very sick at ART initiation, as the effects of ART in 
enabling a return to health and strength can create a sense of need for treatment and 
belief in its efficacy, and past illness experiences are drawn upon to motivate 
continued treatment-taking (Bernays et al., 2015; Nam et al., 2008). Many of these 
factors change in the Treat-all context, where PLHIV are initiating ART at earlier, 
asymptomatic stages of disease, where the time between diagnosis and ART initiation 
may be expedited, and the length of time on ART may eventually be greater than 
previously.  
Evidence from Prevention of Mother to Child Option-B+ (Option-B+) suggests 
retention in care among women on Option-B+ is lower than among women starting 
ART for their own health (Clouse et al., 2014; Knettel et al., 2018; Tenthani et al., 2014). 
HIV status acceptance, treatment readiness and perceived need for treatment in the 
absence of symptoms can undermine pregnant and lactating women’s retention, with 
some disengaging from care once their perceived objective of protecting the baby is 
fulfilled (Cataldo et al., 2017; Katirayi et al., 2016; McLean et al., 2017). While these 
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findings provide important insights into understanding how asymptomatic PLHIV 
may respond to ART, the experiences of pregnant and lactating women are likely to 
differ from those of the general population.  
It is important to understand PLHIV’s experiences with Treat-all care to ensure 
programmes correspond to their needs, and can adequately and appropriately 
support them to engage with treatment and care to improve health outcomes 
(INSIGHT START Study Group, 2015; Song et al., 2018; The TEMPRANO ANRS 
12136 Study Group, 2015). Additionally, from a public health perspective, suboptimal 
adherence among growing cohorts of asymptomatic patients could lead to drug 
resistance, which has been highlighted as a critical threat to eliminating AIDS by 2030 
(Jena, 2013; Wagner and Blower, 2012; World Health Organisation, 2017b, 2017a). 
This heightens the importance of understanding how treatment-taking is experienced 
by asymptomatic PLHIV enrolled in Treat-all care.  
We examine asymptomatic PLHIV’s experiences engaging with Treat-all care in the 
Kingdom of Eswatini (formerly named Swaziland), including how treatment-taking 
is navigated and motivated over the longer term (at least 12 months after initiation).  
Methods 
Study design  
This paper draws on data that were collected between August 2016 and September 
2017, within a longitudinal qualitative study on the experiences of asymptomatic 
PLHIV enrolled in chronic HIV care under the Treat-all policy in Eswatini.  
Study setting  
This study took place in the Shiselweni region of Eswatini, where Médecins Sans 
Frontières (MSF) and the Ministry of Health (MoH) collaboratively provide 
decentralized HIV and tuberculosis care since 2007, with a Treat-all implementation 
pilot beginning in October 2014. Eswatini has the highest reported HIV prevalence 
worldwide, estimated at 35% among women and 19% among men aged 15 to 49 years 
(UNAIDS, 2016), with heterosexual sex being the main transmission route (Swaziland 
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Ministry of Health, 2012). Men are generally infected at older age than women, and 
HIV prevalence peaks at 54% among women aged 35 to 39 years and 49% among men 
aged 45 to 49 years (Swaziland Ministry of Health, 2017).  
The Treat-all pilot project was implemented in the predominantly rural Nhlangano 
health zone, with eight primary healthcare clinics (largely rural, offering integrated 
HIV services) and one secondary health facility (urban, offering HIV care within a 
specific HIV-related care department or as part of antenatal care). Patient enrolment 
to the pilot ended on 31 March 2016, with Treat-all then becoming the standard of 
care in Nhlangano, and adopted into national policy in October 2016. Within the pilot 
project, prompt ART initiation was offered on the day of facility-based HIV care 
registration. Forty-nine per cent of patients initiated on the same day as enrolment to 
HIV care, and the majority of those who deferred initiated ART at a median of 10 
days (Kerschberger et al., 2018). Routine viral load monitoring was available at six 
months on ART and annually thereafter if results showed viral suppression. 
Communication of viral load results was prioritized for those with unsuppressed 
results, who were offered enhanced adherence counselling.  
Participant recruitment  
PLHIV participants were identified and recruited purposively to include only those 
recorded as newly diagnosed (within three months of enrolment to care) and 
considered clinically asymptomatic (WHO disease stage 1 and CD4 count ≥500 
cells/mm3), using the Treat-all patient database as a sampling frame. For the 
purposes of this analysis, we drew upon a subset of the study sample to include those 
who were enrolled at the beginning of the Treat-all pilot, from October 2014 to June 
2015, and who therefore would have been enrolled in at least 12 months at the time 
of first interview (see Table 1). This allowed examination of longer term, sustained 
engagement with treatment and care in the context of Treat-all. We anticipated that 
recruiting young men (aged 16 to 25) would be challenging, as very few young men 
are infected with HIV in Eswatini, and as men often access treatment and care later 
in this setting.  
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Healthcare worker (HCW) participants were sampled purposively, to include those 
from all the nine clinics involved in the pilot, both MoH and MSF staff members, and 
a range of different treatment and care-related positions, such as adherence 
counsellor (HIV-positive peer supporters), nurse, nurse supervisor and doctor (Table 
2).  
Participants were recruited until data saturation was evidenced, that is, when adding 
further participants did not generate new findings relating to the particular topic or 
theme being investigated (O’Reilly and Parker, 2013).  
Data collection and analysis  
Repeat in-depth interviews with PLHIV participants aimed to gain insight into 
changes in participants’ accounts of their experiences with Treat-all over time, and to 
build trust and rapport between interviewer and interviewee, enabling access to 
alternative layers of participants’ narratives beyond those participants may deem to 
be socially desirable. Interviews were based on topic guides and were primarily 
participant-led, with first interviews focusing on the participant’s life history, second 
their experiences of HIV testing and diagnosis, offer of treatment and experience 
starting ART. Subsequent interview(s) explored ongoing treatment-taking, and 
revisited topics explored in earlier interviews to gain greater depth of insight and to 
explore any changes. Interviews were conducted from August 2016 to September 
2017, the majority being held at participant homes, or at an alternative site if 
preferred.  
Interviews with HCW participants explored views and experiences relating to Treat-
all implementation and providing treatment and care to asymptomatic patients. 
These were one-time interviews conducted during February and March 2017, held in 
the clinics where HCWs worked.  
Informed written consent was sought prior to all interviews, including for audio-
recording, which was re-visited verbally at subsequent interviews for PLHIV 
participants. Interviews averaged 80 minutes, ranging from 50 minutes to 1 hour 40 
minutes. Pseudonyms are used to protect participant confidentiality.  
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Detailed field notes were completed for each interview, and audio-recordings were 
translated and transcribed. Data were analysed thematically using coding to identify 
patterns, categories and themes that emerged from participant accounts, drawing 
upon principles of grounded theory to raise findings to a conceptual level (Bradley et 
al., 2007; Glaser, 1999). Initial codes were organized into a coding framework, 
forming the basis of continued analysis in Nvivo 11, which was developed and 
adapted as data collection and analysis progressed. Data collection and analysis 
followed an iterative process, enabling topic guides to be adapted to further probe 
emerging themes.  
Ethics approval was obtained from the Eswatini Scientific and Ethics Committee, the 
London School of Hygiene and Tropical Medicine and MSF Ethics Review Boards 
prior to study commencement.  
Results 
Study participants 
Selecting those enrolled to Treat-all from October 2014 to June 2015 from the sample, 
seventeen PLHIV participants were eligible for inclusion in this analysis, including 
nine women and eight men, with fifteen interviewed three times, one interviewed 
four times and one interviewed twice. PLHIV participants had been on ART for a 
mean of twenty months at the time of the first interview, and there was a mean of 
eight months between the first and the last interview (see Table 6.1). Additionally, 20 
HCW participants were interviewed once (see Table 6.2).  
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Table 6.1: PLHIV participant characteristics (n=17)* 
Gender  
Women 9  
Men 8  
Age 
Young adult: 
- 17-20 years 
- 21-25 years 
 
4 (all women) 
3 (all women)** 
Adult: 
- 26-39 years 
- 40-49 years 
 
5 (1 woman, 4 men) 
5 (1 woman, 4 men) 
Enrolment to Treat-all 
Oct 2014 – Dec 2014 5 
Jan 2015 – Mar 2015 8 
April 2015 – June 2015 4 
Time between enrolment and initiation 
Same day 4 
1-6 days 5 
7-10 days 1 
10 days – 1 month 3 
1-3 months 2 
4-8 months 2 
Treatment category 
On ART 10 
Lost from treatment*** 7 
* Participant information as recorded on project patient database at time of recruitment. ** Young adults 
(aged 16-25 years) and adults (aged 26-49 years) were purposively included in the sample. No young 
men were eligible due to the epidemiology of HIV in Swaziland meaning fewer young men are infected, 
and additionally men can access care later. *** Lost from treatment defined as those with a last recorded 
visit date of at least 4 months from time of sample selection (to allow for those with 3 monthly refills) 
Table 6.2: HCW participant characteristics (n=20) 
Position 
Adherence counsellor 5 
Nurse/nurse supervisor 13 
Doctor 1 
Employer 
MoH 12 
MSF 8 
Facility 
Primary Health Clinic (8 clinics included) 17 
Secondary Health Facility 3 
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Figure 6.1 depicts a summary of the study findings, which are elaborated as follows.  
 
Figure 6.1: Diagram of findings relating to seeking evidence of treatment need and effect and 
their influence on treatment-taking.  
The perceived need for treatment influencing engagement with treatment 
and care  
For PLHIV, perceiving need for treatment was important to motivate their taking it. 
For some, receiving an HIV diagnosis was itself a pointer to the need for treatment: 
“I had heard that if you are positive and do not take the treatment you could die. . .” (Nozipho, 
woman, 19 years). Although clinically asymptomatic, some participants described 
embodied signs of HIV which served to warn them of the potential risk of 
deteriorating health:  
I started taking the treatment because I am afraid of getting sick and even at times I 
would have headache, and I would think probably it has started. (Sifiso, man, 41 
years)  
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Some believed that treatment would prolong their life. This was particularly 
described by men living with HIV, with early initiation of treatment seen as enabling 
maintenance of strength and productivity, potentially reinforcing notions of 
masculine responsibility. Additionally, several PLHIV described experiencing 
physical changes after starting ART, such as increased energy and strength, increased 
weight and feeling healthier, for example no longer experiencing headaches. This 
reinforced a sense of value to the treatment and motivated continued treatment-
taking:  
It is helping ... because most of the time before I started taking the treatment I would 
feel that my body is going down, like when you wake up you’d find that the body is 
very tired most of the time. But then since I started the treatment I feel much better 
and healthier, and my body is energetic (Mandla, man, 36 years 
Doubts about treatment need and effect undermining treatment-taking 
However, not all participants perceived themselves as needing treatment or believed 
that it could benefit them. Several described doubts about the need for treatment in 
the absence of symptoms or signs of ill health:  
The CD4 is high and it is just the positive word that is pointing, there are no other 
signs . . . I will take them when I can see that it [HIV] is now really there. (Zandile, 
woman, 23 years)  
Some patients tell you that there is no need, they will start the treatment when they 
are sick, not now. (HCW15)  
Those who did not experience any changes with ART appeared to doubt its 
effectiveness and the difference that treatment was making to them, which could 
undermine their motivation for taking it.  
The problem I have is that I haven’t seen the effective- ness of the treatment, because 
even when I go to the hospital the weight scale doesn’t reflect much of a change . . . 
nothing changed because when I went there I wasn’t sick, but I just went there 
healthy. (Jabulane, man, 31 years)  
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These doubts could also change over time, as participants sought evidence of the 
treatment’s effectiveness and interpreted their own experiential changes as 
suggesting the treatment was working. For example, Jabulane, quoted from his 
second interview above, went on to interpret his health as improving by the third 
interview:  
With the pills my brother, the way I see it, they are working because ... I used to have 
flu every now and then ... that is when I eventually got tested, but then since I started 
taking the treatment I no longer have such, I don’t get influenza and go to the hospital.  
Where doubts about treatment need and effectiveness were present, these appeared 
linked to PLHIV developing a sense of treatment fatigue over time:  
I used to just get tired and I would sometimes skip some days and not go to collect 
them . . . there were times I just would be quiet and not take it, not because there is no 
food or something, I would just feel annoyed that why am I taking this treatment and 
what is it for? (Khanyisile, woman, 24 years)  
HCW also described such doubts and treatment fatigue as a reason for some PLHIV 
disengaging from treatment and care:  
After some years . . . you can find that a patient would say ‘ahh this treatment, I’m 
not sick anyway’ . . . so they believe they should stop the medication. (HCW10)  
Seeking evidence of the treatment’s effectiveness  
Almost all PLHIV participants described wanting to see the difference that treatment 
was making to the virus and their health prognosis. Some also described a desire to 
hear more about their blood tests:  
I want them to tell me is there something that it is doing, is there a difference. Even 
now I want them to tell me how my CD4 is doing, my CD4 was this much and now 
that I am continuing with the treatment, is it making any difference? (Celiwe, 
woman, 40 years)  
For those who were informed of suppressed viral load results, this appeared to instil 
a belief in the effectiveness of treatment, which could be particularly important for 
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those who initiated ART in the absence of symptoms, and which was said to motivate 
ongoing treatment-taking: “[When told suppressed] it made me to feel free and to continue 
emphatically taking the treatment, because it means it is working.” (Vusi, man, 49 years)  
The role of viral load monitoring as a potentially important tool for supporting 
adherence among patients who initiate ART when healthy under the Treat-all policy 
was reiterated by HCW participants:  
These patients are patients who came in healthy, they had no symptoms, so they are 
going to continue being healthy... they are not going to see what is better for them. So 
viral suppression is important… it would actually be good to have an initial baseline 
viral load and then you do monitoring following. (HCW19)  
HCW recognized the importance of time explaining results:  
I can admit and say we don’t give that oomph for that time as equal as when the viral 
load is unsuppressed… yes we don’t give that attention, maybe we can strengthen 
and say yes even if the patient’s viral load is suppressed… CD4 count is high... we 
need to sit with the patient... and try to give the patient a lot of time and 
understanding. (HCW09)  
Certain participants who were doubtful about the need for treatment and its 
effectiveness described experimenting with treatment-taking, as a means of seeking 
such evidence:  
There was a time… when I would think ‘haw this thing is not doing anything to me’ 
and then I stopped taking them and there was no sign of it being there… I never used 
to take them… I was not taking them well and nothing would happen and it would be 
the same as when I was taking them. (Nobuhle, woman, 17 years)  
Discussion 
This study investigated the experiences of asymptomatic PLHIV engaging with HIV 
care under the Treat-all policy in Eswatini. Our findings suggest that it is important 
for PLHIV to have a sense of the difference treatment is making to them, in terms of 
its influence on their virus and health prognosis. Where PLHIV perceived need for 
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treatment and believed it was effective in improving their health and potentially 
prolonging life, this motivated treatment-taking and supported engagement with 
care. On the other hand, doubts relating to treatment need and effect could 
undermine engagement.  
The biomedical logic framing Treat-all assumes that individuals will adjust their 
actions once they are educated; however, treatment decisions surpass the biomedical 
realm (Beckmann, 2013). There can be dissonance between the biomedical rhetoric 
and lived experiences of those who engage with technologies (Young et al., 2016), 
including in lay interpretations of what constitutes treatment necessity (Kawuma et 
al., 2018). In our study PLHIV could gain evidence of treatment effect through 
experiential, embodied changes with identifiable, physical improvements after being 
on ART, or through viral load monitoring results showing the impact of ART on the 
level of the virus. However, some PLHIV had doubts about the need for treatment 
and its effectiveness in the absence of any symptoms or signs of ill health, which 
could undermine their engagement and cause intermittent treatment-taking. While 
others have examined the factors influencing ART initiation among asymptomatic 
PLHIV within Treat-all (Boyer et al., 2016; Mbonye et al., 2016; Pell et al., 2018), our 
study builds on these findings and provides insight into the influences on ongoing, 
longer term treatment taking, after an average of 20 months on ART.  
Existing evidence from Eswatini suggests PLHIV can find it difficult to accept ART 
within Treat-all when feeling healthy, with the belief that ART is for sick people 
(Adams and Zamberia, 2017; Pell et al., 2018). Experiences with Option-B+ 
programmes in Southern Africa have found some relate taking ART with being ill or 
having a low CD4 count, which can undermine asymptomatic pregnant and lactating 
women’s engagement with treatment (Adams and Zamberia, 2017; Katirayi et al., 
2016). Pound et al. describe treatment-taking as a concretization of illness, rather than 
health (Pound et al., 2005). As HIV treatment for preventative purposes within Treat-
all transforms HIV from an acute to chronic condition, the symptoms of disease and 
efficacy of treatment become less apparent (Zhou, 2016). While some participants in 
our study felt they did not need treatment in the absence of symptoms, others 
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reinterpreted past illnesses and physical experiences such as fatigue, low energy and 
weight loss as signs of HIV, which served to warn them of the potential imminent 
health deterioration without treatment, thereby motivating their engagement with 
care. Such reinterpretations of past events as indications of HIV were also found by 
Zhou, and influenced women’s ART initiation within Option-B+ (2016), suggesting 
the importance of experiential, embodied experience in treatment decisions. Certain 
participants in our study felt that an HIV diagnosis itself pointed to the need for 
treatment. These findings therefore highlight the ways in which conceptions around 
health and treatment need are changing within the context of Treat-all, and they may 
continue to do so as it becomes more commonplace.  
Almost all participants in our study wanted to see the positive effect or difference 
treatment was making to them, seeking evidence of the treatment’s effect either 
through their own embodied experiences or through biomarkers such as CD4 count 
and viral load, which served as indicators of their health status. Although some 
researchers have described the value placed on such indicators (Renju et al., 2017), 
our findings went further by suggesting that viral load monitoring can play an 
important role in supporting adherence to ART, offering patients a means to view the 
effect of treatment on the level of the virus. This may be of particular importance in 
Treat-all contexts where PLHIV are increasingly initiating ART at earlier, 
asymptomatic phases of the disease. Routine viral load monitoring should be 
implemented universally as a tool to promote engagement in treatment and care, 
with communication of both suppressed results, as well as unsuppressed results, 
being emphasized.  
Under previous treatment guidelines, recounting narratives of illness history and 
comparing pre- and post-ART health could motivate continued treatment-taking 
(Bernays et al., 2015; Nam et al., 2008) Although PLHIV are now increasingly 
initiating ART when clinically asymptomatic, findings from Option-B+ suggest that 
interpretations of physical improvements on ART, in particular falling sick less often, 
feeling more energetic and therefore more productive can be important for 
supporting continued treatment-taking (Katirayi et al., 2016; Ngarina et al., 2014; 
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Zhou, 2016). Certain PLHIV in our study who did not experience any such physical 
signs of HIV prior to starting ART, changes on ART or viral load results presented 
doubts about the need for treatment and its effectiveness. This could lead to treatment 
experimentation, where PLHIV could miss doses of treatment, seeking evidence of 
its effect. Conrad describes “non-compliance” as a form of “self-regulation,” where 
patients may alter the course of treatment to test its efficacy (Conrad, 1985), as seen 
in mothers enrolled in Option-B+ (Zhou, 2016). This is particularly problematic as it 
poses risks for drug resistance (World Health Organisation, 2017a), suggesting the 
importance of patients within Treat-all starting treatment when they are ready, when 
they want treatment and exploring means of addressing their concerns about its 
effectiveness. PLHIV who had such doubts were also said to be more likely to 
develop a sense of treatment fatigue over time, where questioning the point of 
treatment undermines the energy for taking it. This could become increasingly 
relevant as Treat-all patients are on treatment for longer periods of time.  
Limitations  
As the Treat-all pilot was implemented by MSF and the MoH, patients may have 
received more support, including greater availability of viral load monitoring. 
However, the pilot aimed to examine the feasibility of Treat-all under routine 
programmatic conditions, and the presence of viral load monitoring enabled unique 
insight into the supportive value of this tool for patients’ treatment-taking. Though 
we were able to include PLHIV who had been enrolled in Treat-all care for longer 
than previously reported, Treat-all was still fairly new at the time of this study. It will 
be important to examine how these findings may change as Treat-all becomes more 
commonplace, as well as to examine experiences of PLHIV with Treat-all who have 
been on ART for longer.  
Conclusion 
This research highlights the importance of PLHIV perceiving need for treatment and 
having evidence of the benefits of their taking it, for motivating their ongoing, 
sustained treatment-taking in the context of Treat-all. Almost all participants 
described a desire for evidence of the need for treatment and its effect, with routine 
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viral load monitoring potentially providing this. This could be particularly important 
for those who initiate ART when asymptomatic, who do not experience the 
transformative effects of ART and who can have doubts about the value of treatment, 
which potentially undermine treatment-taking. It is important that programmes 
consider these findings to adapt patient support, to avoid the risk of PLHIV 
“experimenting” with treatment- taking which could cause drug resistance to 
develop. This could include communicating to patients that there may be no notable 
difference in health status on initiating ART when asymptomatic, and that benefits 
of early ART include prolonging good health. Programmes should also ensure 
routine viral load monitoring is included as an integral component of HIV care within 
the Treat-all policy, with a baseline viral load if possible, and ensuring suppressed 
results are communicated to patients.  
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Overview 
In Chapter 2, I introduced and defined stigma, and explored HIV-related stigma, 
including social judgements of immorality and deviance, which may be attributed to 
HIV infection and people living with HIV. I engaged with the HIV normalisation 
discourse, which posits that increased and earlier access to ART should enable HIV 
stigma reduction and HIV management as a chronic condition akin to other 
conditions such as diabetes. However, evidence suggests that despite increased ART 
access rendering the signs and symptoms of HIV less visible, people living with HIV 
may continue to have discreditable social identities, and anticipated stigma prevails. 
This paper examines how stigma is experienced by people living with HIV in the 
context of Treat-all, and how it frames engagement with treatment and care. 
In this chapter, I draw on data from the main phase of the PhD research. The findings 
highlight the conflicting forces of stigma, in both driving engagement with HIV care, 
as individuals want to prevent the onset of HIV-related symptoms which may 
inadvertently disclose their HIV status to the community, and also undermining 
engagement with HIV care due to the multitude of risks of status exposure that 
engagement presents. Intermittent treatment-taking, and disengagement from care 
were described when the risks of HIV status exposure appeared too great, and 
maintaining a hidden HIV status appeared a priority over and above preserving good 
health for health’s sake. This suggests that treatment-taking and engagement with 
HIV care in the context of Treat-all are fragile, as HIV stigma and risks of HIV status 
exposure require continual navigation by people living with HIV.  
This paper aligns with research objectives 3 and 4: 
3. To explore treatment initiation decision-making 
4. To examine how ongoing engagement in HIV care and treatment-taking is 
navigated over time 
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Abstract 
“Treat-all” programmes aim to improve clinical outcomes and to reduce HIV 
transmission through regular HIV testing and immediate offer of antiretroviral 
therapy (ART) for those diagnosed HIV-positive, irrespective of immunological 
status and symptoms of disease. Global narratives on the benefits of Treat-all 
anticipate reduced HIV-related stigma and increased “normalisation” of HIV with 
Treat-all implementation, whereby HIV is remoulded as a manageable, chronic 
condition where stigmatising symptoms can be concealed. Drawing on Goffman’s 
stigma work, we aimed to investigate how stigma may influence the engagement of 
clinically asymptomatic people living with HIV (PLHIV) with Treat-all HIV care in 
Shiselweni, Eswatini (formerly Swaziland). This longitudinal research comprised 106 
interviews conducted from August 2016 to September 2017, including repeated 
interviews with 30 PLHIV, and one-off interviews with 20 healthcare workers. Data 
were analysed thematically using NVivo 11, drawing upon principles of grounded 
theory to generate findings inductively from participants’ accounts.  
Stigma was pervasive within the narratives of PLHIV, framing their engagement with 
treatment and care. Many asymptomatic PLHIV were motivated to initiate ART in 
order to maintain a “discreditable” status, by preventing the development of visible 
and exposing symptoms. However, engagement with treatment and care services 
could itself be exposing. PLHIV described the ways in which these “invisibilising” 
benefits and exposing risks of ART were continually assessed and navigated over 
time. Where the risk of exposure was deemed too great, this could lead to intermittent 
treatment-taking, and disengagement from care. Addressing HIV related stigma is 
crucial to the success of Treat-all, and should thus be a core component of HIV 
responses.  
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Introduction 
“Treat-all” programmes are being implemented in several African settings, as a 
prevention and treatment strategy for HIV. In line with recent World Health 
Organization (WHO) guidelines, regular HIV testing is encouraged and 
antiretroviral therapy (ART) is offered immediately for those who are diagnosed 
HIV-positive, irrespective of immunological status and symptoms of disease (World 
Health Organisation, 2015). Global narratives on the benefits of Treat-all 
implementation anticipate that earlier and increased access to ART will facilitate the 
“normalisation” of HIV, where it is considered a manageable chronic condition, and 
where stigma can be reduced through management of HIV related symptoms 
enabling HIV status concealment  (Abadía-Barrero and Castro, 2006; Roura et al., 
2009b, 2009a). Castro and Farmer (2005, p.57) describe this transformation of HIV 
from a fatal disease to a chronic, manageable one as having “decreased stigma 
dramatically in Haiti”.  
Stigmatisation can be defined as a social process occurring in the context of power, 
where an individual’s difference, condition or attribute is considered unfavourable 
and linked to negative stereotypes (Link and Phelan, 2006, 2001). While the 
manifestations of stigma are socially constructed and context specific, possessing 
such an attribute generally results in loss of status, devaluation and discrimination, 
and leads to unequal outcomes for the stigmatised individual (Gilbert and Walker, 
2010; Goffman, 1963; Link and Phelan, 2001; Parker and Aggleton, 2003). In his 
seminal work on stigma, Goffman (1963) outlined the distinction between 
“discredited” and “discreditable” identities. Those who are discredited possess an 
evident or visible attribute, requiring them to devise coping mechanisms to manage 
the resulting prejudice and discrimination, which can also be referred to as “enacted 
stigma”. Conversely, conditions which can be hidden from the public eye create 
discreditable identities, where the main focus is managing and concealing 
information to “pass” as “normal”, to avoid becoming discredited and experiencing 
the expected resultant stigma, which can also be referred to as “anticipated stigma” 
(Goffman, 1963; Scambler, 2009; Steward et al., 2008).  
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A growing body of work has explored the relationship between stigma and taking 
ART. Mattes (2014) refers to ART as a “technology of invisibilisation”, as it provides 
an opportunity to maintain status secrecy and to thereby avoid stigma, a concept 
which is also reflected in the work of other scholars (Beckmann, 2013; Moyer, 2012). 
However, while ART may enable the avoidance of enacted stigma (Beckmann and 
Bujra, 2010) and prevent people living with HIV (PLHIV) from being discredited, 
anticipated stigma can persistently prevail in people’s lived experiences with HIV 
(Alonzo and Reynolds, 1995). PLHIV remain discreditable, partly due to the potential 
for symptom development and status exposure, but also because ART does not 
directly address the structural drivers of stigmatisation (Russell et al., 2016b), such as 
poverty, gender inequality and racism (Link and Phelan, 2001). Stigma reflects the 
workings and forms of social inequality, and to properly understand it we must 
consider how some people come to be socially excluded, and the forces that create 
and reinforce such exclusion (Parker and Aggleton, 2003). Additionally, ART does 
not address the fundamental causes of stigma, including the deeply held views of 
powerful groups that lead to stereotyping and labelling (Link and Phelan, 2001), and 
Squire (2010, p.409) argues that the association of HIV with “transgressive sexuality, 
particularly for women, will always render it socially pathological”.  
HIV related stigma presents a major barrier to the prevention and treatment of HIV 
(Mbonye et al., 2013; Stangl et al., 2013; Steward et al., 2008). In African settings, and 
particularly in Southern and Eastern Africa, stigma has been found to discourage 
care-seeking (Maeri et al., 2016), and undermine uptake of HIV testing, ART initiation 
and adherence (Bond, 2010; Genberg et al., 2009; Mbonu et al., 2009; Mbonye et al., 
2013; McGrath et al., 2014; Orne-Gliemann et al., 2016; Sengupta et al., 2011). Stigma 
can undermine adherence and engagement directly, where attempts at status 
concealment such as hiding treatment or selecting clinics far from home contribute 
towards treatment interruptions (Dlamini et al., 2009; Gilbert and Walker, 2010; Katz 
et al., 2013). There are also indirect influences, whereby non-disclosure of HIV status 
results in lack of social support and treatment reminders (Katz et al., 2013). While this 
body of research explores stigma and HIV service engagement for symptomatic 
PLHIV, where the discrediting attributes are made visible by the disease itself, it is 
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not yet known how this may be experienced by clinically asymptomatic PLHIV in the 
context of Treat-all, where the discrediting risk is made manifest only through 
accessing treatment.  
Supporting PLHIV to engage with treatment and care is important for individuals’ 
health outcomes, as delayed treatment and suboptimal adherence have deleterious 
effects on morbidity and mortality (INSIGHT START Study Group, 2015; Song et al., 
2018; The TEMPRANO ANRS 12136 Study Group, 2015). Additionally, suboptimal 
adherence can contribute to drug resistance, which can be transmitted, with resultant 
population level and individual level risks, and which has been highlighted as a 
critical threat to eliminating AIDS by 2030 (World Health Organisation, 2017a, 2017b). 
Without detailed exploration of whether and how stigma is manifested and 
experienced in this context, it is unknown how it may undermine Treat-all efforts. To 
ensure stigma is addressed, it must first be understood, ideally by examining the 
perspective of those affected. In this context, we aim to examine how stigma shapes 
PLHIV experiences with HIV, and engaging with HIV treatment and care services 
under Treat-all in Shiselweni, Eswatini (formerly Swaziland).  
Methods  
This study is situated within the context of a broader research project that used a 
longitudinal qualitative design to examine the lived experiences of clinically 
asymptomatic PLHIV, their engagement with HIV treatment and care, and how these 
changed over time in the context of Treat-all in Shiselweni, Eswatini.  
The study of lived experiences refers to understanding individuals’ experiences, 
choices, and options, and how individuals interpret and make sense of their 
experiences (Given, 2008; Smith, 2004). This approach aims to understand and 
describe individuals’ experiences of their everyday world as they see it 
(Liamputtong, 2013), and to remain as faithful as possible to the phenomenon and 
the context in which it appears in the world (Giorgi and Giorgi, 2008).  
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Study context  
Eswatini has the highest reported HIV prevalence worldwide, estimated at 35% 
among women and 19% among men aged 15–49 years (UNAIDS, 2016). HIV 
prevalence peaks at 54% among women aged 35 to 39 years and 49% among men 
aged 45 to 49 years (Swaziland Ministry of Health, 2017). Most transmission occurs 
through heterosexual sex (Swaziland Ministry of Health, 2012).  
Eswatini is the last remaining absolute monarchy in Africa. Classified as a lower 
middle-income country, it is a small, largely mountainous country with a population 
of 1.2 million people. Sixty per cent of the population lives in poverty, of which 38% 
live in extreme poverty, and income inequality is high (The World Bank, 2018). 
Limited economic opportunity and high unemployment have resulted in widespread 
dependence on labour migration, with most migrant labourers travelling to 
neighbouring South Africa for work (Hickel, 2012). Most people identify as Christian 
(90%), and the main land use is pastoral, and timber forest (Central Intelligence 
Agency, 2018). In the predominantly rural southern region of Shiselweni subsistence 
farming is widely practised, and the region has been particularly affected by drought 
in recent years, which has caused food insecurity (Root et al., 2017). 
In October 2014, a Ministry of Health/Médecins Sans Frontières (MoH/MSF) Treat-all 
implementation pilot began in the predominantly rural Nhlangano health cluster in 
the Shiselweni region. This aimed to contribute towards reduced HIV incidence and 
improved clinical outcomes for PLHIV. The population in Nhlangano largely access 
HIV treatment and care at primary health clinics. The area has eight primary clinics 
and one secondary health facility; some people have to travel long distances, often on 
foot, to reach the nearest clinic. Treat-all was rolled out nationally in October 2016.  
Participant recruitment  
Participants were recruited purposively to include PLHIV enrolled in the Treat-all 
pilot programme who were considered clinically asymptomatic and who would have 
been otherwise ineligible for treatment at the time of ART offer (CD4 count ≥500, 
WHO disease stage 1), and to include a range of treatment-taking experiences (see 
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Table 7.1). The project patient cohort was stratified for gender and age, to include 
young people (aged 16 to 25 years) and adults (aged 26 to 49 years). Healthcare 
workers (HCWs) from the facilities implementing Treat-all (one secondary and eight 
primary care facilities, not HIV-specific) were purposively recruited to include a 
range of positions involved in the delivery of HIV testing, treatment and care, and 
both MoH and MSF personnel. Fieldwork was conducted from February 2015 to 
November 2017. Identified PLHIV were contacted in June 2016 and invited to 
participate in between 2 and 4 interviews over a 12-month period, while HCW were 
invited to participate in 1 interview during March and April 2017.  
Attempts were made to contact 107 PLHIV identified for potential recruitment, 55% 
of whom (n = 59) were non-contactable. Of those who were contactable (n = 48), 30 
agreed and participated, 9 agreed and did not attend the agreed appointment (reason 
for non-participation unknown), 2 refused due to work commitments limiting their 
time in the area, 5 were out of the region and 2 were unwell and therefore unable to 
meet. All HCW who were approached and invited to participate agreed to an 
interview.  
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Table 7.1: Participant characteristics 
Participant information* n 
All PLHIV  30 
Treatment-taking category: 
On ART 18 
Lost From Treatment  12 
Enrolment period: 
Early (Oct 2014 – Mar 2015) 13 
Mid (Apr 2015 – Sep 2015) 12 
Late (Oct 2015 - Mar 2016) 5 
Gender and age: 
Women 
• Young women (17-25 years; average 21) 
• Adults (26 to 46 years; average 33) 
18 
9 
9 
Men 
• Young men (16 to 25 years) 
• Adults (26 to 49 years; average 37) 
12 
0 (none eligible in patient cohort**) 
12 
All HCW 20 
Position: 
Nurse supervisor 5 
Nurse 8 
Adherence counsellor 5 
Doctor 1 
Employer: 
MoH 12 
MSF 8 
*Participant information relates to that recorded on the project patient database at time of 
recruitment; or for HCW the positions they identified with during interviews. ** No young 
men were eligible due to the epidemiology of HIV in Swaziland meaning less young men are 
infected, and additionally men can access care later. 
Table 7.2: Longitudinal interview time frame 
Interview Date 
range 
Participants 
(n) 
Meetings 
(n) 
1 – Life history, family and relationships, 
hopes and aspirations, key life events 
22/08/16 – 
31/10/16 
30* 33 
2 – HIV testing, diagnosis, treatment offer 
and treatment initiation decision-making 
17/11/16 – 
07/02/17 
29 31 
3 – Living with HIV, ongoing treatment-
taking and engagement with HIV services 
25/03/17 – 
08/09/17 
26 27 
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*Certain interviews were conducted over more than one meeting, for example due to length 
of discussion and available time. One participant was lost to follow up after the first interview, 
attempts were made to contact her but she was not available to arrange another meeting. 
Three participants completed 2 interviews and 1 completed 4 interviews.  
Data generation and analysis  
In-depth interviews were conducted to explore a range of topics relating to PLHIV’s 
lives, their experiences of living with HIV, and with treatment and care (see Table 7.2 
for a summary of topics). Interviews were based on topic guides but were primarily 
participant-led, for example, HIV status was not asked about unless participants 
themselves disclosed their diagnosis (which all participants did). Multiple waves of 
data generation were conducted to capture changes over time, and also to benefit 
from developing rapport between participants and the researcher, which produced 
richer quality data. Data generation and analysis followed an iterative process, with 
topic guides for subsequent interviews being based on initial findings, to further test 
and explore particular areas emerging as potentially important. Interviews were 
conducted in siSwati by same-gendered interviewers, mostly held at participants’ 
homes, or another location of their preference if they felt more comfortable (e.g., fixed 
testing site in town). The interviews were audio-recorded following participant 
consent and were then translated and transcribed. Interviews with HCW were 
conducted at clinics, mostly in English, and explored topics relating to their 
experiences implementing Treat-all including offering ART to those considered 
clinically asymptomatic, supporting patients, and related challenges faced by 
patients and HCW.  
Interview transcripts were analysed thematically using NVivo 11, drawing on 
principles of grounded theory to generate findings inductively from participant 
accounts and to actively investigate discrepancies from the majority of themes 
(Bradley et al., 2007; Glaser, 1999; Glaser and Strauss, 1967). Initial coding and themes 
were discussed collaboratively, with a coding framework developing as analysis 
progressed. Repeated interviews with PLHIV were initially analysed per round to 
examine themes across participants’ accounts, and then longitudinally to explore 
how patients’ narratives changed over time. Ethical approval was received from the 
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Swaziland Scientific and Ethics Committee, London School of Hygiene and Tropical 
Medicine and from MSF Ethics Review Board. Pseudonyms are used in this paper for 
PLHIV participants, and HCW participants are referred to as HCW, to ensure 
confidentiality.  
Results  
In total, 106 interviews were conducted between August 2016 and September 2017, 
including 86 interviews with 30 PLHIV (Tables 7.1 and 7.2) and 20 interviews with 
HCW (Table 7.1). Stigma emerged inductively from participants’ accounts of living 
with HIV and engaging with HIV treatment and care services. Stigma was then 
explored further in later interviews to gain greater depth of understanding into the 
ways in which it affected individuals’ sense of identity, their interpretation of their 
diagnosis, and their engagement with treatment and care. HCW interviews also 
highlighted the ways in which stigma frames and influences PLHIV’s engagement 
with treatment and care in the context of Treat-all. Figure 7.1 shows a summarised 
depiction of these findings.  
 
Figure 7.1: How stigma and status concealment versus exposure influence PLHIV’s 
engagement with HIV treatment and care under Treat-all  
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HIV status concealment to avoid anticipated stigma  
Anticipated stigma was pervasive within PLHIV participant narratives, and almost 
all described feeling that they must conceal their HIV status to avoid stigma through 
being singled out and treated differently by those around them. The importance of 
status secrecy also appeared reinforced through health messaging at the point of 
treatment initiation and subsequent clinic visits, with some health workers 
encouraging their patients not to widely disclose their diagnosis.  
When you are HIV-positive you must keep it a secret (Hlobsile, woman (F), second 
interview).  
They [HCW] said going around telling people isn’t a good thing... they explained this 
to us at the clinic that we should tell someone who will not go around talking about 
you (Cebsile, F, third interview).  
Many PLHIV feared the potential negative consequences of having their status 
discovered. The fears should they be identified as taking treatment included not 
wanting to be gossiped about, made a mockery of, or to experience social judgement 
which could result in loss of reputation, social stature and standing, which in turn 
could impede future relationship and marriage prospects.  
It lowers your value when people point at you for taking the treatment. People will 
not respect me the way they do now, and they will not treat me the way they treat me 
now (Nokuthula, F, second interview).  
Commonly held notions of what comprises a good, upstanding citizen, in line with 
Christian values and moral standards, appeared contradictory to, and threatened by, 
views about who gets HIV. Most participant accounts included references to the ways 
in which HIV continues to be abnormal and morally judged, particularly linked to 
the sexual nature of transmission, and with negative connotations regarding the 
sexuality and behaviour of PLHIV.  
I wish that people could take AIDS as a common cold, because it can get anyone, not 
that they take you as an animal, or that you were living a life that is not good, you see 
(Thandi, F, first interview).  
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Religion comes in, and if you do go to church we don’t expect you to be having sex 
when you are not married, but you are actually having sex, so you can’t talk about it 
(laughs) and then at the same time this is a very small community, so everybody 
knows everybody. I know you go to church, and if I then know that you are sleeping 
with this one, it means you are not actually an outstanding Christian if I may say 
(HCW).  
The impact of such anticipated stigma could be strong and harmful. Some 
participants described considering suicide, linked to the humiliation, shame and 
devaluation that could come from having their status known:  
I even wished to kill myself because I had lost so much weight and people in the 
community were making a mockery of me (Sanele, young woman (YF), second 
interview).  
ART offering the potential to maintain good health and a hidden HIV status 
Initiating ART while still largely asymptomatic and with good general health, offered 
both risks and opportunity. ART was a means to avoid signs or symptoms of ill health 
from developing, which could expose one’s HIV status. Avoiding HIV visibility 
appeared more important than maintaining good health itself, with the fear of being 
identified being more pervasive than the fear of experiencing sickness.  
I should just start taking the treatment while I am still walking on my own, while I 
am still healthy, and I shouldn’t go down but instead I should improve from where I 
am now... so that I wouldn’t lie down and be identifiable and then lose weight and 
many other things (Vusi, man (M), second interview).  
Maintaining good health, including strength and energy, enabled the maintenance of 
a sense of normality, being able to work and function as a member of society, 
contradicting stigmatising processes of “othering” and countering feelings of no 
longer being a human. This appeared particularly important for men, who described 
wanting to work and provide for their family, thereby upholding notions of 
masculinity and productivity.  
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When I’m healthy, my family will have something to eat and my children will be able 
to go to school and they wouldn’t have problems... if I might get sick then I think my 
children will struggle because what they get from me it’s something they cannot get 
from anyone [else] (Mandla, M, second interview).  
Many participants described having seen the effects of delayed ART initiation, for 
example, with family members or neighbours becoming sick and bedridden, which 
reinforced their motivation to start treatment before succumbing to these symptoms:  
I saw from my sister, she started them late when she was very sick and I said I do not 
want to get to that stage, let me start them while I am walking because when you are 
sick people then start to gossip about you (Sanele, YF, third interview).  
Though all participants were considered clinically asymptomatic, several described 
experiencing embodied signs of HIV, such as headaches, weakness, lethargy and 
weight loss, which served to warn them of the potential for imminent health 
deterioration and therefore HIV visibility without ART. Perceptions of health and ill-
health appeared to differ experientially from biomedical definitions regarding the 
severity of HIV related disease (e.g., those included in WHO disease staging). For 
some, even receiving an HIV diagnosis pointed to a fragility in their health status, 
reinforcing their sense of needing to start ART.  
When you haven’t tested, you are going to tell yourself that you’re okay but once you 
have things like constant headache and things like that, you must know that those are 
the signs... We know the symptoms, like if your hair is like it has been licked by a calf... 
Forget it just go and start taking the treatment, there’s nothing you can do (Jabulane, 
M, second interview).  
It hurt me... [after HIV diagnosis] you then begin to see yourself that you’re not 
someone who is healthy, you’re someone who is sick (Sifiso, M, third interview).  
Health workers also felt that a key driver for PLHIV to initiate ART before becoming 
symptomatic was the ability of ART to hide their status, relating this to anticipated 
stigma.  
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Usually it is that they don’t want to be sick, to be seen by everyone that this one is 
now sick... once you get sick, be in a wheelchair, they [community members] diagnose 
you as being HIV positive... there will be rumours all over. They still want their status 
to be confidential. They test and initiate but are not ready to disclose in public. It is 
self-discrimination (HCW).  
[Treat-all] has helped us greatly because if a person is initiated today on ART nobody 
will see that the person is HIV positive because there are no hair changes and no 
nothing. By that the stigma... because once the symptoms... manifest, discrimination 
begins... (HCW).  
In addition, certain HCW alluded to this message being reinforced in pre-ART 
sessions with PLHIV:  
They eventually want to take them because we tell them: why do you want people to 
see you that you are sick? Because you could take even when no one is noticing, and 
you will continue (HCW).  
As well as wanting to initiate ART to ensure HIV status concealment, the perceived 
need for, and benefit of ART in enabling a hidden status was said to motivate 
ongoing, continued treatment-taking:  
The thought of stopping treatment never crossed my mind because I am the one who 
will get exposed if I stop taking them... I respect them [ARVs] a lot they have helped 
me, if it was not for them, I would also be visible that I am sick, so really I respect 
them a lot (Welile, F, third interview).  
The risk of HIV status exposure undermining engagement with HIV 
treatment and care 
While many PLHIV appeared motivated to take treatment early to protect a hidden 
status, engagement with HIV treatment and care services could itself be exposing and 
therefore discrediting. Almost all participants described fears of being seen at clinics, 
or having their treatment found:  
When you are going to the hospital you are ashamed, even just walking around you 
are ashamed because you know that people know that you are positive, and then others 
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will point you using their heads and have names for you, you find that they call you 
Khumalo [one who takes] (Sanale, YF, third interview).  
Many PLHIV could go to great lengths to hide their treatment, and at times these 
efforts undermined their capacity to take it. For example, a dose may be missed when 
others were present to avoid being seen and therefore exposed:  
Sometimes you would find that when the time for taking the treatment comes he is 
also in the room, so it would happen that I wouldn’t take them (Nelisiwe, YF, third 
interview).  
I am scared to say ‘yey people get out so that I can take my bag and drink my 
treatment’. I am scared, so I end up skipping, and this makes me stressed 
(Nontokeko, YF, third interview).  
Participants also reported that they feared the risks of being seen at the clinic while 
queuing for ART refills. Some described strategies they adopted in order to minimise 
this risk, including befriending HCW to avoid the need to queue, or choosing a clinic 
further from their home community to avoid the risk of being seen by neighbours. 
However, these strategies were often fragile or less convenient, which inadvertently 
added to the burden and fragility of treatment-taking. This could potentially 
undermine the sustainability of longer-term engagement with treatment and care. 
The strategy of selecting a clinic which was further away from home in order to avoid 
exposure was particularly described by young women and by men, who were less 
easily able to justify their presence at the clinic by citing an alternative and more 
socially acceptable reason than, for example, older women.  
I do not want to lie to you [interviewer surname], I have never queued and I feel like 
I am scared to. I feel like I am not ready to be seen by everyone that I am HIV positive. 
You see where you sit there, I have never sat there... I just come and go inside 
(Hlobsile, F, third interview).  
I transferred from Nhlangano to Big Bend... aunt said I should transfer because people 
around here know me, so they might know me and see me and be gossiping about me... 
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she said it is better that I go where they do not know me (Thobile, F, second 
interview).  
Some PLHIV also described times when they turned back from the clinic without 
collecting their refill due to seeing someone they knew at the clinic and not wanting 
to be exposed:  
They said because I am pregnant I have to go to the VCT and when I looked at it the 
Nhlangano VCT the way it is, I just left everything there and then... it exposes too 
much sisi... I was like I will be discovered by people I work with... so I was like no 
ways (Welile, F, second interview).  
Someone might decide to leave the treatment because there’s a relative of mine in the 
clinic, or the cleaners or something, she knows me and she’s going to talk (HCW).  
Although early initiation on to ART was understood to prevent symptom 
development, some saw ART itself as concomitantly potentially exposing, with fears 
that treatment side effects could cause physical deformities, changes in weight, hair 
and skin colour. This is indicative of the dilemma that the prospect of Treat-all posed 
for asymptomatic PLHIV, as ART could be the catalyst for their status to become 
noticeable, with treatment related side effects perceived as potentially revealing their 
HIV to others.  
I do not want to lie, part of me was saying I should take them but another part was 
saying I shouldn’t take them... I am scared of them making a problem of me and I 
would be like a written book, look at her she doesn’t have a big belly anymore, she is 
finished with a flat ass, you are now written that you are taking treatment you see, I 
was scared of them, telling myself that they [ART] will expose me (Hlobsile, F, third 
interview).  
I thought that the treatment would make me sick and I would be seen by all people 
because I would’ve changed so much than what I was before (Lindiwe, F, second 
interview).  
I was actually afraid of gaining weight because it was now a common thing that once 
you gain weight, whether I have told this person or not, but once I gain weight they 
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are going to say I have started taking the treatment... I was really afraid that people 
were now going to identify me easily (Mandla, M, third interview).  
Maintaining a hidden HIV status whilst engaging with HIV treatment and care 
services thus appeared fragile. Participant accounts were interwoven with 
calculations of perceived benefits and risks of treatment-taking and status exposure, 
which were continually considered and navigated over time. If the risk of exposure 
was deemed too great, this could cause individuals to disengage from treatment and 
care services:  
It is not pleasing to be on a treatment for the rest of your life, and also that you can 
hide it today but for how long? Because there are people that you do not want to know 
about you taking treatment... you can hide it from them today and tomorrow, but they 
will end up finding out about it because the hospital is not mine alone (Nontokeko, 
YF, third interview).  
When you are talked about, and when you are scared, you may end up saying let me 
just stop taking this thing. This is what can make people stop taking treatment 
(Sanele, YF, third interview).  
I was not collecting them anymore... what was in my mind was that I was scared to 
tell my boyfriend that it is my time to collect my treatment, I was scared to do that... 
(Ncobile, YF, fourth interview).  
HIV status acceptance countering anticipated stigma  
The extent to which PLHIV’s engagement with HIV treatment and care services was 
framed by avoiding exposure and anticipated stigma appeared to be influenced by 
their own interpretation of their diagnosis. Only four participants did not mention 
trying to hide their status, and for these participants, their own acceptance of being 
HIV-positive and wanting to live seemed to support their overcoming fear of others’ 
judgement, thereby also supporting their engagement with care.  
Whatever situation you go through, what will help is that you accept yourself first, so 
that you get accepted by other people. When you start having self-stigma [utinyandza 
wena], then at that time you feel like I am not the same as other people... I accepted 
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myself a long time ago, in the beginning. That is what made me live, that I just 
accepted myself. I never found myself as different, even if you could come and say “I 
am not positive”, that does not hurt me... I find that we are the same. You can be 
negative and I know that I am positive, it does not make any difference to me... when 
they said I am positive so what, there is treatment, they say it helps, I will continue 
to live (Philile, F, second interview).  
Such acceptance of status could be challenging in the absence of any symptoms or 
signs of ill health. Some did not perceive the need for ART in the absence of 
symptoms, questioning their diagnosis or the likelihood of experiencing future health 
deterioration, and wanting to wait before starting ART:  
I thought for myself that I do not have to take them because I feel okay... maybe when 
I get sick and I can see that I have to take the treatment (Gcinile, F, second 
interview).  
Some... they say they are not ready, they are still fine... they tell you that there is no 
need, they will start treatment when they are sick, not now (HCW).  
Treat-all could expedite the time from HIV diagnosis to treatment initiation, but for 
many it appeared important to have time to process and come to terms with an HIV 
diagnosis, to feel ready for treatment, and for people to know.  
I think it is still processing for me to accept it... I think that after some time I will end 
up not caring if people know, it is just for now... (Nokuthula, F, third interview).  
I think that as time goes on I will be alright, I will then accept it... but I do not know 
yhiii... what can be done... it is still new, just like losing a mother, you keep thinking 
about her but as the years go by you then forget that she died and I cried at the funeral. 
So I think I will also be alright (Nontokeko, F, third interview).  
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Discussion  
In the context of Treat-all, in a setting with a high prevalence generalised HIV 
epidemic, stigma was pervasive and influential in participants’ accounts of living 
with HIV, and appeared to strongly frame PLHIV’s engagement with treatment and 
care services. On the one hand, treatment appeared as a pulling force, offering the 
potential to preserve good health, so that any symptoms which may expose HIV 
could be avoided. This motivated many PLHIV to want to start treatment early, when 
considered clinically asymptomatic. However, being on treatment and engaged with 
HIV care services could also be exposing, and many had fears around being seen 
collecting refills or having their treatment discovered, which could undermine their 
engagement. Avoiding anticipated stigma appeared so important that some 
participants thought of suicide if they were to be discovered living with the virus, 
and to experience the expected humiliation and devaluation that could result. While 
there is a wealth of research on HIV related stigma and its interplay with use of HIV 
services, to the best of our knowledge this is the first study to unpack in detail the 
ways in which stigma influences asymptomatic PLHIV’s engagement with Treat-all.  
Status concealment appeared as an information management strategy, through 
which PLHIV maintain a discreditable identity and avoid becoming discredited 
(Goffman, 1963). The need to conceal was reinforced by health messaging at clinics, 
potentially implying that there is something inherently wrong with being HIV-
positive (Bernays et al., 2017). Our finding that almost all participants felt they must 
conceal their HIV status due to anticipated stigma has been shown by others (Alonzo 
and Reynolds, 1995; Dlamini et al., 2009; Katz et al., 2013). While all PLHIV 
participants were considered clinically asymptomatic, several described embodied 
signs of HIV, which served to warn them of the potential for imminent health 
deterioration and discrediting without ART, and supported their motivations for 
initiating ART. This also highlights the dissonance between biomedically ascribed 
markers of HIV (e.g., CD4 count and WHO disease stage) and PLHIV’s experiential 
conceptions of their health and illness.  
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The ability of ART to alleviate physical manifestations of HIV have led to it being 
referred to as a technology of “invisibilisation” (Beckmann, 2013; Mattes, 2014), 
enabling social and economic engagement, and therefore providing PLHIV with a 
sense of value (Bernays et al., 2010; Campbell et al., 2011; Mattes, 2014). In our study, 
this manifested in the ability of ART to prevent the development of physical 
symptoms, rather than alleviate them once present. Other studies describe the 
transformative and restorative effects of ART when taken by PLHIV who are very 
unwell, which can then motivate adherence (Bernays et al., 2015; Russell and Seeley, 
2010). Our findings that participants were motivated to start and continue taking 
treatment in the absence of symptoms show how the relationship with ART, and its 
capacity to conceal HIV, are changing under Treat-all.  
While ART can present a technology of “invisibilisation”, some authors have 
suggested that wider treatment availability can generate new forms of stigma (Roura 
et al., 2009a). Although being visibly healthy can conceal an HIV-positive status, 
clinic visits and daily medication use can create privacy concerns and risks of 
exposure (McGrath et al., 2014; Moyer and Hardon, 2014). Many PLHIV in our study 
had concerns about the risk of exposure from engaging with treatment and care, 
which could cause intermittent treatment- taking, interruptions and disengagement 
from treatment and care. Hiding treatment can lead to non-adherence and treatment 
interruptions (Dlamini et al., 2009; Katz et al., 2013; Maeri et al., 2016), and in our 
study several participants described times when they felt unable to take their 
medication if others were present.  
The extensive efforts PLHIV in our study described in order to maintain privacy, such 
as choosing to attend clinics long distances from their home communities, have been 
found by others (Bond, 2010; Gilbert and Walker, 2010; Maeri et al., 2016), and as 
affecting individuals’ ability to remain adherent to ART (McGrath et al., 2014), for 
example, through increasing the burden of treatment and undermining longer-term 
sustainability. However, our findings illustrate the dilemma that individuals 
experience because some perceive that not engaging in treatment, in the hope of 
continuing to remain asymptomatic, may allow a continued invisibility of their HIV 
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status for longer. In the past, the risk of exposure from engaging with treatment could 
potentially be balanced with the risk of exposure from visible signs of HIV before 
starting ART. In the Treat-all context, where PLHIV were visibly asymptomatic 
before initiation, these risks of exposure may actually seem greater with treatment-
taking than without it, as the risk of developing symptoms in the future are perhaps 
more abstract and less current than those experienced presently. There is a risk that 
the effect of this is to delay treatment- seeking. Likewise, while some studies have 
found that PLHIV may have concerns about visibility linked to ART side effects 
(Mattes, 2014; Mbonye et al., 2016, 2013; Zhou, 2016), in our study these concerns 
could influence the cost-benefit weight of ART unfavourably, as treatment may be 
felt to cause changes to appearance which were more exposing than PLHIV’s health 
before starting. If these perceived risks are not addressed within programmes, this 
could undermine the success of Treat-all implementation.  
Self-acceptance of HIV status appeared to counter stigma, helping individuals to 
overcome the fear of others’ judgement and not to internalise stigmatising attitudes 
and shame. The influence of HIV status acceptance on PLHIV’s engagement with 
treatment and care in Swaziland is reported elsewhere (Horter et al., 2017). Others 
have found that status acceptance has supported the choice to live, to overcome fear 
of stigma and to support adherence (Gilbert and Walker, 2010; Katz et al., 2013; Nixon 
et al., 2018). We found that some PLHIV felt it could take time to process and come 
to terms with an HIV-positive result, which may be expedited under Treat-all as the 
time between diagnosis and treatment initiation can be reduced. This highlights the 
importance of considering individual patient readiness and acceptance of HIV status 
within Treat-all and same-day treatment approaches.  
Many authors have described the ways in which HIV is associated with immorality 
and deviant sexual behaviour (Mattes, 2014; Mbonu et al., 2009; Mbonye et al., 2013; 
Moyer and Hardon, 2014; Roura et al., 2009b, 2009a), with PLHIV therefore being 
blamed for their infection, and HIV deemed as a punishment for those who have 
challenged sexual and gendered social norms (Campbell et al., 2011). HIV stigma can 
thus be seen as central to the establishment and maintenance of social order 
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(Foucault, 1978, 1977; Parker and Aggleton, 2003) and control of sexual behaviour 
(Mbonu et al., 2009), which can be reinforced and upheld by religion, with PLHIV 
being considered sinful or evil (Alonzo and Reynolds, 1995; Duffy, 2005). This is of 
particular relevance in the study setting, where the population is predominantly 
Christian, and participation in religious and church activities are an important part 
of culture and personhood.  
Several studies have shown that individuals judged in association with HIV and 
immorality can experience great shame, indignity and humiliation (Campbell et al., 
2011; Gilbert and Walker, 2010; Mbonu et al., 2009; Mbonye et al., 2013). 
Respectability is an important aspect in the social construction of value and 
personhood (Campbell et al., 2011), lending understanding as to why several 
participants in our study who anticipated stigma also contemplated suicide. Our 
finding mirrors that of Moshabela and colleagues (Moshabela et al., 2016, p.27) in 
South Africa, where it was felt “better to die with dignity, than live with shame” from 
being known to be HIV-positive. Additionally, a study conducted in the same region 
of Eswatini as our study (Shiselweni) reported suicidal ideation following HIV 
diagnosis and as a result of anticipated stigma (Root et al., 2017). However, there is 
also a powerful strand of “responsibilisation” which could be emphasised, where 
initiating ART early allows for continued productivity. This could be particularly 
effective for men, by appealing to the prevailing discourse of masculinity, which is 
imbued with the need to provide for their families (Siu et al., 2013). These findings 
highlight the importance of understanding and considering the social experiences of 
individuals as integral to the HIV response, and the need to acknowledge stigma and 
its influence on PLHIV’s lived experiences.  
The longitudinal approach that was adopted in our study supported rapport and 
relationship building between interviewer and participant. This helped with the 
discussion of sensitive topics such as stigma, and facilitated access to alternative 
layers of participants’ narratives, beyond those deemed to be socially acceptable. This 
approach also enabled a greater depth of understanding, and insight to the nuanced 
ways in which stigma accounts changed over time. These findings are situated within 
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a specific time and place, relating to a fairly early stage in the Treat-all pilot, where it 
was uncommon for people who were relatively healthy to be accessing ART, and 
before national implementation. It will therefore be important to see how these 
findings continue to evolve as Treat-all becomes more commonplace. While likely to 
be of relevance to similar contexts, our findings reflect the voices of particular 
participants in a particular context, and therefore should be considered with this in 
mind.  
Conclusion  
With increased and earlier access to ART in a high prevalence, generalised HIV 
epidemic setting, stigma persists to frame PLHIV’s experiences with HIV, and to 
shape their engagement with HIV treatment and care. Taking treatment and 
engaging with care presents both benefits and risks for HIV status concealment, 
which must be continually negotiated and navigated. PLHIV may be motivated to 
initiate ART early to remain hidden by avoiding the development of discrediting 
stigma symbols, i.e. signs and symptoms of HIV. However, engaging with treatment 
and care itself presents risks of exposure at multiple points, and for some this risk 
was deemed too great, with decisions to abandon treatment and care being described. 
Where individuals are engaging with treatment and care as a means to hide their 
status, this is likely to be fragile, with the risk of non-adherence or disengagement 
from care.  
These findings point to the continued need for efforts to address the root causes of 
stigma and stigmatising processes where those with HIV are labelled with harmful 
judgements of difference, deviance and immorality. Regular measurement of 
community HIV stigma index could be beneficial, and programmes should ensure 
individual PLHIV are ready for treatment, have accepted their status and are not 
choosing to take treatment primarily to remain hidden, as this could undermine the 
sustainability of their engagement. Addressing HIV related stigma is crucial for the 
success of Treat-all, and should thus be a core component of HIV responses.  
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Ministry of Health and Médecins sans Frontières (MSF) project staff who supported 
this research. Thank you to Janet Seeley (London School of Hygiene and Tropical 
Medicine (LSHTM)) for input to the research and manuscript write-up, and to Oliver 
Bonnington (LSHTM) for discussion on framing the findings.  
 
 
 
  
215 
 
Chapter 8: Discussion 
Within this chapter, I summarise the overall findings of the research presented in this 
thesis, reflecting on the contribution to existing knowledge, the novel aspects of these 
findings, and their relevance for Treat-all implementation. I reflect on the approaches 
taken within the research, and how my choices may have influenced the emergent 
findings. I also reflect on the ethical dilemmas that arose during the research, and my 
response to these. I consider the strengths and limitations of the research, outline the 
steps taken to disseminate study findings, and propose implications and 
recommendations for policy, practice and potential areas for future research. 
Overall findings  
As I have outlined in this thesis, there are complex social dynamics and contextual 
circumstances which surround people’s experiences with HIV and their engagement 
with treatment and care (Reynolds et al., 2016). It is vital to examine, understand and 
address these broader social dimensions as integral to Treat-all approaches (Keogh 
and Dodds, 2015; Kippax and Stephenson, 2012; Young et al., 2016). However, many 
of the social aspects surrounding Treat-all implementation remain unknown. In order 
for people living with HIV to be adequately and appropriately supported to engage 
with HIV treatment and care and to benefit from Treat-all, their needs and 
experiences must first be understood (Camlin et al., 2016a). The findings of this PhD 
research contribute towards this understanding, providing novel insights into the 
experiences of asymptomatic people living with HIV in the context of Treat-all in 
Eswatini, highlighting how an HIV diagnosis may be processed, decisions to engage 
with care and to initiate treatment taken, and ongoing engagement in care navigated 
over time.  
The ways in which individuals respond to and process an HIV positive result may be 
individually and temporarily varied, potentially extending for a long period of time 
(Gilbert and Walker, 2010; Raveis et al., 1998). The findings I present in Chapter 4 
highlight the importance of the process of status acceptance for engagement with HIV 
care and treatment readiness, which can be challenging in the absence of symptoms 
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associated with disease. Individuals may conceptualise health in terms of embodied 
experiences that can be seen and felt (Zhou, 2016), and within this research, many 
individuals understood HIV infection as occurring alongside the experience of 
common symptoms, which an HIV diagnosis alone could not necessarily address.  
Feeling healthy may discourage treatment initiation, as findings from the Treat-all 
context in Mozambique also suggest, with some individuals struggling to accept their 
HIV positive status as a result, associating HIV with sickness (Magaço et al., 2019). 
The findings I present in this thesis go further in exploring the process of status 
acceptance, and considering the various factors which can influence it, presented in 
Chapter 4. An individual’s acceptance of HIV status could be undermined by 
prevailing judgements of HIV infection resulting from immoral behaviour and 
“promiscuity”, with which most individuals did not identify, therefore not 
perceiving themselves to be at risk of HIV acquisition. In this context, receiving an 
HIV diagnosis could disrupt an individual’s biography and challenge the social 
prescriptions of normality (Bury, 1982), despite the high HIV prevalence, and making 
it all the more difficult for some asymptomatic individuals to accept their diagnosis. 
It appeared important for some individuals to have time to process and come to terms 
with an HIV positive result. HIV-related counselling was seen as crucial for 
providing support and reassurance for the process of HIV status acceptance, as well 
as broader social support and encouragement.  
The biomedical logic framing Treat-all assumes that individuals will adjust their 
behaviour once they are educated, whereas decisions are situated beyond the 
biomedical realm (Beckmann, 2013). The findings presented within this thesis 
highlight the potential dissonance between clinical guidelines and individuals’ 
interpretation of what constitutes treatment necessity (Kawuma et al., 2018). In 
Chapter 5, I examine the narratives of four individuals, situated within the broader 
health system context and drawing upon the accounts of health care workers and 
observational data. These findings further explore the potential complexity of 
adjusting to an HIV diagnosis and the altered self-identity this may require. 
Treatment may represent a concretisation or reinforcement of illness (Pound et al., 
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2005), and the continuum of identity work that treatment-taking may entail can be 
particularly challenging for those without symptoms that signify disease. Thus, 
treatment decisions may be framed within individuals’ embodied experiences, which 
can either provide evidence of treatment need, for example for those who described 
reinterpreting past illnesses as potential signs of HIV, or lack thereof.  
In Chapter 5, I explore how ART initiation decision-making may involve multiple 
encounters with health care workers, and other people and technologies (Rapley, 
2008). For individuals who described having time to undergo this process, and for 
whom the decision to initiate ART appeared intrinsically based, this could instil a 
sense of choice and ownership over the management of their health and treatment-
taking. Having a sense of ownership of health needs (Schulman-Green et al., 2012) 
may enable individuals to prioritise treatment-taking, establishing it within daily 
routines, overcoming challenges and fostering determination and perseverance for 
continuation. Conversely, for those who may feel coerced to test and to initiate 
treatment, which appeared particularly relevant to those engaging with HIV 
treatment and care during pregnancy, this pressure, lack of time and absence of 
perceived choice could influence individuals’ disengagement from care.  
The findings presented in Chapter 6 further highlight the importance of individuals 
having evidence of treatment need and effectiveness for motivating their ongoing 
treatment-taking, drawing upon a sub-sample of 17 individuals who were registered 
as having initiated ART a mean of 20 months prior to their first interview. Within 
Treat-all, conceptions around health and treatment change as HIV treatment is 
increasingly appropriated for preventative purposes, and the symptoms of HIV and 
efficacy of treatment are less apparent (Zhou, 2016). In this thesis, certain individuals 
who had not identified physical signs of HIV prior to initiating ART, and who could 
not see evidence of improvements with treatment, described having doubts about 
treatment which could undermine their motivation for taking it and result in 
intermittent treatment-taking. Some described experimenting with treatment, 
seeking evidence of its efficacy by missing doses to see if there was any resulting 
effect. This may pose risks for drug resistance, which can develop through 
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intermittent treatment-taking (World Health Organisation, 2017a). Understanding 
the potential reasons for what Conrad (1985) describes as patients’ “self-regulation” 
(i.e. where patients may alter the course of treatment to test its efficacy), will enable 
individuals’ needs and priorities to be addressed and incorporated within 
programmes. For those who received viral load results, this appeared to offer a means 
through which the effect of treatment on the level of the virus became visible, thereby 
motivating continued treatment-taking. Routine viral load monitoring could 
therefore be particularly important in the context of Treat-all.  
Despite hopes that increased and earlier access to ART would contribute to the 
normalisation of HIV and HIV stigma reduction (Castro and Farmer, 2005), the 
findings presented in Chapter 7 of this thesis suggest that HIV stigma persists to 
frame individuals’ lived experiences with HIV in the context of Treat-all. Stigma was 
pervasive in the narratives of people living with HIV, both driving and undermining 
engagement with HIV care, and suggesting a fragility surrounding treatment-taking 
in this context. ART may represent a “technology of invisibilisation” (Mattes, 2014), 
by preventing the development of HIV-related symptoms which could expose an 
individual’s HIV status and discredit their social identity. However, this relates to the 
avoidance of an abstract future risk, and individuals’ identities may remain 
discreditable (Goffman, 1963). Engagement with treatment and care presents risks for 
HIV status exposure which individuals continually navigate. For some, this risk 
appeared too great and was linked to disengagement from care or intermittent 
treatment-taking. If stigma is not addressed and included as a core component of HIV 
responses, there is the risk that it will undermine individuals’ ability to engage and 
to sustain engagement with Treat-all care. 
Although not a specific focus of the analyses presented in the papers within this 
thesis, society in Eswatini is patriarchal (see Study context section in Chapter 3), and 
the gendered context influenced the research findings in numerous ways. For 
example, for men, engaging with early treatment within Treat-all was seen to allow 
for continued work and productivity through maintaining good health, appearing to 
align with predominant constructs of masculinity which celebrate strength and 
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productivity. Women’s accounts alluded to the ways in which they would navigate 
the patriarchal context, and engaging with HIV treatment and care could pose 
additional risks for partner abandonment and abuse. The structural drivers of HIV, 
and the influence of gender on people’s lived experiences with HIV in this context 
warrant further investigation.  
Eswatini is predominantly Christian, and the vast majority of the population identify 
as religious (see Methods: Study context). The religious context also influenced the 
study findings, for example through shaping perceptions of HIV risk (as described in 
Chapter 4), and influencing the moral framing of HIV which contributed to 
stigmatising processes (see Chapter 7). There could be dissonance between social 
standards of respectability and having upstanding moral stature, aligned with the 
Christian doctrine, and the complexity of people’s lived reality. As HIV was 
perceived linked to “promiscuity” and “immoral” behaviour, this could make it 
difficult for individuals’ to accept a HIV positive status and the social identity that 
this inferred, potentially undermining their engagement with HIV treatment and 
care.”  
Reflection on the approaches taken within the research 
This section includes aspects relating to reflexivity, paying attention to the ways in 
which the researcher may be shaping the data, as well as broader reflections on my 
choices within the research, which may have influenced the findings, including the 
epistemological approach and the provision of a financial reimbursement or 
contribution to participants for their time. I also reflect upon some of the ethical 
dilemmas that were raised within the research. 
Interview dynamics and data co-production 
In recognition of the co-produced nature of data within interviews, and the role of 
the interviewer in shaping the data (Gubrium and Holstein, 1997; Silverman, 2013), I 
had initially wanted to undertake interviews with participants myself. The desire to 
be present in interviews was so that I could have a direct connection with 
participants, to facilitate understanding their social circumstances and life world, 
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which could aide my interpretation of participant accounts within data analysis, and 
my ability to reflect on the dynamics of data production. However, I also wanted to 
choose the most appropriate approach in the study setting, to be mindful of potential 
power dynamics, ethics and participant comfort. Initially, I piloted the approach and 
conducted one interview with a woman myself. Although I had siSwati lessons twice 
a week, and was learning the language, I was not fluent enough to conduct an 
interview in siSwati, so a researcher accompanied me for the interview to interpret. 
This interview experience raised several concerns relating to ethics and power 
dynamics. The participant lived in a very rural location, around one hour walk from 
the road into the hills, and as we walked together through the community to get to 
her homestead, my presence drew a lot of attention, partly because I was not known 
to the community, exacerbated by my skin colour and the visibility of this difference. 
When I discussed this with her, she said it was fine, as people in the community 
would assume I was from World Vision (charity), or that I was a missionary, which 
would be preferable to assuming I am from the health services or MSF, to avoid risk 
of inadvertently disclosing her HIV status. However, the amount of attention was 
uncomfortable and could have the potential to cause her harm.  
The consent process was slower than had been the case for other interviews, and she 
seemed confused about the research process and in her expectations of what 
participation may involve. Initially she asked if we were offering her a job, and at first 
was reluctant about making a time commitment she could not uphold, saying she felt 
conscious that she could not teach us anything, as her education level is low, before 
saying she would like to take part. This raised questions about the extent to which 
she may have felt able to refuse participation, and about her understanding and 
comfort. Once the interview began, I established good rapport with her, and she 
appeared comfortable and open. However, there were several allusions to 
hierarchical power dynamics, which appeared exacerbated by my race. For example, 
when we arrived, her family members came to greet us, thanked us for visiting and 
said that as I am powerful and respected (presumed due to my skin colour), now the 
rain should come.  
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Following this experience, I wanted to explore this further, and to be led by 
participants’ views, preference and comfort, asking if they would feel more 
comfortable being interviewed by me (a white woman) or by another researcher (a 
Swati woman) prior to meeting with individuals. One woman responded by strongly 
emphasising that she did not want an umlungu (white person) coming to meet her, 
and another responded “What is it that you really want now that you are bringing this 
white woman… no please don’t bring a white lady to me”. I therefore decided that it would 
be more appropriate for these interviews to be conducted by same-gendered siSwati 
speaking Swati researchers, and took other steps to remain close to the process of 
data generation (as described in the Methods Chapter 3, section: Approach to data 
generation, p74).  
The most important factor influencing the choice of interviewer related to participant 
comfort and safety. There may also be relative value in the interviewer having either 
“insider” or “outsider” status (Best, 2003), as described in the methods chapter. It 
appeared that the “insider” status of the interviewer in having presumed shared 
experiences and understanding supported participant comfort and openness, which 
was particularly visible where the participant and interviewer were presumed to be 
age mates, with a relaxed and open dialogue. Age is said to be the main factor 
characterising group association in Swati life, and age cohorts are a particularly 
important means of differentiation among men, with women also identifying with 
age groups, though perhaps on a less formal and regimented level (Kuper, 1986). For 
example, one woman who was similar in age to the interviewer said: “I feel comfortable 
talking to you… it’s like you’re my friend”. However, this “insider” status could make it 
challenging for the interviewer to probe or to make explicit meaning that was 
presumed to be shared and mutually understood, reflected in language such as “as 
you know we men/women…” and “as Swatis we are just like that…” 
Where there were differences in age or presumed social status, this could create 
power dynamics which influenced the interview process. While steps can be taken to 
mitigate these dynamics, it may be impossible to fully equalise power, and it is 
important to explore the ways in which they may influence the interview process and 
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participant accounts which result (Oakley, 1981; Roulston, 2010; Skeggs, 2001). The 
influence of such dynamics could be seen in certain interviews with young women, 
who were often reserved and more closed in their responses to questions or probes. 
For example, one young woman who was 23 years old and recorded as lost from 
treatment said “I do not know what how to answer your questions, they are so strong”. 
Younger participants often appeared to become more comfortable over time, and the 
longitudinal approach to data generation likely aided this relationship building.  
Differences that participants felt in social status could result from perceived 
educational differences, social class or status, for example one man said “I don’t 
understand you since I didn’t go that far in school”. This could potentially result in some 
reluctance for participants to feel fully comfortable and open to share their views, 
fearing they may not be appropriate or acceptable. One interviewer’s surname shares 
a connection with the royal family of Eswatini, which could have also created a 
certain dynamic, respect and formality. The clanship associated with this name holds 
the highest social level, as lineage with the king is pre-eminent and therefore holds 
high attributed social status (Kuper, 1986). For example, one man refers to him as 
“mntfwanenkhosi”, which is a surname extension (said in a sign of respect) that 
directly translates to child/son of the king. This participant would often check in with 
the interviewer to ask if his responses were appropriate, and said “in my opinion, and 
this is not to say that’s how it would be, but it’s just how I see things”. These interviews 
could appear more formal and respectful, with the participant’s narratives seeming 
to be aligned to a narrative deemed to be socially acceptable, and often accordant 
with the predominant health messaging, for example that having multiple concurrent 
partnerships is not acceptable.  
In interviews with health care workers, which I conducted, there were instances 
where my “outsider” status as non-Swati may have enabled probing and exploration 
of topics relating to the “way of life” or the “Swati way”. For example, in allowing 
deeper exploration of gender dynamics:  
“Swazi traditional men, I’m not sure whether I would say they are very tough or 
strong or what. Because, myself I don’t remember when was the last time I was sick. 
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Not because I’m now somebody who is a nurse, but we are not those people who just 
get sick anyhow. Yeah, we are just like that.” (Clinic nurse, man) 
Additionally, in explaining aspects relating to migration and engagement with care: 
Interviewer: when you say for us Swazis it’s unlawful…you mean it’s unlawful for 
people to move to that side…to South Africa? Could you tell me more about that… 
what do you mean by that? 
Participant: being a Swazi…you are not allowed to do your documents that side... 
South Africa is another country… it’s not your own country where you were born 
you see… being a Swazi you have to stay in Swaziland. They [patients] are just 
cheating on their own by relocating there. It’s just that we [clinic] are located along 
the borderline. (Clinic nurse, woman) 
This difference, as well as reassurances of confidentiality, may have created an 
environment where participants felt comfortable to share views which challenge the 
dominant, socially normative narrative, for example relating to the political context 
in Eswatini. This can be seen in the narrative of one participant who spoke openly 
about problems with the current political system and the wealth inequity, identifying 
as wanting democracy rather than the monarchy, which was not common in the 
social context: 
“I think we have got enough money in Swaziland it’s just that somebody is enjoying. 
If people can go to Las Vegas to just buy water to drink, while we are fetching our 
water from the streams, it means you have got a lot of money if you can travel just to 
get water from Las Vegas.” (Clinic nurse, man) 
It is important to reflect on the potential influences of interviewer-interviewee 
dynamics, and to consider the relational environment within which data is generated 
when interpreting and analysing participant accounts.  
Reflections on the research approach 
As described in the methods chapter, the epistemological approach underpinning 
this research is phenomenological and interpretive, aiming to understand the 
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complex world of lived experience from the point of view of those who live it 
(McCaslin and Scott, 2003; Schwandt, 1994). In examining how engagement with HIV 
treatment and care may be experienced in the context of Treat-all, I  aim to 
understand how individuals make sense of this experience (Smith, 2004), and I 
recognise that there is no single interpretive truth (Denzin and Lincoln, 2013). 
Additionally, as the approach that I adopted was largely inductive, this will have 
influenced the findings that were generated, as rather than being predetermined, 
findings emerged from participants’ perspectives, and were primarily exploring 
individuals’ interpretation, understanding and experience. While I also considered 
and explored the broader social and health system context, the primary focus was on 
individuals’ lived experiences, rather than for example being predominantly health 
system or policy focused. The influence of this perspective can be seen by comparing 
the findings presented in Chapter 7 on how stigma frames individuals’ engagement 
with Treat-all care, with that of Bond and colleagues (2019). The findings in Chapter 
7 demonstrate the ways in which stigma frames narratives of living with HIV and 
engaging with treatment and care in the context of Treat-all. Bond and colleagues also 
examine stigma experiences in the context of Treat-all (in Zambia and South Africa), 
but focus on the environment within health facilities which contributes to the 
production of stigma experience for people living with HIV, through exploring the 
spatial organisation of HIV services and material items. These findings both provide 
interesting insights to HIV stigma in the context of Treat-all, from differing 
perspectives. 
Due to the large volume of data that were generated through this research, further 
analysis and publications are planned. For example, there were findings relating to 
how the preventative benefit of ART is understood by people living with HIV, the 
fact that the vast majority had no knowledge of this benefit, although it was seen as 
information that could motivate treatment-taking, and reasons for health care 
workers’ reluctance to share this information with individuals. I chose to present 
findings which emerged most strongly, for example across several participants, and 
appearing to be influential for lived experience and engagement with care, and 
additionally, which aligned with the research aim and objectives. Therefore, while 
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the findings relating to treatment as prevention were interesting, as they 
demonstrated that this preventative benefit was largely unknown, they therefore did 
not appear to frame people living with HIV’s interpretations of Treat-all or narratives 
relating to engagement with care. This choice thereby frames the findings presented 
in this thesis.   
The majority of interviews were conducted in siSwati and subsequently translated, 
which is likely to have influenced the findings to a certain extent. Meanings are 
embodied in the language of participants (Schwandt, 1994), and within this research 
I aimed to interpret and represent such meaning in the way intended by participants 
in their narratives, in order to ground findings within participants’ accounts (Brocki 
and Wearden, 2006) and to authentically present their perspectives as much as 
possible. However, due to differences in the construction of siSwati and English, it 
was not always possible to directly translate, and also convey the meaning of phrases 
or words. Therefore, equivalent translation was used in the instances where there was 
no word available for direct translation, and to convey meaning, with the original 
siSwati word indicated in parentheses. When writing the paper included in Chapter 
5, on choice and ownership regarding treatment-taking under Treat-all, I had initially 
positioned findings to consider the extent to which individuals had a sense of choice 
regarding the decision to initiate ART, and what influenced their experience of 
enacting choice. In this framing, I was interpreting participants’ use of words such as 
“I must take treatment”, “I had to take it” to infer a potential lack of perceived choice. 
However, I could not be confident that the meaning behind these expressions was 
exactly the same in the original siSwati form and in English, and in the accuracy of 
such interpretations. I therefore decided to instead focus on the decision-making 
processes, and how participants’ narratives described and accounted for the thought 
and other processes that individuals could undertake when coming to the decision to 
initiate ART. Some social constructivists consider language as a site of reality 
construction, and will analyse the minutia of language and accounts to infer meaning 
(e.g. Best, 2003). While this is a different level of focus to the approach taken within 
this research, it could be difficult to examine and understand such dynamics due to 
the added layer of translation creating additional distance and complexity.  
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Ethical dilemmas 
The section on Ethics in research in the methods chapter outlined the steps taken 
within this research to uphold ethical principles, and in this section I reflect on some 
of the ethical dilemmas which were faced within the research process, including my 
decisions and responses to such dilemmas. I recognise that informed consent is a 
process (Hewitt, 2007). Consenting to participate, understanding the research process 
and what participation involves is more nuanced than a signature on a consent form, 
and may change over time. I therefore sought to explore and understand how 
participants may have experienced study participation. For example, any potential 
influences the research may have had for them, and how their understanding and 
expectations about their participation aligned with their experience of it.  
A particularly challenging ethical dilemma related to emotive discussions and 
referrals to psychosocial support for certain participants. The nature of discussions 
relating to HIV are inherently sensitive, and while certain approaches such as 
interviews being led by participants and not ending with emotive topics can help 
protect participants from harm, there is still the possibility of emotional distress. I 
had planned to have a referral system whereby any participant who was emotionally 
distressed, in need of psychosocial support, or at risk of harm, would be referred to 
the psychosocial team, and this would be discussed with the participant beforehand 
and their consent sought. However, when discussions relate to past or historic 
trauma, or more complex needs than can be provided for within a predominantly 
biomedical project, where the mental health support is mainly focused around 
adherence and support for engagement with health services, this can be challenging. 
Although I was aware of the patriarchal context in Eswatini from my experience 
living and working in Shiselweni, I was not prepared for the number of participants 
who described their experiences with sexual violence and abuse, which particularly 
related to the life history interviews, as well as to narratives of HIV acquisition. 
Almost every woman in the study described having experienced some form of 
violence or abuse, and sexual non-consent was frequently implicit within 
participants’ accounts. This was confronting, and while reflecting broader social 
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constructs relating to power and gender, was difficult to navigate when forming 
relationships with individuals who were so open in sharing their experiences. It felt 
insufficient to listen without being able to act, to offer or refer to specialist support, 
or to contribute towards dismantling the violent and oppressive social structures 
which exacerbate violence against women. However, within this project, and the 
broader study setting, we were limited with the options of support that could be 
offered.  
The research assistants and I identified several participants as being in need of 
additional psychosocial support, and I had anticipated that being situated within the 
MSF project would aid the referral process. However, in reality the process was more 
complicated. There was resistance to what was perceived as the creation of more 
work for the psychosocial team, and referrals had to fit within the existing operational 
systems, which were largely based around clinic engagement. For example, one 
younger woman who was not on treatment or engaging with care was told she would 
have to go to the clinic to be able to see the counsellor. Eventually we were able to 
navigate these challenges and establish an agreement with the team to refer certain 
individuals, but it was not as easy to refer people for additional support as we had 
hoped.  
Responses to the invitation to participate were varied, even among those who agreed 
to participate, and while the invitation was generally interpreted as a positive 
opportunity some individuals had concerns about why they had been chosen. For 
example, one woman said: 
“I asked myself why they chose me, and I’m going to tell you my sister-in-law, because 
I was asking myself that maybe there’s something I haven’t done alright or maybe God 
has sent these people to me to ask something which will help them and also help me in 
the process… like maybe did I make any mistakes? Or is my illness different to the 
rest? And then I told myself again that no… they want to help us, and it’s not like I 
have told our king’s secret…(laughter)…and I have since moved myself out of that 
problem” (Woman, on treatment) 
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Several participants had concerns regarding confidentiality and how we had 
obtained their contact details. For example, another woman describes her fears and 
confusion when she was first invited to participate: 
“When you called me I was shocked ‘where did this person get my number from and 
what does she want me to do’, and I asked myself ‘does she not want to expose me to 
people’… it was my first time hearing of this research you see…” (Woman, on 
treatment) 
Confidentiality concerns regarding how researchers had obtained participants’ 
contact information partly influenced the decision to not directly emphasise an HIV 
focus when introducing the study. Rather, the research was framed as being about 
health and experiences with health care services in Shiselweni more broadly, and any 
disclosures relating to HIV were led by each individual participant. I felt 
uncomfortable with not being fully open and transparent with participants about the 
HIV focus of research, which could have been unethical, but it seemed most 
important to not presume participants’ HIV status and to allow such conversations 
to be led by individuals, rather than by the researchers. Sensitivity around presuming 
participants’ HIV status or leading with HIV discussions felt particularly pertinent 
given how stigmatised HIV is in this context.  
While most of the individuals who were invited to participate agreed, there were 
several who appeared positive about the research, and agreed to meet, but who either 
frequently rearranged or who then didn’t attend the agreed appointment and 
subsequently became uncontactable. Such participants have been described as “silent 
refusals”, hesitating to participate without explicitly refusing (Kamuya et al., 2013). 
Initially it could be hard for researchers to distinguish certain silent refusal 
participants, particularly those who appeared positive and engaged. For example, 
there was one man who agreed to meet on several different occasions, but each time 
asked to rearrange because of work or other commitments. Silent refusals were 
explored within a study in Kenya, which found that this could be a norm when 
politely refusing strangers or highly respected individuals, perceiving an outright 
refusal as being rude (Kamuya et al., 2015). This can raise ethical dilemmas in how to 
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recognise and respect silent refusal without badgering individuals to participate who 
may not really want to take part. This also needs to be balanced when trying to recruit 
harder to reach individuals, for example those lost from treatment, who may need 
more time and reassurance about what research involvement entails before feeling 
comfortable to take part. For example, one young woman who was lost from 
treatment initially appeared as though she may be silently refusing, but when we 
managed to meet with her to talk through more of what the research would entail, 
she said she had been concerned that the researcher would try to bring her back to 
treatment. When this concern was addressed and the participant was reassured by 
further explaining the confidentiality of discussions, she was then willing to take part.  
It is possible that some health care worker participants felt unable to refuse study 
participation, as a member of the project who was their superior (the head of clinical 
activities, as outlined in the Methods Chapter, section: Main phase: longitudinal 
study; Participant recruitment) requested their participation before I could discuss 
consent and what participation would involve. Health care workers may also have 
perceived the interview as an evaluation of their performance. Once it was possible 
to meet with health care workers and discuss the research further with them, most 
appeared to feel more comfortable. However, some were potentially more open in 
sharing their views than others, and the views reflected were largely professional.  
Taking part in the research appeared to impact on individuals in different ways. 
Several participants described appreciating having a safe, confidential space to talk 
about their lives and HIV, with certain individuals saying they had not spoken about 
their status with anyone else before, and feeling that it was good to talk and to be able 
to get things off their chest, having a cathartic, comforting effect and described as 
reducing stress. Research participation also seemed to impact on experiences with 
HIV for some, for example there were participants for whom interview discussions 
supported their feeling able to talk more openly about their status, possibly 
facilitating disclosure beyond the interview setting. One woman said: 
“Talking to you has made me to be able to talk to another person about my life, whereas 
if you weren’t talking to me, I would feel like it is my chest, my secret to keep and I 
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have to keep quiet and not tell even my friend… I was scared Zet [nickname 
participant has given the interviewer] but now that I am talking to you I feel like it is 
just stupid for me to be scared… Because I am talking with you, I am able to talk to 
someone else [outside of interview] now… hiding it will not work for me.” (Woman, 
on treatment) 
Certain participants who were lost from treatment also described re-thinking their 
treatment-taking and engagement with care following interview discussions, as 
another woman describes: 
“I thought I should start taking them [ART], after you came here, I thought I should 
start taking them because what if I pass it on to my child…” (Woman, lost from 
treatment) 
Additionally, the research could offer reassurance that people’s voices were valued, 
that the government cared for individuals and wanted to hear their views and 
experiences and incorporate them into health services. 
“Having someone to talk to about my status has helped develop me... there’s 
something I’m going to learn from you as we talk and I also feel appreciated that we 
are people as well, and that we are also accepted in the community unlike to feel 
neglected.” (Man, on treatment) 
“I think that there could be some change that is instigated especially if I have been 
abused in some way at the health facility, the research can make a difference in making 
that change happen.” (Young woman, on treatment) 
Many described taking part because they wanted to help others who may have 
similar experiences to them, to encourage people to test and to be able to access care. 
However, there is the potential that this could reflect an expectation which the 
research cannot guarantee to deliver on, as while this research highlights areas for 
potential adaptations to policy and practice, I cannot control to what extent these are 
heard or adopted.  
While the longitudinal nature of the research supported relationship building 
between participants and interviewers, this also requires navigating and warrants 
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reflection. For some individuals, particularly women, their language and 
communication reflected a sense of friendship with the interviewer, with some 
sending Whatsapp messages to say “hi” and to check in between meetings. It felt 
important to try to put boundaries around this relationship and be clear in terms of 
expectations, to protect participants from any potential hurt or disappointment, 
while at the same time appreciating their trust and openness. As participants had 
been involved in the study for some time, we prepared for the study ending by 
reminding participants of what participation would involve at each interview, and 
checking in with how they were feeling about the last interview.  
In the methods chapter, I outlined why I decided to offer participants a small financial 
reimbursement for their time, as well as providing refreshments for each interview. 
Here I will briefly reflect on how these reimbursements may have influenced the 
research process. The use of reimbursements appeared to influence certain 
participants’ attitudes towards research participation in feeling appreciated and 
more positive towards taking the time to take part than they may have felt otherwise, 
as one young woman says: 
“I liked the fact that you also get some… [laughing]  [money] they do not irritate you 
for nothing..” (Young woman, lost from treatment) 
While unlikely to have influenced choices regarding participation at the study outset, 
as reimbursements were not promoted when inviting study participation, these 
reimbursements may have potentially contributed to motivating continued 
engagement with the research.  
Observations raised unique ethical dilemmas. In sessions that were observed, I would 
try to minimise my presence as much as possible, to avoid disturbing the flow of the 
session and individuals’ comfort, for example sitting behind patients or out of their 
line of view, though it is inevitable that my presence will likely have influenced the 
interactions that I observed. It was not feasible to form a relationship with all patients 
or individuals involved in the sessions that I observed, and as I relied upon health 
care workers to introduce the research, my presence, the purpose of the observation, 
and to seek individuals’ consent, this created some distance from what was said and 
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how the research was presented and understood. Certain health care workers seemed 
to interpret my presence in observing their work as an evaluation of their 
performance, and one introduced me to a patient as being there to see whether health 
care workers’ shouted at patients. Having more time with health care workers and 
being able to further explain and reassure them seemed to help with this, but 
ultimately sharing the research findings with clinics and project staff did involve 
critical reflection on the services that were delivered, so it may be inevitable that the 
research would be interpreted as somewhat of an inspection. All individuals were 
given the choice to opt out of having their session observed, or to ask me to leave at 
any point. In observing HIV testing sessions, certain individuals were happy for me 
to observe the pre-test information, but did not want me to be present for the test 
result. Other than that, all individuals gave verbal consent for observations.  
Strengths and limitations 
As this research was positioned within an MSF project piloting Treat-all under 
routine programmatic conditions, this provides a unique opportunity to explore 
individuals’ experiences with Treat-all at an early stage of its implementation, which 
can then inform future policy and practice relating to Treat-all. This Treat-all pilot 
began in October 2014 and had been underway for some time when this research 
commenced. It was therefore possible to recruit participants who had been enrolled 
in the pilot for almost two years, and to explore somewhat longer-term engagement. 
However, some of the findings may change as Treat-all becomes more commonplace. 
These findings are situated within a particular time and place, relating to a context 
within which the concept of treatment for HIV when asymptomatic was fairly 
unfamiliar and not yet the standard of care or incorporated to national treatment 
guidelines, and should be interpreted with this in mind. Additionally, the HIV 
services offered to individuals in this context likely included more patient support 
and routine viral load monitoring than may be included in other settings, due to 
MSF’s support. However, the pilot aimed to investigate the feasibility and 
acceptability of Treat-all under routine programmatic conditions, with lessons to 
inform the national roll-out of Treat-all. Feasibility thereby included reflections on 
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resources (human and financial), and what would be sustainable in contexts beyond 
the MSF programme. The availability of viral load monitoring provided the unique 
opportunity to explore participants’ perspectives and experiences with this tool.  
This research included fieldwork (over the period 2015 to 2017), and the formal and 
informal observations that this enabled aided my interpretation of interview data and 
provided a deeper understanding of the broader study context. As observations were 
conducted with the assistance of an interpreter, this may have resulted in some of the 
nuance in the use of language, and potential meaning of the words that were used by 
participants being missed. The longitudinal nature of the research supported 
relationship building between participants and interviewers, facilitating trust, 
rapport and comfort and creating rich data that offered unique depth of insight into 
the lived experiences of people living with HIV within the context of Treat-all. This 
could have been particularly important for younger participants, who appeared to 
become more comfortable and open over time. The relationship building that was 
facilitated by repeat interviews also aided the discussion of sensitive topics, and 
access to alternative layers of narrative, beyond those deemed to be socially 
acceptable, and often closely aligned with the dominant health messaging. Repeated 
interviews allowed for the exploration of changes in participants’ experiences over 
time, reflecting the evolution in perspectives, interpretations and understanding, and 
the non-static nature of living with HIV and engagement with treatment and care. 
However, repeated interviews were held after a fairly short period of time (mean 8 
months before first and last interview for those who had more than two interviews). 
The regularity and close time proximity of interviews will likely have aided rapport 
building, but may have not allowed for many changes in circumstance or experience, 
for which a longer research time frame with extended spacing of interviews would 
have been needed.  
A range of perspectives are reflected within this research, adding to its value. 
Individuals recorded as lost from treatment, men and young women are included, 
whom we know can all have additional challenges with treatment-taking and 
engagement with care, and whose perspectives are important to understand, in 
234 
 
addition to the perspectives of those who are engaging with care. However, it is still 
possible that the hardest to reach individuals were not included, and these 
individuals may be particularly disadvantaged or have unique challenges relating to 
engagement with HIV treatment and care. Almost half of the identified individuals 
for study recruitment were uncontactable, due to an unavailable or incorrect 
telephone number. This reflects the challenges with follow-up of individuals in this 
context, and these individuals may have had different experiences from those 
included in the research. There were also several silent refusals, i.e. individuals who 
agreed to meet but did not attend the appointment, and who then became 
uncontactable. It was therefore not possible to explore their reasons for non-
participation or to reflect their voices within the study findings. It was not possible 
to recruit young men to the study, as the HIV epidemiology of Eswatini means fewer 
young men are living with HIV, and men often access treatment and care later than 
women. There were therefore no young men registered as newly diagnosed and 
enrolled in the Treat-all pilot who met the study eligibility criteria for CD4 count and 
WHO disease stage. This will have affected the study findings, in not reflecting their 
views and experiences. 
Due to time and resource constraints I took the decision for audio files to be 
transcribed directly in English (translated from the audio), rather than being 
transcribed verbatim and then translated. This is because the same researchers who 
conducted the interviews also conducted transcription and translation, and it would 
have taken double the time to transcribe and then translate, thereby delaying data 
analysis and the time frame for subsequent interviews. Although the original audio 
files could be referred to during data analysis, and transcripts were checked for data 
quality, having the siSwati and English transcripts could have facilitated remaining 
closer to the original use of language. 
Dissemination of research findings 
I took steps to disseminate the research findings at local, national and international 
levels, as follows:  
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Local dissemination: Throughout the research process, I shared and discussed 
preliminary findings with the project, largely through PowerPoint presentations and 
workshop-style discussions. These sessions included presentations to the whole 
project, sessions held with the research and medical teams, and with counsellors and 
others in the psychosocial team. Once data analysis was complete, I also returned to 
the project to share the final findings with members of the project including those at 
coordination and field teams, and prepared a presentation for sharing findings with 
the clinic staff and the Ministry of Health. I had wanted to hold sessions at each of 
the clinics during this visit to share findings with health care workers directly and to 
seek their views on the findings and potential implications. However, this was not 
possible due to project constraints. I met with several of the participants at the study 
end to thank them for their time, to share the key findings with them, to answer any 
questions they may have and to seek their views on the findings. Within these 
meetings I offered a contribution of meat and soap to thank participants for their 
contribution, and prepared a document summarising the findings for these 
participants, which was translated into siSwati. Unfortunately, it was not possible to 
meet with all the study participants, but only those who were interested and 
available. I also prepared a programmatic feedback report with extensive research 
findings and recommendations for policy and practice, as well as a summary of key 
findings document (see Appendix 5).  
National dissemination: I presented preliminary research findings at several 
stakeholder meetings with the Ministry of Health and other partner organisations 
present, in Mbabane, throughout the research process. The programmatic feedback 
report and summary of findings document were distributed to national partners, and 
a member of the Ministry of Health was a co-author on each of the papers prepared 
for publication. I prepared three oral presentations of the research findings, delivered 
at the Eswatini National AIDS conference in July 2016, with one winning an award.  
International dissemination: I delivered an oral presentation on the research findings 
at the MSF Scientific Day conference in May 2016, with an online audience of around 
8,000 people worldwide. I presented a poster at AIDS 2016 in Durban. Additionally, 
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I orally presented research on viral load monitoring and Option B+ at the ASSHH 
conference in Stellenbosch in 2015. Three papers have been published in peer-
reviewed journals and one has been submitted, which it is hoped will contribute 
towards dissemination of research findings, all being open access publications.   
Recommendations 
The findings presented in this thesis highlight the individually varied, potentially 
complex process individuals may go through when coming to terms with an HIV 
diagnosis, deciding when to start treatment, and sustaining engagement in the 
context of Treat-all, with specific support and informational needs for those who are 
asymptomatic.  
Policy relating to Treat-all implementation should include counselling as integral, 
with flexibility to tailor support to meet individuals’ needs for time and intensity of 
support, and with specific provisions for supporting status acceptance and treatment 
readiness. Specifications should be established to allow for some individuals to be 
able to take more time before initiating ART, without feeling pressured, and 
highlighting the importance of individuals having sense of choice regarding this 
process. Stigma should be included as integral to the HIV response, including 
components of support, as well as consideration for how to tackle stigma at its root. 
Viral load monitoring should be routinely available and delivered alongside Treat-
all, with results communicated to patients to support continued treatment-taking. 
Results should be communicated for both suppressed and unsuppressed  
Within practice, counselling and support should be available for diagnosis and 
treatment initiation decision-making, tailored to meet individuals’ needs for support 
and time, ensuring acceptance, readiness and sense of choice regarding ART 
initiation. While this has resource implications, increased support will likely result in 
a wealth of benefits including improved patient outcomes. Approaches should reflect 
conceptualisations of health, illness and treatment beyond the biomedical, to address 
individuals’ potential concerns about the need for treatment in the absence of any 
physical signs of ill health. Areas of focus could include the potential for treatment to 
preserve good health and productivity, which may be particularly appealing to men 
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and which can align with dominant conceptions of masculinity and strength. It 
should be acknowledged that stigma can undermine individuals’ abilities to engage 
with treatment and care, and rather than health messaging encouraging individuals 
to hide their status, which could reinforce stigma processes, individuals should be 
supported towards status acceptance and disclosure, as well as with finding ways to 
navigate the stigmatised environment which surrounds HIV.  
The importance of individuals having evidence of the difference that treatment is 
making for motivating their continued treatment-taking should be recognised within 
programmes, and steps taken to communicate and to meet this need, including in 
communicating viral load results as a potential tool to provide this evidence to 
individuals. Additionally, individuals should be supported to foster a sense of 
ownership over the management of their health and treatment-taking, with support 
for their determination and perseverance in overcoming its challenges, and creating 
a safe space to be able to discuss such challenges without fear of retribution. It is 
important for health services to be delivered in an environment which encourages 
openness and support, where patients feel able to come forwards and share their 
challenges with health care workers without fear of being reprimanded. 
Programmatic targets should be interpreted with an understanding of the individual 
variation in responses to Treat-all care, and pressure for health care workers to 
successfully implement Treat-all should be understood in this context. For example, 
some individuals need more time to engage with treatment and care, and this does 
not reflect on the performance or ability of health care workers to convince them.  
Further research on the structural drivers of HIV and how this shapes individuals’ 
engagement with treatment and care in the context of Treat-all is warranted, 
including the fundamental causes and drivers of stigma, which should be better 
understood and examined in order to consider how stigma may be tackled at its core. 
Additionally, it is important to consider the experiences of individuals who have 
been engaged with Treat-all care for a longer period of time, as well as exploring the 
views and experiences of those experiencing Treat-all once it becomes more 
established and commonplace. For further recommendations see Appendix 4.  
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Conclusion 
A body of scientific evidence demonstrates that Treat-all is efficacious for reducing 
HIV transmission and improving the clinical outcomes of individuals living with HIV 
(Cohen et al., 2011a; INSIGHT START Study Group, 2015; The TEMPRANO ANRS 
12136 Study Group, 2015). However, we have seen from the early findings of Treat-
all trials that this does not directly translate to a reduction in HIV incidence at the 
population level (Havlir et al., 2018; Hayes et al., 2019; Iwuji et al., 2018). The social 
reality surrounding people’s lived experiences with HIV and with engagement in 
care is complex and nuanced. The biomedical paradigm that considers health as an 
absence or containment of disease does not account for the multitude of aspects to 
health, personhood and self, which extend beyond the biomedical (Beckmann, 2013; 
Hickel, 2012). The findings presented within this thesis highlight the perspectives, 
priorities and needs of individuals living with HIV in Eswatini, who must be able to 
engage with HIV treatment and care services in order to experience the benefits of 
Treat-all, which should be incorporated within the HIV response. Additionally, the 
findings of this research explore the potential dissonance between the biomedical 
logic framing Treat-all and individuals’ conceptions of health and treatment need, as 
well as between the priorities of individuals and the priorities of biomedical and 
public health agendas which frame Treat-all. Understanding these perspectives may 
help with considering how such differences may be reconciled, and how challenges 
engaging with treatment and care in the context of Treat-all may be overcome.  
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Appendices 
Appendix 1: Summary of Treat-all trial findings 
Trial name Location Trial information Findings Source 
PopART 
HPTN071 
South 
Africa 
and 
Zambia 
Cluster-randomised trial of population 
impact of combination HIV prevention 
intervention including UTT, with 
primary outcome of HIV incidence 
measured over 3 years (from Dec 2013). 
Includes 21 community clusters in 
Zambia and South Africa (approx. 
600,000 total adults across all 
communities), randomly allocated to 3 
arms: 
Arm A – full PopART package including 
annual HIV testing, and ART offered 
immediately to those tested HIV 
positive (UTT), male circumcision 
referral for HIV negative men, linkage to 
care follow-up 
Arm B – full PopART package but ART 
offered based on national guidelines 
(rather than immediate offer for all, 
HIV incidence measured in a population cohort of 
48,301 adults  
HIV incidence reduction of 30% in Arm B compared to 
Arm C, non-statistically significant reduction of 7% in 
Arm A compared to Arm C 
[The adjusted HIV incidence rate ratio for Arm A compared 
with C was 0.93 (95%CI:0.74-1.18, p=0.51) and for Arm B 
compared with C was 0.70 (95%CI:0.55-0.88, p=0.006)] 
PopART intervention achieved the first two 90s in 
Arms A and B after 3 annual rounds 
Viral suppression of <400 copies/ml at 24 months was: 
Arm A: 72% 
Arm B: 68% 
Arm C: 62% 
Lower rates were found for men and younger adults 
under age 25 years.  
Published testing and ART initiation results: 
Round 2 (Jun 2015 –  Oct 2016): 
79% of men and 84% of women know their HIV status 
CROI conference 
presentation:  
(Hayes et al., 2019) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication: 
(Floyd et al., 2018) 
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though local guidelines adopted UTT in 
2016) 
Arm C – receive standard of care 
(control group) 
 
80% of men and 81% of women with known HIV 
positive status are on ART (of those who remained 
resident in the community  (82% of men and 84% of 
women)) 
93% of men and 95% of women self-reported they 
were on ART and missed 0 pills in the last 3 days  
Sustainable 
East Africa 
Research in 
Community 
Health 
(SEARCH) 
Uganda 
and 
Kenya 
Cluster-randomised trial, with 32 pair-
matched communities in 3 regions. 
Control arm includes baseline HIV 
testing and ART care by national 
guidelines, intervention arm includes 
integrated community-based multi-
disease testing, universal eligibility for 
ART for those positive (UTT), 
streamlined patient-centred ART 
delivery. 335,000 individuals were 
enrolled at baseline (2013-14). Estimated 
completion in 2020. 
During the trial period Uganda and 
Kenya adopted UTT to national 
guidelines (thereby the control arm 
would also receive UTT) 
At year 3, population-level viral suppression was 
higher in the intervention arm (79.7%) than the control 
(68.4%) (RR:1.17; 95%CI:1.11,1.22; P< 0.001).  
At year 3, the intervention arm had 21% lower 
mortality among HIV+ (RR:0.79; 95%CI:0.65,0.96; 
P=0.02) 
Annual HIV incidence in the intervention arm 
decreased from year 1 to year 3 by 30% (RR:0.70; 
95%CI:0.57,0.86; P< 0.001); incidence decreased by 45% 
in Kenya (RR:0.55; 95%CI:0.40,0.76; P< 0.001).  
Three-year cumulative HIV incidence did not differ 
between intervention (0.77%) and control (0.81%) 
(RR:0.95; 95%CI:0.77,1.17; P=0.60). 
Interim data published 2017, after 2 years of intervention: 
96% of HIV-positive individuals diagnosed 
93% of whom had received ART 
90% of whom were virally suppressed 
At baseline, 45% of HIV positive residents were virally 
suppressed 
AIDS 2018 
conference 
presentation: 
(Havlir et al., 2018) 
 
 
 
 
 
 
 
 
 
Publication: 
(Petersen et al., 2017) 
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Population-level suppression was 75% after 1 year and 
80% after 2 years of intervention 
TasP  
ANRS12249 
South 
Africa 
Cluster-randomised trial of 22 
communities in Kwazulu-Natal between 
2012 and 2016, aiming to evaluate the 
feasibility and acceptability of UTT, with 
28,419 individuals eligible for inclusion 
in the trial. 
Control group ART initiation as per 
national guidelines, intervention group 
immediate ART initiation for those 
diagnosed positive (UTT). 
Residents were offered home-based HIV 
testing 6monthly for 2-4 years 
(depending on the cluster) 
HIV positive individuals were referred 
to trial clinics for ART. 
In the control group national guidelines 
were initially ≤350 cells per μL and <500 
cells per μL from January 2015 
Of 8,646 observed people living with HIV Jan 2013 – 
Jan 2016: 
Population viral suppression increased: 
Intervention arm: increase of 17% (from 29.0% 
suppression to 46.2%, p<0.001) 
Control arm: increase of 12% (from 32.4% suppression 
to 44.6%, p<0.001) 
This effect was mainly attributable to repeated home-
based counselling and testing, with limited effect 
attributable to ART (explaining the limited difference 
between trial arms). 
Null effect observed on cumulative HIV incidence.  
Concluding changes in ART guidelines alone not 
sufficient to significantly increase population-level 
viral suppression.  
63% trial participants women and 37% men 
Estimated HIV incidence was 2.11 per 
100 person-years (95% CI 1.84–2.39) in the intervention 
group and 2.27 per 100 person-years (2.00–2.54) in the 
control group (adjusted hazard ratio 1.01, 95% CI 0.87–
1.17; p=0.89) 
 
90-90-90 cascade estimated as:  
AIDS 2018 
conference 
presentation: 
(Larmarange et al., 
2018) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication: 
(Iwuji et al., 2018) 
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91.5% of HIV positive participants knowing their 
status, of whom 58.0% were on ART, 85.3% of whom 
were virally suppressed – 49.4% of all HIV positive 
participants virally suppressed.  
Presumed absence of difference in HIV incidence 
between intervention and control due to low linkage to 
care (only around 30% of individuals registered at trial 
clinic within 6 months of HIV diagnosis). 
 
 
 
 
 
 
 
 
MaxART Eswatini Stepped-wedge randomised trial, 
enrolling 3,485 participants from 2014 to 
2017 across 14 government health 
facilities in the Hhohho region, with 
primary endpoints of retention and viral 
suppression. 
The implementation study aimed to 
determine feasibility, acceptability, 
clinical outcomes, affordability and 
scalability of offering early ART to all 
HIV positive individuals. 
 
Under the UTT intervention, 12 month retention was 
86% and viral suppression rate 79%, compared to 80% 
and 4% respectively under the standard of care 
(control).  
75% of individuals were missing viral load results at 6 
months on ART, and were considered unsuppressed 
(which could largely account for the difference in viral 
suppression between the intervention and control 
arms) 
Adopting UTT led to improved health system 
performance 
 
Average public sector costs per ART patient-year 
remain essentially the same under UTT and standard 
of care (mean cost US$219 compared to US$215 
respectively) 
AIDS 2018 
conference 
presentation: 
(Khan et al., 2018) 
 
 
 
 
 
 
 
 
(MaxART 
Consortium, 2018) 
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The Ya Tsie 
Botswana 
Prevention 
Programme 
(also referred 
to as 
Botswana 
Combination 
Prevention 
Programme 
(BCPP)) 
 
Botswana Pair-matched community-randomized 
trial evaluating the impact of prevention 
interventions on HIV incidence in 30 
rural/semi-urban communities 
throughout Botswana, from 2013-2018. 
Intervention arm: combination 
prevention including scale-up of annual 
HIV testing campaigns and UTT, 
linkage to care, retention in care and 
adherence support, and male 
circumcision referral for HIV negative 
men 
Comparison arm: enhanced care as per 
local guidelines 
Universal ART became standard of care 
in both arms mid-2016. 
A random sample of ~20% of 
households in each community was 
selected for longitudinal HIV incidence 
cohort with annual HIV testing and 
counselling 
 
HIV incidence measured through a sub-sample of 
12,610 participants: 
At baseline, 29% were HIV-infected, of whom 72% 
were already on ART 
The intervention resulted in a reduction in HIV 
incidence of 30% compared to the control, though not 
statistically significant (incidence ratio 0.69, p=0.09) 
 
Annual HIV incidence was measured at 1.35% in 2013 
Trial results 2013-2015 found HIV incidence estimated 
at 1.06% 
 
90-90-90 cascade estimated as: 
83.3% of individuals with HIV knew their status 
87.4% of whom were receiving ART 
96.5% of whom were virally suppressed 
Overall, 70.2% of individuals with HIV were virally 
suppressed 
AIDS 2018 
conference 
presentation: 
(Makhema et al., 
2018) 
 
 
Publication: 
(Statistics Botswana, 
2013) 
(Moyo et al., 2018) 
 
 
(Gaolathe et al., 2016) 
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Appendix 2: Example data generation and capture tools 
Participant Interview 1 Topic Guide – Life History 
Could you tell me your life story, from when you were as young as you can remember? 
[their story, in their words, open narrative – silent probing and encouragement to continue] 
• Childhood, upbringing and key life events 
o What are your earliest memories from your childhood/life? 
o Are there any family stories that were told about you as a baby or a child?  
o Were there certain duties or tasks you had to do as a child? 
o What would you say are some of the key/main events or experiences that 
have happened in your life?  
o How did these experiences impact or affect you? 
• Family structure 
o What was your family structure like? Who did you grow up with (at 
homestead)? 
o What do you remember about [family members described]?  
o How would you describe their personality/characteristics? 
o What do you think you inherited from them? 
o What feelings come up when you think about your parents/grandparents 
[link to family members mentioned above]?  
o Which people would you say were most influential for you during your 
upbringing? Probe role model/ someone looked up to 
• Area/community grew up in (and now) 
o What was the area you grew up in like? 
o What was the community like? 
o What role did/does your family play in the community structure? Probe 
social position 
o Gossip: What are the sources of gossip in the area? What do people talk 
about? What do you think about that? Why is that important? 
• Educational experience 
o What was your experience of school (probe educational level) 
o What was school like for you? 
o What did you like/dislike about it? 
• Hopes and aspirations 
o When you were young, what did you want your future to be like?  
o What did you want to be or do when you grew up? 
o How does your life now compare to what you imagined as a child? 
o Probe work and income – source of income/type of work? Regular income 
or not? 
• Relationship views and experiences  
o Could you tell me about your relationships growing up until now? 
o What were these relationships like?  
o If in current relationship, could you describe what your relationship is 
like/tell me about it? 
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▪ What does your partner do for you 
▪ What do you do for [him/her]?  
▪ What’s important for you in the relationship? 
o If not in current relationship, what do you want for the future?  
o Probe relationship expectations versus reality 
o Probe what’s important versus unacceptable in a relationship 
Anything else to add? Any questions for me? Info for next interview, thanks and close.  
 
Participant Interview 2 Topic Guide 
• Follow-up from 1st interview 
o How have things been since we last met? 
o [Probe specific areas discussed in first interview] – adapt for each participant 
If NOT DISCLOSED: 
• General health, illness, health management and health seeking 
How have you been feeling? 
• [If necessary probe]: Could you tell me about how you manage your health, and 
experiences you have had with illness or ill health generally… 
o Probes: 
o Perceptions around health and ill health/being healthy and being sick, 
signs of ill health, causes of illness/ill health 
o What’s important for good health 
o Main concerns with regards to health 
o Decision-making for approach to take/health seeking e.g. umthandazi 
versus clinic 
o Views and experiences with health services, accessing health services, 
managing health 
▪ Probe traditional med (i.e. when, what, for which health 
purposes) 
▪ Probe health clinic (again, when, which clinic, for what health 
conditions) 
o Which illnesses or health conditions are a particular/main concern 
here/for you?  
o What do people with TB do to manage their health 
o What about HIV? 
 
If DID/DOES DISCLOSE:  
 
• General health, illness, health management and health seeking 
How have you been feeling? 
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[If necessary probe]: Could you tell me about how you manage your health, and 
experiences you have had with illness or ill health generally… 
o Probes: 
o Perceptions around health and ill health/being healthy and being sick, 
signs of ill health, causes of illness/ill health 
o What’s important for good health 
o Main concerns with regards to health 
o Decision-making for approach to take/health seeking e.g. umthandazi 
versus clinic 
o Views and experiences with health services, accessing health services, 
managing health 
▪ Probe traditional med (i.e. when, what, for which health 
purposes) 
▪ Probe health clinic (again, when, which clinic, for what health 
conditions) 
 
• HIV testing experience 
Could you tell me about your experiences testing for HIV from the beginning, your 
story? 
o Probe testing experience from first testing positive, including potential re-
testing, engaging and disengaging or re-engaging with care, what drove 
testing on each occasion, how were circumstances different e.g. this more 
recent time to first time 
o Could use health journey tool 
o Probe motivation to test and perception of HIV risk 
o Probe testing circumstances 
o Probe diagnosis and processing result – what thoughts went through 
your mind at that time, how did you feel then/later? 
o Probe what happened next (after positive result) (e.g. seeking health care, 
talking to someone about it?) 
• HIV health seeking/management 
o What did you know and think about HIV before your diagnosis? 
o How felt about living with HIV – feeling well/unwell / identifying self 
and HIV?  
o Decisions about health seeking (e.g. feel need to access HIV health 
services / perceived value of health services) 
• ART initiation decision-making 
o Experience being offered early ART 
o What HCW said at clinic 
o What happened 
o What they thought about it – what went through their mind 
o Probe reasons/motivation for early ART or reasons for reluctance to start 
ART  
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• Changes with diagnosis 
o Has anything changed since being diagnosed HIV positive?  
o What about after starting ART?  
▪ Probe – if changes, why, where did the perceived need for these 
changes come from? HCW advice versus personal interpretation?  
o General life (including social life, work) 
o How feel about living with HIV/being on ART (physically and 
emotionally) 
o Hopes, dreams, aspirations (link to interview 1) 
o Relationship(s) (current relationship or future hopes, link to interview 1) 
▪ Sexual practices 
Topics to probe: 
➢ Stigma and gossip 
o Probe where comes from, meaning and implications – e.g what happens 
if people talk about you as being HIV positive/on ART, what impact does 
this have on different areas of life? 
o Gender dynamics e.g. association of HIV with “promiscuity” and how 
this may impact men and women differently 
➢ Dirty blood 
o [If participant mentions diagnosis and dirty/unclean blood probe the following:] 
o What does it mean to find blood is dirty? Probe interpretation and 
implication 
o What would the difference be if blood was not dirty?  
o What causes blood to be dirty or clean? 
o NB: wait for participant to mention dirty/unclean blood themselves first, 
if no mention: We have heard some people mention a HIV diagnosis as dirty 
blood or finding their blood is unclean. Is this something you are familiar with? 
What do you think about it? What would make someone to have clean or 
unclean/dirty blood? 
➢ HIV status secrecy 
o Probe where comes from e.g. health messaging? Why felt need to keep 
secret? 
o What would happen if people found out?  
➢ Practitioner-patient relationships 
o Probe what relationship is like with different health practitioners e.g. 
nurse/counsellor  
o Perceived ability to come forward with challenges? 
o What do/say if things not going so well? 
➢ Rules of treatment – expectations and responsibilities alongside treatment-
taking 
o Impact on ART initiation and treatment-taking 
o Impact on life / restrictions 
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o How manage these, what happens if unable to e.g. food security // women 
and condom use? 
End interview: 
Anything else to add? Any questions for me?  
Info for next interview, thanks and close.  
 
Interview 3 Topic guide 
This example was prepared for participant M06 (interview topic guides were individually 
tailored for each participant). 
 
• General Health Concerns 
 
• HIV diagnosis, perception of risk, self-identity 
o Re-visit testing experience 
o Processing diagnosis 
o Perception of risk 
o How he was infected? 
o Views about future, life prospects, fear of death? 
o What do you feel has been taken away from you by HIV diagnosis?  
• Experience with Tx Offer 
o Last time we met we spoke of your testing experience and being offered 
treatment, please tell me about that experience?  
▪ ART initiation decision-making 
▪ Perceived need for tx? 
▪ Probe concerns/fears – how feel now, how overcame, potential 
impact on future tx-taking? 
o Motivation to start tx 
• Ongoing Tx taking 
o Perceived benefits of tx? Views about tx effect? 
o Times when more difficult to take tx? 
o What happens when you have to take the treatment when you are 
amongst/with other people?   
o Things shares with HCW/counsellor, things doesn’t share, views about 
counselling purpose etc 
o Counselling- what is needed, what is counselling to him? What would he 
like in terms of support?  
• Rules of tx 
o Why – where these rules come from, why important, what does he think 
about them, difficulties following? Impact on life? What happens if 
cannot follow (anticipated consequences)? Talk to HCW about it? 
o E.g. not drinking – impact of this on life 
• Stigma/Gossip/talking openly about HV/disclosure 
o Disclosure experiences 
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o Not wanting many people to know his status? Why? 
o Potential impact of hiding status on treatment-taking? 
• HIV transmission, tx as prevention: 
o Views about relationship with partner  
o Condom use –  how he finds using condoms, impact on relationship, 
times when more difficult? What do if run out?  
o Knowledge about tx as prevention? 
o Some people say tx could reduce chance of infecting sexual partner… is 
this something you have heard? Views about it? Probe potential influence 
→ tx-taking? 
• Men and health-seeking / clinic visits  
o Probe more on reasons for differences in health seeking - Why?  
o Why different with him (starting tx with high CD4 count, going to clinic 
healthy)? 
• Research process 
o How found being in the study? 
o Positives 
o Negatives 
o Why chose to take part? 
o How compared to expectations 
o Understanding of study purpose and what happens to data? 
• Anything to add, recommendations, questions for me? 
 
Main areas of focus 
1. Testing experience and HIV diagnosis 
a. Motivation to test 
b. Processing result – acceptance?  
c. Understanding of HIV infection cause/origin 
d. Perception of HIV risk  
2. Practitioner-patient relationships 
a. Things he talks to HCW about/not 
b. Why he doesn’t talk to HCW about certain challenges? 
c. HCW pressuring/threatening/scolding? Consequences of not following 
rules and advice?  
d. Rules of tx 
e. Views about counselling 
f. What he would like in terms of support 
3. Treatment-taking  
a. Decision to initiate early ART – choice versus obligation (seemed as 
though felt had to start), fears and concerns 
b. Challenges with tx taking 
c. Tx-taking interruptions e.g. missing refill appointments 
4. Stigma, hiding status 
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a. Is it important to him to maintain hidden status and not be seen on ART? 
Why? How does he manage this?  
b. Potential impact of this on tx taking? Times where not taken tx because of 
potential exposure? 
c. Potential impact in future/ongoing tx-taking 
Preparation / things to follow up on 
• History of testing – ““We are people who are cautious about our health lives and 
we have been going regularly to the clinics and have been testing after every 3 
months”  - Why? Perception of HIV risk? Why felt need to test regularly in past? 
o He said he tested regularly from being in school (annually since 1998, then 
3 monthly since working at factory) – why? 
• HIV diagnosis experience – contradictions in account – 1st interview says he and 
his wife had been testing negative then it changed with the second child, that the 
wife tested during pregnancy and the virus was found. They sat down and talked 
about it, they accepted because knew virus not transmitted just through sex 
(seemingly important for acceptance) – thought could have come from getting 
hair cut in salon. Said shouldn’t wait to get sick and took the pills. Taking them 
and remind each other to take them every day before going to bed. 2nd interview 
says he tested positive first at Tfokotani and then went straight away to tell his 
wife, thinks he was infected via kukata… 
• Status acceptance? Said he was planning to re-test over Christmas – follow up on 
this, what exactly was he planning to re-test for? Why? How did this go?  
o “since I got tested and accepted when I was tested at Tfokotani that the virus is 
now there and so I have to go and get tested again and maybe the results would 
come back…since the doctor said I should get tested again because maybe they 
would say it is there (virus) yet it was just a mistake from their machines and 
such things happen”. – 2nd interview 
• Self-identity – seemed to identify himself as someone who was healthy, taking 
care of himself, someone who was cautious about health, didn’t feel sick – how 
does he now identify himself as someone who has the virus? 
o 2nd interview: “As people living with HIV I just wish our government would 
take care of us just like he is doing to our grandparents, since we are people 
who are now vulnerable, so if she can make sure that we are provided with 
something so that we can continue being on the treatment” 
• Hopes for a cure? Or a future negative result? Seemed in second interview to be 
hoping there may have been a mix up with the results and wanted to re-test over 
Christmas. 
• Doubts and distrust? “since the doctor said I should get tested again because maybe they 
would say it is there (virus) yet it was just a mistake from their machines and such things 
happen” 
• Perception of HIV risk – did he perceive himself to be at risk? If so why? 
Perception of HIV risk and regular testing when said he didn’t have MCP (first 
interview), then talked about a time where he had several girlfriends in the past 
in the second interview 
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• Understanding/description of where he sees HIV infection as having come from 
– re-visit where he thinks he was infected and probe further for more 
understanding of why he thinks such, could there have been any other way/route 
of infection/cause?? (contradiction in how he described where he thinks he was 
infected in first and second interviews, both described non-sexually – why? What 
does he think about risk of being infected through sex?) 
o First interview said thought infection came through salon 
o Second interview said thought it came through razor with insertion of 
muti (kukata) on his knees 
• Processing result and decision for ART initiation 
o Starting treatment early, not waiting to get sick – why is this important, 
what thought about this 
o In second interview seemed to say he started ART the same day as testing 
positive? Check? Contradiction in account – waiting for disclosure and 
starting with wife? 
• Not feeling sick – motivation for treatment, perceived need for treatment, also 
look at men’s access to clinics generally 
• Practitioner-patient relationships – subservience? Seems to do as told by HCW – 
what does he himself think? Did he feel he had a choice? What might have 
happened if he had refused treatment? 
• Research participation – 1st interview he asked permission to miss work for the 
interview, 2nd and 3rd interviews took place in the evenings after work – why did 
he ask permission to miss work the first time and not the others, what did he tell 
his employers? Did he lose pay for missing work? What did he understand about 
his participation and choice to take part? Check how he understood who has 
access to his information that he shared during the study, and why he thinks he 
was chosen to take part.  
• Consulting tinyanga – why does he think he shouldn’t consult tinyanga? He said 
he would discourage people from consulting tinyanga because it’s not good – 
why? Where did this understanding/view come from (especially as he is someone 
who used to consult them in the past) 
• Importance of privacy, not wanting to be identifiable – “it would be better if these 
people wouldn’t be made to sit where they can be identifiable when they have come to get 
the treatment for TB and HIV” 
 
Health care worker interview topic guide 
Could you tell me a bit about yourself and your role?  
Could you tell me about your best/proudest moment from your time [working as…] 
Could you tell me a story of where [profession] has been hard for you?  
Views and experience of EAA pilot  
Were you involved with the Early Access to ART for All pilot (led by MSF/MOH) in 
Nhlangano? // What was your role in the EAA pilot? 
- Thoughts/views, why implemented, benefits/risks? 
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T&S: ART for early diagnosed, asymptomatic, high CD4 PLHIV 
What do you think about ART initiation for those with high CD4 counts (e.g. 1000)/who 
don’t feel unwell? 
- How PLHIV respond to offer of early ART? 
- How quickly should patients start ART? (Probe time to process result, readiness) 
- Why do patients start early ART? (Probe pt choice versus following HCW advice) 
- Why do patients refuse? When they refuse what reasons do they have/give 
you? 
- What would happen if someone refuses ART? How would you manage 
this/what would you do? Probe consequences to pt and to HCW 
What is your sense of how patients find ongoing treatment-taking amongst those who 
initiated ART early? 
- Reasons for default 
- Reasons for non-adherence 
- How manage 
- Consequences to patient // to HCW? 
- Disclosure – experiences, challenges 
If someone in your family was found to be HIV positive and their CD4 count was high 
what would you advise them? What would you do if it was you? Why? 
 
Health messaging – rules of tx 
What is expected of patients, what rules must they follow or what responsibilities do 
they have? 
- E.g. “taking care of self” less frequent sex, no MCP, condoms 
- E.g. no oily food, no chicken skin, no salty food 
- E.g. No alcohol, no smoking 
- Why, where messaging comes from 
 
Stigma – gossip, hiding status 
- What do people say about PLHIV? 
- Why some want to hide tx/status? 
- Social implications of being seen on ART 
- Men vs women 
- VCT queuing, privacy, confidentiality – e.g. “rather die than be seen on ART” 
Practitioner-patient relationships, patient support 
- Are certain types of patients more challenging than others? 
- Confidentiality – instances when HCW should disclose a patient’s status? 
When?  
- HCW scolding/shouting/forcing? Heard examples? Why… 
 
Gender dynamics – access to health services, health seeking behaviours, communication 
approach 
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T&S: Early ART for young people 
 
T&S and HIV transmission – tx as prevention? 
People are continuing to get infected with HIV, what’s going on? Why is this? How could 
this be changed? 
Some people say that they think EAA will be helpful in terms of reducing HIV 
transmission, what are your thoughts on that? Would you communicate this with 
patients? Why / why not? How?  
 
National implementation T&S/EAA 
Can you tell me what you know about the national policy to implement test and treat? 
What do you think about the plan? 
- Thoughts/views, potential challenges, what’s needed 
 
Recommendations 
What is needed, ideal world… 
Anything else to add on topic that we haven’t discussed today? 
Any questions for me? 
 
Focus Group Discussion Topic Guide 
Introduction 
- Study aim, why invited to participate 
- Confidentiality – request that we all respect each other’s confidentiality and keep 
what is discussed in the group within the group – however, confidentiality cannot 
be 100% guaranteed so please share what you feel comfortable sharing 
- Consent 
- Introductions  – go around in a circle, introduce yourself – your name, age and one 
thing people would find interesting about you 
- Ice breaker – fruit salad  
HIV in the community 
- What are the main health challenges here?  
- What can prevent people from going to the health facility? 
- What about HIV, is that a problem here? 
o Probe HIV prevention, treatment, etc 
o We have heard stories where one person knows that they are HIV positive, 
their partner is negative and they refuse to use condoms, why do you think 
that is? Probe spiteful/purposeful infection 
- Who gets HIV? Are certain people more at risk of HIV than others? 
- Do people talk openly about their HIV status? 
- Is there stigma? What does stigma look like/what happens? 
Anything else to add on topic that we haven’t discussed today? 
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- How is HIV transmitted? 
o Probe most common way for HIV to be transmitted 
- How do people protect themselves from HIV? 
Views on HIV testing and counselling 
- Where can people go to test? (What options are available for HIV testing here?) 
- What do you think about the different options? 
o Probe positives and negatives about each 
- What do you know about community-based HIV testing? 
- What do you think about it? 
- What motivates people to test for HIV? 
- Why do some people refuse to test? 
- Is there any difference between the people that test and don’t test for HIV? 
o Probe difference – what is known, why is there a difference (e.g. men and 
women etc) 
Positive diagnosis and linkage to care 
- What should people do after they have tested positive? 
- What motivates people who are diagnosed HIV positive to go to the clinic? 
- What factors can prevent them from going to the clinic? 
- A lot of the people who test positive don’t go for their follow-up appointment at the 
clinic, why do you think that might be? 
- How could they be better supported to link/access health clinic or how might these 
difficulties be overcome? 
- What are your views about traditional medicines?  
o Probe views about muti and how trad approaches may contradict modern 
medicine seeking 
 
Do you have any recommendations or ideas for how HIV testing and access to treatment 
and care could be improved? What would make things better in the future e.g. in an ideal 
world 
Do you have anything else to add on the topic before we end? 
Any questions for us 
Thank participants for their time and remind them that they can approach any of us 
individually at the end if they have further questions or anything of concern/that they 
would like to discuss.  
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Appendix 3: Ethical Procedures 
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Informed consent forms 
 
   Part 1: Information for Participants 
The Swaziland Ministry of Health and Médecins sans Frontières (MSF), with the London 
School of Hygiene and Tropical Medicine (LSHTM) are carrying out a study investigating 
people’s experiences with health services in Shiselweni, aiming to understand how 
particular health conditions may be managed. These health services and health 
conditions may include HIV, TB, and family planning, among others. 
Purpose of the research 
The purpose of this study is to learn about people’s views and experiences with medical 
services and with managing health conditions. From this we hope to be able to make 
recommendations about how services might be adapted and improved in the future. As 
somebody who lives in Shiselweni, and who uses health facilities here, you have been 
invited to take part in this study to share your views on the study topic, and so that we 
can learn from your experiences using these services. We are inviting you to participate 
in this study by taking part in three to four interviews over the next 12 months, each 
interview will last about one hour. Please read this document carefully and sign below if 
you agree to take part. If anything is unclear, you would like more information or if you 
have any questions please feel free to ask.  
Benefit and potential risks for the individual and the community 
There will be no direct benefit to you from taking part in the study. However, the 
information you share will help us to understand how patient support and health services 
may be improved. Participating in interviews does not carry any direct risks for you as a 
participant. 
Voluntary participation  
Your participation in this interview is voluntary. You may stop at any time without 
giving a reason, and you may choose not to answer certain questions or discuss certain 
topics if you don’t want to. There is no right or wrong answer for anything that is 
discussed, we would like to learn about both good and bad experiences for example with 
the health services. Deciding not to take part will not affect the services you receive in 
any way, and will not result in any loss of benefits regarding medical treatment. We 
would like to record the interviews if you consent to this, solely for the purpose of the 
study, to ensure we capture everything you say. 
Confidentiality 
The information given in the interviews is accessible only to those in the social research 
team: qualified researchers who are trained in confidentiality and are under an oath of 
professional secrecy. The audio recording will only be heard by the research team, it will 
be transcribed onto paper and the original recording will be kept securely for no longer 
than 5 years (when it will be destroyed). All written information collected will be kept 
privately and anonymously (including password protected storage) so that no one can 
link anything you say in the interview back to you. As a participant in the study, you 
have the right to access your recorded interviews if you wish. The researchers will make 
every effort to ensure that the information you provide as part of this study remains 
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confidential. Your identity will not be revealed in any publications, presentations, or 
reports resulting from this research study. 
You will be informed of the results of the study through general information provided to 
the Ministry of Health, through health facilities. 
Should you have questions regarding your rights as a participant in the study please 
contact the Scientific and Ethics Committee of the Ministry of Health (tel: 24047712 or 
24045469, on weekdays between 8am and 4pm), or the social research team on 22077477, 
or at PO BOX 572 Nhlangano Mccalpine, extension 3, plot 442 
Part 2: Consent form for participants 
 
Thank you for considering taking part in this research. The person organising the research 
must explain the project to you before you agree to take part. If you have any questions 
arising from the information sheet above or the explanation given to you please ask the 
researcher before you decide to take part. You will be given a copy of the information 
sheet to keep. 
 
Informed consent: 
- I have been informed by the undersigned person of the purpose and procedures 
of the study, and of the possible benefits and drawbacks of my participation. 
- Any questions I had about my participation in this study have been answered to 
my satisfaction. I will receive a copy of the document I have signed.  
- I was given enough time to make my decision. 
- I am participating to this study on a voluntary basis. I may withdraw at any time 
without giving a reason and my decision not to take part will not affect my care 
as a patient, my position or reputation as a community member, or the services 
that I receive in any way. 
- I agree to allow the MoH and LSHTM-MSF researchers, and the Ethics 
Commissions to see my anonymised data, with the understanding that this data 
will remain confidential. 
 
 
 
I,_____________________________ consent voluntarily to being a participant of this study 
 
I consent to this interview being recorded     
 
I consent to being contacted for follow up interviews                                                                      
(maximum of 4 in total over the next 12 months) 
 
 
Signed ____________________________________           Date ____________________ 
  
 
Signature of the researcher: _______________________  Date ____________________ 
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       Sicephu sekucala: umniningwane welucwaningo 
Litiko letemphilo  libambisene naboDokotela lebangenamncele (MSF Switzerland) Kanye 
ne London School of hygiene and Tropical medicine (LSHTM), benta lucwaningo 
lolubukete kutsi bantfu bahlangane nani basafuna lusito lwetemphilo 
eShiselweni,kuzama kucondzisisa kutsi khambi lini lesingaphuma nalo kuletingcinamba 
tetemphilo bantfu labahlangana nato loku kufaka ekhatsi iHIV, TB nekuhlela umndeni, 
kuletinye. 
Injongo yalolucwaningo 
Injongo yalolucwaningo kucondzisisa tintfo bantfu labahlangana nato basatfola lusito 
lwetemphilo nekutsi khambi lini lelingatfolakala. Kuloku sinelitsemba kutsi 
sitawukhona kuncoma kutsi lolusito lungatfolakala kahle kanjani kute libe sezingeni 
lelisetulu esikhatsini lesitako. Njenge muntfu lohlala eShiselweni futsi lowusebentisako 
umtfolamphilo, uyamenywa kutsi ulungenele lolucwaningo ngekuveta imivo yakho 
kuloludzaba khona sitofundza ngelwati lwakho usatfola lusito lwetemphilo. 
Siyakumema kutsi ube yincenye yalolucwaningo lapho khona sitawucocisana katsatfu 
noma kane ngemnyaka, lokucocisana kutotsatsa sikhatsi lesingaba lihora linye. Uyacelwa 
kutsi ufundzisise lomininingwane bese uyasayina uma uvuma kuba yincenye 
yalolucwaningo. Uma kukhona longakucondzisisi kahle noma udzinga umniningwane 
lowengetiwe noma nje uma unembuto, uyacelwa kutsi ukhululeke ubute. 
Lokungaba yinzuzo Kanye nalokungaba yingoti kuwe Kanye nasemmangweni  
Kute lokuyinzuzo lokucondzene nawe ngekuba yincenye yalolucwaningo.  
Nomakunjalo, Umniningwane lotosinika wona utawusisita kutsi singaba sekela njani 
bantfu Kanye nelusito lolutfolakala emtfolamphilo kutsi singalenta njani lube 
nguloluncono eSwatini. Kute bungoti lobungaba khona ngekungenela lolucwaningo.  
Kutinikela kwakho 
Kungenela lolucwaningo kuyintsandvo yakho. Ungakhetsa kuyekela kuba yincenye 
yalolucwaningo noma nini ngaphandle kwekunika sizatfu, futsi ungakhetsa kungayi 
phendvuli leminye imibuto noma tihloko uma ungafuni. Kute imphendvulo lengiyo 
nalena lengasiyo uma sisacoca, ngoba sifise kufundza ngalokuhle nangalokubi usatfola 
lusito lwetemphilo. Kungenela lolucwaningo angeke kuyitsikamete indlela lotfola ngayo 
lusito lwetemphilo. Singatsandza kutfwebula lenkhulumo yetfu uma nawe kukulungela, 
lomtfwebulo sitawusebentisela tidzingo talolucwaningo kucinisekisa kutsi sikutfola 
konkhe lokushoko. 
Kugcinwa kwetimfihlo 
Umininingwane lotosinika wona sisacocisana nawe utawubonwa licembu lebacwaningi 
kuphela, laba ngebacwaningi labafundzisekile ngekugcina timfihlo baphindze 
bakufungela loko. Umtfwebulo nawo utolalelwa bacwaningi kuphela bese ubhalwa 
phansi ephepheni bese loko lokutfwetjuliwe kuyagcinwa iminyaka lesihlanu 
emvakwaloko bese uyacinywa. Wonkhe umniningwane utawugcinwa uyimfihlo futsi 
kute lapho khona utawumbandzakanyeka khona. Njenge muntfu lolungenele 
lolucwaningo, unalo lilungelo lekulalela lengcogco letfwetjuliwe uma ufuna. Bacwaningi 
batokwenta konkhe lokusemandleni abo kucinisekisa kutsi umininingwane losiniketa 
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wona ugcineke uyimfihlo. Ligama lakho kute lapho litovela khona uma sekwentiwa 
imiphumela yalolucwaningo. 
Utokwatiswa emitfolamphilo ngemiphumela yalolucwaningo nelwati lolutfolakele 
ngelitiko letemphilo. 
Uma kwenteka uba nemibuto mayelana nemalungelo akho njengemuntfu lolungenele 
lolucwaningo, ungashayela baka Scientific and Ethics Committee ngephansi kwelitiko 
letemphilo kuna tinombolo; 24047712 nobe 24055469 ekhatsi neliviki kusuka nga 8 
ekuseni kuya 4 entsambama, noma ushayele lihhovisi lebacwaningi kunayi inombolo; 
22077477, noma ubhalele ku PO box 572 Nhlangano Mccalpine, extension 3, plot 442. 
Sicephu sesibili: Sivumelwano lesingiso 
Siyabonga kutsi uyacabanga kuba yincenye yalolucwaningo. Umuntfu lohlelembisa 
lolucwaningo kumele akuchazele ngalo lolucwaningo ngaphambi kwekube uvume kuba 
yincenye yalo. Uma unemibuto mayelana nalomniningwane lolapha ngetulu, lose 
uchaziwe, uyaniketwa litfuba lekutsi uyibute leyomibuto yakho kumcwaningi 
ngaphambi kwekube uncume kungenela lolucwaningo. Utawuniketwa lipheshana 
lemniningwane kutsi uligcine. 
- Ngatisiwe ngulosayinile ngemlomo kanye nangalokubhaliwe ngekwenhloso 
nemihambo yalolucwaningo,lokuhle nalokubi  kwekuhlanganyela kwami. 
 
- Ngifundzile noma ngichazelekile futsi ngevisisa ngalolwati lolubhaliwe .Yonkhe 
imibuto mayelana nekuhlanganyela kwami kulolucwaningo ngalokwanele 
iphendvulekile .Ngitawutfola ikhophi  yalencwadzi lengiyisayinile. 
 
- Nginikiwe sikhatsi lesanele sekwenta sincumo. 
 
- Ngitikhetsele mine kuhlanganyela kulolucwaningo. Ngingashiya noma nini 
ngaphandle kwekubeka sizatfu futsi sincumo sami sekungalungeneli 
lolucwaningo angeke siphatamise lokuhle mayelana ngekwelashwa 
kwetemphilo kwami. 
 
- Ngiyavumelane ne MoH kanye na MSF kanye nalababeka umtsetfo kutsi babone 
lwati lolufihlakele ngekucondzisisa kutsi lolwati lutogcinwa lungulolufihlakele. 
 
 
 Mine,______________ngiyavuma ngekutinikela kwami kuba yincenye  yalolucwaningo 
 
Ngiyavuma kutsi lengcogco itfwetjulwe       
Ngiyavuma kutsi baphindze bangitsintse mayelana netikhulumo letitako  
   
Singceveto______________________________            Date ____________________ 
 
Singceveto semcwaningi: ______________________     Date ____________________  
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Part 1: Information for HCW participants 
The Swaziland National AIDS Program and Médecins sans Frontières Switzerland (MSF 
Switzerland), with the London School of Hygiene and Tropical Medicine (LSHTM) are 
carrying out a study on Early Access to Antiretroviral Therapy (ART) for all adults with 
HIV (EAAA) in Nhlangano Health zone.  
Purpose of the research 
The purpose of this study is to learn about people’s views and experiences with EAAA, 
decision-making for ART initiation, and ongoing treatment-taking in the context of EAA 
over the long-term. We are inviting you to take part because we would like to learn from 
your experience with the EAAA pilot, whereby treatment is now offered to all people 
diagnosed HIV positive, at any CD4 count. We want to better understand your experience 
working with patients, offering ART to those diagnosed HIV positive and supporting 
patients with ongoing treatment-taking, including the challenges you might face with 
this. We are also conducting interviews with patients enrolled in the EAA pilot, who were 
offered ART at high CD4 counts. From this study we hope to be able to make 
recommendations about how services might be adapted and improved in the future.   
We are inviting you to participate in this study by having an interview that will last about 
one hour. Please read this document carefully and sign below if you agree to take part. If 
anything is unclear, you would like more information or if you have any questions please 
feel free to ask. 
Benefit and potential risks for the individual and the community 
There will be no direct benefit to you from taking part in the study. However, the 
information you share will help us to understand how best to implement EAAA/Test and 
Start in Swaziland, and how health services more broadly might be improved. Sharing 
your views and experiences will provide a better understanding of the working 
conditions of your colleagues and yourself. Participating in interviews does not carry any 
direct risks for you as a participant. 
Voluntary participation  
Your participation in this interview is voluntary. You may stop at any time without 
giving a reason, and you may choose not to answer certain questions or discuss certain 
topics if you don’t want to. There is no right or wrong answer for anything that is 
discussed, we would like to learn about both good and bad experiences. Your decision 
not to take part will not affect your professional position or the services you receive in 
any way, and will not result in any loss of benefits regarding medical treatment. We 
would like to record the interviews if you consent to this, solely for the purpose of the 
study, to ensure we capture everything you say. 
Confidentiality 
The information given in the interviews is accessible only to those in the social research 
team: qualified researchers who are trained in confidentiality and are under an oath of 
professional secrecy. The audio recording will only be heard by the research team, it will 
be transcribed onto paper and the original recording will be kept securely for no longer 
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than 5 years (when it will be destroyed). All written information collected will be kept 
privately and anonymously (including password protected storage) so that no one can 
link anything you say in the interview back to you. As a participant in the study, you 
have the right to access your recorded interviews if you wish. The researchers will make 
every effort to ensure that the information you provide as part of this study remains 
confidential. Your identity will not be revealed in any publications, presentations, or 
reports resulting from this research study. 
You will be informed of the results of the study through general information provided to 
the Ministry of Health, through health facilities. 
Should you have questions regarding your rights as a participant in the study please 
contact the Scientific and Ethics Committee of the Ministry of Health (tel: 24047712 or 
24045469, on weekdays between 8am and 4pm), or the social research team on 22077477, 
or at PO BOX 572 Nhlangano Macalpine, extension 3, plot 442 
Part 2: Consent form for HCW participants 
Thank you for considering taking part in this research. The person organising the research 
must explain the project to you before you agree to take part. If you have any questions 
arising from the information sheet above or the explanation given to you please ask the 
researcher before you decide to take part. You will be given a copy of the information 
sheet to keep. 
- I have been informed by the undersigned person of the purpose and procedures 
of the study, and of the possible benefits and drawbacks of my participation. 
- My questions about my participation in this study have been answered to my 
satisfaction. I will receive a copy of the document I have signed if I wish.  
- I was given enough time to make my decision. 
- I am participating to this study on a voluntary basis. I may withdraw at any time 
without giving a reason and my decision not to take part will not affect my care 
as a patient, my position or reputation as a community member, or the services 
that I receive in any way. 
- I agree to allow the MoH and LSHTM-MSF researchers, and the Ethics 
Commissions to see my anonymised data, with the understanding that this data 
will remain confidential. 
 
 
I,___________________________ consent voluntarily to being a participant of this study 
 
I consent to this interview being recorded     
 
 
Signed ________________________________________           Date ___________________ 
 
 
Signature of the researcher: _______________________         Date ____________________ 
Informed Consent form – Focus Group Discussions 
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PART 1: INFORMATION SHEET FOR PARTICIPANTS     
Assessing linkage to treatment and care within community-based HIV counselling and 
testing initiatives in Shiselweni, Swaziland.  
Principal Investigator: Shona Horter, Qualitative Researcher 
Organisation: Médecins Sans Frontières/Doctors Without Borders (MSF) 
 
We would like to invite you to participate in this study because we feel you can give an 
insight into this area and value your opinion. You should only participate if you want to; 
choosing not to take part will not disadvantage you in any way. Before you decide 
whether you would like to take part or not, it is important for you to understand why the 
study is being done and what your participation will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. If anything is 
unclear, you would like more information or if you have any questions please feel free to 
ask.  
Purpose of the research 
This study is being conducted by Shona Horter on behalf of Médecins Sans Frontières. It 
aims to understand community members’ experiences and views of the community-
based HIV counselling and testing that has been provided by MSF in Shiselweni. We 
would also like to understand the HIV services available here and how people with HIV 
can access treatment and care, including the barriers they might face. We want to explore 
this with you so that we can work towards improving HIV services in Shiselweni. Taking 
part in this research would involve your participation in a focus group discussion which 
will last around 90 minutes. 
Voluntary participation 
Your participation in this research is entirely voluntary. You may stop the discussion at 
any point and chose not to answer any question you don’t want to. There is no right or 
wrong answer to the questions asked, we would like to learn about both good and bad 
experiences and hear how we might be able to improve HIV services. The findings of this 
study can be fed back to you once it has been completed. We will also record the 
discussion solely for the purpose of the study, to ensure we capture everything that is 
said.  
Confidentiality 
The audio recording will only be heard by the research team and translator. It will be 
transcribed onto paper and the original audio recording will be destroyed as soon as the 
study is finished. All written information collected will be kept privately and 
anonymously. Transcripts of the focus group discussion will only be shared with the 
researchers in compliance with the principles of data protection e.g. anonymous and 
password protected format. In the study report it will be ensured that anything you say 
in the discussion cannot be linked back to you as an individual. While we request all 
participants of the focus group discussion respect each other’s confidentiality and not 
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share what is discussed more widely, this confidentiality cannot be guaranteed. If you 
share information during the focus group discussion which indicates risk of harm to 
yourself, like concerns which would require medical intervention or psychological 
support, this may require the interviewer to disclose this risk of harm to a member of staff 
e.g. doctor. This would be discussed with you beforehand and would only be done in 
order to protect your wellbeing. 
Should you have questions regarding your rights as a participant in the study please 
contact the Scientific and Ethics Committee of the Ministry of Health (tel: 24047712 or 
24045469, on weekdays between 8am and 4pm). The Principal Investigator Shona Horter 
can be contacted on 784081276, or at PO BOX 572 Nhlangano Mccalpine, extension 3, plot 
442 
PART 2: CONSENT FORM FOR PARTICIPANTS      
Title of study: Assessing linkage to treatment and care within community-based HIV 
counselling and testing initiatives in Shiselweni, Swaziland.  
Thank you for considering taking part in this research. The person organising the research 
must explain the project to you before you agree to take part. If you have any questions 
arising from the information sheet above or the explanation given to you please ask the 
researcher (Shona Horter) before you decide to take part. You will be given a copy of the 
information sheet to keep. 
Informed consent: 
- I have been informed by the researcher (signed below) about the purpose and 
procedures of the study, and of the possible benefits and drawbacks of my 
participation. 
- Any questions I had about my participation in this study have been answered to 
my satisfaction. I will receive a copy of the document I have signed if I wish.  
- I was given enough time to make my decision. 
- I am participating in this study on a voluntary basis. I may withdraw at any time 
without giving a reason and my decision will not affect my position as a member 
of staff in any way.  
- I agree to allow the MoH and MSF researchers, and the Ethics Commissions to 
see my anonymised interview data, with the understanding that this will remain 
strictly confidential. 
 
 I_____________________________ consent voluntarily to being a participant of this study 
 
Signed _____________________________________            Date _______________ 
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Appendix 4: Findings 
Recommendations from extensive Programmatic Report 
Practice recommendations 
1 Testing 
Community: sensitisation and mobilisation to encourage more people to seek tests 
when asymptomatic, highlighting the potential for a hidden (symptom-free) HIV 
infection and the benefits of knowing your status. Expanding on the use of radio 
programmes could be an effective strategy for encouraging individuals to test, as 
many described such programmes as influencing their test seeking in our study. 
Messages should highlight that anyone can be affected by HIV, regardless of 
relationship and health status, and that testing can enable access to treatment. It could 
also be beneficial to encourage couples testing (ideally prior to pregnancy).  
Counselling: Certain individuals can require more support in preparing to test for 
HIV and processing a HIV positive result than others. Counselling should be tailored 
to individual’s needs, paying particular attention to those testing via provider-
initiated testing (or where the test was not individually motivated/sought), to ensure 
test preparedness and to support HIV status acceptance. 
Health system: Allowing/supporting re-testing, as this study suggests re-testing can 
support individuals in processing a positive result and believing in test accuracy, thus 
progressing towards HIV status acceptance. It also appears important to consider 
testing approaches which support couples testing, particularly related to testing 
during pregnancy, where women can face difficulties and negative consequences of 
disclosure to their partners. Also new approaches such as HIV self-testing could 
facilitate this approach, as seen in other settings. 
2 ART initiation 
Community: Potential to expand upon the use of radio programmes encouraging 
EAA uptake – highlighting the benefits of early ART for enabling maintenance of 
good health, physical strength, productivity and ability to work. Engaging 
community leaders and influential people in encouraging ART uptake, which 
appears to be an effective approach to gaining community members’ buy-in. This 
could be particularly useful for engaging men, through highlighting the benefits of 
early ART which support concepts of masculinity (physical strength, energy, ability 
to work and provide).  
Counselling: ART readiness – our findings suggest that certain individuals need more 
time to feel ready for lifelong ART. The psychological process towards ART readiness 
is individually varied, and influenced by a myriad of factors. Removing pressure 
from HCW (linked to targets and monitoring), and from patients (aggressive follow-
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up approaches, fear of being reprimanded/scolded for delayed access), and keeping 
the door open so patients can come and discuss, ask questions and access treatment 
and care when they feel ready may be beneficial for both HCW and patients. This 
could avoid silent refusals, where patients appear to be initiating ART but do not 
swallow the pills, and could also avoid individuals from initiating before they are 
ready and therefore potentially facing challenges with ongoing engagement and 
adherence, when they may have more doubts about treatment need and effect, and 
less motivation for treatment-taking. Nevertheless, care must be taken not to delay 
ART initiation for patients who have clinical reasons to start ART quickly.  
Counselling should also encourage disclosure, which appears important for access to 
support, encouragement and treatment reminders. Our findings also suggest that 
couples testing may support disclosure. Counselling could aim to reassure and 
address patients’ fears about ART side effects, and consider the cost/benefit analysis 
patients may be undertaking in deciding to initiate ART.  
Health system: Ensure privacy and confidentiality within clinics and health service 
provision, and not differentiating HIV from other health conditions (e.g. different 
coloured treatment booklet, HIV-specific waiting area). Integrated services, such as 
those provided via a one-stop-shop approach, where patients can access treatment 
and care for a variety of health conditions in one room, without others being able to 
know what they are accessing the clinic for, could be preferable. This may help 
patients to overcome fears of potential status exposure, which can prevent some from 
wanting to start ART.  
3 Ongoing treatment-taking: adherence and sustained engagement with treatment 
and care 
Community: Sensitising community members about viral load monitoring, to inform 
PLHIV that they are entitled to know their viral load results, and can request these 
from the clinic if they wish, as this can provide evidence of the treatment’s 
effectiveness. 
Counselling: Enhancing patient choice, involving patients in decisions relating to 
their care and fostering a sense of ownership for their health and treatment-taking. 
Enhancing the potential for viral load monitoring to support adherence – sharing 
suppressed results with patients, and using this as an opportunity to celebrate 
achievements, as evidence of treatment effectiveness, and to encourage their 
continued adherence. Encouraging time and space for discussion and for patients to 
share concerns and ask questions – so they can access support, encouragement, and 
reassurance. Ensuring patients know that there are counsellors available at each of 
the clinics and that they can access support if they wish. Exploring patients’ hopes, 
dreams and plans for the future. Ensuring patients know they can re-engage with 
treatment and care following a treatment interruption, without being scolded or 
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reprimanded. Have clear communication to patients about treatment as prevention, 
to ensure consistent messaging (which is important for honesty, transparency and 
trust in HCW advice), as well as to build on the potential for this to motivate 
treatment-taking, as was suggested in our study.   
Health system: Implementing routine viral load monitoring as a core component of 
Test and Start approaches. Ensuring adequate and consistent treatment supply, with 
no shortages or drug stock outs. Considering health staffing – to ensure there are 
enough staff in clinics to have adequate time with patients, so patients feel able to ask 
questions, share concerns and access support. Providing staff with ongoing training, 
skill and capacity building, and constructive feedback to enhance staff motivation. 
Address the need for emotional/psychological support for staff in their work 
supporting patients, and to counter staff burnout. Considering EAA-specific 
differentiated models of treatment and care to reduce the burden of ART for those 
starting when asymptomatic.  
 
Policy recommendations: the national implementation of Test and Start 
Health infrastructure: It is important to address human resource challenges and 
ensure clinics have adequate staffing, including nurses, adherence counsellors, 
laboratory and pharmacy technicians. It is also important to facilitate ongoing staff 
training for skills, knowledge and capacity in managing Test and Start patients. This 
is particularly important in recognising that Test and Start patients who initiate ART 
when asymptomatic need tailored support and counselling, due to the absence of an 
illness history and therefore the greater potential for doubts and distrust relating to 
the perceived need for treatment and its effectiveness.  
Routine viral load monitoring: appears to be particularly important for Test and Start, 
not only in monitoring treatment success and rates of viral suppression, but also in 
being able to provide evidence of treatment effect to patients, which could motivate 
their ongoing treatment-taking.  
Drug supply: It is of utmost importance to consider drug procurement systems and 
mechanisms to ensure consistent drug supply, avoiding any risk of potential 
treatment shortages, as well as supply of other resources such as those needed for 
blood tests and patient monitoring. It would not be recommended to initiate 
increased numbers of patients onto ART, who feel healthy, but who then have to 
collect refills more frequently or face interruptions in their treatment-taking due to 
lack of treatment availability. It is also important to ensure patient confidence in the 
drug supply chain, and reassurance/trust that there will not be drug shortages in the 
future.  
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Differentiated models of treatment and care: There could be scope to consider the 
potential for differentiated models of treatment and care specific to Test and Start, for 
example a Community ART Group for asymptomatic patients, with tailored 
counselling messages and mutual support, or a buddying system whereby patients 
who are not yet ready for ART could be matched with a patient who is ready/on ART 
and can offer support and encouragement. Such approaches should aim to reduce the 
burden of treatment to patients, as well as reducing the pressure to health services. 
This may also mean to enrol patients into community ART with less restrictive 
criteria, i.e. extending eligibility beyond those who can demonstrate sustained 
adherence.  
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Coding Framework example 
Category Code Description 
Testing 
experience 
Past testing Descriptions of previous 
experiences testing for HIV/testing 
history 
 Choice to test 
- Provider initiated 
testing 
- Compulsory testing 
- Testing incentives 
Descriptions regarding extent to 
which participants felt able to 
choose to test versus encouraged, 
descriptions indicating feeling of 
coercion. Testing during pregnancy. 
 Motivation for testing Why someone decides to test for 
HIV, encouragement to test 
 Concerns about testing 
- Fear about known 
status 
Reasons given for people refusing to 
test for HIV, fear of being told you 
are living with HIV 
 Re-testing Descriptions of re-testing after 
receiving a positive result 
Processing an 
HIV diagnosis  
Dirty blood Where someone makes reference to 
‘dirty blood’ as being HIV positive 
 Test preparedness Expectation for the chance of a 
positive result 
Influence of sense of being prepared 
on processing result 
 Time Descriptions of time to come to 
terms with diagnosis 
 Perceiving HIV risk 
- Views about 
HIV/who gets HIV 
Potential exposure to HIV (cuts, 
caring for people, braiding hair, 
unprotected sex, partner infidelity?) 
Judgements or views about good 
person/bad person, promiscuity 
 Non-acceptance 
- Shock 
- Stress 
- Doubt and disbelief 
- Not feeling unwell 
- Stigma – hiding status 
- Self-judgement, blame 
Reactions to an HIV diagnosis 
which indicate possible status non-
acceptance 
 Acceptance 
- Perceived risk of HIV 
- Expectation chance 
positive result 
- Test preparedness 
- Counselling 
- Disclosure of HIV 
status 
Factors which may 
influence/support status acceptance 
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- Support 
- Hope 
 Counselling Descriptions of counselling 
surrounding test and diagnosis, 
perceived importance of counselling 
for supporting process 
 HIV information and 
education 
Awareness, understanding, views 
about HIV 
 Confidentiality Where participants mention 
confidentiality concerns or the 
perceived importance of privacy etc 
for testing 
Accessing 
health care 
Perceived need for health 
care/treatment 
e.g. symptoms, diagnosis, how need 
for treatment is 
understood/conceptualised 
 Attitudes and beliefs about 
health care 
- Value placed on 
health care/ART 
- Trust  
Views about health services and 
potential benefits, valuing ART for 
life, potential doubts or scepticism, 
trust of HCW advice 
 Alternative health systems 
- Contradictions 
traditional medicine 
and ART 
- Religious beliefs/faith 
healing 
Beliefs and practices relating to 
alternative health systems 
(traditional, faith), how these may 
contradict, support, influence 
conceptions of health and 
engagement with care 
Self-identity 
and HIV 
Symptoms/signs of HIV e.g. headache/nausea, what is taken 
to signify HIV or what signs and 
symptoms are attributed with it 
 Identifying as well/unwell What it means to be healthy or sick, 
descriptions of seeing self in terms 
of health 
 Associating HIV and death The death / kufa, imminence of 
death 
 Normalising HIV ART and Panadol, HIV and 
influenza, normalising 
discourse/narratives 
 Moralising HIV Differentiating HIV and other 
diseases/conditions – transmission 
 Uncertainty about the future e.g. what will happen in 2022 (when 
government aims to “end HIV” 
 The life of treatment, 
dependency  
Dependency on ART/treatment 
 Living with HIV Descriptions about HIV e.g. now 
like this, now in this situation 
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 Hope for a cure Mentioning hoping for a cure or 
asking questions about this 
Treatment 
initiation 
decision-
making 
Treatment offer 
- Repercussions with 
delaying 
How tx is proposed by HCW, health 
messaging 
Understanding of portrayed 
implications delayed ART e.g. you 
will die, baby will die, etc 
 Choice 
- Obligation/duty to act 
- Valuing health and 
life 
Descriptions relating to choice for tx 
 Readiness Time to process result and feel 
ready for tx, importance of 
readiness for tx 
 CD4 count Descriptions of CD4 count at ART 
offer, understanding about CD4 
count and treatment-taking 
 Situated rationalities Mentions of weighing up different 
factors in decision, conflicting 
priorities 
 Perceived need for treatment e.g. not feeling sick – questioning 
need for treatment 
Motivation 
for starting 
early ART 
 Described reasons for 
starting/wanting tx 
 Perceived benefits of early 
ART 
- Avoiding health 
deterioration 
- Not wanting to be 
visibly sick/bedridden 
and identifiable HIV+ 
- Belief in treatment 
effectiveness 
 
Views about possible benefits of 
early ART initiation  
 Familiarity 
- Seeing effect of 
starting ART 
later/when ill 
- Seeing others die 
without ART 
- Seeing improvements 
in others on ART 
 
Observed treatment 
experiences/effects 
Those who describe having seen 
people within their 
family/neighbourhood who were 
known to be HIV positive and their 
treatment-taking 
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 Knowledge and 
understanding relating to 
EAA  
Seeking information 
Radio, health talks, knowledge and 
familiarity early ART 
Examples where individuals have 
actively sought more information 
e.g. through internet, consulting 
peers etc 
 Receiving support and 
encouragement 
e.g. seeking advice from family 
members/friends/others (with 
disclosure) 
Concerns 
about ART 
Fear of side effects 
- Myths/commonly 
held views about tx 
- Fears about becoming 
identifiable due to 
side effects 
 
e.g. treatment eating brain, causing 
liver damage 
 
e.g. changes to body shape 
 Lifelong treatment 
- Young people 
No going back – once start cannot 
stop, length of tx 
 Potential inability to adhere Concerns about forgetting time to 
take tx, self-efficacy 
 Concerns about future 
treatment shortages 
- Government goals to 
end HIV by 2022 
Better not to start than to start and 
stop 
Potential implication for those who 
have started tx, fear 
 Being seen on ART e.g. collecting refills at clinic, being 
exposed 
 Confusion and distrust e.g. changes in health 
messaging/treatment guidelines 
Treatment-
taking 
experience 
Perceived and experienced 
benefits of tx 
 
Descriptions of wanting to see 
changes with treatment, 
interpretations of such benefits 
through symptom/perceived health 
improvements or through VL 
results 
 Doubts relating to tx need 
and effect 
Not seeing/experiencing changes on 
ART, confusion 
 Ownership and self-
responsibility 
Determination, motivation for 
treatment-taking e.g. I am the driver 
of this life 
 Treatment-taking routine Treatment journey, incorporating 
HIV and ART to life, time for 
treatment, reminders 
 Treatment-taking challenges 
- Forgetting 
- Hiding tx 
- Tx interruptions 
Descriptions relating to various 
challenges faced with treatment 
which can undermine individuals’ 
ability to take it 
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- Missing doses 
- Experimenting 
- Tx fatigue 
- Food shortages 
- Losing hope 
- Situated rationalities 
Retention in care challenges 
including silent refusals and silent 
transfers 
Situated rationalities refers to 
conflicting priorities which 
contradict and can undermine tx-
taking e.g. work commitments 
Stigma and 
disclosure 
Consequences and 
manifestations of stigma 
- Gender dynamics 
- Social implications 
Descriptions including association 
of symptoms and HIV, feeling no 
longer a person, discrimination, 
gossip, isolation or ostracising, 
shame and embarrassment, 
implications for social stature and 
reputation of having known HIV+ 
status  
 Hiding status, secrecy 
- Changing clinic to 
avoid exposure 
- Hiding treatment 
- Implications for 
engagement 
Avoiding stigma and gossip 
Descriptions of hiding/not hiding 
status.  
Potential implications of hiding 
status and tx on engagement with 
care and tx-taking 
 Drivers of stigma 
- Association of HIV 
and stigma 
- Morality and 
moralising 
- Lack of knowledge 
Mention/descriptions of the way 
HIV was introduced as influencing 
how it is viewed now 
Description of lack of knowledge 
influencing stigma 
Contradiction Christianity and 
image of who gets HIV 
 Disclosure experience 
- Fear of disclosure 
- Benefits of disclosure 
- Perceived importance 
of disclosure 
- Disclosure and 
treatment-taking 
- Disclosure and status 
acceptance 
Descriptions of disclosure 
experience, whether disclosed or 
not and to who/disclosure 
circumstances 
Negative consequences of 
disclosure – perceived and 
experienced, concerns about 
disclosure. 
Perceived importance of disclosure 
and benefits anticipated and 
experienced. Disclosure-treatment-
taking link, and link between status 
acceptance and disclosure.  
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Appendix 5: Dissemination of study findings 
MSF Scientific Day Conference Oral Presentation May 2016 
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International AIDS Conference Durban 2016 – poster presentation 
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Eswatini National AIDS Conference Oral Presentations July 2016 
1 Linkage to HIV care in the context of Treat-all 
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2 Stigma and engagement with treatment and care within Treat-all (award won)
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3 Practitioner-patient relationships framing engagement with Treat-all care 
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Feedback for participants document 
Health Services Research in Shiselweni   
Shona Horter, Velibanti Dlamini, Zanele Thabede, October 2017 
We conducted research in Shiselweni, Swaziland from June 2016 to September 2017, 
with our partners the Swaziland Ministry of Health, Medecins Sans Frontieres, and 
the London School of Hygiene and Tropical Medicine. This research aimed to explore 
people’s views about, and experiences with the health services in Shiselweni, to 
understand how particular health conditions may be managed and to see how health 
services could be improved.  
Key recommendations that have come from this research: 
➢ The importance of privacy and confidentiality in clinics, patients value 
integrated services where certain conditions are not considered differently, 
one-stop-shop approach where all services can be obtained in one room is 
ideal, using the same colour of treatment booklet for all health conditions if 
possible 
➢ The need to support and allow for individual patient readiness – everyone 
takes a different amount of time to feel ready to start treatment, people should 
feel able to take the time they need, and come to the clinic to discuss and ask 
questions in the meantime. People should not be shouted at or reprimanded 
for wanting to start treatment later, or for re-engaging with treatment and care 
after a gap in treatment-taking.  
➢ Patients would like to be able to have more time with HCW, to discuss any 
concerns they might be having and to ask questions 
➢ Patients appreciate friendly, open and approachable HCW, who can give 
them support, reassurance and encouragement 
➢ Patients found routine monitoring blood tests, in particular viral load results, 
useful for seeing evidence of the effectiveness of treatment. This supported 
and motivated ongoing treatment-taking. Patients should be able to get their 
viral load checked routinely and should be given their results when they are 
available.  
➢ HIV testing: patients should not feel they have to test for HIV, the tests are 
encouraged but are not forced, people should be given information and then 
be able to choose if they want to test. Where tests are suggested by HCW a 
patient should be able to access counselling, information and support – this is 
your right as a patient, you can ask for more information if you are unclear 
and can access counselling after the test if you would like it.  
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Key findings: 
The findings presented here relate to services that are provided for HIV, but other 
health conditions were also discussed and explored in this research, including family 
planning and tuberculosis.  
HIV testing 
• Some wanted to test for HIV knowing they could get now treatment at any 
CD4 count – which actually motivated their testing.  
• Many people knew that it is good to test for HIV regularly, even if you don’t 
feel sick or don’t see yourself as at risk of HIV specifically, HIV can affect 
anyone and there are advantages of knowing your status early and then being 
able to access treatment and care early too. 
• Some people wanted to re-test for HIV, to verify if their result was really true. 
Most who re-tested seemed to find this helped them to accept their HIV status 
and believe in the test accuracy.  
• Some felt that testing as a couple was helpful, and made it easier to disclose 
and access treatment and care if one or both partners were found to be 
positive. Testing as a couple meant there was a HCW available to support 
with the results, and could offer counselling and advice to those with different 
results – like when one partner tests positive and one tests negative. This was 
seen to make it easier for the couple to accept each other’s results.  
 
Starting early treatment: 
• Patients felt there were many benefits to starting treatment early, even 
without having any symptoms or feeling unwell, including the positive 
effects early treatment has for health. It was seen that early treatment enables 
good health, energy, strength and productivity, so people who started early 
felt able to continue as normal, to work, socialise, have a relationship/get 
married, and have babies if they wanted to. 
• Lots of people said they had seen the effects of starting treatment late or not 
at all, with many having family members or neighbours who they had seen 
become very sick, or even die, as a result of late or no access to treatment.  
• Treatment was seen as enabling life – it was seen that with early treatment 
you can live for longer and keep good health. Some felt that if people start 
treatment late their recovery can be hindered and treatment side effects can 
be worse 
• Quite a few people had fears about treatment side effects. Most people in the 
study who had side effects said they were not too bad and that they only 
lasted for a few weeks after starting treatment, until their bodies adjusted to 
the treatment. Those who were afraid of side effects, or who experienced 
them, said it was reassuring to know they could go to the clinic at any time 
and discuss side effects they were experiencing with the treatment. Those 
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who did report side effects said they were taken seriously by HCW, 
something was done to help them, and that they then felt better afterwards.  
• How long it took people to feel ready to start treatment was really varied. 
Some went to test already wanting to start ART if the result was positive 
• Some people needed more time to come to terms with a positive result, and 
to feel ready for treatment. Some had concerns about being able to remember 
to take treatment every day, though most who took treatment said this 
became easier over time, and that things could help like having a family 
member who knew they were on treatment and who could help, encourage 
and remind them to take treatment.  
• Talking to someone about a positive test result could be important, as it can 
enable access to support, encouragement, reassurance, hopes for the future, 
as well as making it easier to take treatment (without feeling as though it 
needs to be hidden).  
• People said HCW support, as well as support and encouragement from a 
partner, family members or friends, could really help them to feel ready to 
start taking treatment and also to continue to take it.  
Ongoing treatment-taking: 
• It seemed important to be able to see the difference treatment was making, 
which could be difficult to identify for those who started treatment when they 
were not sick. Some had doubts about the treatment’s effectiveness, as they 
couldn’t see physical improvements that came about after starting treatment. 
The blood tests that are taken at the clinic were seen to really help with this, 
as being able to see that the level of the virus is going down, or that the CD4 
count is going up, could help give evidence of the effect of treatment and 
therefore motivate continued treatment-taking.  
• Some people spoke about missing some doses of treatment to see if this had 
an effect on their body, and because they wanted to see evidence of the need 
for treatment and its effectiveness. This could be really dangerous, as taking 
treatment sometimes and sometimes not taking it can cause the risk of drug 
resistance to develop, which can make it more difficult to find a successful 
and effective treatment in the future. If you have doubts about the 
effectiveness of your treatment talk to your HCW about it, or ask them to do 
a viral load test for you, so that you can make sure that your virus is being 
kept suppressed by the treatment – this will show you that the treatment is 
really working.  
• Those who felt like they owned their treatment-taking – that they had decided 
to take treatment for themselves, for their health, and their future, appeared 
to be more motivated and determined to continue taking it. It seems like it is 
important for people to feel as though their treatment is theirs, and to want to 
take it for themselves. This can help people to feel able to prioritise treatment-
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taking, and overcome any difficulties they might face, as they know how 
important the treatment is for enabling a long, healthy life ahead. 
• It seemed to help people to have plans, hopes and dreams for the future – 
thinking about what you want to do and planning how you might be able to 
achieve your aspirations. Then the treatment could be seen as a tool through 
which to achieve your dreams, which can make it feel more positive.  
• Lots of people said they didn’t want to be seen at the clinic collecting 
treatment refills, as they feared being gossiped about and stigmatised as a 
result. Many people said they would change the treatment container to avoid 
the rattling noise pills can make. It seemed really important for clinics to offer 
privacy, confidentiality and integrated services – which could help people 
overcome fears of being seen on treatment.  
• Some people felt like they didn’t have enough time with HCW at clinics, that 
HCW could seem like they are too busy, with long queues of patients outside, 
and that they didn’t always seem open to hearing patient’s questions, 
concerns, or challenges. This is important and needs to be addressed within 
the health systems, so that patients feel able to come forwards and talk, ask 
questions and share – and therefore are able to also access support. You 
shouldn’t feel the need to hide any difficulties you are having, there are 
counsellors who are available to offer support with overcoming such 
difficulties, who should be able offer a listening ear, and to help you problem 
solve.  
 
We would like to say a big thank you to all of those who shared their time, views, 
experiences and opinions. This research would not have been possible without your 
contribution. We hope as a result of you sharing your views about health services in 
Shiselweni, that it might be possible for services to be better adapted to meet people’s 
needs, and to provide support for patients in the future.  
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Summary of key findings document 
Qualitative research investigating how people living with HIV engage with HIV 
treatment and care in the context of a Test and Start/Early Access to ART for All pilot 
in Shiselweni, Swaziland: 
Summary of key findings and recommendations 
Shona Horter, October 2017 
1. Entry into care – mode of testing 
• Motivations for HIV testing: 
o Knowledge of EAA appeared to motivate some to test for HIV: Certain 
participants wanted to test knowing they could receive ART if tested 
positive, rather than having to wait for their CD4 count to reach a 
certain point for treatment eligibility.  
o Several participants said they wouldn’t have tested had it not been for 
HCW encouragement 
o Radio programmes said to encourage many to test, even those 
asymptomatic and who didn’t have specific HIV risk perception – 
community mobilisation emphasising any one can be affected, 
encouraging all to know status for healthy, long life.  
o Some also wanted to test for HIV because of signs or symptoms of ill 
health, or perceiving HIV risk 
o Some felt they didn’t have a choice but to test for HIV, and could only 
access other services e.g. related to pregnancy if they tested, thus in 
some cases provider initiated tests could be experienced as coercive 
• Participants testing for HIV via provider initiated testing potentially needed 
more support for test preparedness, status acceptance and treatment 
readiness, highlighting the need for an individually tailored approach 
• However, it also appeared that provider initiated testing is a means to reach 
those who may not otherwise test for HIV, and to encourage access to care 
• Our findings emphasise the importance of ensuring patient choice for HIV 
testing and avoiding mandatory testing, or testing which could be perceived 
or experienced as coercive. Where the choice and ownership lies with the 
patient it appears more likely this will also translate to ART readiness, and 
motivation for adherence (see later sections). 
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• Re-testing for HIV following a positive result: 
o Many PLHIV participants described re-testing following receiving a 
positive result, to verify the HIV test accuracy, thus for those who did 
not believe their diagnosis this could support the process of status 
acceptance.  
o Some PLHIV participants described re-testing to check their CD4 
count (to see whether it had changed over time) 
o Re-testing also appeared as a means to re-engage with treatment and 
care, as it was perceived easier to test again and start afresh (as though 
first time tester), than potentially have to confess late access to care 
and risk being scolded and reprimanded by HCW.  
o Though all participants were recorded on the project database as being 
newly diagnosed, during interviews several participants described 
having been diagnosed HIV positive at an earlier point, some several 
years ago, and re-testing as though for the first time 
• Couples testing was seen to enable disclosure 
Recommendations: 
➢ Community: Enhance community mobilisation approaches such as radio 
programmes – encouraging testing for all, even if not experiencing any 
symptoms, encouraging early treatment prolonging life. Also involvement of 
community leaders in mobilisation – said to be more trusted, respected and 
influential members who could therefore positively influence care-seeking 
➢ Community: re-examine invitation approach for partner involvement and 
couples testing? Better for couple to test together before pregnancy than to 
rely on woman having to disclose to man, and potentially be judged as having 
bought HIV into the family, with negative ramifications including potentially 
being shunned or abused 
➢ Counselling: Take care for those testing via provider-initiated tests, ensure 
test preparedness, patient choice and ability to opt out, even where the test is 
encouraged for health purposes, where patients feel as though they are 
choosing to test they may be better able to process and accept a positive result 
and have more sense of ownership (and therefore motivation) for treatment-
taking 
➢ Counselling: Emphasise that it is OK for people to take time to process a 
positive result and feel ready to come back to care when they want to, rather 
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than feeling pressured to comply and initiate ART straight away (if not 
ready/accepted diagnosis), particularly for those who are asymptomatic and 
with high CD4 counts 
➢ Health system: Avoid “compulsory” testing approaches – or those potentially 
perceived as coercive e.g. denying access to other health services without HIV 
test. Re-testing potentially enabling progression towards status acceptance – 
offer re-tests where possible? 
2. ART initiation 
• ART Readiness: 
o Time for ART readiness varied for different individuals 
o Readiness for ART appeared supported by HIV status acceptance, 
disclosure of status (and access to support and encouragement 
therein), support, encouragement and reassurance, counselling, 
and hope for the future of life with ART  
• HCW could feel pressured to “convince” patients to initiate ART and 
comply, which then led to patients experiencing pressure. HCW pressure 
was described linked to monitoring information capturing the number of 
diagnoses versus initiations, which could be judged as a reflection of staff 
competency. However, in reality HCW cannot control for an individual’s 
psychological process of readiness, which can be very varied. Due to the 
experienced pressure to initiate ART, and feeling unable to refuse, some 
patients would take the treatment home with them and not swallow the 
pills, thereby silently refusing (whilst appearing to remain engaged with 
treatment and care). 
• The importance of patient choice for ART initiation was highlighted by 
participants, including wanting to take treatment for self, sense of 
ownership, valuing health and life, which was seen to support and foster 
treatment-taking motivation as compared to treatment-taking due to 
sense of obligation.  
• Factors motivating ART initiation: 
o Many wanted to prevent HIV visibility through protecting good 
health and therefore avoiding development of symptoms that 
could be seen and judged by community members as indicative of 
HIV, to avoid anticipated stigma. 
o The advantage of early ART protecting good health and therefore 
enabling productivity was described, particularly by men, and 
appeared important for being able to work and provide for family. 
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o The perceived need for and benefits of treatment, and belief in 
treatment effectiveness were emphasised by participants as being 
important for ART initiation: 
▪ Perceived need for treatment appeared supported by 
status acceptance, and signs and symptoms that could be 
seen as indicative of HIV infection. 
▪ Perceived benefits of treatment were supported by 
familiarity, i.e. seeing others recover on ART or 
deteriorate/die without ART. 
• Factors undermining ART initiation: 
o Concerns about ART side effects could undermine desires to 
initiate treatment, with fears of becoming visible through side 
effects e.g. weight change, lipodystrophy, skin colour changes. 
Side effects could pose a particular challenge for those who were 
asymptomatic and therefore could feel worse after starting ART 
than they did before, which could undermine perceived need 
for/benefits of treatment and motivation for taking it. 
o It appeared important to PLHIV participants to have access to 
reassurance and information about side effects – knowing what to 
expect, knowing they could report side effects to HCW, that they 
would be taken seriously and something would be done to address 
any such experiences.  
o PLHIV had concerns about their potential inability to adhere to 
treatment-taking demands including the required lifelong 
commitment of treatment, remembering to take ART on time 
every day, and also to adhere to the “rules of treatment” e.g. 
healthy diet, no alcohol, no smoking, condom use, less sexual 
partners. This prevented some participants from feeling able to 
start ART.  
o Some participants had concerns about the potential for future 
treatment shortages. Many understood that it was better not to 
start treatment than to start and stop, due to the risk of resistance 
developing, and thus this could deter them from wanting to 
initiate ART. HCW participants also raised concerns about the 
potential for future treatment shortages with national 
implementation of Test and Start. 
o Disclosure of HIV status could particularly pose a barrier to 
treatment initiation for women, with risks highlighted for those 
testing and initiating ART during pregnancy – it appeared there 
could be initiation, adherence and retention in care challenges 
linked to fear of disclosure and hiding treatment, or not feeling 
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able to take it without partner consent and support. Couples 
testing was seen to enable disclosure (i.e. where the couple would 
come and test as though neither knew positive status, with HCW 
then available to support serodiscordant results if needed). This 
then was seen to support engagement with treatment and care. 
Recommendations:  
➢ Community: Could build upon the notion that early ART supports concepts 
of masculinity and productivity – early ART enabling you to stay healthy, 
strong, energetic and productive. Build on messages encouraging couples 
testing, ideally before pregnancy, as it appeared easier to test together for 
disclosure and subsequent access to and engagement with treatment and care 
➢ Counselling: Emphasise the benefits of early ART for good health, long 
life/future and productivity. Provide information on side effects and invite 
patients to report any side effects, reassuring them that these will be 
addressed if needed. Consider that patients may be making decisions 
regarding ART initiation based on risk/benefit analysis – how to address this 
and reassure concerns? 
➢ Counselling: ART readiness appeared influenced by multiple factors, and 
varied for each individual in terms of time to readiness (with some ready on 
testing for HIV, and some needing more time) – need to remove pressure to 
HCW to convince patients to start ART (targets, monitoring etc), and also 
remove pressure to individual PLHIV; not seeing it as a failure (for HCW or 
for patient) if patient is not ready for ART, rather keeping door open for 
patients to come back and talk, even if they are not yet ready for ART. 
Importance of patient choice, readiness and ownership. 
➢ Health system: Integrated services appeared preferable to counter fears of 
HIV status exposure when accessing treatment and care, importance of 
privacy, confidentiality, and non-differential treatment of HIV compared to 
other health conditions. Possible to have treatment booklet for HIV the same 
colour as for other conditions?  
3. Adherence and retention in care 
• Many wanted to see the difference treatment was making for them, and 
evidence of the treatment effect, particularly those who hadn’t had 
physical symptoms prior to ART initiation, for whom this could be hard 
to qualify. This appeared important for their belief in treatment 
effectiveness, perceived benefits of treatment and need for treatment, 
which motivated treatment-taking. 
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o Experimenting – some patients who appeared to doubt the 
treatment need and effect would experiment by missing certain 
doses or having a treatment interruption, wanting to see if 
something would happen that evidenced the treatment need and 
effect (and testing the likelihood of threatened consequences and 
repercussions of non-adherence, emphasised by HCW, being 
realised) 
• Belief in treatment need/effectiveness could be supported by viral load 
monitoring, which appeared particularly important for those with no 
physical symptoms prior to ART initiation, who can struggle to see 
treatment effect. Others felt that weight changes or gaining strength and 
energy could be an indication that treatment was working. 
• Ownership and self-responsibility for treatment-taking appeared 
important for motivation and determination. Patients who chose to take 
treatment for themselves and their health, and had a sense of ownership, 
appeared more driven to overcome challenges and prioritise treatment 
over other areas of life, such as work commitments which could otherwise 
contradict treatment  
o There appeared less motivation for treatment-taking where the 
ART initiation decision was not intrinsically based (i.e. taking 
treatment because perceived have to/obligation/no choice rather 
than taking for self, health, life) 
• Wanting to take treatment to live, having hopes, aspirations and plans for 
the future appeared to support and motivate treatment-taking 
• Importance of treatment support – including emotional support (e.g. 
encouragement, reassurance), practical support (e.g. treatment 
reminders), and financial support (e.g. money to get to the clinic). 
Counselling, being able to talk to HCW and receive ongoing 
encouragement appeared particularly important  
• Insufficient time with HCW was raised as a potential challenge, with 
many participants feeling unable to share challenges and concerns with 
HCW, and ask questions. Where HCW appeared friendly, open, 
approachable, trustworthy and to have time for dialogue this seemed to 
help PLHIV feel able to discuss their questions and concerns, which in 
turn enabled access to support for their continued treatment-taking 
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• There appeared to be inconsistent messaging around Treatment as 
Prevention. Many PLHIV participants said they have heard of the concept, 
mainly through community, radio or informal channels. Most presented 
limited understanding and most said they did not believe in TasP and 
sexual transmission, though there appeared consensus that ART could 
reduce the risk of infecting a baby with HIV. There appeared contradiction 
between HCW advice, messages around risk of reinfection, unprotected 
sex causing unsuppressed viral loads, and the need to always use 
condoms. Most HCW participants said they were not comfortable telling 
patients about TasP. However, the contradictory messaging could 
potentially cause distrust in HCW advice if not careful – some PLHIV 
described trusting HCW advice (that TasP is not true) over other channels. 
This could also present a missed opportunity, as many said TasP would 
motivate treatment-taking, and many in serodiscordant relationships had 
concerns about transmitting HIV to their negative partner. 
• Fear of status exposure undermining adherence and engagement with 
treatment and care: 
o Hiding treatment potentially leading to non-adherence (not taking tx 
when others are around, not accessing treatment support and 
reminders due to non-disclosure) 
o Hiding status potentially leading to disengagement or treatment 
interruptions e.g. if people from community present at clinic – 
individuals may not proceed to wait/queue and collect refill 
o Importance of integrated services, non-differential treatment for HIV, 
avoiding identifying factors e.g. not using different coloured 
treatment booklet, treatment containers making noise 
Recommendations: 
➢ Counselling: At present, the counselling emphasis is for those whose viral 
load results are unsuppressed. Many felt viral load monitoring could provide 
evidence of treatment effectiveness and could motivate treatment-taking, it 
therefore could be important to inform patients of their suppressed results, 
celebrating their achievements and reinforcing treatment-taking 
continuation.   
➢ Counselling & community: Treatment as prevention communication should 
be reconsidered. Not communicating the preventative benefit of treatment to 
patients could be a missed opportunity, as it was said to have potential to 
motivate treatment-taking. Also not informing patients about TasP could 
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undermine their trust in HCW, as the inconsistency in messaging could be 
seen as a form of limiting information to exert control.  
➢ Counselling: create space for patients to share their concerns and ask 
questions, encouraging discussion and exploring patients’ hopes, dreams and 
plans for the future.  
➢ Counselling: emphasising patient ownership, involvement of patients in their 
care – feeling responsible for their health and treatment-taking 
➢ Health system: importance of viral load monitoring – need to ensure systems 
are in place to incorporate routine viral load monitoring as a core component 
of Test and Start/EAA, ideally for baseline and routine thereafter. Also need 
to ensure sufficient resources (including staffing) to communicate results to 
patients.  
➢ Health system: staffing shortages, particularly described in terms of the nurse 
to patient ratio: resources, including clinics having sufficient space/rooms for 
consultations, drug procurement and supply chain to ensure no risk of 
shortages/stock outs.  
 
